US20030187026A1 - Kinase inhibitors - Google Patents

Kinase inhibitors Download PDF

Info

Publication number
US20030187026A1
US20030187026A1 US10/295,833 US29583302A US2003187026A1 US 20030187026 A1 US20030187026 A1 US 20030187026A1 US 29583302 A US29583302 A US 29583302A US 2003187026 A1 US2003187026 A1 US 2003187026A1
Authority
US
United States
Prior art keywords
pyridin
yloxy
indol
ethylamine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/295,833
Inventor
Qun Li
Keith Woods
Gui-Dong Zhu
John Fischer
Jianchun Gong
Tongmei Li
Virajkumar Gandhi
Sheela Thomas
Garrick Packard
Xiaohong Song
Jason Abrams
Robert Diebold
Jurgen Dinges
Charles Hutchins
Vincent Stoll
Saul Rosenberg
Vincent Giranda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to US10/295,833 priority Critical patent/US20030187026A1/en
Priority to PCT/US2002/039915 priority patent/WO2003051366A2/en
Priority to US10/317,914 priority patent/US6831175B2/en
Priority to AU2002353147A priority patent/AU2002353147A1/en
Priority to JP2003552299A priority patent/JP2005516927A/en
Priority to EP02790126A priority patent/EP1463505A2/en
Priority to CA002470214A priority patent/CA2470214A1/en
Priority to TW91136090A priority patent/TW200301122A/en
Priority to ARP020104851 priority patent/AR037832A1/en
Assigned to ABBOTT LABORATORIES reassignment ABBOTT LABORATORIES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HUTCHINS, CHARLES, WOODS, KEITH W., VINCENT L. GIRANDA, GONG, JIANCHUN, LI, QUN, DIEBOLD, ROBERT, LI, TONGMEI, ZHU, GUI-DONG, DINGES, JURGEN, PACKARD, GARRICK K., ABRAMS, JASON N., GANDHI, VIRAJKUMAR, ROSENBERG, SAUL H., SONG, XIAOHONG, STOLL, VINCENT S., THOMAS, SHEELA A., FISCHER, JOHN P.
Publication of US20030187026A1 publication Critical patent/US20030187026A1/en
Priority to MXPA04005810 priority patent/MXPA04005810A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4

Definitions

  • the present invention relates to compounds which are useful for inhibiting protein kinases, methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
  • Protein kinases have been clearly shown to be important in the progression of many disease states that are induced by the inappropriate proliferation of cells. These kinases are often found to be up-regulated in many hyperproliferative states such as cancer. These kinases may be important in cell signaling, where their inappropriate activation induces cells to proliferate (e.g. EGFR, ERBB2, VEGFR, FGFR, PDGFR, c-Met, IGF-1R, RET, TIE2). Alternatively, they may be involved in signal transduction within cells (e.g. c-Src, PKC, Akt, PKA, c-Abl, PDK-1). Often these signal transduction genes are recognized proto-oncogenes.
  • kinases control cell cycle progression near the G1-S transition (e.g. Cdk2, Cdk4), at the G2-M transition (e.g. Wee1, Myt1, Chk1, Cdc2) or at the spindle checkpoint (Plk, Aurora1 or 2, Bub1 or 3).
  • kinases are intimately linked to the DNA damage response (e.g. ATM, ATR, Chk1, Chk2). Disregulation of these cellular functions; cell signaling, signal transduction, cell cycle control, and DNA repair, are all hallmarks of hyperproliferative diseases, particularly cancer. It is therefore likely that pharmacological modulation of one or more kinases would be useful in slowing or stopping disease progression in these diseases.
  • X is selected from the group consisting of C(R 8 ) and N; wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido;
  • X′ is selected from the group consisting of C and N;
  • Y is selected from the group consisting of C and N;
  • Y′ is selected from the group consisting of C(R 9 ) and N; wherein R 9 is selected from the group consisting of hydrogen and -L 2 -L 3 (R 3 )(R 6 );
  • Z is selected from the group consisting of C and N;
  • L 1 is selected from the group consisting of a bond, —O—, —NR 5 —, alkenyl, alkynyl, —C(O)—, —S—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R 5 )—, —N(R 5 )S(O) 2 —, —C(R 12 ) 2 —, —C(R 12 ) 2 N(R 5 )—, —N(R 5 )C(O)—, and —C(O)N(R 5 )—; wherein each group is drawn with its left end attached to R 1 and its right end attached to the aromatic ring;
  • L 2 is selected from the group consisting of a bond, —O—, —C(R 12 ) 2 —, —S—, —N(R 5 )—, —N(R 5 )C(O)—, and —C(O)N(R 5 )—;
  • L 3 is selected from the group consisting of a bond, alkylidene and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of alkoxy, amino, cyano, and hydroxy;
  • R 1 is selected from the group consisting of aryl, heteroaryl, and heterocycle
  • R 2 and R 4 are independently absent or selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, arylalkynyl, cyano, cyanoalkenyl, halo, heteroaryl, heterocycle, hydroxyalkyl, and nitro; or
  • R 2 and L 1 together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle; or
  • R 4 and L 2 together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle; provided that when L 3 is alkylidene, R 4 and L 2 , together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle;
  • R 3 is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;
  • R 6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;
  • R 5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl;
  • R 7 is absent or selected from the group consisting of hydrogen, alkyl, cyanoalkenyl, and -L 2 -L 3 (R 3 )(R 6 ); or
  • R 7 and L 1 together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle;
  • each R 12 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo, heteroaryl, heterocycle, and nitro.
  • the present invention provides a compound of formula (II)
  • L 1 is selected from the group consisting of a bond, —O—, —N(R 5 )—, alkenyl, alkynyl, —N(R 5 )C(O)—, and —C(O)N(R 5 )—;
  • L 2 is selected from the group consisting of a bond, —O—, —N(R 5 )—, —N(R 5 )C(O)—, and —C(O)N(R 5 )—;
  • L 3 is selected from the group consisting of a bond, alkylidene, and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of amino, cyano, and hydroxy;
  • R 1 is selected from the group consisting of aryl, heteroaryl, and heterocycle
  • R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl; wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; or
  • R 2 and L 1 together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, pyrazolyl, and phenyl; or
  • R 4 and L 2 together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, phenyl, pyridinyl, and pyrrolyl; wherein the ring can be optionally substituted with oxo;
  • R 4 and L 2 together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, phenyl, pyridinyl, and pyrrolyl; wherein the ring can be optionally substituted with oxo;
  • R 3 is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;
  • R 6 are independently selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, and heteroarylalkoxy, heteroaryloxy, and heterocycle;
  • R 5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl;
  • X is selected from the group consisting of C(R 8 ) and N; wherein R 8 is selected from the group consisting of hydrogen, amino, carboxy, cyano, and halo.
  • the present invention provides a compound of formula (III)
  • L 1 is selected from the group consisting of a bond, —O—, —N(R 5 )—, alkenyl, alkynyl, and —N(R 5 )C(O)—;
  • L 2 is selected from the group consisting of a bond, —O—, —N(R 5 )—, —N(R 5 )C(O)—, and —C(O)N(R 5 )—;
  • L 3 is alkylene, wherein the alkylene is substituted with one or two substituents independently selected from the group consisting of amino and hydroxy;
  • R 1 is selected from the group consisting of aryl, heteroaryl, and heterocycle
  • R 2 and R 4 are independently selected from the group consisting of hydrogen and halo;
  • R 3 and R 6 are independently selected from the group consisting of hydrogen, aryl, arylalkoxy, and heteroaryl; provided that when L 1 and L 2 are bonds, at least one of R 3 and R 6 is other than hydrogen; and
  • R 5 is selected from the group consisting of hydrogen and alkyl.
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N, wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is alkenyl; L 2 is selected from the group consisting of a bond, —O—, —C(R 12 ) 2 —, —S—, —N(R 5 )—, —N(R 5 )C(O)—, and —C(O)N(R 5 )—; L 3 is a bond or selected from the group consisting of alkylidene and alkylene, wherein the alkylidene and the alky
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N, wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is alkenyl; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino,
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N, wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is alkenyl; L 2 is —O—; L 1 is alkenyl; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is alkenyl; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R 3 is hydrogen; R 6 is heteroaryl;
  • the present invention provides a compound of formula (I) wherein X is N; and X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is alkenyl; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R 3 is hydrogen; R 6 is aryl
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N, wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; and X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is alkenyl; L 2 is —O—; L 3 is a bond; R 1 is heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is alkenyl; L 2 is —O—; L 3 is a bond; R 1 is heteroaryl; R 2 and R 4 are hydrogen; R 3 is absent; R 6 is heterocycle; and R 7 is hydrogen.
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N, wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is alkenyl; L 2 is —N(R 5 )C(O)—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, ary
  • the present invention provides a compound of formula (I) wherein X is N; and X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is alkenyl; L 2 is —N(R 5 )C(O)—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R 3
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is alkenyl; L 2 is —N(R 5 )C(O)—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R 3 is
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N, wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is alkynyl; L 2 is selected from the group consisting of a bond, —O—, —C(R 12 ) 2 —, —S—, —N(R 5 )—, —N(R 5 )C(O)—, and —C(O)N(R 5 )—; L 3 is a bond or selected from the group consisting of alkylidene and alkylene, wherein the alkylidene and the al
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N, wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is alkynyl; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N, wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is a bond; L 2 is selected from the group consisting of a bond, —O—, —C(R 12 ) 2 —, —S—, —N(R 5 )—, —N(R 5 )C(O)—, and —C(O)N(R 5 )—; L 3 is a bond or selected from the group consisting of alkylidene and alkylene, wherein the alkylidene and the alkylene
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N, wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; and X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is a bond; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino,
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is a bond; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R 3 is hydrogen; R 6 is aryl; and
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is a bond; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R 3 is hydrogen; R 6 is heteroaryl; and
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N, wherein R 8 is hydrogen; X′ is N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is a bond; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is N; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is a bond; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 2 is absent; R 4 is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R 3 is hydrogen; R 6 is aryl;
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is N; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is a bond; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 2 is absent; R 4 is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R 3 is hydrogen; R 6 is heteroaryl;
  • the present invention provides a compound of formula (I) wherein X is C(R 8 ), wherein R 8 is hydrogen; X′ is C; Y is N; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is a bond; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 2 is absent; R 4 is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R
  • the present invention provides a compound of formula (I) wherein X is C(R 8 ), wherein R 8 is hydrogen; X′ is C; Y is N; Y′ is C(R 9 ), wherein R is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is a bond; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 2 is absent; R 4 is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R 3
  • the present invention provides a compound of formula (I) wherein X is C(R 8 ), wherein R 8 is hydrogen; X′ is C; Y is N; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is N; L 1 is a bond; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 4 is absent; R 2 is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R
  • the present invention provides a compound of formula (I) wherein X is C(R 8 ), wherein R 8 is hydrogen; X′ is C; Y is N; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is N; L 1 is a bond; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 4 is absent; R 2 is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is N; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is N; L 1 is a bond; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 4 is absent; R 2 is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R 3 is hydrogen; R 6 is aryl;
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is N; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is N; L 1 is a bond; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 4 is absent; R 2 is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R 3 is hydrogen; R 6 is heteroaryl;
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N, wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is —C—; L 1 is a bond; L 2 is —N(R 5 )—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylal
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is a bond; L 2 is —N(R 5 )—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R 3 is hydrogen; R 5 is
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is a bond; L 2 is —N(R 5 )—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R 3 is hydrogen; R 5 is
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N, wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is a bond; L 2 is —N(R 5 )C(O)—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, aryl
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is a bond; L 2 is —N(R 5 )C(O)—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R 3 is hydrogen
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is a bond; L 2 is —N(R 5 )C(O)—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R 3 is hydrogen
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N, wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is —N(R 5 )—; L 2 is selected from the group consisting of a bond, —O—, —C(R 12 ) 2 —, —S—, —N(R 5 )—, —N(R 5 )C(O)—, and —C(O)N(R 5 )—; L 3 is a bond or selected from the group consisting of alkylidene and alkylene, wherein the alkyliden
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N, wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is —N(R 5 )—; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkyn
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is —N(R 5 )—; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is L 1 -L 3 (R 3 )(R 6 ); Z is C; L 1 is —N(R 5 )—; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N, wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is a bond; L 2 is a bond; L 3 is a bond; R 2 and R 4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thi
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N; wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is selected from the group consisting of a bond, —O—, —N(R 5 )—, alkenyl, alkynyl, —C(O)—, —S—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R 5 )—, —N(R 5 )S(O) 2 —, —C(R 12 ) 2 —, —C(R 12 ) 2 —,
  • the present invention provides a compound of formula (1) wherein X is selected from the group consisting of C(R 8 ) and N, wherein R 8 is hydrogen; X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; L 1 is a bond; L 3 is alkylidene, wherein the alkylidene is substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl wherein the heteroaryl is isoquinolinyl; R 4 and L 2 , together with the carbon atoms to which they are attached, form a heterocycle wherein the heterocycle is pyrrolidinyl substituted with oxo; R 3 is hydrogen; R 6 is heteroaryl, wherein the heteroaryl is indolyl; and R 7 is hydrogen.
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N; wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; and X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; R 2 and L 1 , together with the carbon atoms to which they are attached, form a ring that is aryl wherein the aryl ring is phenyl; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 3 is absent; R 6 is heteroaryl; and R 7 is
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; R 2 and L 1 , together with the carbon atoms to which they are attached, form a ring that is aryl wherein the aryl ring is phenyl; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 3 is absent; R 6 is heteroaryl; and R 7 is hydrogen.
  • the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; R 2 and L 1 , together with the carbon atoms to which they are attached, form a ring that is aryl wherein the aryl ring is phenyl; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 3 is absent; R 6 is aryl; and R 7 is hydrogen.
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N; wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; R 2 and L 1 , together with the carbon atoms to which they are attached, form a ring that is heteroaryl wherein the heteroaryl is pyrazolyl; L 2 is a bond; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R 3 is hydrogen
  • the present invention provides a compound of formula (I) wherein X is C(R 8 ), wherein R 8 is hydrogen; X′ is N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; R 2 and L 1 , together with the carbon atoms to which they are attached, form a ring that is heteroaryl wherein the heteroaryl is pyrazolyl; L 2 is a bond; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 3 is hydrogen; R 6 is aryl; and R 7 is absent.
  • the present invention provides a compound of formula (I) wherein X is C(R 8 ), wherein R 8 is hydrogen; X′ is N; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; R 2 and L 1 , together with the carbon atoms to which they are attached, form a ring that is heteroaryl wherein the heteroaryl is pyrazolyl; L 2 is a bond; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is aryl; R 3 is hydrogen; R 6 is aryl; and R 7 is absent.
  • the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R 8 ) and N; wherein R 8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; R 7 and L 1 , together with the carbon atoms to which they are attached, form a ring selected from the group consisting aryl, heteroaryl and heterocycle; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R 3 is hydrogen; and R 6 is selected from the group consisting of C(R 8
  • the present invention provides a compound of formula (I) wherein X is N; and X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; R 7 and L 1 , together with the carbon atoms to which they are attached, form a ring that is a heteroaryl wherein the heteroaryl is pyridinyl; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 3 is hydrogen; and R 6 is heteroaryl.
  • the present invention provides a compound of formula (I) wherein X is N; and X′ is C; Y is C; Y′ is C(R 9 ), wherein R 9 is -L 2 -L 3 (R 3 )(R 6 ); Z is C; R 7 and L 1 , together with the carbon atoms to which they are attached, form a ring that is a heteroaryl wherein the heteroaryl is pyridinyl; L 2 is —O—; L 3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R 1 is heteroaryl; R 3 is hydrogen; and R 6 is aryl.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a therapeutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
  • the invention provides a method of inhibiting protein kinases in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I), or a therapeutically acceptable salt thereof.
  • alkenyl refers to a group derived from a straight or branched chain hydrocarbon of up to six atoms containing at least one double bond.
  • alkoxy refers to an alkyl group attached to the parent molecular moiety through an oxygen atom.
  • alkoxyalkyl refers to an alkoxy group attached to the parent molecular moiety through an alkyl group.
  • alkoxycarbonyl refers to an alkoxy group attached to the parent molecular moiety through an alkyl group.
  • alkyl refers to a group derived from a straight or branched chain saturated hydrocarbon of one to six atoms.
  • alkylene refers to a divalent group derived from a straight or branched chain saturated hydrocarbon of one to six atoms.
  • alkylcarbonyl refers to an alkyl group attached to the parent molecular moiety through a carbonyl group.
  • alkylidene refers to an alkenyl group in which one carbon atom of the carbon-carbon double bond belongs to the moiety to which the alkenyl group is attached.
  • alkylsulfonyl refers to an alkyl group attached to the parent molecular moiety through a sulfonyl group.
  • alkynyl refers to a group derived from a straight or branched chain hydrocarbon of two to six atoms containing at least one triple bond.
  • amino refers to an amino group attached to the parent molecular moiety through a carbonyl group.
  • amino refers to —NR a R b , wherein R a and R b are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, aryl, arylalkenyl, arylalkyl, cycloalkyl, haloalkylcarbonyl, (NR c R d )alkylcarbonyl, heteroaryl, heteroarylalkenyl, heteroarylalkyl, heterocycle, (heterocycle)alkenyl, and (heterocycle)alkyl, wherein the aryl, the aryl part of the arylalkenyl, the arylalkyl, the heteroaryl, the heteroaryl part of the heteroarylalkenyl and the heteroarylalkyl, the heterocycle, and the heterocycle part of the (heterocycle)al
  • aminoalkyl refers to an amino group attached to the parent molecular moiety through an alkyl group.
  • aryl refers to a phenyl group, or a bicyclic or tricyclic fused ring system wherein one or more of the fused rings is a phenyl group.
  • Bicyclic fused ring systems are exemplified by a phenyl group fused to a cycloalkyl group, as defined herein, or another phenyl group.
  • Tricyclic fused ring systems are exemplified by a bicyclic fused ring system fused to a cycloalkyl group, as defined herein, or another phenyl group.
  • aryl include, but are not limited to, anthracenyl, azulenyl, fluorenyl, indanyl, indenyl, naphthyl, phenyl, and tetrahydronaphthyl.
  • the aryl groups of the present invention can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylthio, amino, aminoalkyl, a second aryl group, arylalkoxy, arylalkyl, arylcarbonyl, carboxy, cyano, cycloalkyl, halo, haloalkoxy, haloalkyl, heteroaryl, heteroarylalkoxy, heteroarylalkyl, heterocycle, (heterocycle)alkoxy, (heterocycle)alkyl, hydroxy, hydroxyalkyl, nitro, oxo, —C( ⁇ NOH)NH 2 , —C( ⁇ NH)NH 2 ; wherein the second aryl group, the aryl part of the arylalkoxy, the arylal
  • arylalkenyl refers to an aryl group attached to the parent molecular moiety through an alkenyl group.
  • arylalkoxy refers to an aryl group attached to the parent molecular moiety through an alkoxy group.
  • arylalkyl refers to an aryl group attached to the parent molecular moiety through an alkyl group.
  • arylalkylamino refers to an arylalkyl group attached to the parent molecular moiety through a nitrogen atom, wherein the nitrogen atom is substituted with hydrogen.
  • arylalkylidene refers to an aryl group attached to the parent molecular moiety through an alkylidene group
  • arylalkylthio refers to an arylalkyl group attached to the parent molecular moiety through a sulfur atom.
  • arylalkynyl refers to an aryl group attached to the parent molecular moiety through an alkynyl group.
  • arylcarbonyl refers to an aryl group attached to the parent molecular moiety through a carbonyl group.
  • aryloxy refers to an aryl group attached to the parent molecular moiety through an oxygen atom.
  • arylsulfonyl refers to an aryl group attached to the parent molecular moiety through an sulfonyl group.
  • arylthio refers to an aryl group attached to the parent molecular moiety through a sulfur atom.
  • carbonyl refers to a —C(O)— group.
  • cyano refers to —CN.
  • cyanoalkenyl refers to a cyano group attached to the parent molecular moiety through an alkenyl group
  • cycloalkyl refers to a saturated monocyclic, bicyclic, or tricyclic hydrocarbon ring system having three to twelve carbon atoms.
  • Examples of cycloalkyl groups include cyclopropyl, cyclopentyl, bicyclo[3.1.1]heptyl, adamantyl, and the like.
  • (cycloalkyl)alkylidene refers to a cycloalkyl group attached to the parent molecular moiety through an alkylidene group.
  • halo refers to F, Cl, Br, or I.
  • haloalkoxy refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.
  • haloalkyl refers to an alkyl group substituted by one, two, three, or four halogen atoms.
  • haloalkylcarbonyl refers to an haloalkyl group attached to the parent molecular moiety through a carbonyl group.
  • heteroaryl refers to an aromatic five- or six-membered ring where at least one atom is selected from the group consisting of N, O, and S, and the remaining atoms are carbon.
  • the five-membered rings have two double bonds, and the six-membered rings have three double bonds.
  • the heteroaryl groups are connected to the parent molecular group through a substitutable carbon or nitrogen atom in the ring.
  • heteroaryl also includes systems where a heteroaryl ring is fused to an aryl group, as defined herein, a heterocycle group, as defined herein, or an additional heteroaryl group.
  • Heteroaryls are exemplified by benzothienyl, benzoxadiazolyl, benzofuranyl, benzimidazolyl, benzotriazolyl, cinnolinyl, furyl, imidazolyl, indazolyl, indolyl, isoxazolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxadiazolyl, oxadiazolyl, oxazolyl, purinyl, thiazolyl, thienopyridinyl, thienyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, pyrido[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl,
  • heteroaryl groups of the present invention can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkynyl, alkylcarbonyl, amino, aminoalkyl, aryl, arylalkoxy, arylalkyl, arylalkylthio, arylalkynyl, aryloxy, carboxy, cyano, cycloalkyl, halo, haloalkoxy, haloalkyl, a second heteroaryl group, heteroarylalkoxy, heteroarylalkyl, heterocycle, (heterocycle)alkoxy, (heterocycle)alkyl, hydroxy, hydroxyalkyl, nitro, and oxo, wherein the aryl, the aryl part of the arylalkoxy, the arylalkyl, the arylalky
  • heteroarylalkenyl refers to a heteroaryl group attached to the parent molecular moiety through an alkenyl group.
  • heteroarylalkoxy refers to a heteroaryl group attached to the parent molecular moiety through an alkoxy group.
  • heteroarylalkyl refers to a heteroaryl group attached to the parent molecular moiety through an alkyl group.
  • heteroarylalkylidene refers to a heteroaryl group attached to the parent molecular moiety through an alkylidene group.
  • heteroaryloxy refers to a heteroaryl group attached to the parent molecular moiety through an oxygen atom.
  • heteroarylsulfonyl refers to a heteroaryl group attached to the parent molecular moiety through a sulfonyl group.
  • heterocycle refers to cyclic, non-aromatic, three-, four-, five-, six-, or seven-membered rings containing at least one atom selected from the group consisting of oxygen, nitrogen, and sulfur.
  • the five-membered rings have zero or one double bonds and the six- and seven-membered rings have zero, one, or two double bonds.
  • the heterocycle groups of the invention are connected to the parent molecular group through a substitutable carbon or nitrogen atom in the ring.
  • heterocycle also includes systems where a heterocycle ring is fused to an aryl group, as defined herein, or an additional heterocycle group.
  • Heterocycle groups of the invention are exemplified by aziridinyl, azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl, dihydro[1,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl, dihydroindolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, and the like.
  • heterocycle groups of the present invention can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylidene, amino, aminoalkyl, aryl, arylalkoxy, arylalkyl, arylalkylidene, cyano, (cycloalkyl)alkylidene, halo, haloalkoxy, haloalkyl, heteroaryl, heteroarylalkoxy, heteroarylalkyl, heteroarylalkylidene, iminohydroxy, a second heterocycle, (heterocycle)alkoxy, (heterocycle)alkyl, (heterocycle)alkylidene, hydroxy, hydroxyalkyl, nitro, and oxo, wherein the aryl, the aryl part of the arylalkoxy and the
  • (heterocycle)alkenyl refers to a heterocycle group attached to the parent molecular moiety through an alkenyl group.
  • (heterocycle)alkoxy refers to a heterocycle group attached to the parent molecular group through an oxygen atom.
  • (heterocycle)alkyl refers to a heterocycle group attached to the parent molecular moiety through an alkyl group.
  • (heterocycle)alkylidene refers to a heterocycle group attached to the parent molecular moiety through an alkylidene group.
  • hydroxy refers to —OH.
  • hydroxyalkyl refers to a hydroxy group attached to the parent molecular moiety through an alkyl group.
  • aminohydroxy refers to ⁇ N(OH).
  • —NR c R d refers to two groups, R c and R d , which are attached to the parent molecular moiety through a nitrogen atom.
  • R c and R d are each independently selected from hydrogen and alkyl.
  • (NR c R d )alkyl refers to a —NR c R d group attached to the parent molecular moiety through an alkyl group.
  • (NR c R d )alkylcarbonyl refers to a (NR c R d )alkyl group attached to the parent molecular moiety through a carbonyl group.
  • nitro refers to —NO 2 .
  • sulfonyl refers to —S(O) 2 —.
  • the compounds of the present invention can exist as therapeutically acceptable salts.
  • terapéuticaally acceptable salt represents salts or zwitterionic forms of the compounds of the present invention which are water or oil-soluble or dispersible, which are suitable for treatment of diseases without undue toxicity, irritation, and allergic response; which are commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use.
  • the salts can be prepared during the final isolation and purification of the compounds or separately by reacting an amino group with a suitable acid.
  • Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate, phosphate,
  • amino groups in the compounds of the present invention can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.
  • acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.
  • Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
  • a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
  • the cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N′-dibenzylethylenediamine.
  • Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
  • the present compounds can also exist as therapeutically acceptable prodrugs.
  • therapeutically acceptable prodrug refers to those prodrugs or zwitterions which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
  • prodrug refers to compounds which are transformed in vivo to parent compounds of formula (I) for example, by hydrolysis in blood.
  • the invention contemplates various geometric isomers and mixtures thereof resulting from the arrangement of substituents around these carbon-carbon double bonds. It should be understood that the invention encompasses both isomeric forms, or mixtures thereof, which possess the ability to inhibit protein kinases. These substituents are designated as being in the E or Z configuration wherein the term “E” represents higher order substituents on opposite sides of the carbon-carbon double bond, and the term “Z” represents higher order substituents on the same side of the carbon-carbon double bond.
  • the compounds can be administered alone or in combination with other anticancer agents.
  • the specific therapeutically effective dose level for any particular patient will depend upon factors such as the disorder being treated and the severity of the disorder; the activity of the particular compound used; the specific composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration; the route of administration; the rate of excretion of the compound employed; the duration of treatment; and drugs used in combination with or coincidently with the compound used.
  • the compounds can be administered orally, parenterally, osmotically (nasal sprays), rectally, vaginally, or topically in unit dosage formulations containing carriers, adjuvants, diluents, vehicles, or combinations thereof.
  • parenteral includes infusion as well as subcutaneous, intravenous, intramuscular, and intrasternal injection.
  • Parenterally adminstered aqueous or oleaginous suspensions of the compounds can be formulated with dispersing, wetting, or suspending agents.
  • the injectable preparation can also be an injectable solution or suspension in a diluent or solvent.
  • acceptable diluents or solvents employed are water, saline, Ringer's solution, buffers, monoglycerides, diglycerides, fatty acids such as oleic acid, and fixed oils such as monoglycerides or diglycerides.
  • the anticancer effect of parenterally administered compounds can be prolonged by slowing their absorption.
  • One way to slow the absorption of a particular compound is administering injectable depot forms comprising suspensions of crystalline, amorphous, or otherwise water-insoluble forms of the compound.
  • the rate of absorption of the compound is dependent on its rate of dissolution which is, in turn, dependent on its physical state.
  • Another way to slow absorption of a particular compound is administering injectable depot forms comprising the compound as an oleaginous solution or suspension.
  • injectable depot forms comprising microcapsule matrices of the compound trapped within liposomes, microemulsions, or biodegradable polymers such as polylactide-polyglycolide, polyorthoesters or polyanhydrides.
  • biodegradable polymers such as polylactide-polyglycolide, polyorthoesters or polyanhydrides.
  • the rate of drug release can be controlled.
  • Transdermal patches can also provide controlled delivery of the compounds.
  • the rate of absorption can be slowed by using rate controlling membranes or by trapping the compound within a polymer matrix or gel.
  • absorption enhancers can be used to increase absorption.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound can optionally comprise diluents such as sucrose, lactose, starch, talc, silicic acid, aluminum hydroxide, calcium silicates, polyamide powder, tableting lubricants, and tableting aids such as magnesium stearate or microcrystalline cellulose.
  • Capsules, tablets and pills can also comprise buffering agents, and tablets and pills can be prepared with enteric coatings or other release-controlling coatings.
  • Powders and sprays can also contain excipients such as talc, silicic acid, aluminum hydroxide, calcium silicate, polyamide powder, or mixtures thereof. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons or substitutes therefore.
  • Liquid dosage forms for oral administration include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs comprising inert diluents such as water. These compositions can also comprise adjuvants such as wetting, emulsifying, suspending, sweetening, flavoring, and perfuming agents.
  • Topical dosage forms include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and transdermal patches.
  • the compound is mixed under sterile conditions with a carrier and any needed preservatives or buffers.
  • These dosage forms can also include excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Suppositories for rectal or vaginal administration can be prepared by mixing the compounds with a suitable non-irritating excipient such as cocoa butter or polyethylene glycol, each of which is solid at ordinary temperature but fluid in the rectum or vagina.
  • a suitable non-irritating excipient such as cocoa butter or polyethylene glycol, each of which is solid at ordinary temperature but fluid in the rectum or vagina.
  • Ophthalmic formulations comprising eye drops, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.
  • the total daily dose of the compounds administered to a host in single or divided doses can be in amounts from about 0.1 to about 200 mg/kg body weight or preferably from about 0.25 to about 100 mg/kg body weight.
  • Single dose compositions can contain these amounts or submultiples thereof to make up the daily dose.
  • the Akt1 assay uses His-Akt1-S36, a truncated Akt1 containing a His tag at the N-terminus, amino acid 139-460 of Akt1 and the following point mutations: S378A, S381A, T450D and S473D.
  • the His-Akt1-S36 assay is run in 96 well plates by incubating 1 nM His-Akt1-S36, 5 ⁇ M Biotin-BAD-peptide (Biotin) and 5 ⁇ M 33 P-ATP in 50 ⁇ L of reaction buffer (20 mM HEPES, pH 7.5, 10 mM MgCl 2 , 0.009% Triton X-100) for 30 minutes at room temperature.
  • Akt2, Akt3, PKA, PKC, Erk2, Chk1, Cdc2, Src, CK2, MAPK AP kinase 2, and SGK are carried out similarly using their specific biotinylated peptide substrates and buffer conditions.
  • Compounds of the invention inhibited Akt by 0-100% at a concentration of 1 ⁇ M.
  • Preferred compounds had percent inhibitions of between 77 and 100 at 1 ⁇ M and more preferred compounds had percent inhibitions of between 92 and 100 at 1 ⁇ M.
  • the compounds of the invention are useful in treating disorders which are caused or exacerbated by increased protein kinase levels.
  • This invention is intended to encompass compounds having formula (I) when prepared by synthetic processes or by metabolic processes. Preparation of the compounds of the invention by metabolic processes include those occurring in the human or animal body (in vivo) or processes occurring in vitro.
  • compounds of formula (2) (Z is Cl, Br, I, or OTf) can be converted to compounds of formula (4) by treatment with compounds of formula (3) in the presence of triphenylphosphine and an activating agent such as DEAD.
  • the reaction can be carried out neat or in the presence of a solvent such as THF, diethyl ether, and MTBE.
  • the reaction temperature is typically about ⁇ 10° C. to about 35° C. and reaction times are typically about 8 to about 24 hours.
  • Compounds of formula (4) can be converted to compounds of formula (Ia) by treatment with compounds of formula (5) (M is selected from B(OH) 2 ; Sn(R a ) 3 , where R a is an alkyl or aryl group; and hydrogen) in the presence of a palladium catalyst and an optional additive such as triethylamine.
  • a palladium catalyst include Pd(PPh 3 ) 4 , and Pd(OAc) 2 and P(o-tol) 3 .
  • Representative solvents include toluene, acetonitrile, and DME.
  • the reaction is typically conducted at temperatures between about 60° C. and about 110° C. and reaction times are typically about 4 to about 12 hours.
  • Scheme 2 shows that compounds of formula (6) (Z 1 and Z 2 are independently Cl, Br, I, or OTf) can be converted to compounds of formula (8) by treatment with compounds of formula (7) according to the procedure described in Scheme 1. These compounds can be converted to compounds of formula (9) by treatment with benzophenone imine, a palladium catalyst, and a base.
  • palladium catalysts include Pd 2 dba 3 and a ligand such as BINAP, dppf, or dppe.
  • Representative bases include sodium tert-butoxide and potassium tert-butoxide.
  • the reaction is conducted in a solvent such as toluene, acetonitrile, or DME; at temperatures from about 60° C. to about 90° C.; and at times from about 8 to about 24 hours.
  • Compounds of formula (9) can be treated with compounds of formula (10) in the presence of an acid such as acetic acid and then treated with sodium cyanoborohydride to provide compounds of formula (Ib).
  • Representative solvents include methanol and ethanol. The reaction is typically conducted at about 20° C. to about 70° C. and reaction times are typically about 1 to about 4 hours.
  • Scheme 3 shows the preparation of compounds of formula (Ic).
  • Compounds of formula (11) (Z is Br) can be treated with a palladium catalyst under CO atmosphere to provide compounds of formula (12).
  • palladium catalysts include PdCl 2 .dppf, PdCl 2 and BINAP, and PdCl 2 .dppe.
  • Representative solvents include THF, water, DME, and mixtures thereof. The reaction is typically conducted at about 80° C. to about 100° C. and reaction times are typically between 12 and 24 hours.
  • Compounds of formula (12) can be converted to compounds of formula (Ic) by treatment with a substituted amine in the presence of a coupling agent.
  • Representative coupling agents include EDC, HOBt, DCC, DMAP, and mixtures thereof.
  • solvents used include dichloromethane, DMF, and DME. The reaction is typically conducted at about 0° C. to about 35° C. and reaction times are typically about 12 to about 24 hours.
  • Scheme 5 shows the synthesis of compounds of formula (Ie).
  • Compounds of formula (15) can be converted to compounds of formula (16) by treatment with a reducing agent.
  • reducing agents include Pd/C and ammonium formate, Pd/C and hydrogen, and PtO 2 and hydrogen.
  • Representative solvents include methanol and ethanol. The reaction is typically conducted at about 50° C. to about 70° C. for about 15 minutes to about 2 hours.
  • Compounds of formula (16) can be converted to compounds of formula (Ie) by treatment with an electrophile such as a halo-substituted heteroaryl group.
  • electrophile such as a halo-substituted heteroaryl group.
  • solvents used in these reactions include ethanol and methanol. The reaction is typically conducted at about 50° C. to about 70° C. for about 6 to about 18 hours.
  • compounds of formula (8) can be converted to compounds of formula (If) (where L 2 is a bond) by treatment with compounds of formula (17) (M is B(OR z ) 2 , wherein R z is hydrogen or alkyl) in the presence of a palladium catalyst and a base such as cesium carbonate or sodium carbonate.
  • a palladium catalyst and a base such as cesium carbonate or sodium carbonate.
  • Representative palladium catalysts include PdCl 2 .dppf, Pd(PPh 3 ) 4 , and PdCl 2 (PPh 3 ) 2 .
  • solvents used in these reactions include DMF, DME, and NMP.
  • the reaction is typically conducted at about 30° C. to about 100° C. for about 4 to about 12 hours.
  • Example 1A A mixture of Example 1A (0.8 g, 3.27 mmol), 4-vinylpyridine (0.69 g, 5.53 mmol), tri-o-tolylphosphine (0.6 g, 1.96 mmol), palladium acetate (0.16 g, 0.65 mmol) and triethylamine (0.66 g, 6.53 mmol) in acetonitrile (15 mL) was stirred for 8 hours at 80° C. The reaction solution was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (Na 2 SO 4 ), filtered, and concentrated under vacuum.
  • Example 2A The desired product was prepared by substituting Example 2A for Example 1A in Example 1B. MS (DCI/NH 3 ) m/e 471 (M+H) + .
  • Example 2B A solution of Example 2B (603 mg, 1.28 mmol) in dichloromethane (20 mL) at room temperature was treated with 4N HCl in dioxane (5 mL), stirred for 2 hours, and concentrated. The residue was dissolved in water (1.5 mL) and freeze-dried to provide the desired product as the hydrochloride salt (610 mg, 99%).
  • Example 2B 500 mg, 1.06 mmol
  • dichloromethane 5 mL
  • trifluoroacetic acid 5 mL
  • the residue was dissolved in water (1.5 mL) and freeze-dried to provide the desired product as the trifluoroacetate salt (643 mg, 85%).
  • Example 2C A solution of Example 2C (150 mg, 0.400 mmol) in acetic acid (2.4 mL) at room temperature was treated portionwise with NaNO 2 (117 mg. 1.70 mmol), stirred for 18 hours, quenched with water (40 ⁇ L), stirred for an additional hour, poured into 2N NaOH, and extracted with isopropanol/dichloromethane. The combined extracts were concentrated. The residue was treated with LiOH.H 2 O (25 mg) in THF/water (1 mL/0.5 mL), heated to 55° C. overnight, diluted with dichloromethane, washed with water, dried (MgSO 4 ), filtered, and concentrated.
  • the desired product was prepared as the trifluoroacetate salt by substituting 2-tert-butoxycarbonylamino-3-benzo[b]thiophen-3-yl-propan-1-ol for L-Boc-tryptophanol in Example 2A then proceeding as described for Examples 2B and 2D.
  • the desired product was prepared as the hydrochloride salt by substituitng L-Boc-(4-(2,6-dichlorobenzyloxy)phenyl)alaninol for L-Boc-tryptophanol in Example 2A then proceeding as described for Examples 2B and 2C.
  • the desired product was prepared as the hydrochloride salt by substituting L-Boc-3-benzyloxyalaminol for L-Boc-tryptophanol in Example 2A then proceeding as described for Examples 2B and 2C.
  • Example 9A A mixture of Example 9A (9.37 g, 43.3 mmol), 4-vinylpyridine (14.0 mL, 130 mmol), tri-o-tolylphosphine (13.5 g, 44.4 mmol), palladium acetate (2.65 g, 11.8 mmol) and triethylamine (120 mL, 0.861 mol) in acetonitrile (40 mL) was heated to reflux overnight and partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (Na 2 SO 4 ), filtered, and concentrated under vacuum.
  • Example 9B The desired product was prepared as the trifluoracetate salt by substituting Example 9B and (1S,2S)-2-(dimethylamino)-1-phenylpropan-1-ol for 3-bromo-5-hydroxypyridine and L-Boc-tryptophanol, respectively, in Example 2A then proceeding as described for Examples 2B and 2D.
  • the desired product was prepared as the trifluoracetate salt by substituting L-Boc-(2-naphthyl)alaminol for L-Boc-tryptophanol in Example 92A then proceeding as described for Examples 2B and 2D.
  • the concentrate was purified by flash column chromatography on silica gel with 4% methanol/dichloromethane to provide the desired product (2.18 g, 36%).
  • Example 11A A mixture of Example 11A (1.88 g, 7.2 mmol), benzophenone imine (1.22 mL), Pd 2 (dba) 3 (66 mg), BINAP (125 mg), sodium tert-butoxide (0.97 g), and toluene (19 mL) was heated to 80° C. overnight and concentrated. The residue was purified by flash column chromatography on silica gel with ethyl acetate to provide a solid (2.44 g). This was stirred with 2N HCl (aq.) (5.0 mL) in THF (50 mL) at room temperature for 2 hours and concentrated.
  • 2N HCl aq.
  • Example 11B A mixture of Example 11B (52 mg, 0.264 mmol), L-Boc-tryptophanal (J. Med. Chem., 1985, 28(12), 1874.) (80 mg, 0.277 mmol) and acetic acid (80 ⁇ L) in methanol (4 mL) was stirred at room temperature for 3 hours, refluxed for 2 hours, cooled to room temperature, treated with sodium cyanoborohydride (35 mg) stirred for 1 hour, and filtered. The filtrate was concentrated and the residue was purified by HPLC on a C18 column with 0-100% CH 3 CN/H 2 O/0.1% TFA to provide the designed product (43 mg, 35%). MS (DCI/NH 3 ) m/e 470 (M+H) + .
  • Example 11C A solution of Example 11C (40 mg, 0.085 mmol) in dichloromethane (3.0 mL) at room temperature was treated with 4N HCl in dioxane (0.5 mL), stirred for 1 hour, and concentrated to provide the desired product as the hydrochloride salt (30 mg, 74%).
  • Example 12A A mixture of Example 12A in HBr/HOAc (30%, 50 mL) was stirred at 100° C. for 8 hours, cooled to room temperature and concentrated. The concentrate was partitioned between ethyl acetate and saturated Na 2 CO 3 (aq.). The organic layer was washed with brine, dried (Na 2 SO 4 ), filtered, and concentrated under vacuum. Purification by flash column chromatography on silica gel with 30% ethyl acetate/hexane provided the desired product (0.51 g, 72%). MS (DCI/NH 3 ) m/e 209 (M+H) + .
  • Example 12B The desired product was prepared by substituting Example 12B for 3-bromo-5-hydroxypyridine in Example 2A (0.78 g, 66%). MS (DCI/NH 3 ) m/e 481 (M+H) + .
  • Example 13A (1.50 g, 3.125 mmol), Pd 2 (dba) 3 (71 mg, 0.078 mmol) and tri-o-tolylphosphine (71 mg, 0.23 mmol) in DMF (30 mL) was treated with 4-vinylpyridine (492 mg, 4.68 mmol) and triethylamine (1.30 mL, 9.4 mmol), purged with nitrogen, and heated to 100° C. for 4 hours. The mixture was cooled to room temperature, treated with ethyl acetate (200 mL), washed with brine, dried (MgSO 4 ), filtered, and concentrated.
  • Example 2A 500 mg, 1.12 mmol
  • Pd 2 Cl 2 (PPh 3 ) 2 77 mg, 0.112 mmol
  • CuI 52 mg, 0.27 mmol
  • DMF 7 mL
  • trimethylsilylacetylene 475 ⁇ L, 3.36 mmol
  • triethylamine 468 ⁇ L, 3.36 mmol
  • the residual oil was purified by flash column chromatography on silica gel with 1:2 ethyl acetate/hexanes to provide the desired product (417 mg, 80%).
  • MS (APCI) m/e 464 (M+H) + .
  • Example 14A 400 mg, 0.86 mmol
  • THF 6 mL
  • tetrabutylammonium fluoride 1.0 M solution in THF, 1.12 mL, 1.12 mmol
  • ethyl acetate 50 mL
  • washed with brine dried (MgSO 4 )
  • MS (APCI) m/e 392 (M+H) + .
  • Example 14B A mixture of Example 14B (150 mg, 0.384 mmol), 4-bromopyridine hydrochloride (75 mg, 0.34 mmol), Pd 2 Cl 2 (PPh 3 ) 2 (27 mg, 0.0384 mmol), and CuI (18 mg, 0.093 mmol), was purged with nitrogen, treated with DMF (4 mL) and triethylamine (214 mL, 1.54 mmol), stirred at 50° C. for 20 hours, cooled to room temperature, treated with ethyl acetate (50 mL), washed with brine, dried (MgSO 4 ), filtered, and concentrated. The residual oil was purified by flash column chromatography on silica gel with 2:1 ethyl acetate/hexanes to provide the desired product (122 mg, 68%). MS (APCI) m/e 469 (M+H) + .
  • Example 14D 40 mg, 0.11 mmol
  • 5% Pd/BaSO 4 8.1 mg
  • quinoline 8.1 ⁇ L
  • methanol 3 mL
  • the filtrate was concentrated and the residual oil was purified by HPLC on a C18 column with 0-100% CH 3 CN/H 2 O/0.1% TFA to provide the desired product (30 mg, 75%).
  • Example 11B A mixture of Example 11B (200 mg, 1.0 mmol), HOBt (210 mg), EDC (290 mg), DMAP (25 mg) and Boc-homophenylalanine was stirred at room temperature overnight and concentrated. The residue was dissolved in ethyl acetate, washed sequentially with water, 5% NaHCO 3 , and water, dried (MgSO 4 ), filtered, and concentrated. The residue was purified by flash column chromatography on silica gel with 3% methanol/dichloromethane to provide the desired product (192 mg, 41%). MS (DCI/NH 3 ) m/e 459 (M+H) + .
  • Example 2A A solution of Example 2A (1.30 g, 3.02 mmol) and PdCl 2 .dppf (123 mg) in THF/water (6.3 mL/6.3 mL) was heated to 100° C. under CO (800 psi) for 19 hours, cooled to room temperature, and diluted with water. The mixture was extracted with dichloromethane and the combined extracts were washed with water, dried (MgSO 4 ), filtered, and concentrated to provide the desired product (912 mg, 76%). MS (DCI/NH 3 ) m/e 396 (M+H) + .
  • Example 17A A solution of Example 17A (410 mg, 1.0 mmol), 4-aminopyridine (100 mg, 1.0 mmol), EDC (960 mg), and HOBt (680 mg) in DMF (10 mL) was stirred at room temperature overnight, diluted with dichloromethane, washed with water, dried (MgSO 4 ), filtered, and concentrated. The residue was purified by flash column chromatography on silica gel with ethyl acetate/methanol (8:1) to provide the desired product (87 mg, 18%). MS (DCI/NH 3 ) m/e 488 (M+H) + .
  • Example 18A A mixture of Example 18A (1.60 g, 6.3 mmol) and LiOH.H 2 O (2.64 g) in THF/water (50 mL/50 mL) was stirred at room temperature for 2 hours. The THF was removed under vacuum and the aqueous layer was acidified with 1N HCl (aq.). The solid was collected by filtration and dried to provide the desired product. MS (DCI/NH 3 ) m/e 227 (M+H) + .
  • Example 19A A mixture of Example 19A (2.0 g, 9.387 mmol) and SOCl 2 (3.5 mL, 47.9 mmol) in benzene (10 mL) was stirred at room temperature for 24 hours and concentrated to provide the desired product (2.167 g, 99%).
  • (DCI/NH 3 ) m/e 231, 233, 235 (M+H) + .
  • the desired product was prepared as the hydrochloride salt by substituting Example 9B and N-tert-butoxylcarbonylaminoethanol (200 mg, 1.00 mmol) for 3-bromo-5-hydroxypyridine and L-Boc-tryptophanol, respectively, in Examples 2A and 2C.
  • Example 19C 100 mg, 0.285 mmol
  • Example 19B (66.0 mg, 0.285 mmol)
  • triethylamine 250 ⁇ L, 1.79 mmol
  • DMF 5 mL
  • the aqueous layer was extracted three times with dichloromethane and the combined extracts were washed with water, dried (MgSO 4 ), filtered, and concentrated.
  • the residue was chromatographed on silica gel with dichloromethane/methanol/NH 4 OH (100:5:0.5) to provide the free base.
  • the material was treated with 2M HCl/Et 2 O to provide the hydrochloride salt (34.0 mg, 22%).
  • Example 20A A solution of Example 20A (247 mg, 0.600 mmol), ammonium formate (400 mg, 6.34 mmol) and 10% Pd/C (25 mg) in methanol (10 mL) was heated to reflux for 30 minutes, cooled to room temperature, filtered through diatomaceous earth (Celite®), and concentrated. The concentrate was purified by flash column chromatography on silica gel with ethyl acetate/hexanes (1:1) to provide the desired product (200 mg, 87%). MS (DCI/NH 3 ) m/e 382 (M+H) + .
  • Example 20B A solution of Example 20B (41.2 mg, 0.108 mmol) and 2-amino-4-chloropyrimidine (14.0 mg, 0.108 mmol) in ethanol (0.5 mL) was heated to 80° C. for 13 hours and purified by flash column chromatography on silica gel with dichloromethane/methanol/NH 4 OH (100:5:0.5) to provide the desired product (50 mg, 98%). MS (DCI/NH 3 ) m/e 475(M+H) + .
  • Example 21A A solution of Example 21A (1.0 g, 4.3 mmol) in 30% H 2 SO 4 (10 mL) at 0° C. was treated with NaNO 2 (386 mg, 5.6 mmol), stirred for 5 hours, treated with a solution of NaI (2.1 g, 14 mmol) in H 2 O (2 mL), stirred for 2 hours, treated with additional NaI (2.1 g, 14 mmol), stirred for 2 hours, poured into 30% NaOH (aq.) (200 mL) at 0° C. and extracted three times with 10% methanol/ethyl acetate. The combined organic phases were dried (MgSO 4 ), filtered, and concentrated.
  • Example 21C 100 mg, 0.35 mmol
  • THF 3 mL
  • 9-BBN 0.5 M solution in THF, 0.70 mL, 0.35 mmol
  • cannulated into a mixture of Example 21B 108 mg, 0.32 mmol
  • PdCl 2 (dppf) 26 mg, 0.032 mmol
  • Cs 2 CO 3 228 mg, 0.7 mmol
  • the mixture was treated with ethyl acetate (50 mL), washed with brine, dried (MgSO 4 ), filtered, and concentrated.
  • the residual oil was purified by flash column chromatography on silica gel with 80% ethyl acetate/hexanes to provide the desired product (69 mg, 40%).
  • Example 2A A solution of Example 2A (250 mg, 0.56 mmol) in ethylene glycol dimethyl ether (20.0 mL) at room temperature was treated with tetrakis(triphenylphosphine)palladium(0) (32 mg, 0.03 mmol), stirred for 10 minutes, treated with a solution of (4-cyanophenyl)boronic acid (123 mg, 0.84 mmol) in ethanol (5.0 mL), stirred for 15 minutes, treated with 2M Na 2 CO 3 (aq.) (1.4 mL), heated to reflux for 4 hours, cooled to room temperature, and concentrated.
  • tetrakis(triphenylphosphine)palladium(0) 32 mg, 0.03 mmol
  • 4-cyanophenyl)boronic acid 123 mg, 0.84 mmol
  • 2M Na 2 CO 3 aq.
  • Example 22A A solution of Example 22A (20 mg, 0.043 mmol) in dichloromethane (2.0 mL) at 0° C. was treated dropwise with trifluoroacetic acid (0.5 mL) and stirred for 2 hours while warming to room temperature. The reaction mixture was concentrated to provide the desired product as the trifluoroacetate salt (27 mg, 88%).
  • Example 23A 500 mg, 1.8 mmol
  • Example 23B 600 mg, 3.5 mmol
  • Pd 2 (dba) 3 42 mg; 0.045 mmol
  • BINAP 56 mg; 0.09 mmol
  • sodium tert-butoxide 350 mg; 3.6 mmol
  • the combined extracts were washed successively with saturated NaHCO 3 , water, and brine, dried (Na 2 SO 4 ), and concentrated.
  • the concentrate was purified by flash column chromatography on silica gel with 3% methanol/dichloromethane to provide the desired product (97 mg, 18%).
  • Example 23C A mixture-of Example 23C (175 mg, 0.58 mmol), benzophenone imine (150 mg, 0.83 mmol), Pd 2 (dba) 3 (54 mg, 0.06 mmol), BINAP (55 mg, 0.09 mmol), and sodium tert-butoxide (80 mg, 0.82 mmol) in 3 mL toluene was heated to 75-80° C. for 4 hours and concentrated. The concentrate was purified by flash column chromatography on silica gel with 3% methanol/dichloromethane to provide the desired product (150 mg, 64%).
  • Example 23D A mixture of Example 23D (145 mg; 0.36 mmol) in 3 mL THF at room temperature was treated with 10 drops of water and 3 drops of conc. HCl, stirred for 2 hours, and concentrated. The residue was partitioned between ethyl acetate and concentrated NaHCO 3 (aq). The aqueous layer was extracted three times with ethyl acetate. The combined extracts were washed with brine, dried (MgSO 4 ), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 10% methanol/dichloromethane to provide the desired product (59 mg, 68%).
  • Example 23E A mixture of Example 23E (55 mg, 0.23 mmol) and L-Boc-tryptophanal (84 mg, 0.29 mmol) in 2 mL dichloromethane at room temperature was treated with Ti(iPrO) 4 (1 mL), stirred for 2 hours, and concentrated. The residue was dissolved in 2 mL ethanol, treated with NaBH 3 CN (30 mg; 0.46 mmol), stirred for 2 hours, diluted with water, and filtered. The filter cake was washed with methanol and the filtrate was concentrated. The residue was suspended in methanol/dichloromethane and filtered. The filtrate was concentrated and the concentrate was purified by flash column chromatography on silica gel with 5% methanol/dichloromethane to provide the desired product (28 mg, 24%).
  • Example 23F A solution of Example 23F (26 mg, 0.05 mmol) in 2 mL dichloromethane at room temperature was treated with 0.5 mL TFA, stirred for 3 hours, and concentrated. The concentrate was purifed by reverse phase HPLC on a C18 column with 0-100% CH 3 CN/H 2 O/0.1% TFA and the residue was dissolved in water and lyophilized to provide the desired product as the trifluoroacetate salt (27 mg, 70%).
  • a sealed tube was charged with 5-hydroxyisoquinoline (0.15 g, 1.03 mmol), 3,5-dibromopyridine (0.24 g, 1.03 mmol), potassium carbonate (0.27 g, 2.0 mmol) and DMF (4 mL).
  • the reaction was heated to 240° C. for 10 minutes in a personal chemistry microwave.
  • the reaction was partitioned between water and ethyl acetate.
  • the aqueous layer was extracted twice with ethyl acetate.
  • the combined extracts were concentrated and the residue was purified by flash column chromatography on silica gel with 2:1 ethyl acetate/hexanes to provide the desired product (0.071 g, 23%).
  • Example 25A A mixture of Example 25A (11.4 g, 64 mmol) in 200 mL THF was cooled to ⁇ 78° C., treated with 1.6 M nBuLi in hexanes (100 mL, 160 mmol), warmed to 0 ° C., stirred for 1 hour, treated with a solution of DMF (22 g, 215 mmol) in 100 mL THF, warmed to room temperature, stirred for 1 hour, diluted with brine, and extracted three times with ethyl acetate. The combined extracts were washed with water, washed twice with brine, dried (MgSO 4 ), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 3% methanol/dichloromethane to provide the desired product (9.1 g, 69%).
  • Example 25B A solution of Example 25B (870 mg, 4.2 mmol) in 3N HCl (aq.) (10 mL) was heated to reflux overnight, and extracted three times with diethyl ether. The aqueous layer was adjusted to pH>7 with solid K 2 CO 3 and extracted six times with 20% isopropanol/chloroform. The combined extracts were dried (Na 2 SO 4 ), filtered, and concentrated to provide the desired product (450 mg; 87%).
  • Example 25C 450 mg, 3.68 mmol
  • Example 25D 605 mg, 3.68 mmol
  • 20 mL ethanol and 1.2 mL of 10% NaOH (aq) was heated to reflux for 3 hours and concentrated.
  • the solid was collected and rinsed with ethyl acetate to provide the desired product (740 mg, 80%).
  • Example 25F 100 mg, 0.45 mmol
  • L-Boc-tryptophan 150 mg, 0.49 mmol
  • Example 16A Boc-homophenylalanine
  • Example 27A (0.25 g, 0.86 mmol) and Example 2A (0.444 g, 1.00 mmol) in 6 mL of DMF was treated with Pd 2 (dba) 3 (0.08 g, 0.086 mmol), tri-o-tolylphosphine (0.02 g, 0.04 mmol), and triethylamine (0.15 mL, 1.0 mmol), heated to 75° C. in a sealed tube for 8 hours, and concentrated. The residue was purified by flash column chromatography on silica gel with 2.5% methanol/dichloromethane to provide the desired product (0.125 g, 30%).
  • Example 27B A solution of Example 27B (0.125 g, 0.25 mmol) in dichloromethane (3 mL) at room temperature was treated with TFA (400 ⁇ L), stirred for 1 hour, and concentrated. The concentrate was azeotropically distilled with diethyl ether two times and the residue was purified by reverse phase HPLC on a C18 column with 0-100% CH 3 CN/H 2 O/0.1% TFA to provide the desired product as the di-trifluoroacetate salt (0.110 g, 70%).
  • the desired product was prepared by substituting D-Boc-tryptophanol for L-Boc tryptophanol in Example 2A.
  • Example 2A A solution of Example 2A (1 g, 2.23 mmol) in DMA (15 mL) was treated with hexamethylditin (1.8 mL, 5.6 mmol) and Pd(PPh 3 ) 4 (0.4 g, 0.2 mmol), heated to 75° C. for 1.5 days, added to water, and extracted three times with ethyl acetate. The combined extracts were concentrated and the residue was purified by flash column chromatography on silica gel with 1:1 hexanes/ethyl acetate to provide the desired product (0.4 g, 34%).
  • Example 32A 0.2 g, 0.31 mmol
  • 6-bromophthalimide 0.084 g, 0.4 mmol
  • DMF dimethyl methyl
  • Pd 2 dba 3 0.02 mmol
  • tri-o-tolylphosphine 0.2 g, 0.01 mmol
  • triethylamine 0.06 mL, 0.4 mmol
  • the reaction was heated to 75° C. for 6 hours in a sealed tube and concentrated.
  • the residue was purified by flash column chromatography on silica gel with 1:1 hexanes/ethyl acetate to provide the desired product (0.116 g, 55%).
  • Example 33A A solution of Example 33A (1.02 g, 4.47 mmol) in CCl 4 (22 mL) was treated with AIBN (0.065 g, 0.4 mmol) and NBS (0.955 g, 5.4 mmol), heated to reflux for 4 hours, washed with water, dried (Na 2 SO 4 ), filtered, and concentrated to provide the desired product (1.1 g, 79%).
  • Example 33B A solution of Example 33B (1.1 g, 3.57 mmol) in THF (20 mL) at room temperature was treated with 1N NH 3 in methanol (7.14 mL, 7.14 mmol), stirred for 24 hours, and filtered. The filter cake was washed with diethyl ether (100 mL) to provide the desired product (0.4 g, 52%).
  • Example 34A (6.5 g, 37 mmol) in acetic acid (100 mL) at room temperature was treated with Br 2 (4 mL, 84 mmol), stirred for 1 hour and 15 minutes, poured into water (200 mL), and filtered. The solid was washed with water (2 ⁇ 100 mL), and hexanes (2 ⁇ 100 mL), dissolved in diethyl ether, washed with brine (50 mL), and concentrated to provide the desired product (8.5 g, 89%).
  • Example 34B A solution of Example 34B (6.28 g, 24.4 mmol) in THF (75 mL) was treated with concentrated HCl (aq.) (15 mL) and water (15 mL), heated to reflux for 1 hour, and concentrated to remove the THF.
  • the aqueous solution was treated with additional water (5 mL) and concentrated HCl (5 mL), cooled to 0° C., treated with a solution of NaNO 2 (1.85 g, 26.84 mmol) in water (10 mL) in 5 portions, warmed to room temperature gradually over a 2-hour period, and stirred overnight at room temperature.
  • the reaction was heated to reflux for 6 hours, and filtered.
  • the solid was washed with water (50 mL) and diethyl ether (50 mL) and dried under vacuum to provide the desired product (3.0 g, 54%).
  • Example 34C A solution of Example 34C (0.4 g, 1.8 mmol) in POCl 3 (2.5 mL) was heated to 100° C. for 2 hours, and poured slowly onto ice. The aqueous layer was cooled to 0° C. and adjusted to pH 5-7 with 50% NaOH. The aqueous layer was extracted with ethyl acetate (2 ⁇ 50 mL), and the combined organic layers were concentrated. The residue was purified by flash column chromatography on silica gel with 4:1 hexanes/ethyl acetate to provide the desired product (0.190 g, 43%).
  • Example 34D A solution of Example 34D (2.6 g, 10.6 mmol) in ethanol (70 mL) was treated with hydrazine monohydrate (3 mL, 90% solution), stirred at room temperature for 3 days, and filtered. The solid washed with water (50 mL) and diethyl ether (50 mL) and dried under vacuum to provide the desired product (2.5 g, 100%).
  • Example 34E A solution of Example 34E (3.5 g, 14 mmol) in water (50 mL) was heated to reflux, treated dropwise with a solution of CuSO 4 (2.8 g, 17.5 mmol) in water (20 mL), refluxed for 2 hours, cooled to room temperature, adjusted to pH 7 with saturated NaHCO 3 (aq), and extracted with ethyl acetate (2 ⁇ 25 mL). The combined extracts were concentrated and the residue was purified by flash column chromatography on silica gel with 1:1 hexanes/ethyl acetate to provide the desired product (0.7 g, 24%).
  • the desired product was prepared by as the trifluoroacetate salt substituting 5-bromo-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one for 6-bromophthalimide (L. Sun, et al., J. Med. Chem., 1998, 41, 2588.) in Example 32.
  • Example 41A A solution of Example 41A (5.46 g, 21.3 mmol) and 3,5-dibromopyridine (5.03 g, 21.3 mmol) in DMF (25 mL) at room temperature was treated with NaH (60% in mineral oil, 1.08 g, 25.6 mmol) in several portions. The reaction was stirred at room temperature for 20 minutes, heated to 60° C. for 2 hours, and poured into water. The aqueous layer was extracted with diethyl ether and the combined extracts were washed with water, dried (MgSO 4 ), filtered, and concentrated.
  • Example 41C A mixture of Example 41C (159 mg, 0.345 mmol), RaNi 2800 (525 mg), ammonia (2 mL), and triethylamine (2 mL) in methanol (20 mL) was stirred under hydrogen (60 psi) at room temperature for 73 hours and concentrated. The residue was triturated with ethyl acetate and methanol. The resulting solid was dissolved in trifluoroacetic acid (1 mL), stirred for 5 minutes at room temperature, and concentrated. The residue was purified by HPLC on a C18 column with 0-100% CH 3 CN/H 2 O/0.1% TFA to provide the desired product as the trifluoroacetate salt (64 mg, 26%).
  • Example 43A A solution of Example 43A (1.5 g, 5.6 mmol) in nitrobenzene (10 mL) was refluxed for 5 minutes, filtered, cooled to room temperature and filtered again. The solid was washed with hexanes and dried to provide the desired product (0.68 g, 55%). MS (DCI/NH 3 ) m/e 225 (M+H) + .
  • Example 43B The desired product was prepared by substituting Example 43B for 3-bromo-5-hydroxypyridine in Example 2A. Purification by flash column chromatography on silica gel with 100% ethyl acetate provided the desired product (0.89 g, 72%). MS (DCI/NH 3 ) m/e 497 (M+H) + .
  • Example 43C A mixture of Example 43C (0.33 g, 0.67 mmol), pyridine-4-boronic acid (0.13 g, 0.99 mmol), cesium floride (0.2 g, 1.34 mmol) and tetrakistriphenylphosphine palladium (0.038 g, 0.034 mmol) in DMF (10 mL) was stirred at 100° C. for 8 hours, treated with ethyl acetate (10 mL), washed with brine, dried (MgSO 4 ), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 10% methanol/dichloromethane to provide the desired product (0.25 g, 76%). MS (DCI/NH 3 ) m/e 495 (M+H) + .
  • Example 22 To a solution of Example 22 (200 mg, 0.43 mmol) in toluene (7.0 ml) and methanol (0.5 ml) were added hydroxylamine hydrochloride (33 mg, 0.48 mmol) and potassium tert-butoxide (54 mg, 0.48 mmol) and the mixture was stirred for 8 h at room temperature under a nitrogen atmosphere. Another portion of hydroxylamine hydrochloride (33 mg, 0.48 mmol) and potassium tert-butoxide (54 mg, 0.48 mmol) was added and the mixture was heated to 80° C. for 16 h. The mixture was concentrated and purified by column chromatography on silica gel using dichloromethane/methanol (15:1) as solvent system. Obtained were 130 mg (61%) of the product as a white powder.
  • Example 75C 4-vinylpyridine in Example 2B.
  • Purification on silica gel eluting with 100% ethyl acetate provided the title compound (0.15 g, 49%).
  • Example 80A A suspension solution of Example 80A (1.5 g, 6.2 mmol) in POCl 3 (40 ml) was treated with PCl 5 (1.55 g, 7.4 mmol) and introduced HCl gas until solution was saturated. The reaction was stirred at 60° C. for 6 hours and concentrated under vacumm.
  • Example 80B A mixture of Example 80B (1.8 g, 6.5 mmol), P (0.48 g, 15.5 mmol) and HI (3 ml, 48%) in acetic acid (20 ml) was refluxed for 8 hours, filtrated under hot condition and concentrated under vacumm. The residue was basified by adding sodium hydroxide solution, treated with ethyl acetate (200 mL), washed with brine, dried (MgSO 4 ), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 30% ethyl acetate/hexane to provide the title compound (0.81 g, 50%). MS (DCI/NH 3 ) m/e 244 (M+H) + .
  • Example 80D for Example 27A in Example 27B.
  • Example 89A A suspension of Example 89A (439 mg, 1.58 mmol), (BOC) 2 O (1.040 g, 4.77 mmol), DMAP (50 mg, 0.41 mmol), and triethylamine (670 ⁇ L, 4.81 mmol) in THF (10 mL) was stirred at rt overnight. Reaction was concentrated and chromatographed on silica gel eluting with AcOEt:hexane (1:1) to give the title compound (511 mg, 68%). MS (DCI/NH 3 ) m/z 477, 479(M+1).
  • Example 89B was converted to the title compound according to the procedures described for Example 51, Steps 4 and 5. MS (DCI/NH 3 ) m/z 314(M+1) + .
  • Example 90B A solution of Example 90B (616 mg, 2.76 mmol), BOC 2 O (1.81 g), DMAP (67 mg), and triethylamine (1.15 mL) in acetonitrile (15 mL) was stirred at rt for 2 h. The reaction was concentrated and the residue was chromatographed on silica gel eluting with AcOEt:hexane (3:7) to give the title compound (1.18 g, 71%). MS (DCI/NH 3 ) m/z 423 (M+1) + .
  • the desired product was prepared by substituting 5-bromo-2-fluorobenzonitrile for 6-bromoisoquinoline in Example 27A.
  • Example 97A for in Example 27A in Example 27B.
  • Example 97B 120 mg, 0.25 mmol
  • 98% hydrazine 5 mL
  • poured over ice diluted with brine
  • extracted with ethyl acetate dried over MgSO 4 , and concentrated.
  • Purification by flash chromatography (7% MeOH/CH 2 Cl 2 ) provided the desired product (103 mg, 84%).
  • Example 27C A solution of Example 27C (175 mg, 0.35 mmol), N-Boc-glycine (91 mg, 0.52 mmol), EDC (100 mg), iPr 2 EtN (0.30 mL) and DMAP (10 mg) in CH 2 Cl 2 (7 mL) was stirred at room temperature overnight, diluted with EtOAc, washed with water and brine, dried (MgSO 4 ), filtered, and concentrated. The residue was purified by flash column chromatography on silica gel with 3% methanol/CH 2 Cl 2 to provide the desired product (112 mg, 58%).
  • Example 102A A solution of Example 102A (26.6 g; 121 mmol) and manganese(IV) oxide (53 g; 610 mmol) in p-dioxane (500 mL) was heated at reflux for 4 hrs., cooled, filtered through Celite®, evaporated, and purified by flash chromatography (5-10% Et 2 O/hexane) to yield the desired product as a nearly colorless oil that solidified upon standing (20.5 g; 78%).
  • Example 102C A mixture of Example 102C (10.08 g, 47.8 mmol), hexamethyl-di-tin 2 (18 g, 55 mmol) and tetrakis(triphenylphosphine)palladium (5.5 g, 4.8 mmol) in toluene (100 ml) was stirred at 95° C. for 6 h. The mixture was then evaporated and the residue was taken into ethyl acetate (300 ml), washed with saturated sodium bicarbonate (100 ml), water (100 ml) and brine (100 ml).
  • Example Example 102D was prepared by substituting Example 27A in Example 27B.
  • Example 103A (665 mg; 3.0 mmol) in thionyl chloride (7 mL) was heated at reflux for 2 hrs., concentrated, and azeotroped with toluene to give a colorless oil that was carried on with no further purification.
  • Example 103C for Example 102B in Example 102C.
  • the desired product was prepared as the trifluoroacetate salt by substituting N-[2-trimethylsilanyl)ethoxy ⁇ methyl)-2-imidazolyl lithium chloride for methyl magnesium bromide in Example 102 without doing the last step.
  • Example 109A 40 mg; 0.06 mmol
  • MeOH 4 mL
  • conc. HCl 1 mL
  • heated at reflux for 6 hrs. concentrated and purified by reverse phase HPLC on a C18 column with 0-100% CH 3 CN/H 2 O/0.1% TFA to provide the desired product as the trifluoroacetate salt.
  • Example 35A The reaction between Example 35A and morpholine was carried out according to the procedure described by U. Wrstonono, K. Majewska, J. Dudzinska-Usarewicz, M. Bemas, Pharmzie, 1986, 41, 472-474.
  • Example 102C (500 mg; 2.37 mmol) was added to a mixture of 60% NaH (115 mg; 2.84 mmol) in DMF (10 mL). After 15 min. at r.t. iodomethane (456 mg; 3.21 mmol) was added, the reaction was stirred for 2 hrs then diluted with water and extracted with EtOAc. The extracts were rinsed with water and brine, dried (MgSO 4 ), evaporated, and isolated by flash chromatography (1:1 Et 2 O:hexane) to give the desired product (360 mg; 67%).
  • Example 35A The reaction between Example 35A and N-methyl piperazine was carried out according to the procedure described by U. Wrstonono, K. Majewska, J. Dudzinska-Usarewicz, M. Bemas, Pharmzie, 1986, 41, 472-474.
  • Example 35A The reaction between Example 35A and dimethylamine was carried out according to the procedure described by U. Wrstonono, K. Majewska, J. Dudzinska-Usarewicz, M. Bemas, Pharmzie, 1986, 41, 472-474.
  • Example 116A (0.03 g, 0.06 mmol) in 2 mL of MeOH was cooled to 0° C. then treated with aniline (0.018 g 0.2 mmol), NaBH 3 CN (0.004 g, 0.06 mmol) and AcOH (1 ml). The mixture was allowed to warm to room temperature overnight. The mixture was diluted with ethyl acetate (20 ml), washed with water (10 ml) and brine (10 ml). The ethyl acetate was evaporated off and the residue was used without further purification.
  • Example 116A (0.03 g, 0.06 mmol) was dissolved in 2 mL of MeOH and cooled to 0° C., then treated with NaBH 4 (0.003 g, 0.08 mmol). The mixture was allowed to warm to room temperature over 2 h. The mixture was diluted with ethyl acetate (20 ml), washed with water (10 ml) and brine (10 ml). The ethyl acetate was evaporated off and the residue was used without further purification.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds having the formula
Figure US20030187026A1-20031002-C00001
are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.

Description

  • This application is a continuation-in-part of U.S. patent application Ser. No. 10/023,363, filed Dec. 13, 2001, which is hereby incorporated by reference.[0001]
    • TECHNICAL FIELD
  • The present invention relates to compounds which are useful for inhibiting protein kinases, methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds. [0002]
    • BACKGROUND OF THE INVENTION
  • Protein kinases have been clearly shown to be important in the progression of many disease states that are induced by the inappropriate proliferation of cells. These kinases are often found to be up-regulated in many hyperproliferative states such as cancer. These kinases may be important in cell signaling, where their inappropriate activation induces cells to proliferate (e.g. EGFR, ERBB2, VEGFR, FGFR, PDGFR, c-Met, IGF-1R, RET, TIE2). Alternatively, they may be involved in signal transduction within cells (e.g. c-Src, PKC, Akt, PKA, c-Abl, PDK-1). Often these signal transduction genes are recognized proto-oncogenes. Many of these kinases control cell cycle progression near the G1-S transition (e.g. Cdk2, Cdk4), at the G2-M transition (e.g. Wee1, Myt1, Chk1, Cdc2) or at the spindle checkpoint (Plk, Aurora1 or 2, Bub1 or 3). Furthermore, kinases are intimately linked to the DNA damage response (e.g. ATM, ATR, Chk1, Chk2). Disregulation of these cellular functions; cell signaling, signal transduction, cell cycle control, and DNA repair, are all hallmarks of hyperproliferative diseases, particularly cancer. It is therefore likely that pharmacological modulation of one or more kinases would be useful in slowing or stopping disease progression in these diseases. [0003]
    • SUMMARY OF THE INVENTION
  • In its principle embodiment the present invention provides a compound of formula (I) [0004]
    Figure US20030187026A1-20031002-C00002
  • or a therapeutically acceptable salt thereof, wherein [0005]
  • X is selected from the group consisting of C(R[0006] 8) and N; wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido;
  • X′ is selected from the group consisting of C and N; [0007]
  • Y is selected from the group consisting of C and N; [0008]
  • Y′ is selected from the group consisting of C(R[0009] 9) and N; wherein R9 is selected from the group consisting of hydrogen and -L2-L3(R3)(R6);
  • Z is selected from the group consisting of C and N; [0010]
  • provided that 0, 1, or 2 of X, X′, Y, Y′, and Z are N; [0011]
  • L[0012] 1 is selected from the group consisting of a bond, —O—, —NR5—, alkenyl, alkynyl, —C(O)—, —S—, —S(O)—, —S(O)2—, —S(O)2N(R5)—, —N(R5)S(O)2—, —C(R12)2—, —C(R12)2N(R5)—, —N(R5)C(O)—, and —C(O)N(R5)—; wherein each group is drawn with its left end attached to R1 and its right end attached to the aromatic ring;
  • L[0013] 2 is selected from the group consisting of a bond, —O—, —C(R12)2—, —S—, —N(R5)—, —N(R5)C(O)—, and —C(O)N(R5)—;
  • L[0014] 3 is selected from the group consisting of a bond, alkylidene and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of alkoxy, amino, cyano, and hydroxy;
  • R[0015] 1 is selected from the group consisting of aryl, heteroaryl, and heterocycle;
  • R[0016] 2 and R4 are independently absent or selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, arylalkynyl, cyano, cyanoalkenyl, halo, heteroaryl, heterocycle, hydroxyalkyl, and nitro; or
  • R[0017] 2 and L1, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle; or
  • R[0018] 4 and L2, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle; provided that when L3 is alkylidene, R4 and L2, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle;
  • R[0019] 3 is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;
  • R[0020] 6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;
  • provided that when L[0021] 1 and L2 are bonds, at least one of R3 and R6 is other than hydrogen;
  • R[0022] 5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl;
  • R[0023] 7 is absent or selected from the group consisting of hydrogen, alkyl, cyanoalkenyl, and -L2-L3(R3)(R6); or
  • R[0024] 7 and L1, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle; and
  • each R[0025] 12 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo, heteroaryl, heterocycle, and nitro.
  • In another embodiment the present invention provides a compound of formula (II) [0026]
    Figure US20030187026A1-20031002-C00003
  • or a therapeutically acceptable salt thereof, wherein [0027]
  • L[0028] 1 is selected from the group consisting of a bond, —O—, —N(R5)—, alkenyl, alkynyl, —N(R5)C(O)—, and —C(O)N(R5)—;
  • L[0029] 2 is selected from the group consisting of a bond, —O—, —N(R5)—, —N(R5)C(O)—, and —C(O)N(R5)—;
  • L[0030] 3 is selected from the group consisting of a bond, alkylidene, and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of amino, cyano, and hydroxy;
  • R[0031] 1 is selected from the group consisting of aryl, heteroaryl, and heterocycle;
  • R[0032] 2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl; wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; or
  • R[0033] 2 and L1, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, pyrazolyl, and phenyl; or
  • R[0034] 4 and L2, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, phenyl, pyridinyl, and pyrrolyl; wherein the ring can be optionally substituted with oxo;
  • provided that when L[0035] 3 is alkylidene, R4 and L2, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, phenyl, pyridinyl, and pyrrolyl; wherein the ring can be optionally substituted with oxo;
  • R[0036] 3 is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;
  • R[0037] 6 are independently selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, and heteroarylalkoxy, heteroaryloxy, and heterocycle;
  • provided that when L[0038] 1 and L2 are bonds, at least one of R3 and R6 is other than hydrogen;
  • R[0039] 5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; and
  • X is selected from the group consisting of C(R[0040] 8) and N; wherein R8 is selected from the group consisting of hydrogen, amino, carboxy, cyano, and halo.
  • In another embodiment the present invention provides a compound of formula (III) [0041]
    Figure US20030187026A1-20031002-C00004
  • or a therapeutically acceptable salt thereof, wherein [0042]
  • L[0043] 1 is selected from the group consisting of a bond, —O—, —N(R5)—, alkenyl, alkynyl, and —N(R5)C(O)—;
  • L[0044] 2 is selected from the group consisting of a bond, —O—, —N(R5)—, —N(R5)C(O)—, and —C(O)N(R5)—;
  • L[0045] 3 is alkylene, wherein the alkylene is substituted with one or two substituents independently selected from the group consisting of amino and hydroxy;
  • R[0046] 1 is selected from the group consisting of aryl, heteroaryl, and heterocycle;
  • R[0047] 2 and R4 are independently selected from the group consisting of hydrogen and halo;
  • R[0048] 3 and R6 are independently selected from the group consisting of hydrogen, aryl, arylalkoxy, and heteroaryl; provided that when L1 and L2 are bonds, at least one of R3 and R6 is other than hydrogen; and
  • R[0049] 5 is selected from the group consisting of hydrogen and alkyl.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0050] 8) and N, wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is alkenyl; L2 is selected from the group consisting of a bond, —O—, —C(R12)2—, —S—, —N(R5)—, —N(R5)C(O)—, and —C(O)N(R5)—; L3 is a bond or selected from the group consisting of alkylidene and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is selected from the group consisting of aryl, heteroaryl, and heterocycle; R2 and R4 are independently absent or selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, arylalkynyl, cyano, cyanoalkenyl, halo, heteroaryl, heterocycle, hydroxyalkyl, and nitro; R3 is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl; and each R12 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo, heteroaryl, heterocycle, and nitro.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0051] 8) and N, wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is alkenyl; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0052] 8) and N, wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is alkenyl; L2 is —O—; L1 is alkenyl; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R[0053] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is alkenyl; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is heteroaryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; and X′ is C; Y is C; Y′ is C(R[0054] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is alkenyl; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is aryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0055] 8) and N, wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; and X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is alkenyl; L2 is —O—; L3 is a bond; R1 is heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is absent; R6 is heterocycle; and R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R[0056] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is alkenyl; L2 is —O—; L3 is a bond; R1 is heteroaryl; R2 and R4 are hydrogen; R3 is absent; R6 is heterocycle; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0057] 8) and N, wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is alkenyl; L2 is —N(R5)C(O)—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; and X′ is C; Y is C; Y′ is C(R[0058] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is alkenyl; L2 is —N(R5)C(O)—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is heteroaryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R[0059] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is alkenyl; L2 is —N(R5)C(O)—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is aryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0060] 8) and N, wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is alkynyl; L2 is selected from the group consisting of a bond, —O—, —C(R12)2—, —S—, —N(R5)—, —N(R5)C(O)—, and —C(O)N(R5)—; L3 is a bond or selected from the group consisting of alkylidene and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is selected from the group consisting of aryl, heteroaryl, and heterocycle; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, arylalkynyl, cyano, cyanoalkenyl, halo, heteroaryl, heterocycle, hydroxyalkyl, and nitro; R3 is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl; and each R12 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo, heteroaryl, heterocycle, and nitro.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0061] 8) and N, wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is alkynyl; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0062] 8) and N, wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is a bond; L2 is selected from the group consisting of a bond, —O—, —C(R12)2—, —S—, —N(R5)—, —N(R5)C(O)—, and —C(O)N(R5)—; L3 is a bond or selected from the group consisting of alkylidene and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is selected from the group consisting of aryl, heteroaryl, and heterocycle; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, arylalkynyl, cyano, cyanoalkenyl, halo, heteroaryl, heterocycle, hydroxyalkyl, and nitro; R3 is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl; and each R12 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo, heteroaryl, heterocycle, and nitro.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0063] 8) and N, wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; and X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is a bond; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R[0064] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is a bond; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is aryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R[0065] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is a bond; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is heteroaryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0066] 8) and N, wherein R8 is hydrogen; X′ is N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is a bond; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is heteroaryl; and R7 is absent.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is N; Y′ is C(R[0067] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is a bond; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R2 is absent; R4 is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is aryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is N; Y′ is C(R[0068] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is a bond; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R2 is absent; R4 is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is heteroaryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is C(R[0069] 8), wherein R8 is hydrogen; X′ is C; Y is N; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is a bond; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R2 is absent; R4 is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is aryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is C(R[0070] 8), wherein R8 is hydrogen; X′ is C; Y is N; Y′ is C(R9), wherein R is -L2-L3(R3)(R6); Z is C; L1 is a bond; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R2 is absent; R4 is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is heteroaryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is C(R[0071] 8), wherein R8 is hydrogen; X′ is C; Y is N; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is N; L1 is a bond; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R4 is absent; R2 is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is aryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is C(R[0072] 8), wherein R8 is hydrogen; X′ is C; Y is N; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is N; L1 is a bond; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R4 is absent; R2 is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is heteroaryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is N; Y′ is C(R[0073] 9), wherein R9 is -L2-L3(R3)(R6); Z is N; L1 is a bond; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R4 is absent; R2 is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is aryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is N; Y′ is C(R[0074] 9), wherein R9 is -L2-L3(R3)(R6); Z is N; L1 is a bond; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R4 is absent; R2 is selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is heteroaryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0075] 8) and N, wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is —C—; L1 is a bond; L2 is —N(R5)—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R[0076] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is a bond; L2 is —N(R5)—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R6 is heteroaryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R[0077] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is a bond; L2 is —N(R5)—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R6 is aryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0078] 8) and N, wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is a bond; L2 is —N(R5)C(O)—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R[0079] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is a bond; L2 is —N(R5)C(O)—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is heteroaryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R[0080] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is a bond; L2 is —N(R5)C(O)—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R6 is aryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0081] 8) and N, wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is —N(R5)—; L2 is selected from the group consisting of a bond, —O—, —C(R12)2—, —S—, —N(R5)—, —N(R5)C(O)—, and —C(O)N(R5)—; L3 is a bond or selected from the group consisting of alkylidene and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is selected from the group consisting of aryl, heteroaryl, and heterocycle; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, arylalkynyl, cyano, cyanoalkenyl, halo, heteroaryl, heterocycle, hydroxyalkyl, and nitro; R3 is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl; and each R12 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino; aryl, cyano, halo, heteroaryl, heterocycle, and nitro.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0082] 8) and N, wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is —N(R5)—; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R[0083] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is —N(R5)—; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R6 is heteroaryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R[0084] 9), wherein R9 is L1-L3(R3)(R6); Z is C; L1 is —N(R5)—; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is hydrogen; R5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R6 is aryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0085] 8) and N, wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is a bond; L2 is a bond; L3 is a bond; R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R3 is absent; R6 is heterocycle; and R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0086] 8) and N; wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is selected from the group consisting of a bond, —O—, —N(R5)—, alkenyl, alkynyl, —C(O)—, —S—, —S(O)—, —S(O)2—, —S(O)2N(R5)—, —N(R5)S(O)2—, —C(R12)2—, —C(R12)2N(R5)—, —N(R5)C(O)—, and —C(O)N(R5)—, wherein each group is drawn with its left end attached to R1 and its right end attached to the aromatic ring; L3 is alkylidene, wherein the alkylidene is optionally substituted with one or two substituents independently selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is selected from the group consisting of aryl, heteroaryl, and heterocycle; R4 and L2, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle; R3 is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; R5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl; and each R12 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo, heteroaryl, heterocycle, and nitro.
  • In another embodiment, the present invention provides a compound of formula (1) wherein X is selected from the group consisting of C(R[0087] 8) and N, wherein R8 is hydrogen; X′ is C; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; L1 is a bond; L3 is alkylidene, wherein the alkylidene is substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl wherein the heteroaryl is isoquinolinyl; R4 and L2, together with the carbon atoms to which they are attached, form a heterocycle wherein the heterocycle is pyrrolidinyl substituted with oxo; R3 is hydrogen; R6 is heteroaryl, wherein the heteroaryl is indolyl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0088] 8) and N; wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; and X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; R2 and L1, together with the carbon atoms to which they are attached, form a ring that is aryl wherein the aryl ring is phenyl; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R3 is absent; R6 is heteroaryl; and R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R[0089] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; R2 and L1, together with the carbon atoms to which they are attached, form a ring that is aryl wherein the aryl ring is phenyl; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R3 is absent; R6 is heteroaryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; X′ is C; Y is C; Y′ is C(R[0090] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; R2 and L1, together with the carbon atoms to which they are attached, form a ring that is aryl wherein the aryl ring is phenyl; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R3 is absent; R6 is aryl; and R7 is hydrogen.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0091] 8) and N; wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X′ is selected from the group consisting of C and N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; R2 and L1, together with the carbon atoms to which they are attached, form a ring that is heteroaryl wherein the heteroaryl is pyrazolyl; L2 is a bond; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R3 is hydrogen; R6 is selected from the group consisting of aryl, heterocycle, and heteroaryl; and R7 is absent or selected from the group consisting of hydrogen, alkyl, and cyanoalkenyl.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is C(R[0092] 8), wherein R8 is hydrogen; X′ is N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; R2 and L1, together with the carbon atoms to which they are attached, form a ring that is heteroaryl wherein the heteroaryl is pyrazolyl; L2 is a bond; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R3 is hydrogen; R6 is aryl; and R7 is absent.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is C(R[0093] 8), wherein R8 is hydrogen; X′ is N; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; R2 and L1, together with the carbon atoms to which they are attached, form a ring that is heteroaryl wherein the heteroaryl is pyrazolyl; L2 is a bond; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is aryl; R3 is hydrogen; R6 is aryl; and R7 is absent.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is selected from the group consisting of C(R[0094] 8) and N; wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido; X is C; Y is C; Y′ is C(R9), wherein R9 is -L2-L3(R3)(R6); Z is C; R7 and L1, together with the carbon atoms to which they are attached, form a ring selected from the group consisting aryl, heteroaryl and heterocycle; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is selected from the group consisting of aryl, heterocycle, and heteroaryl; R3 is hydrogen; and R6 is selected from the group consisting of aryl, heterocycle, and heteroaryl.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; and X′ is C; Y is C; Y′ is C(R[0095] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; R7 and L1, together with the carbon atoms to which they are attached, form a ring that is a heteroaryl wherein the heteroaryl is pyridinyl; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R3 is hydrogen; and R6 is heteroaryl.
  • In another embodiment, the present invention provides a compound of formula (I) wherein X is N; and X′ is C; Y is C; Y′ is C(R[0096] 9), wherein R9 is -L2-L3(R3)(R6); Z is C; R7 and L1, together with the carbon atoms to which they are attached, form a ring that is a heteroaryl wherein the heteroaryl is pyridinyl; L2 is —O—; L3 is alkylene, wherein the alkylene is optionally substituted with one substituent selected from the group consisting of alkoxy, amino, cyano, and hydroxy; R1 is heteroaryl; R3 is hydrogen; and R6 is aryl.
  • In another embodiment the invention provides a pharmaceutical composition comprising a compound of formula (I), or a therapeutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier. [0097]
  • In another embodiment the invention provides a method of inhibiting protein kinases in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I), or a therapeutically acceptable salt thereof. [0098]
    • DETAILED DESCRIPTION OF THE INVENTION
  • As used in the present specification the following terms have the meanings indicated: [0099]
  • The term “alkenyl,” as used herein, refers to a group derived from a straight or branched chain hydrocarbon of up to six atoms containing at least one double bond. [0100]
  • The term “alkoxy,” as used herein, refers to an alkyl group attached to the parent molecular moiety through an oxygen atom. [0101]
  • The term “alkoxyalkyl,” as used herein, refers to an alkoxy group attached to the parent molecular moiety through an alkyl group. [0102]
  • The term “alkoxycarbonyl,” as used herein, refers to an alkoxy group attached to the parent molecular moiety through an alkyl group. [0103]
  • The term “alkyl,” as used herein, refers to a group derived from a straight or branched chain saturated hydrocarbon of one to six atoms. [0104]
  • The term “alkylene,” as used herein, refers to a divalent group derived from a straight or branched chain saturated hydrocarbon of one to six atoms. [0105]
  • The term “alkylcarbonyl,” as used herein, refers to an alkyl group attached to the parent molecular moiety through a carbonyl group. [0106]
  • The term “alkylidene,” as used herein, refers to an alkenyl group in which one carbon atom of the carbon-carbon double bond belongs to the moiety to which the alkenyl group is attached. [0107]
  • The term “alkylsulfonyl,” as used herein, refers to an alkyl group attached to the parent molecular moiety through a sulfonyl group. [0108]
  • The term “alkynyl,” as used herein, refers to a group derived from a straight or branched chain hydrocarbon of two to six atoms containing at least one triple bond. [0109]
  • The term “amido,” as used herein, refers to an amino group attached to the parent molecular moiety through a carbonyl group. [0110]
  • The term “amino,” as used herein, refers to —NR[0111] aRb, wherein Ra and Rb are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, aryl, arylalkenyl, arylalkyl, cycloalkyl, haloalkylcarbonyl, (NRcRd)alkylcarbonyl, heteroaryl, heteroarylalkenyl, heteroarylalkyl, heterocycle, (heterocycle)alkenyl, and (heterocycle)alkyl, wherein the aryl, the aryl part of the arylalkenyl, the arylalkyl, the heteroaryl, the heteroaryl part of the heteroarylalkenyl and the heteroarylalkyl, the heterocycle, and the heterocycle part of the (heterocycle)alkenyl and the (heterocycle)alkyl can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, nitro, and oxo.
  • The term “aminoalkyl,” as used herein, refers to an amino group attached to the parent molecular moiety through an alkyl group. [0112]
  • The term “aryl,” as used herein, refers to a phenyl group, or a bicyclic or tricyclic fused ring system wherein one or more of the fused rings is a phenyl group. Bicyclic fused ring systems are exemplified by a phenyl group fused to a cycloalkyl group, as defined herein, or another phenyl group. Tricyclic fused ring systems are exemplified by a bicyclic fused ring system fused to a cycloalkyl group, as defined herein, or another phenyl group. Representative examples of aryl include, but are not limited to, anthracenyl, azulenyl, fluorenyl, indanyl, indenyl, naphthyl, phenyl, and tetrahydronaphthyl. The aryl groups of the present invention can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylthio, amino, aminoalkyl, a second aryl group, arylalkoxy, arylalkyl, arylcarbonyl, carboxy, cyano, cycloalkyl, halo, haloalkoxy, haloalkyl, heteroaryl, heteroarylalkoxy, heteroarylalkyl, heterocycle, (heterocycle)alkoxy, (heterocycle)alkyl, hydroxy, hydroxyalkyl, nitro, oxo, —C(═NOH)NH[0113] 2, —C(═NH)NH2; wherein the second aryl group, the aryl part of the arylalkoxy, the arylalkyl, and the arylcarbonyl, the heteroaryl, the heteroaryl part of the heteroarylalkoxy and the heteroarylalkyl, the heterocycle, and the heterocycle part of the (heterocycle)alkoxy and the (heterocycle)alkyl can be further optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkyl, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, and nitro.
  • The term “arylalkenyl,” as used herein, refers to an aryl group attached to the parent molecular moiety through an alkenyl group. [0114]
  • The term “arylalkoxy,” as used herein, refers to an aryl group attached to the parent molecular moiety through an alkoxy group. [0115]
  • The term “arylalkyl,” as used herein, refers to an aryl group attached to the parent molecular moiety through an alkyl group. [0116]
  • The term “arylalkylamino,” as used herein, refers to an arylalkyl group attached to the parent molecular moiety through a nitrogen atom, wherein the nitrogen atom is substituted with hydrogen. [0117]
  • The term “arylalkylidene,” as used herein, refers to an aryl group attached to the parent molecular moiety through an alkylidene group [0118]
  • The term “arylalkylthio,” as used herein, refers to an arylalkyl group attached to the parent molecular moiety through a sulfur atom. [0119]
  • The term “arylalkynyl,” as used herein, refers to an aryl group attached to the parent molecular moiety through an alkynyl group. [0120]
  • The term “arylcarbonyl,” as used herein, refers to an aryl group attached to the parent molecular moiety through a carbonyl group. [0121]
  • The term “aryloxy,” as used herein, refers to an aryl group attached to the parent molecular moiety through an oxygen atom. [0122]
  • The term “arylsulfonyl,” as used herein, refers to an aryl group attached to the parent molecular moiety through an sulfonyl group. [0123]
  • The term “arylthio,” as used herein, refers to an aryl group attached to the parent molecular moiety through a sulfur atom. [0124]
  • The term “carbonyl,” as used herein, refers to a —C(O)— group. [0125]
  • The term “carboxy,” as used herein, refers to —C(O)OH. [0126]
  • The term “cyano,” as used herein, refers to —CN. [0127]
  • The term “cyanoalkenyl,” as used herein, refers to a cyano group attached to the parent molecular moiety through an alkenyl group [0128]
  • The term “cycloalkyl,” as used herein, refers to a saturated monocyclic, bicyclic, or tricyclic hydrocarbon ring system having three to twelve carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclopentyl, bicyclo[3.1.1]heptyl, adamantyl, and the like. [0129]
  • The term “(cycloalkyl)alkylidene,” as used herein, refers to a cycloalkyl group attached to the parent molecular moiety through an alkylidene group. [0130]
  • The term “halo,” or “halogen,” as used herein, refers to F, Cl, Br, or I. [0131]
  • The term “haloalkoxy,” as used herein, refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom. [0132]
  • The term “haloalkyl,” as used herein, refers to an alkyl group substituted by one, two, three, or four halogen atoms. [0133]
  • The term “haloalkylcarbonyl,” as used herein, refers to an haloalkyl group attached to the parent molecular moiety through a carbonyl group. [0134]
  • The term “heteroaryl,” as used herein, refers to an aromatic five- or six-membered ring where at least one atom is selected from the group consisting of N, O, and S, and the remaining atoms are carbon. The five-membered rings have two double bonds, and the six-membered rings have three double bonds. The heteroaryl groups are connected to the parent molecular group through a substitutable carbon or nitrogen atom in the ring. The term “heteroaryl” also includes systems where a heteroaryl ring is fused to an aryl group, as defined herein, a heterocycle group, as defined herein, or an additional heteroaryl group. Heteroaryls are exemplified by benzothienyl, benzoxadiazolyl, benzofuranyl, benzimidazolyl, benzotriazolyl, cinnolinyl, furyl, imidazolyl, indazolyl, indolyl, isoxazolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxadiazolyl, oxadiazolyl, oxazolyl, purinyl, thiazolyl, thienopyridinyl, thienyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, pyrido[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl, quinolinyl, thieno[2,3-c]pyridinyl, tetrazolyl, triazinyl, and the like. The heteroaryl groups of the present invention can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkynyl, alkylcarbonyl, amino, aminoalkyl, aryl, arylalkoxy, arylalkyl, arylalkylthio, arylalkynyl, aryloxy, carboxy, cyano, cycloalkyl, halo, haloalkoxy, haloalkyl, a second heteroaryl group, heteroarylalkoxy, heteroarylalkyl, heterocycle, (heterocycle)alkoxy, (heterocycle)alkyl, hydroxy, hydroxyalkyl, nitro, and oxo, wherein the aryl, the aryl part of the arylalkoxy, the arylalkyl, the arylalkylthio, the arylalkynyl, and the aryloxy, the second heteroaryl group, the heteroaryl part of the heteroarylalkoxy and the heteroarylalkyl, the heterocycle, and the heterocycle part of the (heterocycle)alkoxy and the (heterocycle)alkyl can be further optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, nitro, and oxo. [0135]
  • The term “heteroarylalkenyl,” as used herein, refers to a heteroaryl group attached to the parent molecular moiety through an alkenyl group. [0136]
  • The term “heteroarylalkoxy,” as used herein, refers to a heteroaryl group attached to the parent molecular moiety through an alkoxy group. [0137]
  • The term “heteroarylalkyl,” as used herein, refers to a heteroaryl group attached to the parent molecular moiety through an alkyl group. [0138]
  • The term “heteroarylalkylidene,” as used herein, refers to a heteroaryl group attached to the parent molecular moiety through an alkylidene group. [0139]
  • The term “heteroaryloxy,” as used herein, refers to a heteroaryl group attached to the parent molecular moiety through an oxygen atom. [0140]
  • The term “heteroarylsulfonyl,” as used herein, refers to a heteroaryl group attached to the parent molecular moiety through a sulfonyl group. [0141]
  • The term “heterocycle,” as used herein, refers to cyclic, non-aromatic, three-, four-, five-, six-, or seven-membered rings containing at least one atom selected from the group consisting of oxygen, nitrogen, and sulfur. The five-membered rings have zero or one double bonds and the six- and seven-membered rings have zero, one, or two double bonds. The heterocycle groups of the invention are connected to the parent molecular group through a substitutable carbon or nitrogen atom in the ring. The term “heterocycle” also includes systems where a heterocycle ring is fused to an aryl group, as defined herein, or an additional heterocycle group. Heterocycle groups of the invention are exemplified by aziridinyl, azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl, dihydro[1,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl, dihydroindolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, and the like. The heterocycle groups of the present invention can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylidene, amino, aminoalkyl, aryl, arylalkoxy, arylalkyl, arylalkylidene, cyano, (cycloalkyl)alkylidene, halo, haloalkoxy, haloalkyl, heteroaryl, heteroarylalkoxy, heteroarylalkyl, heteroarylalkylidene, iminohydroxy, a second heterocycle, (heterocycle)alkoxy, (heterocycle)alkyl, (heterocycle)alkylidene, hydroxy, hydroxyalkyl, nitro, and oxo, wherein the aryl, the aryl part of the arylalkoxy and the arylalkyl, the heteroaryl, the heteroaryl part of the heteroarylalkoxy, the heteroarylalkyl, and the heteroarylalkylidene, the second heterocycle, and the heterocycle part of the (heterocycle)alkoxy, the (heterocycle)alkyl, and the (heterocycle)alkylidene can be further optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, nitro, and oxo. [0142]
  • The term “(heterocycle)alkenyl,” as used herein, refers to a heterocycle group attached to the parent molecular moiety through an alkenyl group. [0143]
  • The term “(heterocycle)alkoxy,” as used herein, refers to a heterocycle group attached to the parent molecular group through an oxygen atom. [0144]
  • The term “(heterocycle)alkyl,” as used herein, refers to a heterocycle group attached to the parent molecular moiety through an alkyl group. [0145]
  • The term “(heterocycle)alkylidene,” as used herein, refers to a heterocycle group attached to the parent molecular moiety through an alkylidene group. [0146]
  • The term “hydroxy,” as used herein, refers to —OH. [0147]
  • The term “hydroxyalkyl,” as used herein, refers to a hydroxy group attached to the parent molecular moiety through an alkyl group. [0148]
  • The term “iminohydroxy,” as used herein, refers to ═N(OH). [0149]
  • The term “—NR[0150] cRd” as used herein, refers to two groups, Rc and Rd, which are attached to the parent molecular moiety through a nitrogen atom. Rc and Rd are each independently selected from hydrogen and alkyl.
  • The term “(NR[0151] cRd)alkyl,” as used herein, refers to a —NRcRd group attached to the parent molecular moiety through an alkyl group.
  • The term “(NR[0152] cRd)alkylcarbonyl,” as used herein, refers to a (NRcRd)alkyl group attached to the parent molecular moiety through a carbonyl group.
  • The term “nitro,” as used herein, refers to —NO[0153] 2.
  • The term “oxo,” as used herein, refers to ═O. [0154]
  • The term “sulfonyl,” as used herein, refers to —S(O)[0155] 2—.
  • The compounds of the present invention can exist as therapeutically acceptable salts. [0156]
  • The term “therapeutically acceptable salt,” as used herein, represents salts or zwitterionic forms of the compounds of the present invention which are water or oil-soluble or dispersible, which are suitable for treatment of diseases without undue toxicity, irritation, and allergic response; which are commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting an amino group with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate, and undecanoate. Also, amino groups in the compounds of the present invention can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. [0157]
  • Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N′-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine. [0158]
  • The present compounds can also exist as therapeutically acceptable prodrugs. The term “therapeutically acceptable prodrug,” refers to those prodrugs or zwitterions which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use. The term “prodrug,” refers to compounds which are transformed in vivo to parent compounds of formula (I) for example, by hydrolysis in blood. [0159]
  • When any variable, substituent, or term (e.g. aryl, heterocycle, R[0160] 12, etc.) occurs more than one time in a formula or generic structure, its definition at each occurrence is independent of the definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable combinations.
  • Because carbon-carbon double bonds exist in the present compounds, the invention contemplates various geometric isomers and mixtures thereof resulting from the arrangement of substituents around these carbon-carbon double bonds. It should be understood that the invention encompasses both isomeric forms, or mixtures thereof, which possess the ability to inhibit protein kinases. These substituents are designated as being in the E or Z configuration wherein the term “E” represents higher order substituents on opposite sides of the carbon-carbon double bond, and the term “Z” represents higher order substituents on the same side of the carbon-carbon double bond. [0161]
  • Asymmetric centers exist in the compounds of the present invention. These centers are designated by the symbols “R” or “S,” depending on the configuration of substituents around the chiral carbon atom. It should be understood that the invention encompasses all stereochemical isomeric forms, or mixtures thereof, which possess the ability to inhibit protein kinases. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, or direct separation of enantiomers on chiral chromatographic columns. Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art. [0162]
  • In accordance with methods of treatment and pharmaceutical compositions of the invention, the compounds can be administered alone or in combination with other anticancer agents. When using the compounds, the specific therapeutically effective dose level for any particular patient will depend upon factors such as the disorder being treated and the severity of the disorder; the activity of the particular compound used; the specific composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration; the route of administration; the rate of excretion of the compound employed; the duration of treatment; and drugs used in combination with or coincidently with the compound used. The compounds can be administered orally, parenterally, osmotically (nasal sprays), rectally, vaginally, or topically in unit dosage formulations containing carriers, adjuvants, diluents, vehicles, or combinations thereof. The term “parenteral” includes infusion as well as subcutaneous, intravenous, intramuscular, and intrasternal injection. [0163]
  • Parenterally adminstered aqueous or oleaginous suspensions of the compounds can be formulated with dispersing, wetting, or suspending agents. The injectable preparation can also be an injectable solution or suspension in a diluent or solvent. Among the acceptable diluents or solvents employed are water, saline, Ringer's solution, buffers, monoglycerides, diglycerides, fatty acids such as oleic acid, and fixed oils such as monoglycerides or diglycerides. [0164]
  • The anticancer effect of parenterally administered compounds can be prolonged by slowing their absorption. One way to slow the absorption of a particular compound is administering injectable depot forms comprising suspensions of crystalline, amorphous, or otherwise water-insoluble forms of the compound. The rate of absorption of the compound is dependent on its rate of dissolution which is, in turn, dependent on its physical state. Another way to slow absorption of a particular compound is administering injectable depot forms comprising the compound as an oleaginous solution or suspension. Yet another way to slow absorption of a particular compound is administering injectable depot forms comprising microcapsule matrices of the compound trapped within liposomes, microemulsions, or biodegradable polymers such as polylactide-polyglycolide, polyorthoesters or polyanhydrides. Depending on the ratio of drug to polymer and the composition of the polymer, the rate of drug release can be controlled. [0165]
  • Transdermal patches can also provide controlled delivery of the compounds. The rate of absorption can be slowed by using rate controlling membranes or by trapping the compound within a polymer matrix or gel. Conversely, absorption enhancers can be used to increase absorption. [0166]
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound can optionally comprise diluents such as sucrose, lactose, starch, talc, silicic acid, aluminum hydroxide, calcium silicates, polyamide powder, tableting lubricants, and tableting aids such as magnesium stearate or microcrystalline cellulose. Capsules, tablets and pills can also comprise buffering agents, and tablets and pills can be prepared with enteric coatings or other release-controlling coatings. Powders and sprays can also contain excipients such as talc, silicic acid, aluminum hydroxide, calcium silicate, polyamide powder, or mixtures thereof. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons or substitutes therefore. [0167]
  • Liquid dosage forms for oral administration include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs comprising inert diluents such as water. These compositions can also comprise adjuvants such as wetting, emulsifying, suspending, sweetening, flavoring, and perfuming agents. [0168]
  • Topical dosage forms include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and transdermal patches. The compound is mixed under sterile conditions with a carrier and any needed preservatives or buffers. These dosage forms can also include excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Suppositories for rectal or vaginal administration can be prepared by mixing the compounds with a suitable non-irritating excipient such as cocoa butter or polyethylene glycol, each of which is solid at ordinary temperature but fluid in the rectum or vagina. Ophthalmic formulations comprising eye drops, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention. [0169]
  • The total daily dose of the compounds administered to a host in single or divided doses can be in amounts from about 0.1 to about 200 mg/kg body weight or preferably from about 0.25 to about 100 mg/kg body weight. Single dose compositions can contain these amounts or submultiples thereof to make up the daily dose. [0170]
  • Determination of Biological Activity [0171]
  • Enzymatic Assays: [0172]
  • The Akt1 assay uses His-Akt1-S36, a truncated Akt1 containing a His tag at the N-terminus, amino acid 139-460 of Akt1 and the following point mutations: S378A, S381A, T450D and S473D. The His-Akt1-S36 assay is run in 96 well plates by incubating 1 nM His-Akt1-S36, 5 μM Biotin-BAD-peptide (Biotin) and 5 μM [0173] 33P-ATP in 50 μL of reaction buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 0.009% Triton X-100) for 30 minutes at room temperature. The reactions are stopped by adding 25 μL of stopping buffer (4M NaCl and 0.1M EDTA). The samples are transferred to a Flash plate coated with streptavidin. The phosphorylation of BAD-peptide in the reactions is measured by counting the plate with the TopCount. Other kinase assays (Akt2, Akt3, PKA, PKC, Erk2, Chk1, Cdc2, Src, CK2, MAPK AP kinase 2, and SGK) are carried out similarly using their specific biotinylated peptide substrates and buffer conditions. Compounds of the invention inhibited Akt by 0-100% at a concentration of 1 μM. Preferred compounds had percent inhibitions of between 77 and 100 at 1 μM and more preferred compounds had percent inhibitions of between 92 and 100 at 1 μM. Thus, the compounds of the invention are useful in treating disorders which are caused or exacerbated by increased protein kinase levels.
  • Synthetic Methods [0174]
  • Abbreviations which have been used in the descriptions of the scheme and the examples that follow are: DEAD for diethyl azodicarboxylate; THF for tetrahydrofuran; MTBE for methyl tert-butyl ether, PPh[0175] 3 for triphenylphosphine; OAc for acetate; P(o-tol)3 for tri-o-tolylphoshphine; dba for dibenzylideneacetone; DME for 1,2-dimethoxyethane; BINAP for 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl; DMAP for 4-dimethylaminopyridine; dppf for diphenylphosphinoferrocene; dppe for diphenylphosphinoethane; EDC for 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride; HOBt for 1-hydroxybenzotriazole; DCC for 1,3-dicyclohexylcarbodiimide; DMF for dimethylformamide; NMP for N-methylpyrrolidinone; DMSO for dimethylsulfoxide; Boc for tert-butoxycarbonyl; TFA for trifluoroacetic acid; DIBAL for diisobutylaluminum hydride; n-BuLi for n-butyllithium; 9-BBN for 9-borabicyclo[3.3.1]nonane; OiPr for isopropoxide; DMA for dimethylacetamide; AIBN for 2,2′-azobisisobutyronitrile; TEA for triethylamine; and NBS for N-bromosuccinimide.
  • The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes which illustrate the methods by which the compounds of the invention may be prepared. The groups L[0176] 1, L2, L3, R1, R2, R3, R4, R6, and R7 are as defined above unless otherwise noted below.
  • This invention is intended to encompass compounds having formula (I) when prepared by synthetic processes or by metabolic processes. Preparation of the compounds of the invention by metabolic processes include those occurring in the human or animal body (in vivo) or processes occurring in vitro. [0177]
    Figure US20030187026A1-20031002-C00005
  • As shown in Scheme 1, compounds of formula (2) (Z is Cl, Br, I, or OTf) can be converted to compounds of formula (4) by treatment with compounds of formula (3) in the presence of triphenylphosphine and an activating agent such as DEAD. The reaction can be carried out neat or in the presence of a solvent such as THF, diethyl ether, and MTBE. The reaction temperature is typically about −10° C. to about 35° C. and reaction times are typically about 8 to about 24 hours. [0178]
  • Compounds of formula (4) can be converted to compounds of formula (Ia) by treatment with compounds of formula (5) (M is selected from B(OH)[0179] 2; Sn(Ra)3, where Ra is an alkyl or aryl group; and hydrogen) in the presence of a palladium catalyst and an optional additive such as triethylamine. Examples of palladium catalysts include Pd(PPh3)4, and Pd(OAc)2 and P(o-tol)3. Representative solvents include toluene, acetonitrile, and DME. The reaction is typically conducted at temperatures between about 60° C. and about 110° C. and reaction times are typically about 4 to about 12 hours.
    Figure US20030187026A1-20031002-C00006
  • Scheme 2 shows that compounds of formula (6) (Z[0180] 1 and Z2 are independently Cl, Br, I, or OTf) can be converted to compounds of formula (8) by treatment with compounds of formula (7) according to the procedure described in Scheme 1. These compounds can be converted to compounds of formula (9) by treatment with benzophenone imine, a palladium catalyst, and a base. Examples of palladium catalysts include Pd2 dba3 and a ligand such as BINAP, dppf, or dppe. Representative bases include sodium tert-butoxide and potassium tert-butoxide. Typically, the reaction is conducted in a solvent such as toluene, acetonitrile, or DME; at temperatures from about 60° C. to about 90° C.; and at times from about 8 to about 24 hours.
  • Compounds of formula (9) can be treated with compounds of formula (10) in the presence of an acid such as acetic acid and then treated with sodium cyanoborohydride to provide compounds of formula (Ib). Representative solvents include methanol and ethanol. The reaction is typically conducted at about 20° C. to about 70° C. and reaction times are typically about 1 to about 4 hours. [0181]
    Figure US20030187026A1-20031002-C00007
  • Scheme 3 shows the preparation of compounds of formula (Ic). Compounds of formula (11) (Z is Br) can be treated with a palladium catalyst under CO atmosphere to provide compounds of formula (12). Examples of palladium catalysts include PdCl[0182] 2.dppf, PdCl2 and BINAP, and PdCl2.dppe. Representative solvents include THF, water, DME, and mixtures thereof. The reaction is typically conducted at about 80° C. to about 100° C. and reaction times are typically between 12 and 24 hours.
  • Compounds of formula (12) can be converted to compounds of formula (Ic) by treatment with a substituted amine in the presence of a coupling agent. Representative coupling agents include EDC, HOBt, DCC, DMAP, and mixtures thereof. Examples of solvents used include dichloromethane, DMF, and DME. The reaction is typically conducted at about 0° C. to about 35° C. and reaction times are typically about 12 to about 24 hours. [0183]
    Figure US20030187026A1-20031002-C00008
  • As shown in Scheme 4, compounds of formula (13) can be hydrolyzed to provide compounds of formula (14) using methods known to those of ordinary skill in the art. Compounds of formula (14) can be converted to compounds of formula (Id) using the conditions described in Scheme 3. [0184]
    Figure US20030187026A1-20031002-C00009
  • Scheme 5 shows the synthesis of compounds of formula (Ie). Compounds of formula (15) can be converted to compounds of formula (16) by treatment with a reducing agent. Examples of reducing agents include Pd/C and ammonium formate, Pd/C and hydrogen, and PtO[0185] 2 and hydrogen. Representative solvents include methanol and ethanol. The reaction is typically conducted at about 50° C. to about 70° C. for about 15 minutes to about 2 hours.
  • Compounds of formula (16) can be converted to compounds of formula (Ie) by treatment with an electrophile such as a halo-substituted heteroaryl group. Examples of solvents used in these reactions include ethanol and methanol. The reaction is typically conducted at about 50° C. to about 70° C. for about 6 to about 18 hours. [0186]
    Figure US20030187026A1-20031002-C00010
  • As shown in Scheme 6, compounds of formula (8) can be converted to compounds of formula (If) (where L[0187] 2 is a bond) by treatment with compounds of formula (17) (M is B(ORz)2, wherein Rz is hydrogen or alkyl) in the presence of a palladium catalyst and a base such as cesium carbonate or sodium carbonate. Representative palladium catalysts include PdCl2.dppf, Pd(PPh3)4, and PdCl2(PPh3)2. Examples of solvents used in these reactions include DMF, DME, and NMP. The reaction is typically conducted at about 30° C. to about 100° C. for about 4 to about 12 hours.
    Figure US20030187026A1-20031002-C00011
  • As shown in Scheme 7, compounds of formula (9) can be reacted with compounds of formula (18) using the conditions described in Scheme 3 to provide compounds of formula (Ig). [0188]
  • The present invention will now be described in connection with certain preferred embodiments which are not intended to limit its scope. On the contrary, the present invention covers all alternatives, modifications, and equivalents as can be included within the scope of the claims. Thus, the following examples, which include preferred embodiments, will illustrate the preferred practice of the present invention, it being understood that the examples are for the purposes of illustration of certain preferred embodiments and are presented to provide what is believed to be the most useful and readily understood description of its procedures and conceptual aspects.[0189]
    • EXAMPLE 1 N,N-dimethyl-N-[2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine Example 1A N-{2-[(5-bromopyridin-3-yl)oxy]ethyl}-N,N-dimethylamine
  • A solution of N,N-dimethylethanolamine(0.5 mL) in DMF (10 mL) at room temperature was treated with sodium hydride (0.2 g, 8.4 mmol), stirred for 30 minutes, and treated with 3,5-dibromopyridine (1.0 g, 4.2 mmol). The mixture was stirred at 90° C. for 8 hours, and partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (Na[0190] 2SO4), filtered, and concentrated under vacuum. Purification by flash column chromatography on silica gel with 50% ethyl acetate/hexane provided the desired product (0.8 g, 78%). MS (DCI/NH3) m/e 246 (M+H)+.
    • Example 1B N,N-dimethyl-N-[2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine
  • A mixture of Example 1A (0.8 g, 3.27 mmol), 4-vinylpyridine (0.69 g, 5.53 mmol), tri-o-tolylphosphine (0.6 g, 1.96 mmol), palladium acetate (0.16 g, 0.65 mmol) and triethylamine (0.66 g, 6.53 mmol) in acetonitrile (15 mL) was stirred for 8 hours at 80° C. The reaction solution was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (Na[0191] 2SO4), filtered, and concentrated under vacuum. Purification by flash column chromatography on silica gel with 10% methanol/dichloromethane provided the desired product (0.64 g, 73%). MS (DCI/NH3) m/e 270 (M+H)+; 1H NMR (DMSO-d6) δ 8.58 (d, J=6.0 Hz, 2H), 8.39 (s, 1H), 8.24 (s, 1H), 7.73 (s, 1H), 7.56 (d, J=6.0 Hz, 1H), 7.56 (m, 2H), 7.45 (d, J=16.5 Hz, 2H), 4.19 (t, J=6.0 Hz, 2H), 2.67 (t, J=6.0 Hz, 2H), 2.23 (s, 6H).
    • EXAMPLE 2 (1S)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine Example 2A tert-butyl (1S)-2-[({5-hydroxypyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylcarbamate
  • A solution of 3-bromo-5-hydroxypyridine (2.0 g, 11.5 mmol), L-Boc-tryptophanol (3.67 g, 12.6 mmol), and triphenylphosphine (4.53 g, 17.3 mmol) at 0° C. was treated dropwise with DEAD (3.01 g, 17.3 mmol), warmed to room temperature, stirred overnight, and concentrated. The concentrate was purified by flash column chromatography on silica gel with hexane/ethyl acetate (4:1) to provide the desired product (4.55 g, 88.7%). MS (DCI/NH[0192] 3):m/e 446, 448 (M+H)+.
    • Example 2B tert-butyl (1S)-2-(1H-indol-3-yl)-1-[(5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylcarbamate
  • The desired product was prepared by substituting Example 2A for Example 1A in Example 1B. MS (DCI/NH[0193] 3) m/e 471 (M+H)+.
    • Example 2C (1S)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine
  • A solution of Example 2B (603 mg, 1.28 mmol) in dichloromethane (20 mL) at room temperature was treated with 4N HCl in dioxane (5 mL), stirred for 2 hours, and concentrated. The residue was dissolved in water (1.5 mL) and freeze-dried to provide the desired product as the hydrochloride salt (610 mg, 99%). MS (DCI/NH[0194] 3) m/e 371 (M+H)+, 1HNMR (CD3OD) δ 8.76 (d, J=6.8 Hz, 2H), 8.52 (d, J=1.4 Hz, 1H), 8.38 (d, J=2.4 Hz, 1H), 8.16 (d, J=7.1 Hz, 2H), 7.86 (d, J=16.6 Hz, 1H), 7.77 (m, 1H), 7.60 (d, J=8.1 Hz, 1H), 7.52 (d, J=8.1 Hz, 1H), 7.50 (d, J=16.6 Hz, 1H), 7.39 (d, J=8.1 Hz, 1H), 7.28 (s, 1H), 7.13 (m, 1H), 7.03 (m, 1H), 4.39 (dd, J=3.4, 10.5 Hz, 1H), 4.25 (dd, J=5.4, 10.5 Hz, 1H), 4.00 (m, 1H), 3.30 (m, 2H).
    • Example 2D (1S)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine
  • A solution of Example 2B (500 mg, 1.06 mmol) in dichloromethane (5 mL) at room temperature was treated with trifluoroacetic acid (5 mL), stirred for 2 hours, and concentrated. The residue was dissolved in water (1.5 mL) and freeze-dried to provide the desired product as the trifluoroacetate salt (643 mg, 85%). MS (DCI/NH[0195] 3) m/c 371 (M+H)+; 1HNMR (CD3OD) δ 8.83 (d, J=7 Hz, 2H), 8.77 (br s, 1H), 8.58 (br s, 1H), 8.39 (br s, 1H), 8.29 (d, J=7 Hz, 2H), 7.98 (d, J=17 Hz, 1H), 7.82 (d, J=17 Hz, 1H), 7.61 (d, J=7 Hz, 1H), 7.48 (d, J=7 Hz, 1H), 7.28 (s, 1H), 7.09-7.14 (m, 1H), 6.99-7.04 (m, 1H), 4.50-4.57 (m, 1H), 4.39-4.45 (m, 1H), 4.02-4.08 (m, 1H), 3.30-3.38 (m, 2H).
    • EXAMPLE 3 (1R)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine
  • The desired product was prepared as the hydrochloride salt by substituting D-Boc-tryptophanol for L-Boc-tryptophanol in Example 2A then proceeding as described for to Examples 2B and 2C. MS (DCI/NH[0196] 3) m/e 371 (M+H)+; 1HNMR (CD3OD) δ 8.76 (d, J=6.1 Hz, 2H), 8.52 (m, 1H), 8.37 (m, 1H), 8.17 (d, J=6.1 Hz, 2H), 7.86 (d, J=16.6 Hz, 1H), 7.79 (m, 1H), 7.59 (d, J=7.8 Hz, 1H), 7.53 (d, J=16.6 Hz, 1H), 7.50 (d, J=16.6 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.23 (s, 1H), 7.12 (m, 1H), 7.02 (m, 1H), 4.38 (dd, J=3.1, 10.5 Hz, 1H), 4.25 (dd, J=5.4, 10.5 Hz, 1H), 3.99, (m, 1H), 3.26 (m, 2H).
    • EXAMPLE 4 1-(1H-indol-3-yl)-3-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)propan-2-ol
  • A solution of Example 2C (150 mg, 0.400 mmol) in acetic acid (2.4 mL) at room temperature was treated portionwise with NaNO[0197] 2 (117 mg. 1.70 mmol), stirred for 18 hours, quenched with water (40 μL), stirred for an additional hour, poured into 2N NaOH, and extracted with isopropanol/dichloromethane. The combined extracts were concentrated. The residue was treated with LiOH.H2O (25 mg) in THF/water (1 mL/0.5 mL), heated to 55° C. overnight, diluted with dichloromethane, washed with water, dried (MgSO4), filtered, and concentrated. The residue was purified by HPLC on a C18 column with 0-100% CH3CN/H2O/0.1% TFA to provide the desired product as the trifluoroacetate salt (9.7 mg, 5%). MS (DCI/NH3) m/e 372 (M+H)+; 1H NMR (DMSO-d6) δ 10.82 (s, 1H), 8.85 (d, J=6.6 Hz, 2H), 8.49 (s, 1H), 8.37 (s, 1H), 8.08 (d, J=6.6 Hz, 2H), 7.90 (d, J=16.5 Hz, 1H), 7.79 (m, 1H), 7.65 (d, J=16.6 Hz, 1H), 7.56 (d, J=7.8 Hz, 1H), 7.32 (d, J=8.1 Hz, 1H), 7.18 (d, J=2.2 Hz, 1H), 7.04 (m, 1H), 6.95 (m, 1H), 4.06 (m, 2H), 3.83 (m, 1H), 3.03 (dd, J=6.2, 14.5 Hz, 1H), 2.91 (dd, J=6.2, 14.5 Hz, 1H).
    • EXAMPLE 5 (1S)-2-(1-benzothien-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting 2-tert-butoxycarbonylamino-3-benzo[b]thiophen-3-yl-propan-1-ol for L-Boc-tryptophanol in Example 2A then proceeding as described for Examples 2B and 2D. MS (DCI/NH[0198] 3) m/e 388 (M+H)+; 1H NMR (DMSO-d6) δ 8.87 (d, J=6.3 Hz, 2H), 8.55 (s, 1H), 8.49 (br.s, 2H), 8.40 (d, J=7.2 Hz, 1H), 8.10 (d, J=6.3 Hz, 2H), 8.02 (d, J=7.2 Hz, 1H), 7.96 (d, J=7.2 Hz, 1H), 7.90 (d, J=16.2 Hz, 1H), 7.80 (m, 1H), 7.68 (s, 1H), 7.63 (d, J=16.2 Hz, 1H), 7.42 (m, 2H), 4.36 (dd, J=3.1, 10.6 Hz, 1H), 4.20 (dd, J=5.3, 10.6 Hz, 1H), 3.99 (m, 1H), 3.36 (m, 2H).
    • EXAMPLE 6 (1S)-2,2-diphenyl-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine
  • The desired product was prepared as the hydrochloride salt by substituting L-Boc-diphenylalaminol for L-Boc-tryptophanol in Example 2A then proceeding as described for Examples 2B and 2C. MS (DCI/NH[0199] 3) m/e 408 (M+H)+; 1H NMR (DMSO-d6) δ 8.89 (d, J=6.8 Hz, 2H), 8.57 (s, 1H), 8.45 (br s, 2H), 8.42 (d, J=2.4 Hz, 1H), 8.16 (d, J=6.8 Hz, 2H), 7.99 (d, J=16.6 Hz, 1H), 7.84 (s, 1H), 7.73 (d, J=16.6 Hz, 1H), 7.62 (m, 2H), 7.49 (m, 2H), 7.39 (m, 2H), 7.28 (m, 3H), 7.18 (m, 1H), 4.77 (m, 1H), 4.46 (m, 2H), 4.03 (m, 1H).
    • EXAMPLE 7 (1S)-1-{4-[(2,6-dichlorobenzyl)oxy]benzyl}-2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethylamine
  • The desired product was prepared as the hydrochloride salt by substituitng L-Boc-(4-(2,6-dichlorobenzyloxy)phenyl)alaninol for L-Boc-tryptophanol in Example 2A then proceeding as described for Examples 2B and 2C. MS (DCI/NH[0200] 3) m/e 506, 508, 510 (M+H)+; 1H NMR (CD3OD) δ 8.81 (d, J=7.1 Hz, 2H), 8.71 (d, J=1.0 Hz, 1H), 8.55 (d, J=2.7 Hz, 1H), 8.28 (d, J=7.1 Hz, 2H), 8.25 (m, 1H), 7.99 (d, J=16.3 Hz, 1H), 7.79 (d, J=16.3 Hz, 1H), 7.46 (d, J=1.7 Hz, 1H), 7.43 (s, 1H), 7.36 (m, 1H), 7.30 (m, 2H), 7.05 (m, 2H), 5.28 (s, 2H), 4.45(dd, J=3.1, 10.5 Hz, 1H), 4.31 (dd, J=5.8, 10.5 Hz, 1H), 3.95 (m, 1H), 3.21 (m, 2H).
    • EXAMPLE 8 (1S)-2-(benzyloxy)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine
  • The desired product was prepared as the hydrochloride salt by substituting L-Boc-3-benzyloxyalaminol for L-Boc-tryptophanol in Example 2A then proceeding as described for Examples 2B and 2C. MS (DCI/NH[0201] 3) m/e 362 (M+H)+; 1H NMR (CD3OD) δ 8.80-8.89 (m, 4H), 8.53-8.62 (m, 3H), 8.28-8.34 (m, 3H), 8.00-8.06 (m, 1H), 7.98 (d, J=16.3 Hz, 1H), 7.87 (d, J=16.3 Hz, 1H), 7.28-7.43 (m, 3H), 4.66 (s, 2H), 4.56-4.64 (m, 2H), 3.94-3.99 (m, 1H), 3.83-3.87 (m, 2H).
    • EXAMPLE 9 N,N-dimethyl-N-[(1S,2S)-1-methyl-2-phenyl-2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine Example 9A 5-bromopyridin-3-yl Acetate
  • A mixture of 3-bromo-5-hydroxypyridine (9.00 g, 51.7 mmol), acetic anhydride (6.0 mL) and triethylamine (12.0 mL) in THF (50 mL) was heated to reflux overnight, cooled to room temperature, diluted with diethyl ether, washed with water, 5% NaHCO[0202] 3, water, and brine, dried (MgSO4), filtered, and concentrated to provide the desired product (9.37 g, 84%).
    • Example 9B 5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-ol
  • A mixture of Example 9A (9.37 g, 43.3 mmol), 4-vinylpyridine (14.0 mL, 130 mmol), tri-o-tolylphosphine (13.5 g, 44.4 mmol), palladium acetate (2.65 g, 11.8 mmol) and triethylamine (120 mL, 0.861 mol) in acetonitrile (40 mL) was heated to reflux overnight and partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (Na[0203] 2SO4), filtered, and concentrated under vacuum. Purification by flash column chromatography on silica gel with 5% methanol/dichloromethane containing 0.5% ammonia provided the acetate (8.53 g). This was stirred with LiOH.H2O (6.00 g, 143 mmol) in THF/water (40 mL/20 mL) at room temperature for 4 hours, concentrated, adjusted to pH 7 with 1N HCl (aq.), and filtered. The filter cake was washed with water and dried under vacuum at 60° C. to provide the desired product (7.23 g, 84%). MS (DCI/NH3) m/e 199 (M+H)+; 1H NMR (CD3OD) δ 8.51 (m, 2H), 8.24 (d, J=1.4 Hz, 1H), 8.04 (d, J=2.4 Hz, 1H), 7.61 (m, 2H), 7.50 (m, 1H), 7.49 (d, J=16.6 Hz, 1H), 7.27 (d, J=16.6 Hz, 1H).
    • Example 9C N,N-dimethyl-N-[(1S,2S)-1-methyl-2-phenyl-2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine
  • The desired product was prepared as the trifluoracetate salt by substituting Example 9B and (1S,2S)-2-(dimethylamino)-1-phenylpropan-1-ol for 3-bromo-5-hydroxypyridine and L-Boc-tryptophanol, respectively, in Example 2A then proceeding as described for Examples 2B and 2D. MS (DCI/NH[0204] 3) m/e 360 (M+H)+; 1H NMR (DMSO-d6) δ 8.78 (d, 2H), 8.44 (s, 1H), 8.33 (d, 1H), 7.94 (d, 1H), 7.80 (s, 1H), 7.75 (d, 1H), 7.59 (d, 2H), 7.46-7.34 (m, 5H), 5.84 (d, 1H), 3.55-3.45 (m, 1H), 2.95 (s, 3H), 2.84 (s, 3H), 1.02 (d, 3H).
    • EXAMPLE 10 (1S)-2-(2-naphthyl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine
  • The desired product was prepared as the trifluoracetate salt by substituting L-Boc-(2-naphthyl)alaminol for L-Boc-tryptophanol in Example 92A then proceeding as described for Examples 2B and 2D. MS (DCI/NH[0205] 3) m/e 382 (M+H)+; 1HNMR (DMSO-d6) δ 8.88 (d, J=6.8 Hz, 2H), 8.57 (d, J=1.0 Hz, 1H), 8.43 (d, J=2.4 Hz, 1H), 8.15 (d, J=6.8 Hz, 2H), 7.99 (d, J=16.6 Hz, 1H), 7.90 (m, 5H), 7.73 (d, J=16.6 Hz, 1H), 7.50 (m, 3H), 4.35 (dd, J=3.4, 10.5 Hz, 1H), 4.21 (dd, J=5.4, 10.5 Hz, 1H), 3.97 (m, 1H), 3.32 (dd, J=5.8, 13.6 Hz, 1H), 3.21 (dd, J=9.2, 13.6 Hz, 1H).
    • EXAMPLE 11 N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-{5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}amine Example 11A 3-bromo-5-[(E)-2-pyridin-4-ylvinyl]pyridine
  • A solution of 3,5-dibromopyridine (5.56 g, 23.4 mmol), 4-vinylpyridine (5.1 mL), palladium acetate (1.05 g), tri-o-tolylphosphine (5.00 g) and triethylamine (33 mL) in acetonitrile (100 mL) was heated overnight at 80° C. and concentrated. The residue was partitioned between 5% NaHCO[0206] 3 and dichloromethane and filtered. The filtrate was separated and the organic layer was washed with water, dried (MgSO4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 4% methanol/dichloromethane to provide the desired product (2.18 g, 36%). (DCI/NH3) m/e 261, 263 (M+H)+.
    • Example 11B 5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-amine
  • A mixture of Example 11A (1.88 g, 7.2 mmol), benzophenone imine (1.22 mL), Pd[0207] 2(dba)3 (66 mg), BINAP (125 mg), sodium tert-butoxide (0.97 g), and toluene (19 mL) was heated to 80° C. overnight and concentrated. The residue was purified by flash column chromatography on silica gel with ethyl acetate to provide a solid (2.44 g). This was stirred with 2N HCl (aq.) (5.0 mL) in THF (50 mL) at room temperature for 2 hours and concentrated. The residue was dissolved in 0.5N HCl (aq.) (100 mL) and washed three times with ethyl acteate. The aqueous layer was adjusted to pH 11 with 1N NaOH and extracted with dichloromethane. The combined extracts were washed with water, dried (MgSO4), filtered, and concentrated to provide the desired product (1.23 g, 87%). MS (DCI/NH3) m/e 198 (M+H)+; 1H NMR (DMSO-d6) δ 8.55 (m; 2H), 8.00 (d, J=1.7 Hz, 1H), 7.89 (d, J=2.4 Hz, 1H), 7.56 (m, 2H), 7.42 (d, J=16.6 Hz, 1H), 7.17 (d, J=16.6 Hz, 1H), 7.15 (m, 1H).
    • Example 11C tert-butyl (1S)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}amino)methyl]ethylcarbamate
  • A mixture of Example 11B (52 mg, 0.264 mmol), L-Boc-tryptophanal (J. Med. Chem., 1985, 28(12), 1874.) (80 mg, 0.277 mmol) and acetic acid (80 μL) in methanol (4 mL) was stirred at room temperature for 3 hours, refluxed for 2 hours, cooled to room temperature, treated with sodium cyanoborohydride (35 mg) stirred for 1 hour, and filtered. The filtrate was concentrated and the residue was purified by HPLC on a C18 column with 0-100% CH[0208] 3CN/H2O/0.1% TFA to provide the designed product (43 mg, 35%). MS (DCI/NH3) m/e 470 (M+H)+.
    • Example 11D N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-{5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}amine
  • A solution of Example 11C (40 mg, 0.085 mmol) in dichloromethane (3.0 mL) at room temperature was treated with 4N HCl in dioxane (0.5 mL), stirred for 1 hour, and concentrated to provide the desired product as the hydrochloride salt (30 mg, 74%). MS (DCI/NH[0209] 3) m/e 370 (M+H)+; 1H NMR (DMSO-d6) δ 11.09 (br s, 1H), 8.90 (d, J=5.8 Hz, 2H), 8.47 (br s, 2H), 8.33 (s, 1H), 8.22 (d, J=1.8 Hz, 1H), 8.14 (d, J=5.8 Hz, 2H), 7.98 (s, 1H), 7.94 (d, J=16.5 Hz, 1H), 7.86 (d, J=16.5 Hz, 1H), 7.62 (d, J=7.9 Hz, 1H), 7.37 (d, J=4.5 Hz, 1H), 7.36 (s, 1H), 7.08 (m, 1H), 6.98 (m, 1H), 3.71 (m, 1H), 3.67 (m, 1H), 3.54 (m, 1H), 3.15 (m, 2H).
    • EXAMPLE 12 (1S)-2-({2-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-3-ylmethyl)ethylamine Example 12A 3-(benzyloxy)-5-bromo-2-chloropyridine
  • A solution of 3-(benzyloxy)-5-bromopyridine N-oxide (2.0 g, 7.1 mmol) in POCl[0210] 3 (20 mL) was stirred at 100° C. for 7 hours, cooled to room temperature, concentrated, treated with ethyl acetate (50 mL), washed with brine, dried (MgSO4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 10% ethyl acetate/hexane to provide the desired product (1.0 g, 40%). MS (DCI/NH3) m/e 299 (M+H)+.
    • Example 12B 5-bromo-2-chloro-3-hydroxypyridine
  • A mixture of Example 12A in HBr/HOAc (30%, 50 mL) was stirred at 100° C. for 8 hours, cooled to room temperature and concentrated. The concentrate was partitioned between ethyl acetate and saturated Na[0211] 2CO3 (aq.). The organic layer was washed with brine, dried (Na2SO4), filtered, and concentrated under vacuum. Purification by flash column chromatography on silica gel with 30% ethyl acetate/hexane provided the desired product (0.51 g, 72%). MS (DCI/NH3) m/e 209 (M+H)+.
    • Example 12C tert-butyl (1S)-2-[(5-bromo-2-chloropyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylcarbamate
  • The desired product was prepared by substituting Example 12B for 3-bromo-5-hydroxypyridine in Example 2A (0.78 g, 66%). MS (DCI/NH[0212] 3) m/e 481 (M+H)+.
    • Example 12D (1S)-2-({2-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-3-ylmethyl)ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 12C for Example 2A in Examples 2B and 2D. MS (DCI/NH[0213] 3) m/e 405, 407 (M+H)+; 1H NMR (DMSO-d6) δ 11.04 (s, 1H), 8.72 (d, J=6.0 Hz, 2H), 8.30 (s, 1H), 8.23 (br s, 2H), 7.84 (s, 1H), 7.78 (d, J=6.0 Hz, 2H), 7.70 (d, J=16.8 Hz, 1H), 7.62 (d, J=8.1 Hz, 1H), 7.50 (d, J=16.8 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.28 (s, 1H), 7.10 (t, J=7.2 Hz, 1H), 7.00 (t, J=7.2 Hz, 1H), 4.38 (m; 1H), 4.18 (m, 1H), 3.91 (m, 1H), 3.20 (m, 2H).
    • EXAMPLE 13 (1S)-2-({6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-3-ylmethyl)ethylamine Example 13A tert-butyl (1S)-2-[(5-bromo-6-chloropyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylcarbamate
  • A solution of 5-bromo-6-chloro-3-hydroxypyridine (2.50 g, 12 mmol) N-α-(tert-butoxycarbonyl)-L-tryptophanol (3.77 g, 18 mmol) and triphenylphosphine (4.72 g, 18 mmol) in THF (100 mL) was stirred at 0° C. for 20 minutes, treated with DEAD (2.83 mL, 18 mmol), stirred for 1 hour, warmed to room temperature, stirred for 15 hours, treated with ethyl acetate (300 mL), washed with brine, dried (MgSO[0214] 4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 25% ethyl acetate/hexane to provide the desired product (4.58 g, 80%). MS (APCI) m/e 480, 482 (M+H)+.
    • Example 13B tert-butyl (1S)-2-({6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-3-ylmethyl)ethylcarbamate
  • A solution Example 13A (1.50 g, 3.125 mmol), Pd[0215] 2(dba)3 (71 mg, 0.078 mmol) and tri-o-tolylphosphine (71 mg, 0.23 mmol) in DMF (30 mL) was treated with 4-vinylpyridine (492 mg, 4.68 mmol) and triethylamine (1.30 mL, 9.4 mmol), purged with nitrogen, and heated to 100° C. for 4 hours. The mixture was cooled to room temperature, treated with ethyl acetate (200 mL), washed with brine, dried (MgSO4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 75% ethyl acetate/hexanes to provide the desired product (1.37 g, 87%). MS (APCI) m/e 505, 507 (M+H)+.
    • Example 13C (1S)-2-({6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-3-ylmethyl)ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 13B for Example 2B in Example 2D. MS (APCI) m/e 405,407 (M+H)[0216] +; 1H NMR (300 MHz, CD3OD) δ 8.76 (d, J=6.7 Hz, 2H), 8.18 (d, J=2.7 Hz, 1H), 8.15 (d, J=6.5 Hz, 2H), 7.95 (d, J=16.2 Hz, 1H), 7.86 (d, J=3.0 Hz, 1H), 7.58 (d, J=7.8 Hz, 1H), 7.43 (d, J=16.3 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.23 (s, 1H), 7.13 (t, J=7.1 Hz, 1H), 7.03 (t, J=7.8 Hz, 1H), 4.38 (dd, J=10.5, 3.0 Hz, 1H), 4.25 (dd, J=10.6, 5.8 Hz, 1H), 3.97 (m, 1H), 3.31 (m, 2H); Anal. Calcd for C23H21ClN4O.2.3TFA: C, 49.69; H, 3.52; N, 8.40. Found: C, 49.82; H, 3.48; N, 8.32.
    • EXAMPLE 14 (1S)-2-(1H-indol-3-yl)-1-({[5-(pyridin-4-ylethynyl)pyridin-3-yl]oxy}methyl)ethylamine Example 14A tert-butyl (1S)-2-(1H-indol-3-yl)-1-[({5-[(trimethylsilyl)ethynyl]pyridin-3-yl}oxy)methyl]ethylcarbamate
  • A mixture of Example 2A (500 mg, 1.12 mmol), Pd[0217] 2Cl2(PPh3)2 (77 mg, 0.112 mmol), and CuI (52 mg, 0.27 mmol) was purged with nitrogen, treated with DMF (7 mL), trimethylsilylacetylene (475 μL, 3.36 mmol) and triethylamine (468 μL, 3.36 mmol) stirred at 50° C. for 15 hours, cooled to room temperature, treated with ethyl acetate (50 mL), washed with brine, dried (MgSO4), filtered, and concentrated. The residual oil was purified by flash column chromatography on silica gel with 1:2 ethyl acetate/hexanes to provide the desired product (417 mg, 80%). MS (APCI) m/e 464 (M+H)+.
    • Example 14B tert-butyl (1S)-2-[(5-ethynylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylcarbamate
  • A solution of Example 14A (400 mg, 0.86 mmol) in THF (6 mL) at room temperature was treated with tetrabutylammonium fluoride (1.0 M solution in THF, 1.12 mL, 1.12 mmol), stirred for 1 hour, treated with ethyl acetate (50 mL), washed with brine, dried (MgSO[0218] 4), filtered, and concentrated. The residual oil was purified by flash column chromatography on silica gel with 40% ethyl acetate/hexanes to provide the desired product (290 mg, 86%). MS (APCI) m/e 392 (M+H)+.
    • Example 14C tert-butyl (1S)-2-(1H-indol-3-yl)-1-({[5-(pyridin-4-ylethynyl)pyridin-3-yl]oxy}methyl)ethylcarbamate
  • A mixture of Example 14B (150 mg, 0.384 mmol), 4-bromopyridine hydrochloride (75 mg, 0.34 mmol), Pd[0219] 2Cl2(PPh3)2 (27 mg, 0.0384 mmol), and CuI (18 mg, 0.093 mmol), was purged with nitrogen, treated with DMF (4 mL) and triethylamine (214 mL, 1.54 mmol), stirred at 50° C. for 20 hours, cooled to room temperature, treated with ethyl acetate (50 mL), washed with brine, dried (MgSO4), filtered, and concentrated. The residual oil was purified by flash column chromatography on silica gel with 2:1 ethyl acetate/hexanes to provide the desired product (122 mg, 68%). MS (APCI) m/e 469 (M+H)+.
    • Example 14D (1S)-2-(1H-indol-3-yl)-1-({[5-(pyridin-4-ylethynyl)pyridin-3-yl]oxy}methyl)ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 14C for Example 2B in Example 2D. MS (APCI) m/e 369 (M+H)[0220] +; 1H NMR (300 MHz, CD3OD) δ 8.76 (d, J=6.5 Hz, 2H), 8.47 (d, J=1.7 Hz, 1H), 8.42 (d, J=2.7 Hz, 1H), 7.92 (d, J=6.5 Hz, 2H), 7.66 (dd, J=2.7, 1.7 Hz, 1H), 7.58 (d, J=7.8 Hz, 1H), 7.38 (d, J=8.2 Hz, 1H), 7.23 (s, 1H), 7.13 (td, J=7.1, 1.0 Hz, 1H), 7.03 (td, J=7.8, 1.1 Hz, 1H), 4.34 (dd, J=10.1, 3.0 Hz, 1H), 4.19 (dd, J=10.5, 5.8 Hz, 1H), 3.98 (m, 1H), 3.28 (m, 2H); Anal. Calcd for C23H20N4O.3.3 TFA: C, 47.74; H, 3.15; N, 7.52. Found: C, 47.53; H, 3.18; N, 7.48.
    • EXAMPLE 15 (1S)-2-(1H-indol-3-yl)-1-[({5-[(Z)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine
  • A mixture of Example 14D (40 mg, 0.11 mmol), 5% Pd/BaSO[0221] 4 (8.1 mg) and quinoline (8.1 μL) in methanol (3 mL) was stirred under hydrogen (20 psi) at room temperature for 12 minutes and filtered. The filtrate was concentrated and the residual oil was purified by HPLC on a C18 column with 0-100% CH3CN/H2O/0.1% TFA to provide the desired product (30 mg, 75%). MS (APCI) m/e 369 (M−H)−; 1H NMR (300 MHz, CD3OD) δ 8.57 (d, J=6.8 Hz, 2H), 8.29 (d, J=2.4 Hz, 1H), 8.04 (s, 1H), 7.69 (d, J=6.4 Hz, 2H), 7.57 (d, J=7.8 Hz, 1H), 7.53 (d, J=7.8 Hz, 1H), 7.40 (d, J=8.1 Hz, 1H), 7.33 (t, J=1.7 Hz, 1H), 7.21 (s, 1H), 7.14 (m, 2H), 7.02 (td, J=8.1, 1.0 Hz, 1H), 6.95 (d, J=12.2 Hz, 1H), 4.24 (dd, J=10.5, 3.0 Hz, 1H), 4.08 (dd, J=10.5, 5.6 Hz, 1H), 3.92 (m, 1H), 3.26 (m, 2H); Anal. Calcd for C23H22N4O.3.6 TFA: C, 46.45; H, 3.30; N, 7.17. Found: C, 46.56; H, 3.35; N, 7.34.
    • EXAMPLE 16 (2S)-2-amino-4-phenyl-N-{5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}butanamide Example 16A tert-butyl (1S)-3-phenyl-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}amino)carbonyl]propylcarbamate
  • A mixture of Example 11B (200 mg, 1.0 mmol), HOBt (210 mg), EDC (290 mg), DMAP (25 mg) and Boc-homophenylalanine was stirred at room temperature overnight and concentrated. The residue was dissolved in ethyl acetate, washed sequentially with water, 5% NaHCO[0222] 3, and water, dried (MgSO4), filtered, and concentrated. The residue was purified by flash column chromatography on silica gel with 3% methanol/dichloromethane to provide the desired product (192 mg, 41%). MS (DCI/NH3) m/e 459 (M+H)+.
    • Example 16B (2S)-2-amino-4-phenyl-N-{5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}butanamide
  • The desired product was prepared as the hydrochloride salt by substituting Example 16A for Example 2B in Example 2C (173 mg, 89%). MS (DCI/NH[0223] 3) m/e 359 (M+H)+; 1H NMR (DMSO-d6) δ 12.03 (s, 1H), 8.97 (s, 1H), 8.91 (d, J=6.6 Hz, 2H), 8.85 (s, 1H), 8.70 (d, J=4.1 Hz, 2H), 8.60 (s, 1H), 8.28 (d, J=6.6 Hz, 2H), 8.09 (d, J=16.5 Hz, 1H), 7.68 (d, J=16.5 Hz, 1H), 7.24 (m, 5H), 4.33 (m, 1H), 2.78 (m, 2H), 2.25 (m, 2H).
    • EXAMPLE 17 5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-N-pyridin-4-ylnicotinamide Example 17A 5-{[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propyl]oxy}nicotinic Acid
  • A solution of Example 2A (1.30 g, 3.02 mmol) and PdCl[0224] 2.dppf (123 mg) in THF/water (6.3 mL/6.3 mL) was heated to 100° C. under CO (800 psi) for 19 hours, cooled to room temperature, and diluted with water. The mixture was extracted with dichloromethane and the combined extracts were washed with water, dried (MgSO4), filtered, and concentrated to provide the desired product (912 mg, 76%). MS (DCI/NH3) m/e 396 (M+H)+.
    • Example 17B tert-butyl (1S)-2-(1H-indol-3-yl)-1-[({5-[(pyridin-4-ylamino)carbonyl]pyridin-3-yl}oxy)methyl]ethylcarbamate
  • A solution of Example 17A (410 mg, 1.0 mmol), 4-aminopyridine (100 mg, 1.0 mmol), EDC (960 mg), and HOBt (680 mg) in DMF (10 mL) was stirred at room temperature overnight, diluted with dichloromethane, washed with water, dried (MgSO[0225] 4), filtered, and concentrated. The residue was purified by flash column chromatography on silica gel with ethyl acetate/methanol (8:1) to provide the desired product (87 mg, 18%). MS (DCI/NH3) m/e 488 (M+H)+.
    • Example 17C 5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-N-pyridin-4-ylnicotinamide
  • The desired product was prepared as the hydrochloride salt by substituting Example 17B for Example 2B in Example 2C (27 mg, 31%). MS (DCI/NH[0226] 3) m/e 388 (M+H)+; 1H NMR (DMSO-d6) δ 11.32 (br s, 1H), 11.04 (br s, 1H), 8.83 (d, J=1.4 Hz, 1H), 8.69 (apparent d, J=6.8 Hz, 2H), 8.59 (d, J=2.7 Hz, 1H), 8.15 (br s, 2H), 8.08 (apparent d, J=6.8 Hz, 2H), 7.85 (dd, J=1.4, 2.7 Hz, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.38 (d, J=8.12 Hz, 1H), 7.29 (d, J=2.7 Hz, 1H), 7.10 (m, 1H), 7.01 (m, 1H), 4.33 (m, 1H), 4.16 (m, 1H), 3.87 (m, 1H), 3.16 (m, 2H).
    • EXAMPLE 18 N-(aminoethyl)-5-[(E)-2-pyridin-4-ylvinyl]nicotinamide Example 18A Ethyl 5-[(E)-2-pyridin-4-ylvinyl]nicotinate
  • The desired product was prepared by substituting 3-bromo-5-ethoxycarbonylpyridine for Example 1A in Example 1B. MS (DCI/NH[0227] 3) m/e 355 (M+H)+.
    • Example 18B 5-[(E)-2-pyridin-4-ylvinyl]nicotinic Acid
  • A mixture of Example 18A (1.60 g, 6.3 mmol) and LiOH.H[0228] 2O (2.64 g) in THF/water (50 mL/50 mL) was stirred at room temperature for 2 hours. The THF was removed under vacuum and the aqueous layer was acidified with 1N HCl (aq.). The solid was collected by filtration and dried to provide the desired product. MS (DCI/NH3) m/e 227 (M+H)+.
    • Example 18C N-(aminoethyl)-5-[(E)-2-pyridin-4-ylvinyl]nicotinamide
  • The desired product was prepared as the hydrochloride salt by substituting Example 18B and N-tert-butoxycarbonylaminoethylamine for Example 17A and 4-aminopyridine, respectively, in Examples 17B and 17C. MS (DCI/NH[0229] 3) m/e 384 (M+H)+; 1HNMR (DMSO-d6) δ 9.19 (t, J=5.4 Hz, 1H), 9.09 (d, J=1.7 Hz, 1H), 9.01 (d, J=2.0 Hz, 1H), 8.89 (d, J=6.5 Hz, 2H), 8.82 (dd, J=1.7, 2.0 Hz, 1H), 8.18 (d, J=6.5 Hz, 2H), 8.07 (d, J=16.6 Hz, 1H), 7.87 (d, J=16.6 Hz, 1H), 3.72 (br s, 2H), 3.59 (m, 2H), 3.05 (m, 2H).
    • EXAMPLE 19 N-[(2E)-3-(4-bromophenyl)prop-2-enyl]-N-[2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine Example 19A (2E)-3-(4-bromophenyl)prop-2-en-1-ol
  • A solution of ethyl 4-bromocinnamide (5.430 g, 22.07 mmol) in toluene (20 mL) at −78° C. was treated over 10 minutes with DIBAL (1.5 M in toluene, 37.0 mL, 55.5 mmol), stirred for 30 minutes at −78° C., warmed to room temperature, stirred for 1 hour, quenched with 10% HCl (aq.), and extracted twice with diethyl ether. The combined extracts were washed with water and brine, dried (MgSO[0230] 4), filtered, and concentrated to provide the desired product (4.463 g, 95%). MS (DCI/NH3) m/e 212, 214 (M+H)+, 228, 230 (M+18)+.
    • Example 19B 1-bromo-4-[(1E)-3-chloroprop-1-enyl]benzene
  • A mixture of Example 19A (2.0 g, 9.387 mmol) and SOCl[0231] 2 (3.5 mL, 47.9 mmol) in benzene (10 mL) was stirred at room temperature for 24 hours and concentrated to provide the desired product (2.167 g, 99%). (DCI/NH3) m/e 231, 233, 235 (M+H)+.
    • Example 19C 2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethanamine
  • The desired product was prepared as the hydrochloride salt by substituting Example 9B and N-tert-butoxylcarbonylaminoethanol (200 mg, 1.00 mmol) for 3-bromo-5-hydroxypyridine and L-Boc-tryptophanol, respectively, in Examples 2A and 2C. MS (DCI/NH[0232] 3) m/e 242 (M+H)+; 1H NMR (CD3OD) δ 8.88 (d, J=6.1 Hz, 2H), 8.59 (s, 1H), 8.43 (s, 1H), 8.19 (d, J=6.1 Hz, 2H), 8.03 (d, J=16.3 Hz, 1H), 8.01 (s, 1H), 7.82 (d, J=16.3 Hz, 1H), 4.42 (t, J=4.9 Hz, 2H), 3.28 (m, 2H).
    • Example 19D N-[(2E)-3-(4-bromophenyl)prop-2-enyl]-N-[2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine
  • A solution of Example 19C (100 mg, 0.285 mmol), Example 19B (66.0 mg, 0.285 mmol), and triethylamine (250 μL, 1.79 mmol) in DMF (5 mL) at room temperature was stirred for 3 days, and poured into water. The aqueous layer was extracted three times with dichloromethane and the combined extracts were washed with water, dried (MgSO[0233] 4), filtered, and concentrated. The residue was chromatographed on silica gel with dichloromethane/methanol/NH4OH (100:5:0.5) to provide the free base. The material was treated with 2M HCl/Et2O to provide the hydrochloride salt (34.0 mg, 22%). MS (DCI/NH3) m/e 436,438 (M+H)+; 1HNMR (CDCl3) δ 8.61 (m, 2H), 8.37 (d, J=1.7 Hz, 1H), 8.27 (d, J=2.7 Hz, 1H), 7.37 (m, 4H), 7.26 (m, 5H), 7.25 (d, J=16.3 Hz, 1H), 7.05 (d, J=16.3 Hz, 1H), 6.53 (d, J=15.9 Hz, 1H), 6.31 (dt, J=6.1, 15.9 Hz, 1H), 4.23 (t, J=5.1 Hz, 2H), 3.53 (dd, J=1.1, 6.1 Hz, 1H), 3.13 (t, J=5.1 Hz, 1H).
    • EXAMPLE 20 N4-(3-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}phenyl)pyrimidine-2,4-diamine Example 20A tert-butyl (1S)-2-(1H-indol-3-yl)-1-[(3-nitrophenoxy)methyl]ethylcarbamate
  • The desired product was prepared by substituting 3-nitrophenol for 3-bromo-5-hydroxypyridine in Example 2A (257 mg, 61%). MS (DCI/NH[0234] 3) m/e 412 (M+H)+, 419 (M+18)+.
    • Example 20B tert-butyl (1S)-2-(3-aminophenoxy)-1-(1H-indol-3-ylmethyl)ethylcarbamate
  • A solution of Example 20A (247 mg, 0.600 mmol), ammonium formate (400 mg, 6.34 mmol) and 10% Pd/C (25 mg) in methanol (10 mL) was heated to reflux for 30 minutes, cooled to room temperature, filtered through diatomaceous earth (Celite®), and concentrated. The concentrate was purified by flash column chromatography on silica gel with ethyl acetate/hexanes (1:1) to provide the desired product (200 mg, 87%). MS (DCI/NH[0235] 3) m/e 382 (M+H)+.
    • Example 20C tert-butyl (1S)-2-{3-[(2-aminopyrimidin-4-yl)amino]phenoxy}-1-(1H-indol-3-ylmethyl)ethylcarbamate
  • A solution of Example 20B (41.2 mg, 0.108 mmol) and 2-amino-4-chloropyrimidine (14.0 mg, 0.108 mmol) in ethanol (0.5 mL) was heated to 80° C. for 13 hours and purified by flash column chromatography on silica gel with dichloromethane/methanol/NH[0236] 4OH (100:5:0.5) to provide the desired product (50 mg, 98%). MS (DCI/NH3) m/e 475(M+H)+.
    • Example 20D N4-(3-1[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy phenyl)pyrimidine-2,4-diamine
  • The desired product was prepared as the hydrochloride salt by substituting Example 20C for Example 2B in Example 2C (33 mg, 81%). MS (DCI/NH[0237] 3) m/e 375 (M+H)+; 1H NMR (DMSO-d6) δ 12.3 (br s, 1H), 10.8 (br s, 1H), 8.35 (br s, 4H), 7.85 (d, J=7.1 Hz, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.45 (br s, 2H), 7.37 (d, J=7.8 Hz, 1H), 7.30 (m, 2H), 7.09 (m, 1H), 6.99 (m, 1H), 6.75 (m, 1H), 6.35 (m, 1H), 4.17 (dd, J=3.4, 10.5 Hz, 1H), 4.03 (dd, J=5.8, 10.5 Hz, 1H), 3.77 (m, 1H), 3.18 (d, J=7.5 Hz, 2H).
    • EXAMPLE 21 (1R)-3-{6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}-1-(1H-indol-3-ylmethyl)propylamine Example 21A 6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-amine
  • A solution of 3-amino-5-bromo-6-chloropyridine (2.0 g, 9.64 mmol), Pd[0238] 2(dba)3 (440 mg, 0.48 mmol), tri-o-tolylphosphine (438 mg, 1.44 mmol), 4-vinylpyridine (2.08 mL, 19.28 mmol), and triethylamine (4.03 mL, 29 mmol) in DMF (30 mL) was stirred at 100° C. for 15 hours, cooled to room temperature, treated with ethyl acetate (200 mL), washed twice with brine, dried (MgSO4), filtered and concentrated. The residual solid recrystallized from hexanes/dichloromethane to provide desired product (1.86 g, 84%). MS (APCI) m/e 232 (M+H)+.
    • Example 21B 2-chloro-5-iodo-3-[(E)-2-pyridin-4-ylvinyl]pyridine
  • A solution of Example 21A (1.0 g, 4.3 mmol) in 30% H[0239] 2SO4 (10 mL) at 0° C. was treated with NaNO2 (386 mg, 5.6 mmol), stirred for 5 hours, treated with a solution of NaI (2.1 g, 14 mmol) in H2O (2 mL), stirred for 2 hours, treated with additional NaI (2.1 g, 14 mmol), stirred for 2 hours, poured into 30% NaOH (aq.) (200 mL) at 0° C. and extracted three times with 10% methanol/ethyl acetate. The combined organic phases were dried (MgSO4), filtered, and concentrated. The residual solid was purified by flash column chromatography on silica gel with 70% ethyl acetate/hexanes to provide the desired product (1.03 g, 70%). MS (DCI) m/e 343 (M+H)+.
    • Example 21C tert-butyl (1S)-1-(1H-indol-3-ylmethyl)prop-2-enylcarbamate
  • A suspension of methyltriphenylphosphonium bromide (5.65 g, 15.81 mmol) in THF (50 mL) at 0° C. was treated with n-BuLi (2.5 M solution in hexane, 6.33 mL, 15.81 mmol), stirred for 10 minutes, warmed to room temperature, stirred for 30 minutes, cooled to 0° C., treated with a solution of L-Boc-tryptophanal (3.80 g, 13.2 mmol) in THF (10 mL), stirred for 2 hours, treated with diethyl ether (200 mL), washed with brine, dried (MgSO[0240] 4), filtered, and concentrated. The residual oil was purified by flash column chromatography on silica gel with 20% ethyl acetate/hexanes to provide the desired product (700 mg, 18%). MS (DCI) m/e 287 (M+H)+.
    • Example 21D tert-butyl (1R)-3-{6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}-1-(1H-indol-3-ylmethyl)propylcarbamate
  • A solution of Example 21C (100 mg, 0.35 mmol) in THF (3 mL) at 0° C. was treated with 9-BBN (0.5 M solution in THF, 0.70 mL, 0.35 mmol), stirred overnight while gradually warming to room temperature, cannulated into a mixture of Example 21B (108 mg, 0.32 mmol), PdCl[0241] 2(dppf) (26 mg, 0.032 mmol) and Cs2CO3 (228 mg, 0.7 mmol) in DMF, purged with nitrogen, and stirred at 50° C. for 8 hours. The mixture was treated with ethyl acetate (50 mL), washed with brine, dried (MgSO4), filtered, and concentrated. The residual oil was purified by flash column chromatography on silica gel with 80% ethyl acetate/hexanes to provide the desired product (69 mg, 40%).
    • Example 21E (1R)-3-{6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}-1-(1H-indol-3-ylmethyl)propylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 21D for Example 2B in Example 2D. MS (APCI) m/e 403, 405 (M+H)[0242] +; 1H NMR (300 MHz, CD3OD) δ 8.78 (d, J=6.8 Hz, 2H), 8.19 (d, J=1.7 Hz, 1H), 8.18 (d, J=6.8 Hz, 2H), 7.97 (d, J=2.4 Hz, 1H), 7.93 (d, J=16.3 Hz, 1H), 7.48 (d, J=7.8 Hz, 1H), 7.34 (d, J=9.5 Hz, 1H), 7.33 (d, J=16.0 Hz, 1H), 7.20 (s, 1H), 7.11 (td, J=7.1, 1.0 Hz, 1H), 7.00 (td, J=6.8, 1.0 Hz, 1H), 3.55 (p, J=6.4 Hz, 1H), 3.16 (m, 2H), 2.82 (m, 2H), 2.06 (m, 2H); Anal. Calcd for C24H23ClN4.2.8 TFA: C, 49.23; H, 3.60; N, 7.76. Found: C, 49.11; H, 3.64; N, 7.66.
    • EXAMPLE 22 4-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)benzonitrile Example 22A tert-butyl (1S)-2-{[5-(4-cyanophenyl)pyridin-3-yl]oxy}-1-(1H-indol-3-ylmethyl)ethylcarbamate
  • A solution of Example 2A (250 mg, 0.56 mmol) in ethylene glycol dimethyl ether (20.0 mL) at room temperature was treated with tetrakis(triphenylphosphine)palladium(0) (32 mg, 0.03 mmol), stirred for 10 minutes, treated with a solution of (4-cyanophenyl)boronic acid (123 mg, 0.84 mmol) in ethanol (5.0 mL), stirred for 15 minutes, treated with 2M Na[0243] 2CO3 (aq.) (1.4 mL), heated to reflux for 4 hours, cooled to room temperature, and concentrated. The concentrate was purified by flash column chromatography on silica gel with hexanes/ethyl acetate (1:1) to provide the desired product (230 mg, 88%). MS (DCI/NH3) m/e 469 (M+H)+.
    • Example 22B 4-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)benzonitrile
  • A solution of Example 22A (20 mg, 0.043 mmol) in dichloromethane (2.0 mL) at 0° C. was treated dropwise with trifluoroacetic acid (0.5 mL) and stirred for 2 hours while warming to room temperature. The reaction mixture was concentrated to provide the desired product as the trifluoroacetate salt (27 mg, 88%). MS (DCI/NH[0244] 3) m/e 369 (M+H)+; 1H NMR (DMSO-d6) δ 11.02 (s, 1H), 8.63 (d, J=1.9 Hz, 1H), 8.42 (d, J=2.8 Hz, 1H), 8.21 (br s, 2H), 7.99-7.92 (m, 4H), 7.73 (t, J=1.9 Hz, 1H), 7.61 (d, J=8.1 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.29 (d, J=2.5 Hz, 1H), 7.10 (m, 1H), 7.01 (m, 1H), 4.36 (dd, J=10.6, 3.1 Hz, 1H), 4.19 (dd, J=10.9, 5.9 Hz, 1H), 3.89-3.82 (m, 1H), 3.16 (d, J=7.2 Hz, 2H).
    • EXAMPLE 23 N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N′-isoquinolin-5-ylpyridine-3,5-diamine Example 23A Isoquinolin-5-yl Trifluoromethanesulfonate
  • A mixture of 5-hydroxyisoquinoline (1.6 g; 11.0 mmol) and triethylamine (1.38 g; 13.6 mmol) in dichloromethane (25 mL) at 0° C. was treated slowly with triflic anhydride (3.35 g; 12.1 mmol), stirred overnight while warming to room temperature, diluted with dichloromethane, washed twice with water and saturated NH[0245] 4Cl (aq.), once with water and brine, dried (Na2SO4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 7% ethyl acetate/dichloromethane to provide the desired product (1.54 g; 50%).
    • Example 23B 3-amino-5-bromopyridine
  • A solution of 3M NaOH (250 mL) at room temperature was treated with bromine (25.9 g, 162 mmol), stirred for 15 minutes, treated with 5-bromonicotinamide (25 g, 124 mmol), stirred for 45 minutes, heated to 85-100° C. for 3 hours, cooled to room temperature, adjusted to pH 1 with 10% HCl (aq.) washed twice with diethyl ether. The aqueous layer was adjusted to pH˜10-11 with solid NaOH, and extracted four times with diethyl ether and twice with dichloromethane. The combined extracts were dried (MgSO[0246] 4), filtered, and concentrated to provide the desired product (13.3 g, 62%).
    • Example 23C N-(5-bromopyridin-3-yl)isoquinolin-5-amine
  • A mixture Example 23A (500 mg, 1.8 mmol), Example 23B (600 mg, 3.5 mmol), Pd[0247] 2(dba)3 (42 mg; 0.045 mmol), BINAP (56 mg; 0.09 mmol), and sodium tert-butoxide (350 mg; 3.6 mmol) in 10 mL toluene was heated to reflux for 2 hours, diluted with water, and extracted three times with ethyl acetate. The combined extracts were washed successively with saturated NaHCO3, water, and brine, dried (Na2SO4), and concentrated. The concentrate was purified by flash column chromatography on silica gel with 3% methanol/dichloromethane to provide the desired product (97 mg, 18%).
    • Example 23D N-(diphenylmethylene)-N′-isoquinolin-5-ylpyridine-3,5-diamine
  • A mixture-of Example 23C (175 mg, 0.58 mmol), benzophenone imine (150 mg, 0.83 mmol), Pd[0248] 2(dba)3 (54 mg, 0.06 mmol), BINAP (55 mg, 0.09 mmol), and sodium tert-butoxide (80 mg, 0.82 mmol) in 3 mL toluene was heated to 75-80° C. for 4 hours and concentrated. The concentrate was purified by flash column chromatography on silica gel with 3% methanol/dichloromethane to provide the desired product (150 mg, 64%).
    • Example 23E N-isoquinolin-5-ylpyridine-3,5-diamine
  • A mixture of Example 23D (145 mg; 0.36 mmol) in 3 mL THF at room temperature was treated with 10 drops of water and 3 drops of conc. HCl, stirred for 2 hours, and concentrated. The residue was partitioned between ethyl acetate and concentrated NaHCO[0249] 3 (aq). The aqueous layer was extracted three times with ethyl acetate. The combined extracts were washed with brine, dried (MgSO4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 10% methanol/dichloromethane to provide the desired product (59 mg, 68%).
    • Example 23F tert-butyl (1S)-2-(1H-indol-3-yl)-1-({[5-(isoquinolin-5-ylamino)pyridin-3-yl]amino}methyl)ethylcarbamate
  • A mixture of Example 23E (55 mg, 0.23 mmol) and L-Boc-tryptophanal (84 mg, 0.29 mmol) in 2 mL dichloromethane at room temperature was treated with Ti(iPrO)[0250] 4 (1 mL), stirred for 2 hours, and concentrated. The residue was dissolved in 2 mL ethanol, treated with NaBH3CN (30 mg; 0.46 mmol), stirred for 2 hours, diluted with water, and filtered. The filter cake was washed with methanol and the filtrate was concentrated. The residue was suspended in methanol/dichloromethane and filtered. The filtrate was concentrated and the concentrate was purified by flash column chromatography on silica gel with 5% methanol/dichloromethane to provide the desired product (28 mg, 24%).
    • Example 23G N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N′-isoquinolin-5-ylpyridine-3,5-diamine
  • A solution of Example 23F (26 mg, 0.05 mmol) in 2 mL dichloromethane at room temperature was treated with 0.5 mL TFA, stirred for 3 hours, and concentrated. The concentrate was purifed by reverse phase HPLC on a C18 column with 0-100% CH[0251] 3CN/H2O/0.1% TFA and the residue was dissolved in water and lyophilized to provide the desired product as the trifluoroacetate salt (27 mg, 70%). MS (ESI(+)) m/e 409 (M+H)+; 1H NMR (DMSO-d6, 500 MHz) δ 11.02 (s, 1H), 9.44 (s, 1H), 9.07 (s, 1H), 8.57 (d, J=9 Hz, 1H), 7.95-8.01 (m, 2H), 7.88-7.93 (m, 2H), 7.68-7.73 (m, 3H), 7.57-7.59 (m, 1H), 7.53 (d, J=8 Hz, 1H), 7.38 (d, J=8 Hz, 1H), 7.24-7.27 (m, 1H),7.09 (t, J=9 Hz, 1H), 6.89 (t, J=9 Hz, 1H), 6.92 (s, 1H), 6.83 (br s, 1H), 3.33-3.40 (m, 1H), 3.00-3.14 (m, 4H); Anal. Calcd for C25H24N6.3TFA.3H2O: C, 46.28; H, 4.13; N, 10.44; F, 21.25. Found: C, 46.32; H, 3.54; N, 10.02; F, 21.58.
    • EXAMPLE 24 N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-[5-(isoquinolin-5-yloxy)pyridin-3-yl]amine Example 24A 5-[(5-bromopyridin-3-yl)oxy]isoquinoline
  • A sealed tube was charged with 5-hydroxyisoquinoline (0.15 g, 1.03 mmol), 3,5-dibromopyridine (0.24 g, 1.03 mmol), potassium carbonate (0.27 g, 2.0 mmol) and DMF (4 mL). The reaction was heated to 240° C. for 10 minutes in a personal chemistry microwave. The reaction was partitioned between water and ethyl acetate. The aqueous layer was extracted twice with ethyl acetate. The combined extracts were concentrated and the residue was purified by flash column chromatography on silica gel with 2:1 ethyl acetate/hexanes to provide the desired product (0.071 g, 23%). [0252]
    • Example 24B N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-[5-(isoquinolin-5-yloxy)pyridin-3-yl]amine
  • The desired product was prepared by substituting Example 24A for Example 23C in Examples 23D then proceeding as described for Examples 23E, 23F, and 23G. MS (ESI) m/e 410 (M+H)[0253] +; 1H NMR (DMSO-d6, 300 MHz) δ 11.00 (br s, 1H),9.47 (br s, 1H), 8.58 (d, J=8 Hz, 1H), 7.97-8.03 (m, 1H), 7.92-7.94 (m, 1H), 7.85-7.87 (m, 1H), 7.79-7.82 (m, 2H), 7.66-7.72 (m, 2H), 7.51-7.54 (m, 1H), 7.26-7.36 (m, 3H), 7.02-7.08 (m, 1H), 6.94-6.98 (m, 1H), 6.68-6.71 (m, 1H), 6.39 (br s, 1H), 3.73-3.80 (m, 1H), 3.43-3.52 (m, 2H), 3.16-3.19 (m, 2H);
  • Anal. Calcd for C[0254] 25H23N5O3TFA: C, 49.53; H, 3.46; N, 9.30; F, 22.76. Found: C, 49.44; H, 3.58; N, 9.14; F, 22.30.
    • EXAMPLE 25 (2S)-2-amino-3-(1H-indol-3-yl)-N-[5-(1,6-naphthyridin-2-yl)pyridin-3-yl]propanamide Example 25A 2,2-dimethyl-N-pyridin-4-ylpropanamide
  • A mixture of 4-aminopyridine (10 g, 106 mmol) and pivaloyl chloride (12.9 g, 107 mmol) in 200 mL dichloromethane was cooled to 0° C. and treated slowly with triethylamine (10.9 g, 108 mmol), warmed to room temperature, stirred overnight, and diluted with water. The aqueous layer was extracted three times with dichloromethane and the combined extracts were washed with brine, dried (Na[0255] 2SO4), filtered, and concentrated. The product was recrystallized from toluene to provide the desired product (14 g, 74%).
    • Example 25B N-(3-formylpyridin-4-yl)-2,2-dimethylpropanamide
  • A mixture of Example 25A (11.4 g, 64 mmol) in 200 mL THF was cooled to −78° C., treated with 1.6 M nBuLi in hexanes (100 mL, 160 mmol), warmed to [0256] 0° C., stirred for 1 hour, treated with a solution of DMF (22 g, 215 mmol) in 100 mL THF, warmed to room temperature, stirred for 1 hour, diluted with brine, and extracted three times with ethyl acetate. The combined extracts were washed with water, washed twice with brine, dried (MgSO4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 3% methanol/dichloromethane to provide the desired product (9.1 g, 69%).
    • Example 25C 4-aminonicotinaldehyde
  • A solution of Example 25B (870 mg, 4.2 mmol) in 3N HCl (aq.) (10 mL) was heated to reflux overnight, and extracted three times with diethyl ether. The aqueous layer was adjusted to pH>7 with solid K[0257] 2CO3 and extracted six times with 20% isopropanol/chloroform. The combined extracts were dried (Na2SO4), filtered, and concentrated to provide the desired product (450 mg; 87%).
    • Example 25D 5-acetylnicotinamide
  • A mixture of 5-bromonicotinamide (2.5 g, 12.4 mmol), tributyl(1-ethoxyvinyl)tin (5.0 g, 13.8 mmol) and dichlorobis(triphenylphosphine)palladium(II) (800 mg, 1.1 mmol) in 25 mL toluene was heated to reflux for 3 hours. The mixture was cooled to room temperature, treated with 25 mL 2N HCl (aq.), and stirred for 1 hour. The aqueous layer was washed with ethyl acetate, adjusted to pH>7 with solid K[0258] 2CO3, and extracted six times into 20% isopropanol/chloroform. The combined extracts were dried (Na2SO4), filtered, and concentrated to provide the desired product (1.6 g, 78%).
    • Example 25E 5-(1,6-naphthyridin-2-yl)nicotinamide
  • A mixture of Example 25C (450 mg, 3.68 mmol) and Example 25D (605 mg, 3.68 mmol) in 20 mL ethanol and 1.2 mL of 10% NaOH (aq) was heated to reflux for 3 hours and concentrated. The solid was collected and rinsed with ethyl acetate to provide the desired product (740 mg, 80%). [0259]
    • Example 25F 5-(1,6-naphthyridin-2-yl)pyridin-3-amine
  • The desired product was prepared by substituting Example 25E for 5-bromonicotinamide in Example 23B. [0260]
    • Example 25G tert-butyl (1S)-1-(1H-indol-3-ylmethyl)-2-{[5-(1,6-naphthyridin-2-yl)pyridin-3-yl]amino}-2-oxoethylcarbamate
  • The desired product was prepared by substituting Example 25F (100 mg, 0.45 mmol) and L-Boc-tryptophan (150 mg, 0.49 mmol) for Example 11B and Boc-homophenylalanine, respectively, in Example 16A. [0261]
    • Example 25H (2S)-2-amino-3-(1H-indol-3-yl)-N-[5-(1,6-naphthyridin-2-yl)pyridin-3-yl]propanamide
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 25G for Example 2B in Example 2D. MS (ESI) m/e 409 (M+H)[0262] +; 1H NMR (DMSO-d6, 500 MHz) δ 11.04 (br s, 1H), 10.91 (s, 1H), 9.50 (s, 1H), 9.23 (d, J=3 Hz, 1H), 8.95 (d, J=3 Hz, 1H), 8.77-8.83 (m, 3H), 8.42 (d, J=8 Hz, 1H), 8.28-8.32 (m, 2H), 7.97-8.00 (m, 1H), 7.65-7.69 (m, 1H), 7.37 (d, J=8 Hz, 1H), 7.26-7.28 (m, 1H), 7.06-7.11 (m, 1H), 6.96-7.01 (m, 1H), 4.18-4.25 (m, 1H), 3.25-3.45 (m, 2H); Anal. Calcd for C24H20N6O.3TFA.1H2O: C, 46.88; H, 3.28; N, 10.93; F, 22.25. Found: C, 47.19; H, 3.39; N, 11.14; F, 21.81.
    • EXAMPLE 26 N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-[5-(1,6-naphthyridin-2-yl)pyridin-3-yl]amine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 25F for Example 23E in Examples 23F and 23G. MS (ESI) m/e 395 (M+H)[0263] +; 1H NMR (DMSO-d6, 500 MHz) δ 11.07 (br s, 1H), 9.51 (s, 1H), 8.74-8.83 (m, 3H), 8.27 (d, J=9 Hz, 1H), 8.18 (d, J=4 Hz, 1H), 7.93-7.97 (m, 4H), 7.60-7.64 (m, 1H), 7.39 (d, J=9 Hz, 1H), 7.34 (d, J=4 Hz, 1H), 7.06-7.12 (m, 1H), 6.96-7.02 (m, 1H), 6.78 (br s, 1H), 3.40-3.67 (m, 3H), 3.11-3.16 (m, 2H); Anal. Calcd for C24H22N6.3.25TFA: C, 47.88; H, 3.33; N, 10.98; F, 24.21. Found: C, 47.51; H, 3.29; N, 10.94; F, 24.16.
    • EXAMPLE 27 (1S)-2-(1H-indol-3-yl)-1-{[(5-isoquinolin-6-ylpyridin-3-yl)oxy]methyl}ethylamine Example 27A 6-(trimethylstannyl)isoquinoline
  • A solution of 6-bromoisoquinoline (0.35 g, 1.7 mmol) in DMA (6 mL) was treated with hexamethylditin (0.55 mL, 1.9 mmol) and Pd(PPh[0264] 3)4 (0.23 g, 0.2 mmol), stirred at 100° C. for 1 hour, diluted with water, and extracted three times with ethyl acetate. The combined extracts were concentrated and the residue was purified by flash column chromatography on silica gel with 1:1 hexanes/ethyl acetate to provide the desired product (0.247 g, 50%).
    • Example 27B tert-butyl (1S)-2-(1H-indol-3-yl)-1-{[(5-isoquinolin-6-ylpyridin-3-yl)oxy]methyl}ethylcarbamate
  • A solution of Example 27A (0.25 g, 0.86 mmol) and Example 2A (0.444 g, 1.00 mmol) in 6 mL of DMF was treated with Pd[0265] 2(dba)3 (0.08 g, 0.086 mmol), tri-o-tolylphosphine (0.02 g, 0.04 mmol), and triethylamine (0.15 mL, 1.0 mmol), heated to 75° C. in a sealed tube for 8 hours, and concentrated. The residue was purified by flash column chromatography on silica gel with 2.5% methanol/dichloromethane to provide the desired product (0.125 g, 30%).
    • Example 27C (1S)-2-(1H-indol-3-yl)-1-{[(5-isoquinolin-6-ylpyridin-3-yl)oxy]methyl}ethylamine
  • A solution of Example 27B (0.125 g, 0.25 mmol) in dichloromethane (3 mL) at room temperature was treated with TFA (400 μL), stirred for 1 hour, and concentrated. The concentrate was azeotropically distilled with diethyl ether two times and the residue was purified by reverse phase HPLC on a C18 column with 0-100% CH[0266] 3CN/H2O/0.1% TFA to provide the desired product as the di-trifluoroacetate salt (0.110 g, 70%). MS (ESI) m/e 395 (M+H)+; 1H NMR (DMSO-d6, 300 MHz) δ 11.02 (br s, 1H), 9.52 (s, 1H), 8.76 (d, J=3 Hz, 1H), 8.62 (d, J=8 Hz, 1H), 8.44-8.46 (m, 2H), 8.38 (d, J=9 Hz, 1H), 8.11-8.20 (m, 3H), 8.04-8.08 (m, 1H), 7.83-7.86 (m, 1H), 7.62 (d, J=9 Hz, 1H), 7.37-7.40 (m, 1H), 7.31 (d, J=3 Hz, 1H), 7.08-7.12 (m, 1H), 6.99-7.03 (m, 1H), 4.37-4.41 (m, 1H), 4.18-4.23 (m, 1H), 3.86-3.91 (m, 1H), 3.16-3.20 (m, 2H); Anal. Calcd for C25H22N4O.2TFA.H2O: C, 49.35; H, 3.61; N, 7.43; F, 22.67. Found: C, 49.04; H, 3.55; N, 7.42; F, 22.28.
    • EXAMPLE 28 (1R)-2-(1H-indol-3-yl)-1-{[(5-quinolin-6-ylpyridin-3-yl)oxy]methyl}ethylamine Example 28A tert-butyl (1R)-2-[(5-hydroxypyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylcarbamate
  • The desired product was prepared by substituting D-Boc-tryptophanol for L-Boc tryptophanol in Example 2A. [0267]
    • Example 28B (1R)-2-(1H-indol-3-yl)-1-{[(5-quinolin-6-ylpyridin-3-yl)oxy]methyl}ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting 28A for 2A in Example 27B then removing the Boc group as in Example 27C. MS (ESI) m/e 395 (M+H)[0268] +; 1H NMR (DMSO-d6, 500 MHz) δ 11.02 (s, 1H), 8.97-9.00 (m, 1H), 8.74 (d, J=3 Hz, 1H), 8.50-8.54 (m, 1H), 8.39-8.42 (m, 2H), 8.18-8.23 (m, 3H), 8.13-8.17 (m, 1H), 7.81-7.83 (m, 1H), 7.61-7.66 (m, 2H), 7.39 (d, J=8 Hz, 1H), 7.31 (d, J=3 Hz, 1H), 7.07-7.10 (m, 1H), 6.99-7.02 (m, 1H), 4.38-4.41 (m, 1H), 4.21-4.24 (m, 1H), 3.79-3.83 (m, 1H), 3.16-3.19 (m, 2H).
    • EXAMPLE 29 (1S)-2-[(6-chloro-5-isoquinolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 13A for Example 2A in Example 27. MS (APCI) m/e 429, 431 (M+H)[0269] +; 1H NMR (300 MHz, CD3OD) δ 9.77 (s, 1H), 8.63 (d, J=6.4 Hz, 1H), 8.54 (d, J=8.8 Hz, 1H), 8.43 (d, J=6.4 Hz, 1H), 8.30 (s, 1H), 8.27 (d, J=3.1 Hz, 1H), 8.06 (dd, J=8.4, 1.7 Hz, 1H), 7.58 (s, 1H), 7.56 (d, J=5.4 Hz, 1H), 7.35 (d, J=8.1 Hz, 1H), 7.22 (s, 1H), 7.10 (td, J=7.1, 1.4 Hz, 1H), 7.00 (td, J=7.8, 1.0 Hz, 1H), 4.37 (dd, J=10.5, 3.4 Hz, 1H), 4.24 (dd, J=10.5, 5.8 Hz, 1H), 3.98 (m, 1H), 3.27 (m, 2H); Anal. Calcd for C25H21ClN4O.2.25TFA: C, 51.69; H, 3.42; N, 8.17. Found: C, 51.75; H, 3.39; N, 8.13.
    • EXAMPLE 30 (1S)-2-[(2-chloro-5-isoquinolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamine
  • The desired product was prepared as the trifluoracetate salt by substituting Example 12C for Example 2A in Example 27 (0.02 g, 80%). MS (DCI/NH[0270] 3) m/e 429, 431 (M+H)+; 1H NMR (DMSO-d6) δ 11.04 (s, 1H), 9.50 (s, 1H), 8.62 (d, J=6.0 Hz, 1H), 8.57 (s, 1H), 8.44 (s, 1H), 8.35 (d, J=9.0 Hz, 1H), 8.22 (s, 2H), 8.13 (d, J=9.0 Hz, 1H), 8.00 (d, J=6.0 Hz, 1H), 7.98 (s, 1H), 7.64 (d, J=7.5 Hz, 1H), 7.38 (d, J=7.5 Hz, 1H), 7.30 (s, 1H), 7.10 (t, J=7.2 Hz, 1H), 7.00 (t, J=7.2 Hz, 1H), 4.46 (m, 1H), 4.30 (m, 1H), 3.92 (m, 1H), 3.21 (m, 2H).
    • EXAMPLE 31 (1R)-1-(1H-indol-3-ylmethyl)-3-(5-isoquinolin-6-ylpyridin-3-yl)propylamine Example 31A 6-(5-bromopyridin-3-yl)isoquinoline
  • A solution of 3,5-dibromopyridine (284 mg, 1.2 mmol), Pd[0271] 2(dba)3 (110 mg, 0.12 mmol) and tri-o-tolylphosphine (110 mg, 0.36 mmol) in DMF (15 mL) was treated with Example 27A (500 mg, 1.2 mmol) and triethylamine (500 μL, 3.6 mmol), purged with nitrogen, heated to 70° C. for 6 hours, cooled to room temperature, treated with ethyl acetate (100 mL), washed with brine, dried (MgSO4), filtered, and concentrated. The residual oil was purified by flash column chromatography on silica gel with ethyl acetate to provide the desired product (110 mg, 32%). MS (APCI) m/e 285, 287 (M+H)+.
    • Example 31B (1R)-1-(1H-indol-3-ylmethyl)-3-(5-isoquinolin-6-ylpyridin-3-yl)propylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 31A for Example 21B in Example 21D then removing the Boc protecting group as described for Example 21E. MS (DCI/NH[0272] 3) m/e 458 (M+H)+; 1H NMR (CD3OD) δ 9.78 (s, 1H), 8.97 (d, J=1.1 Hz, 1H), 8.64 (d, J=6.4 Hz, 1H), 8.61 (d, J=8.9 Hz, 1H), 8.55 (s, 1H), 8.53 (s, 1H), 8.47 (d, J=6.5 Hz, 1H), 8.25 (dd, J=8.4, 1.7 Hz, 1H), 8.23 (s, 1H), 7.49 (d, J=7.9 Hz, 1H), 7.30 (d, J=8.2 Hz, 1H), 7.22 (s, 1H), 7.06 (td, J=7.1, 1.0 Hz, 1H), 6.97 (td, J=7.1, 1.0 Hz, 1H), 3.59 (p, J=6.5 Hz, 1H), 3.18 (dd, J=7.1, 3.4 Hz, 2H), 2.99 (m, 2H), 2.15 (m, 2H).
    • EXAMPLE 32 5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1H-isoindole-1,3(2H)-dione Example 32A tert-butyl (1S)-2-(1H-indol-3-yl)-1-({[5-(trimethylstannyl)pyridin-3-yl]oxy{methyl)ethylcarbamate
  • A solution of Example 2A (1 g, 2.23 mmol) in DMA (15 mL) was treated with hexamethylditin (1.8 mL, 5.6 mmol) and Pd(PPh[0273] 3)4 (0.4 g, 0.2 mmol), heated to 75° C. for 1.5 days, added to water, and extracted three times with ethyl acetate. The combined extracts were concentrated and the residue was purified by flash column chromatography on silica gel with 1:1 hexanes/ethyl acetate to provide the desired product (0.4 g, 34%).
    • Example 32B tert-butyl (1S)-2-{[5-(1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)pyridin-3-yl]oxy}-1-(1H-indol-3-ylmethyl)ethylcarbamate
  • A solution of Example 32A (0.2 g, 0.31 mmol) and 6-bromophthalimide (0.084 g, 0.4 mmol) in DMF (2 mL) was treated with Pd[0274] 2 dba3 (0.04 g, 0.02 mmol), tri-o-tolylphosphine (0.02 g, 0.01 mmol), and triethylamine (0.06 mL, 0.4 mmol). The reaction was heated to 75° C. for 6 hours in a sealed tube and concentrated. The residue was purified by flash column chromatography on silica gel with 1:1 hexanes/ethyl acetate to provide the desired product (0.116 g, 55%).
    • Example 32C 5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1H-isoindole-1,3(2H)-dione
  • The desired product was prepared as the trifluoracetate salt by substituting Example 32B for Example 27B in Example 27C. MS (ESI) m/e 413 (M+H)[0275] +; 1H NMR (DMSO-d6, 300 MHz) δ 11.43 (s, 1H), 11.02 (br s, 1H), 8.67 (d, J=3 Hz, 1H), 8.42 (d, J=6 Hz, 1H), 8.14-8.18 (m, 4H), 7.92-7.96 (m, 1H), 7.79-7.81 (m, 1H), 7.61 (d, J=9 Hz, 1H), 7.38 (d, J=9 Hz, 1H), 7.30 (d, J=3 Hz, 1H), 7.08-7.12 (m, 1H), 6.98-7.03 (m, 1H), 4.35-4.40 (m, 1H), 4.17-4.22 (m, 1H), 3.83-3.88 (m, 1H), 3.13-3.17 (m, 2H). Anal. Calcd for C24H20N4O3.2.1TFA: C, 51.96; H, 3.42; N, 8.59; F, 18.30. Found: C, 51.45; H, 3.46; N, 8.56; F, 17.47.
    • EXAMPLE 33 5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)isoindolin-1-one Example 33A Methyl 4-bromo-2-methylbenzoate
  • A solution of 4-bromo-2-methyl benzoic acid (1.0 g, 4.7 mmol) in methanol (24 mL) was treated with 20 drops of HCl, heated at reflux for 6 hours, and concentrated to provide the desired product (1.07 g, 100%). [0276]
    • Example 33B Methyl 4-bromo-2-(bromomethyl)benzoate
  • A solution of Example 33A (1.02 g, 4.47 mmol) in CCl[0277] 4 (22 mL) was treated with AIBN (0.065 g, 0.4 mmol) and NBS (0.955 g, 5.4 mmol), heated to reflux for 4 hours, washed with water, dried (Na2SO4), filtered, and concentrated to provide the desired product (1.1 g, 79%).
    • Example 33C 5-bromoisoindolin-1-one
  • A solution of Example 33B (1.1 g, 3.57 mmol) in THF (20 mL) at room temperature was treated with 1N NH[0278] 3 in methanol (7.14 mL, 7.14 mmol), stirred for 24 hours, and filtered. The filter cake was washed with diethyl ether (100 mL) to provide the desired product (0.4 g, 52%).
    • Example 33D 5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)isoindolin-1-one
  • The desired product was prepared as the trifluoroacetate salt by substituitng Example 33C for 6-bromophthalimide in Example 32. MS (ESI) m/e 399 (M+H)[0279] +; 1H NMR (DMSO-d6, 300 MHz) δ 11.03 (br s, 1H), 8.63 (s, 1H), 8.57 (s, 1H), 8.35 (br s, 3H), 7.90 (s, 1H), 7.78 (s, 2H), 7.67 (s, 1H), 7.61 (d, J=8 Hz, 1H), 7.37 (d, J=8 Hz, 1H), 7.79 (d, J=2 Hz, 1H), 7.03-7.10 (m, 1H), 6.96-7.01 (m, 1H), 4.32-4.36 (m, 1H), 4.17-4.22 (m, 1H), 3.80-3.83 (m, 1H), 3.18 (d, J=8 Hz, 2H), 2.50 (s, 2H).
    • EXAMPLE 34 (1S)-2-[(5-cinnolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamine Example 34A N-(2-acetylphenyl)acetamide
  • A solution of 2′-aminoacetophenone (5.0 g, 37 mmol) in dichloromethane (150 mL) at room temperature was treated with triethylamine (5.3 mL, 40 mmol) and acetyl chloride (3.2 mL, 45 mmol), stirred for 3 hours, then washed with water. The aqueous layer was extracted with ethyl acetate (2×20 mL) and the combined extracts were concentrated to provide the desired product (6.5 g, 100%). [0280]
    • Example 34B N-(2-acetyl-4-bromophenyl)acetamide
  • A solution Example 34A (6.5 g, 37 mmol) in acetic acid (100 mL) at room temperature was treated with Br[0281] 2 (4 mL, 84 mmol), stirred for 1 hour and 15 minutes, poured into water (200 mL), and filtered. The solid was washed with water (2×100 mL), and hexanes (2×100 mL), dissolved in diethyl ether, washed with brine (50 mL), and concentrated to provide the desired product (8.5 g, 89%).
    • Example 34C 6-bromocinnolin-4(1H)-one
  • A solution of Example 34B (6.28 g, 24.4 mmol) in THF (75 mL) was treated with concentrated HCl (aq.) (15 mL) and water (15 mL), heated to reflux for 1 hour, and concentrated to remove the THF. The aqueous solution was treated with additional water (5 mL) and concentrated HCl (5 mL), cooled to 0° C., treated with a solution of NaNO[0282] 2 (1.85 g, 26.84 mmol) in water (10 mL) in 5 portions, warmed to room temperature gradually over a 2-hour period, and stirred overnight at room temperature. The reaction was heated to reflux for 6 hours, and filtered. The solid was washed with water (50 mL) and diethyl ether (50 mL) and dried under vacuum to provide the desired product (3.0 g, 54%).
    • Example 34D 6-bromo-4-chlorocinnoline
  • A solution of Example 34C (0.4 g, 1.8 mmol) in POCl[0283] 3 (2.5 mL) was heated to 100° C. for 2 hours, and poured slowly onto ice. The aqueous layer was cooled to 0° C. and adjusted to pH 5-7 with 50% NaOH. The aqueous layer was extracted with ethyl acetate (2×50 mL), and the combined organic layers were concentrated. The residue was purified by flash column chromatography on silica gel with 4:1 hexanes/ethyl acetate to provide the desired product (0.190 g, 43%).
    • Example 34E 6-bromo-4-hydrazinocinnoline
  • A solution of Example 34D (2.6 g, 10.6 mmol) in ethanol (70 mL) was treated with hydrazine monohydrate (3 mL, 90% solution), stirred at room temperature for 3 days, and filtered. The solid washed with water (50 mL) and diethyl ether (50 mL) and dried under vacuum to provide the desired product (2.5 g, 100%). [0284]
    • Example 34F 6-bromocinnoline
  • A solution of Example 34E (3.5 g, 14 mmol) in water (50 mL) was heated to reflux, treated dropwise with a solution of CuSO[0285] 4 (2.8 g, 17.5 mmol) in water (20 mL), refluxed for 2 hours, cooled to room temperature, adjusted to pH 7 with saturated NaHCO3 (aq), and extracted with ethyl acetate (2×25 mL). The combined extracts were concentrated and the residue was purified by flash column chromatography on silica gel with 1:1 hexanes/ethyl acetate to provide the desired product (0.7 g, 24%).
    • Example 34G (1S)-2-[(5-cinnolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 34F for 6-bromophthalimide in Example 32. MS (ESI) m/e 396 (M+H)[0286] +; 1H NMR (DMSO-d6, 300 MHz) δ 11.04 (s, 1H), 9.43 (d, J=6 Hz, 1H), 8.78 (d, J=2 Hz, 1H), 8.60 (d, J=8 Hz, 1H), 8.45-8.49 (m, 2H), 8.30-8.34 (m, 1H), 8.26 (d, J=6 Hz, 1H), 8.21-8.25 (m, 2H), 7.89 (t, J=2 Hz, 1H), 7.63 (d, J=8 Hz, 1H), 7.39 (d, J=8 Hz, 1H), 7.31 (d, J=2 Hz, 1H), 7.08-7.12 (m, 1H), 7.01-7.04 (m, 1H), 4.38-4.42 (m, 1H), 4.22-4.26 (m, 1H), 3.83-3.88 (m, 1H), 3.17-3.20 (m, 2H).
    • EXAMPLE 35 (1S)-2-{[5-(1H-indazol-5-yl)pyridin-3-yl]oxy}-1-(1H-indol-3-ylmethyl)ethylamine Example 35A 5-bromo-1H-indazole
  • A mixture of 5-bromo-2-fluorobenzaldehyde (10 g, 49.2 mmol) and 98% hydrazine (20 mL) was heated to reflux for 5 hours, poured over ice, and filtered. The solid was recrystallized from H[0287] 2O/methanol to provide the desired product (3.7 g, 38%).
    • Example 35B (1S)-2-{[5-(1H-indazol-5-yl)pyridin-3-yl]oxy}-1-(1H-indol-3-ylmethyl)ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 35A for 6-bromophthalimide in Example 32. MS (ESI) m/e 384 (M+H)[0288] +; 1H NMR (DMSO-d6, 300 MHz) δ 13.22 (br s, 1H), 11.04 (br s, 1H), 8.62 (d, J=2 Hz, 1H), 8.33 (d, J=3 Hz, 1H), 8.13-8.21 (m, 3H), 8.12 (s, 1H), 7.67-7.72 (m, 3H), 7.64 (d, J=8 Hz, 1H), 7.39 (d, J=8 Hz, 1H), 7.30 (d, J=2 Hz, 1H), 7.06-7.13 (m, 1H), 6.98-7.04 (m, 1H), 4.14-4.39 (m, 2H), 3.33-3.38 (m, 1H), 3.13-3.16 (m, 2H); Anal. Calcd for C23H21N5O.2TFA.H2O: C, 51.52; H, 4.00; N, 11.13. Found: C, 51.80; H, 3.61; N, 11.03.
    • EXAMPLE 36 5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1,3-dihydro-2H-indol-2-one
  • The desired product was prepared as the trifluoroacetate salt by substituting 5-bromooxindole for 6-bromophthalimide in Example 32. MS (APCI) m/e 399 (M+H)[0289] +; 1H NMR (300 MHz, CD3OD) δ 8.59 (s, 1H), 8.35 (s, 1H), 7.92 (s, 1H), 7.60 (d, J=6.9 Hz, 1H), 7.58 (s, 1H), 7.55 (d, J=10.1 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.24 (s, 1H), 7.13 (t, J=7.6 Hz, 1H), 7.03 (d, J=8.0 Hz, 1H), 7.03 (t, J=7.5 Hz, 1H), 4.45 (dd, J=10.5, 3.2 Hz, 1H), 4.31 (dd, J=10.5, 5.8 Hz, 1H), 4.01 (m, 1H), 3.62 (s, 2H), 3.32 (m, 1H), 3.29 (m, 1H); Anal. Calcd for C24H22N4O2.2.5 TFA: C, 50.96; H, 3.61; N, 8.20. Found: C, 50.96; H, 3.62; N, 8.12.
    • EXAMPLE 37 (1S)-2-{[5-(2,1,3-benzoxadiazol-5-yl)pyridin-3-yl]oxy}-1-(1H-indol-3-ylmethyl)ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting 5-chloro-2,1,3-benzoxadiazole for 6-bromophthalimide in Example 32. MS (APCI) m/e 386 (M+H)[0290] +; 1H NMR (300 MHz, CD3OD) δ 8.64 (s, 1H), 8.44 (s, 1H), 8.18 (s, 1H), 8.05 (d, J=10.4 Hz, 1H), 7.81 (d, J=10.9 Hz, 1H), 7.78 (s, 1H), 7.59 (d, J=6.7 Hz, 1H), 7.37 (d, J=7.1 Hz, 1H), 7.24 (s, 1H), 7.12 (t, J=8.1 Hz, 1H), 7.03 (t, J=6.9 Hz, 1H), 4.44 (dd, J=10.5, 3.1 Hz, 1H), 4.29 (dd, J=10.6, 5.8 Hz, 1H), 3.99 (m, 1H), 3.32 (s, 1H), 3.30 (s, 1H); Anal. Calcd for C22H19N5O2.2.45 TFA: C, 48.60; H, 3.25; N, 10.53. Found: C, 48.68; H, 3.48; N, 10.58.
    • EXAMPLE 38 (1S)-2-(1H-indol-3-yl)-1-{[(5-thieno[2,3-c]pyridin-2-ylpyridin-3-yl)oxy]methyl}ethylamine Example 38A 2-(trimethylstannyl)thieno[2,3-c]pyridine
  • A solution of thieno[2,3-c]pyridine (J. Wikel, et al., J. Heterocycl. Chem., 1993, 30, 289) (2.0 g, 14.8 mmol) in THF (50 mL) at −78° C. was treated with n-butyllithium (2.5 M solution in hexane, 7.1 mL, 17.8 mmol), warmed to 0° C., stirred for 15 minutes, cooled to −78° C., treated slowly with trimethyltin chloride (3.54 g, 17.8 mmol) in THF (10 mL), warmed to room temperature for 2 hours, and partitioned between ethyl acetate and brine. The ethyl acetate solution was washed with water, and concentrated. The residue was purified by flash chromatography (10-35% ethyl acetate in hexane) to provide the desired product (3.15 g, 71%). MS (APCI) m/e 298 (M+H)[0291] +.
    • Example 38B (1S)-2-(1H-indol-3-yl)-1-{[(5-thieno[2,3-c]pyridin-2-ylpyridin-3-yl)oxy]methyl}ethylamine
  • The desired product was prepared as the trifluoroacetate by substituting Example 38A for Example 27A in Examples 27B and 27C. MS (APCI) m/e 402 (M+H)[0292] +; 1H NMR (300 MHz, CD3OD) δ 9.58 (s, 1H), 8.78 (s, 1H), 8.63 (d, J=6.4 Hz, 1H), 8.49 (s, 1H), 8.36 (d, J=6.4 Hz, 1H), 8.20 (s, 1H), 7.86 (s, 1H), 7.60 (d, J=8.6 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.25 (s, 1H), 7.12 (t, J=8.1 Hz, 1H), 7.03 (t, J=7.5 Hz, 1H), 4.45 (dd, J=10.6, 3.2 Hz, 1H), 4.30 (dd, J=10.5, 5.7 Hz, 1H), 4.02 (m, 1H), 3.32 (s, 1H), 3.30 (s, 1H); Anal. Calcd for C23H20N4OS.3.6 TFA: C, 44.73; H, 2.93; N, 6.91. Found: C, 44.74; H, 2.91; N, 6.77.
    • EXAMPLE 39 (3Z)-5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydro-2H-indol-2-one
  • The desired product was prepared by as the trifluoroacetate salt substituting 5-bromo-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one for 6-bromophthalimide (L. Sun, et al., J. Med. Chem., 1998, 41, 2588.) in Example 32. MS (APCI) m/e 476 (M+H)[0293] +; 1H NMR (400 MHz, DMSO-d6) δ 13.33 (br s, 1H), 11.05 (s, 1H), 11.04 (d, J=6.5 Hz, 1H), 8.64 (s, 1H), 8.34 (s, 1H), 8.22 (br s, 2H), 8.09 (s, 1H), 7.91 (s, 1H), 7.74 (br s, 1H), 7.62 (d, J=7.7 Hz, 1H), 7.51 (dd, J=8.3 Hz, 1H), 7.40 (s, 1H), 7.38 (d, J=8.3 Hz, 1H), 7.30 (d, J=2.2 Hz, 1H), 7.1 (dd, J=7.9 Hz, 1H), 7.01 (d, J=7.7 Hz, 1H), 7.00 (d, J=8.0 Hz, 1H), 6.85 (br s, 1H), 6.39 (s, 1H), 4.37 (dd, J=12.00, 3.1 Hz, 1H), 4.20 (dd, J=8.00, 6.0 Hz, 1H), 3.15-3.21 (m, 1H); Anal. Calcd for C29H25N5O2.2.6TFA: C, 53.21; H, 3.60; N, 9.07. Found: C, 53.36; H, 3.67; N, 8.92.
    • EXAMPLE 40 6-(5-{[(2R)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1,3-benzothiazol-2(3H)-one
  • The desired product was prepared by substituting 6-bromo-2-benzothiazolinone for 6-bromophthalimide in Example 32. MS (APCI) m/e 417 (M+H)[0294] +; 1H NMR (300 MHz, CD3OD) δ 8.52 (s, 1H), 8.31 (d, J=2.4 Hz, 1H), 7.77 (d, J=1.7 Hz, 1H), 7.71 (t, J=1.7 Hz, 1H), 7.59 (d, J=7.8 Hz, 1H), 7.56 (dd, J=6.0, 1.7 Hz, 1H), 7.39 (d, J=8.2 Hz, 1H), 7.25 (d, J=8.2 Hz, 1H), 7.23 (s, 1H), 7.14 (t, J=7.2 Hz, 1H), 7.03 (t, J=7.2 Hz, 1H), 4.41 (dd, J=12.0, 3.4 Hz, 1H), 4.26 (dd, J=9.0, 5.7 Hz, 1H), 3.97-4.02 (m, 1H); Anal. Calcd for C23H20N4O2.1.9 TFA: C, 50.84; H, 3.49; N, 8.85. Found: C, 51.22; H, 3.67; N, 8.49.
    • EXAMPLE 41 2-(1H-indol-3-yl)-2-(5-isoquinolin-6-ylpyridin-3-yl)ethanamine Example 41A tert-butyl 3-(cyanomethyl)-1H-indole-1-carboxylate
  • A solution of 3-cyanomethylindole (7.50 g, 48 mmol), di-tert-butyl dicarbonate (11.5 g, 52.8 mmol), and DMAP (300 mg) in dichloromethane (200 mL) was stirred at room temperature overnight. The mixture was concentrated and the residue was purified by flash column chromatography on silica gel with dichloromethane to provide the desired product (11.44 g, 93%). MS (DCI/NH[0295] 3) m/e 257 (M+H)+.
    • EXAMPLE 41B tert-butyl 3-[(5-bromopyridin-3-yl)(cyano)methyl]-1H-indole-1-carboxylate
  • A solution of Example 41A (5.46 g, 21.3 mmol) and 3,5-dibromopyridine (5.03 g, 21.3 mmol) in DMF (25 mL) at room temperature was treated with NaH (60% in mineral oil, 1.08 g, 25.6 mmol) in several portions. The reaction was stirred at room temperature for 20 minutes, heated to 60° C. for 2 hours, and poured into water. The aqueous layer was extracted with diethyl ether and the combined extracts were washed with water, dried (MgSO[0296] 4), filtered, and concentrated. The residue was purified by flash column chromatography on silica gel with ethyl acetate/hexanes (1:7) to provide the desired product (336 mg, 4%). MS (DCI/NH3) m/e 413 (M+H)+.
    • EXAMPLE 41C tert-butyl 3-[cyano(5-isoquinolin-6-ylpyridin-3-yl)methyl]-1H-indole-1-carboxylate
  • The desired product was prepared by substituting Example 41B for Example 2A in Example 27B. MS (DCI/NH[0297] 3) m/e 461 (M+H)+.
    • Example 41D 2-(1H-indol-3-yl)-2-(5-isoquinolin-6-ylpyridin-3-yl)ethanamine
  • A mixture of Example 41C (159 mg, 0.345 mmol), RaNi 2800 (525 mg), ammonia (2 mL), and triethylamine (2 mL) in methanol (20 mL) was stirred under hydrogen (60 psi) at room temperature for 73 hours and concentrated. The residue was triturated with ethyl acetate and methanol. The resulting solid was dissolved in trifluoroacetic acid (1 mL), stirred for 5 minutes at room temperature, and concentrated. The residue was purified by HPLC on a C18 column with 0-100% CH[0298] 3CN/H2O/0.1% TFA to provide the desired product as the trifluoroacetate salt (64 mg, 26%). MS (DCI/NH3) m/e 365 (M+H)+; 1H NMR (CD3OD) δ 9.80 (s, 1H), 9.12 (br s, 1H), 8.87 (br s, 1H), 8.68 (s, 1H), 8.64 (m, 3H), 8.51 (d, J=6.6 Hz, 1H), 8.35 (dd, J=1.6, 8.4 Hz, 1H), 7.52 (d, J=8.1 Hz, 1H), 7.50 (s, 1H), 7.42 (d, J=8.4 Hz, 1H), 7.15 (m, 1H), 7.03 (m, 1H), 4.95 (t, J=7.8 Hz, 1H), 3.91 (m, 2H).
    • EXAMPLE 42 2-(1H-indol-3-yl)-3-(5-isoquinolin-6-ylpyridin-3-yl)propan-1-amine Example 42A (2Z)-3-(5-bromopyridin-3-yl)-2-(1H-indol-3-yl)acrylonitrile
  • A solution of 3-cyanomethylindole (156 mg, 1.0 mmol) in anhydrous ethanol (1.5 mL) at room temperature was treated with 21% sodium ethoxide in ethanol (450 μL), stirred for 1 hour, treated with 3-bromopyridine-5-carboxaldehyde (J. Heterocycl. Chem., 1995, 32, 1801.) (187 mg, 1.0 mmol), stirred overnight, and concentrated. The residue was purified by flash column chromatography on silica gel with 2% methanol/dichloromethane to provide the desired product (52 mg, 16%). MS (DCI/NH[0299] 3) m/e 325 (M+H)+.
    • Example 42B 2-(1H-indol-3-yl)-3-(5-isoquinolin-6-ylpyridin-3-yl)propan-1-amine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 42A for Example 41B in Examples 41C and 41D. MS (DCI/NH[0300] 3) m/e 379 (M+H)+; 1H NMR (CD3OD) δ 9.70 (s, 1H), 8.88 (s, 1H), 8.61 (d, J=6.6 Hz, 1H), 8.47 (m, 2H), 8.86 (d, J=6.6 Hz, 1H), 8.03 (s, 1H), 7.86 (s, 1H), 7.83 (dd, J=1.6, 8.4 Hz, 1H), 7.54 (d, J=7.8 Hz, 1H), 7.45 (d, J=8.1 Hz, 1H), 7.21 (s, 1H), 7.17 (m, 1H), 7.04 (m, 1H), 8.82 (m 1H), 3.61 (m, 2H), 3.36 (dd, J=4.1, 13.4 Hz, 1H), 3.30 (m, 1H).
    • EXAMPLE 43 (1S)-2-(1H-indol-3-yl)-1-[[(6-pyridin-4-ylquinolin-3-yl)oxy]methyl}ethylamine Example 43A 6-bromo-3-hydroxyquinoline-4-carboxylic Acid
  • A solution of 5-bromoisatin (2.26 g, 10 mmol) and potassium hydroxide (4.48 g, 80 mmol) in water (10 mL) was warmed until the materials were dissolved then cooled to room temperature, treated with bromopyruvic acid (2.3 g, 14 mmol), stirred for 6 days, adjusted to pH<7 with concentrated HCl, and filtered. The solid was washed with water and ethanol and dried to provide the desired product (1.5 g, 58%). MS (DCI/NH[0301] 3) m/e 269 (M+H)+.
    • Example 43B 6-bromo3-hydroxyquinoline
  • A solution of Example 43A (1.5 g, 5.6 mmol) in nitrobenzene (10 mL) was refluxed for 5 minutes, filtered, cooled to room temperature and filtered again. The solid was washed with hexanes and dried to provide the desired product (0.68 g, 55%). MS (DCI/NH[0302] 3) m/e 225 (M+H)+.
    • Example 43C tert-butyl (1S)-2-[(6-bromoquinolin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylcarbamate
  • The desired product was prepared by substituting Example 43B for 3-bromo-5-hydroxypyridine in Example 2A. Purification by flash column chromatography on silica gel with 100% ethyl acetate provided the desired product (0.89 g, 72%). MS (DCI/NH[0303] 3) m/e 497 (M+H)+.
    • Example 43D tert-butyl (1S)-2-(1H-indol-3-yl)-1-{[(6-pyridin-4-ylquinolin-3-yl)oxy]methyl}ethylcarbamate
  • A mixture of Example 43C (0.33 g, 0.67 mmol), pyridine-4-boronic acid (0.13 g, 0.99 mmol), cesium floride (0.2 g, 1.34 mmol) and tetrakistriphenylphosphine palladium (0.038 g, 0.034 mmol) in DMF (10 mL) was stirred at 100° C. for 8 hours, treated with ethyl acetate (10 mL), washed with brine, dried (MgSO[0304] 4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 10% methanol/dichloromethane to provide the desired product (0.25 g, 76%). MS (DCI/NH3) m/e 495 (M+H)+.
    • Example 43E (1S)-2-(1H-indol-3-yl)-1-{[(6-pyridin-4-ylquinolin-3-yl)oxy]methyl}ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 43D for Example 27B in Example 27C. MS (DCI/NH[0305] 3) m/e 395 (M+H)+; 1H NMR (DMSO-d6) δ 10.89 (s, 1H), 8.74 (d, J=3.0 Hz, 1H), 8.71 (d, J=5.0 Hz, 2H), 8.25 (s, 1H), 8.07 (d, J=9.0 Hz, 1H), 7.99 (d, J=9.0 Hz, 1H), 7.83 (d, J=5.0 Hz, 2H), 7.72 (d, J=3.0 Hz, 1H), 7.58 (d; J=7.5 Hz, 1H), 7.35 (d, J=8.4 Hz, 1H), 7.23 (s, 1H), 7.06 (t, J=7.5 Hz, 1H), 6.95 (t, J=8.4 Hz, 1H), 4.05 (m, 2H), 3.53 (m, 1H), 3.01 (dd, J=6.3, 14.9 Hz, 1H), 2.87 (dd, J=6.9, 14.9 Hz, 1H).
    • EXAMPLE 44 (3Z)-3-[(2S)-2-amino-3-(1H-indol-3-yl)propylidene]-5-isoquinolin-6-yl-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one Example 44A tert-butyl (1S,2Z)-2-(5-bromo-2-oxo-1,2-dihydro-3H-pyrrolo[2,3-b]pyridin-3-ylidene)-1-(1H-indol-3-ylmethyl)ethylcarbamate
  • A mixture of 5-bromo-7-aza-oxindole (D. Mazeas, et al., Heterocycles 1999, 50, 1065.) (213 mg, 1.0 mmol), L-BOC-tryptophanal (290 mg, 1.0 mmol) and piperidine (40 μL) in ethanol was refluxed for 2.5 hours and concentrated. The residue was triturated with dichloromethane (1 mL) and hexane (6 mL) and dried to provide the desired product (512 mg). MS (DCI/NH[0306] 3) m/e 483, 485 (M+H)+.
    • Example 44B (3Z)-3-[(2S)-2-amino-3-(1H-indol-3-yl)propylidene]-5-isoquinolin-6-yl-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one
  • The desired product was prepared by substituting Example 44A (260 mg) for Example 2A in Example 27. MS (DCI/NH[0307] 3) m/e 432 (M+H)+; 1H NMR (CD3OD) δ 9.57 (s, 1H), 8.64 (d, J=2.5 Hz, 1H), 8.52 (d, J=7.6 Hz, 1H), 8.26 (s, 1H), 8.24 (s, 1H), 8.08 (d, J=6.4 Hz, 1H), 7.64 (s, 1H), 7.60 (dd, J=8.7, 1.7 Hz, 1H), 7.55 (d, J=6.6 Hz, 1H), 7.54 (d, J=7.1 Hz, 1H), 7.33 (dd, J=7.0, 1.1 Hz, 1H), 7.29 (dd, J=3.3, 1.3 Hz, 1H), 7.26 (dd, J=7.1, 1.0 Hz, 1H), 6.26 (d, J=2.2 Hz, 1H), 4.20 (s, 1H), 3.94 (d, J=6.8 Hz, 1H), 3.61 (s, 1H), 2.78 (d, J=14.7 Hz, 1H), 2.68 (dd, J=16.3, 6.9 Hz, 1H). New Examples Following the procedures described in Example 1, using the appropriate alcohols, the following compounds were made.
    • EXAMPLE 45 3-Butoxyl-5-[2-(4-pyridinyl)vinyl]pyridine
  • MS (DCI/NH[0308] 3) m/e 255 (M+1). 1H NMR (DMSO-d6): δ 8.58 (d; J=6.0 Hz, 1H), 8.39 (s; 1H), 8.22 (s; 1H), 7.70 (s; 1H), 7.56 (d; J=6.0 Hz, 1H), 7.56 (d, J=16.5 Hz, 1H), 7.45 (d; J=16.5 Hz, 2H), 4.12 (t; J=8.6 Hz, 3H), 1.74 (m; 2H), 1.47 (m; 2H), 0.96 (t; J=8.6 Hz, 2H).
    • EXAMPLE 46 3-Methoxyl-5-[2-(4-pyridinyl)vinyl]pyridine
  • MS (DCI/NH[0309] 3) m/e 213 (M+1). 1H NMR (DMSO-d6): δ ppm 8.58 (m, 2H), 8.41 (d, J=1.7 Hz, 1H), 8.24 (d, J=2.7 Hz, 1H), 7.71 (m, 1H) 7.57 (m, 3H), 7.47 (d, J=16.5 Hz, 1H), 3.89 (s, 3H).
    • EXAMPLE 47 S-3-[2-Amino-3-phenyl-propyloxyl]-5-[2-(4-pyridinyl)vinyl]pyridine Hydrochloride
  • MS (DCI/NH[0310] 3) m/e 332 (M+1). 1H NMR (DMSO-d6): δ 8.58 (d; J=6.0 Hz, 2H), 8.40 (s; 1H), 8.25 (s; 1H), 7.69 (s; 1H), 7.56 (d; J=6.0 Hz, 1H), 7.56 (d; J=16.5 Hz, 1H), 7.43 (d; J=16.5 Hz, 1H), 7.26 (m; 5H), 3.94 (m; 2H), 3.28 (m; 1H), 2.87 (dd; J=6.0 Hz and 13.5 Hz, 1H), 2.65 (dd; J=9 Hz, 13.5 Hz, 1H).
    • EXAMPLE 48 3-[2-(1H-3-Indolyl)-ethoxyl]-5-[2-(4-pyridinyl)vinyl]pyridine Hydrochloride
  • MS (DCI/NH[0311] 3): m/z 342 (M+1). 1H NMR (DMSO-d6): δ 10.39 (br s, 1H), 8.60 (d, J=6.6 Hz, 2H), 8.38 (d, J=2.5 Hz, 1H), 8.25 (d, J=3.3 Hz, 1H), 7.72 (dd, J=2.5, 3.3 Hz, 1H), 7.62 (d, J=8.5 Hz, 1H), 7.55 (d, J=17.4 Hz, 1H), 7.36 (d, J=8.1 Hz, 1H), 7.54 (d, J=6.6 Hz, 2H), 7.28 (d, J=3.3 Hz, 1H), 4.36 (t, J=7.5 Hz, 2H), 3.11 (t, J=3.11 Hz, 2H).
    • EXAMPLE 49 3-[2-(1H-3-Indolyl)-propyloxyl]-5-[2-(4-pyridinyl)vinyl]pyridine
  • MS (DCI/NH[0312] 3): m/z 356 (M+1). 1H NMR (DMSO-d6): δ 10.79 (br s, 1H), 8.57 (m, 2H), 8.39 (d, J=1.7 Hz, 1H), 8.25 (d, J=3.1 Hz, 1H), 7.69 (t, J=2.0 Hz, 1H), 7.56 (m, 2H), 7.55 (d, J=16.6 Hz, 1H), 7.52 (m, 1H), 7.43 (d, J=16.6 Hz, 1H), 7.33 (d, J=8.1 Hz, 1H), 7.15 (d, J=2.4 Hz, 1H), 7.06 (m, 1H), 6.96 (m, 1H), 4.16 (t, J=6.5 Hz, 2H), 2.89 (t, J=8.1 Hz, 2H), 2.14 (m, 2H).
    • EXAMPLE 50 S-3-[2-Amino-3-(4-benzyloxy]phenyl)-propyloxyl]-5-[2-(4-pyridinyl)vinyl]pyridine Hydrochloride
  • MS (DCI/NH[0313] 3): m/z 438 (M+1). 1H NMR (DMSO-d6): δ 10.04 (br s, 3H), 8.86 (d, J=7.5 Hz, 2H), 8.54 (s, 1H), 8.39 (d, J=3.3 Hz, 1H), 8.13 (d, J=7.5 Hz, 2H), 7.98 (d, J=17.4 Hz, 1H), 7.88 (m, 1H), 7.73 (d, J=17.4 Hz, 1H), 7.39 (m, 5H), 7.24 (d, J=9.0 Hz, 2H), 6.99 (d, J=9.0 Hz, 2H), 4.28 (dd, J=3.9, 11.5 Hz, 1H), 5.07 (s, 2H), 4.12 (dd, J=6.5, 11.5 Hz, 1H), 3.29 (m, 1H), 3.05 (m, 2H).
    • EXAMPLE 51 3-(Piperidin-4-yl)-5-[2-(4-pyridinyl)vinyl]pyridine
  • MS (DCI/NH[0314] 3): m/z 282 (M+1). 1H NMR (DMSO-d6): δ 8.55 (m, 2H), 8.34 (d, J=1.7 Hz, 1H), 8.18 (d, J=2.7 Hz, 1H), 7.72 (m, 1H), 7.62 (m, 2H), 7.52 (d, J=16.3 Hz, 1H), 7.35 (d, J=16.3 Hz, 1H), 4.66 (m, 1H), 3.10 (m, 2H), 2.78 (m, 2H), 2.06 (m, 2H), 1.70 (m, 2H).
    • EXAMPLE 52 R-3-{2-Amino-3-benzyloxypropyloxyl}-5-[2-(4-pyridinyl)vinyl]pyridine Hydrochloride
  • MS (DCI/NH[0315] 3): m/z 362 (M+1). 1H NMR (CD3CD): δ 8.84 (m, 2H), 8.81 (m, 1H), 8.58 (m, 1H), 8.53 (m, 1H), 8.32 (m, 2H), 7.98 (d, J=16.3 Hz, 1H), 7.87 (d, J=16.3 Hz, 1H), 7.35 (m, 5H), 4.66 (s, 2H), 3.95 (m, 2H), 3.85 (m, 1H).
    • EXAMPLE 53 3-(1-Methyl-imidazole-4-methoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine
  • MS (DCI/NH[0316] 3): m/z 393 (M+1). 1H NMR (CD3OD): δ 8.52 (m, 2H), 8.39 (d, J=1.6 Hz, 1H), 8.27 (d, J=2.5 Hz, 1H), 7.84 (m, 1H), 7.69 (s, 1H), 7.62 (m, 2H), 7.53 (d, J=16.5 Hz, 1H), 7.88 (d, J=16.5 Hz, 1H), 7.15 (s, 1H), 5.29 (s, 2H), 3.78 (s, 3H).
    • EXAMPLE 54 S-3-{2-Amino-3-[3-hydroxylphenyl]-propyloxyl}-5-[2-(4-pyridinyl)vinyl]pyridine Trifluoroacetic Acid Salt
  • MS (DCI/NH[0317] 3): m/z 348 (M+1). 1H NMR (DMSO-d6): δ 8.84 (d, j=6.8 Hz, 2H), 8.54 (m, 1H), 8.37 (d, J=2.7 Hz, 1H), 8.06 (d, J=6.8 Hz, 2H), 7.91 (m, J=16.6 Hz, 1H), 7.62 (d, J=16.6 Hz, 1H), 7.09 (d, J=8.5 Hz, 2H), 6.73 (d, J=8.5 Hz, 2H), 4.22 (dd, J=3.1, 10.5 Hz, 1H), 4.06 (dd, J=5.4, 10.5 Hz, 1H), 3.77 (m, 1H), 2.93 (m, 2H).
    • EXAMPLE 55 S-3-{2-Amino-3-[3-cyanophenyl]-propyloxyl}-5-[2-(4-pyridinyl)vinyl]pyridine Hydrochloride Salt
  • MS (DCI/NH[0318] 3): m/z 357 (M+1). 1H NMR (DMSO-d6): δ 8.92 (d,j=6.4 Hz, 2H), 8.66 (s, 1H), 8.49 (d, J=1.8 Hz, 1H), 8.21 (d, J=6.4 Hz, 2H), 8.13 (s, 1H), 8.06 (d, J=16.5 Hz, 1H), 7.90 (d, J=16.5 Hz, 1H), 7.83 (d, J=8.2 Hz, 2H), 7.59 (d, J=8.2 Hz, 2H), 4.40 (dd, J=3.4, 10.7 Hz, 1H), 4.24 (dd, J=5.8, 10.7 Hz, 1H), 3.91 (m, 1H), 3.29 (dd, J=6.1, 13.7 Hz, 1H), 3.16 (dd, J=8.5, 13.7 Hz, 1H).
    • EXAMPLE 56 3-[1-(4-Cyanobenzyl)-imidazole-4-methoxyl]-5-[2-(4-pyridinyl)vinyl]pyridine
  • MS (DCI/NH[0319] 3): m/z 394 (M+1). 1HNMR (CD3OD) δ 8.51 (d; J=6.1 Hz, 2H), 8.33 (d, J=1.5 Hz, 1H), 7.94 (d, J=2.5 Hz, 1H), 7.93 (s, 1H), 7.67 (d, J=8.2 Hz, 2H), 7.62 (d, J=6.1 Hz, 2H), 7.48 (m, 1H), 7.47 (d, J=16.5 Hz, 1H), 7.30 (d, J=16.5 Hz, 1H), 7.27 (s, 1H), 7.25 (d, J=8.2 Hz, 2H), 5.47 (s, 2H), 5.26 (s, 2H).
    • EXAMPLE 57 S-3-[2-Amino-3-(1-methyl-1H-3-indolyl)-propyloxyl]-5-[2-(4-pyridinyl)vinyl]pyridine Hydrochloride Salt
  • MS (DCI/NH[0320] 3): m/z 385 (M+1). 1HNMR (CD3OD) δ 8.87 (d; J=6.8 Hz, 2H), 8.55 (s, 1H), 8.41 (d, J=2.7 Hz, 1H), 8.13 (d, J=6.8 Hz, 2H), 7.96 (d, J=6.8 Hz, 2H), 7.96 (d, J=16.6 Hz, 1H), 7.86 (m, 1H), 7.71 (d, J=16.6 Hz, 1H), 7.65 (d, J=8.1 Hz, 1H), 7.42 (d, J=8.1 Hz, 1H), 7.29 (s, 1H), 7.17 (m, 1H), 7.04 (m, 1H), 4.84 (dd, J=3.4, 10.5 Hz, 1H), 4.21 (dd, J=5.8, 10.5 Hz, 1H), 3.90 (m, 1H), 3.19 (m, 2H), 3.17 (s, 3H).
    • EXAMPLE 58 S-3-[2-Dimethylamino-3-(1H-3-indolyl)-propyloxyl]-5-[2-(4-pyridinyl)vinyl]pyridine Hydrochloride Salt
  • MS (DCI/NH[0321] 3): m/z 399 (M+1). 1HNMR (DMSO-d6) δ 8.88 (d; J=6.6 Hz, 2H), 8.58 (s, 1H), 8.45 (s, 1H), 8.16 (d, J=6.6 Hz, 2H), 7.96 (d, J=16.5 Hz, 1H), 7.95 (s, 1H), 7.76 (d, J=16.5 Hz, 1H), 7.74 (d, J=7.8 Hz, 1H), 7.35 (d, J=8.1 Hz, 1H), 7.29 (d, J=2.2 Hz, 1H), 7.07 (m, 1H), 6.97 (m, 1H), 4.54 (dd, J=1.6, 11.9 HZ), 4.35 (dd, J=5.0, 11.9 Hz, 1H), 3.95 (m, 1H), 3.51 (dd, J=3.1, 13.7 Hz, 1H), 3.29 (dd, J=11.5, 13.7 Hz, 1H), 2.96 (s, 6H).
    • EXAMPLE 59 S-3-[2-Amino-3-(1-naphthyl)-propyloxyl]-5-[2-(4-pyridinyl)vinyl]pyridine Hydrochloride Salt
  • MS (DCI/NH[0322] 3): m/z 382 (M+1). 1HNMR (DMSO-d6) δ 8.66 (d; J=6.1 Hz, 2H), 8.48 (d, J=1.4 Hz, 1H), 8.32 (d, J=2.7 Hz, 1H), 8.20 (m, 1H), 7.98 (m, 1H), 7.90 (m, 1H), 7.69 (m, 3H), 7.60 (m, 3H), 7.46 m, 3H), 4.25 (dd, J=2.7, 10.5 Hz, 1H), 4.09 (dd, J=5.1, 10.5 Hz, 1H), 3.92 (m, 1H), 3.53 (m, 2H).
    • EXAMPLE 60 3-(2-Aminoethoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine Hydrochcloride Salt
  • MS (DCI/NH[0323] 3) m/e 242 (M+1). 1H NMR (CD3OD): δ 8.88 (d, J=6.1 Hz, 2H), 8.59 (s, 1H), 8.43 (s, 1H), 8.19 (d, J=6.1 Hz, 2H), 8.03 (d, J=16.3 Hz, 1H), 8.01 (s, 1H), 7.82 (d, J=16.3 Hz, 1H), 4.42 (t, J=4.9 Hz, 2H), 3.28 (m, 2H).
    • EXAMPLE 61 3-(3-Aminopropyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine Hydrochloride Salt
  • MS (DCI/NH[0324] 3) m/e 256 (M+1). 1H NMR (DMSO-d6): δ 8.88 (d; J=6.4 Hz, 2H), 8.53 (d; J=1.4 Hz, 1H), 8.40 (d, J=2.7 Hz, 1H), 8.15 (d, J=6.4 Hz, 2H), 8.00 (d, J=16.6 Hz, 1H), 7.93 (m, 1H), 7.78 (d, J=16.6 Hz, 1H), 4.27 (t, J=6.1 Hz, 2H), 2.99 (m, 2H), 2.10 m(m, 2H).
    • EXAMPLE 62 S-3-(2-Amino3-methylbutyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine Hydrochloride Salt
  • MS (DCI/NH[0325] 3) m/e 284 (M+1). 1H NMR (DMSO-d6): δ 8.85 (d; J=6.5 Hz, 2H), 8.54 (d; J=1.4 Hz, 1H), 8.40 (d, J=3.1 Hz, 1H), 8.09 (d, J=6.5 Hz, 2H), 7.95 (d, J=16.3 Hz, 1H), 7.90 (m, 1H), 7.71 (d, J=16.3 Hz, 1H), 4.39 (m, 1H), 4.24 (m, 1H), 3.08 (m, 1H), 2.10 (m, 1H), 1.06 (d, J=8.1 Hz, 3H), 1.03 (d, J=7.8 Hz, 3H).
    • EXAMPLE 63 3-(1-Methyl-3-piperidinyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine Trifluoroacetic Acid Salt
  • MS (DCI/NH[0326] 3) m/z 296 (M+H). 1H NMR (DMSO-d6): δ 8.82 (d, 2H), 8.53 (s, 1H), 8.41 (d, 1H), 8.00 (t, 2H), 7.88 (dd, 2H), 7.59 (dd, 2H), 4.53 (dd, 1H), 4.37 (dd, 1H), 3.89 (bs, 1H), 3.64 (bs, 1H), 3.24-3.13 (m, 1H), 3.01 (s, 3H), 2.35-2.28 (m, 1H), 2.13-2.07 (m, 1H), 2.02-1.93 (m, 1H), 1.90-1.83 (m, 1H).
    • EXAMPLE 64 3-(2-Chlorobenzyl)-5-[2-(4-pyridinyl)vinyl]pyridine Trifluoroacetic Acid Salt
  • MS (DCI/NH[0327] 3) m/z 323 (M+H). 1H NMR (DMSO-d6): δ 8.84 (d, 2H), 8.53 (s, 1H), 8.44 (d, 1H), 8.07 (d, 2H), 7.96-7.92 (m, 2H), 7.70-7.67 (m, 2H), 7.57-7.55 (m, 1H), 7.46-7.43 (m, 2H), 5.33 (s, 2H). 6
    • Example 65 3-(N-Benzyl-N-methylaminoethoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine Trifluoroacetic Acid Salt
  • MS (DCI/NH[0328] 3) m/z 346 (M+H). 1H NMR (DMSO-d6): δ 8.80 (d, 2H), 8.53 (s, 1H), 8.37 (d, 1H), 7.98 (d, 2H), 7.87 (d, 1H), 7.81 (s, 1H), 7.60 (d, 1H), 7.58-7.47 (m, 5H), 4.58-4.50 (m, 2H), 3.59-3.56 (m, 2H), 2.85 (s, 3H), 2.79 (t, 2H).
    • EXAMPLE 66 3-(6-(N,N-Dimathylamino)hexyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine Trifluoroacetic Acid Salt
  • MS (DCI/NH[0329] 3) m/z 326 (M+H). 1H NMR (DMSO-d6): δ 8.82 (d, 2H), 8.49 (d, 1H), 8.33 (d, 1H), 8.04 (d, 2H), 7.89 (d, 1H), 7.80 (t, 1H), 7.66 (d, 1H), 4.14 (t, 2H), 3.06-3.02 (m, 2H), 2.78 (s, 3H), 2.77 (s, 3H), 1.82-1.76 (m, 2H), 1.68-1.62 (m, 2H), 1.51-1.45 (m, 2H), 1.40-1.34 (m, 2H).
    • EXAMPLE 67 3-(2-Thiophenoxyl-ethoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine Trifluoroacetic Acid Salt
  • MS (DCI/NH[0330] 3) m/z 335 (M+H). 1H NMR (DMSO-d6): δ 8.76 (d, 2H), 8.46 (s, 1H), 8.27 (d, 1H), 7.93 (d, 1H), 7.80 (d, 1H), 7.77-7.74 (m, 2H), 7.59 (d, 1H), 7.43-742 (m, 1H), 7.36-7.31 (m, 3H), 7.24-7.16 (m, 1H), 4.33 (t, 2H), 3.43 (t, 2H).
    • EXAMPLE 68 3-(1-Methyl-3-pyrrolidinyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine Trifluoroacetic Acid Salt
  • MS (DCI/NH[0331] 3) m/z 282 (M+H). 1H NMR (DMSO-d6): δ 8.75 (d, 2H), 8.52 (s, 1H), 8.31 (d, 1H), 7.88 (d, 2H), 7.80-7.77 (m, 2H), 7.57 (d, 1H), 5.36-5.30 (m, 1H), 3.46-3.39 (m, 1H), 3.23-3.15 (m, 1H), 2.97-2.95 (m, 1H), 2.91 (s, 3H), 2.73-2.63 (m, 1H), 2.36-2.25 (m, 1H), 2.17-2.09 (m, 1H).
    • EXAMPLE 69 3-[(1-Methyl-2-piperidinyl)methoxyl]-5-[2-(4-pyridinyl)vinyl]pyridine Trifluoroacetic Acid Salt
  • MS (DCI/NH[0332] 3) m/z 310 (M+H). 1H NMR (DMSO-d6): δ 8.81 (d, 2H), 8.54-8.53 (m, 1H), 8.40-8.38 (m, 1H), 8.01-7.99 (m, 2H), 7.91-7.85 (m, 2H), 7.64-7.59 (m, 1H), 4.55-4.52 (m, 1H), 4.38-4.31 (m, 1H), 3.71-3.62 (m, 1H), 3.55-3.45 (m, 1H), 3.35-3.23 (m, 1H), 2.91 (s, 3H), 2.88 (dt, 1H), 2.10-1.52 (m, 5H).
    • EXAMPLE 70 3-(1-Pyridinyl-ethoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine Trifluoroacetic Acid Salt
  • MS (DCI/NH[0333] 3) m/z 304 (M+H). 1H NMR (DMSO-d6) δ 8.81 (d, 2H), 8.73 (d, 2H), 8.48 (s, 1H), 8.34 (d, 1H), 8.01 (d, 1H), 7.85-7.81 (m, 2H), 7.74 (d, 2H), 7.57 (d, 1H), 5.89 (q, 1H), 1.65 (d, 3H).
    • EXAMPLE 71 4-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-N-hydroxyl-benzamidine Trifluoroacetic Acid Salt Example 71A 4-{5-[(2S)-2-BOCamino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-N-hydroxyl-benzamidine
  • To a solution of Example 22 (200 mg, 0.43 mmol) in toluene (7.0 ml) and methanol (0.5 ml) were added hydroxylamine hydrochloride (33 mg, 0.48 mmol) and potassium tert-butoxide (54 mg, 0.48 mmol) and the mixture was stirred for 8 h at room temperature under a nitrogen atmosphere. Another portion of hydroxylamine hydrochloride (33 mg, 0.48 mmol) and potassium tert-butoxide (54 mg, 0.48 mmol) was added and the mixture was heated to 80° C. for 16 h. The mixture was concentrated and purified by column chromatography on silica gel using dichloromethane/methanol (15:1) as solvent system. Obtained were 130 mg (61%) of the product as a white powder. [0334]
  • MS (DCI/NH[0335] 3) m/z 487 (M-OH+2H).
    • EXAMPLE 71B
  • 4-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-N-hydroxyl-benzamidine Trifluoroacetic Acid Salt [0336]
  • The desired product was prepared by substituting Example 71A for Example 22A in example 22B. MS (DCI/NH[0337] 3) m/z 369 (M−NHOH). 1H NMR (DMSO-d6) δ 11.02 (s, 1H), 8.63 (d, 1H), 8.40 (d, 1H), 8.23 (bs, 2H), 8.01-7.91 (m, 2H), 7.85-7.79 (m, 2H), 7.71 (t, 1H), 7.62 (d, 1H), 7.38 (d, 1H), 7.29 (d, 1H), 7.10 (t, 1H), 7.01 (q, 1H), 4.35 (dd, 1H), 4.19 (dd, 1H), 3.85-3.82 (m, 1H), 3.16 (m, 2H).
    • EXAMPLE 72 4-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-benzamidine Trifluoroacetic Acid Salt Example 72A 4-{5-[(2S)-2-BOC-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-benzamidine
  • To a solution of the product of Example 71 (110 mg, 0.22 mmol) in glacial acetic acid (5.0 ml) was added acetic anhydride (0.15 ml, 1.6 mmol) and the mixture was stirred for 2 h at ambient temperature. The acetic anhydride was hydrolyzed by addition of water (0.1 ml), 10% palladium on charcoal (25 mg) was added and the mixture was stirred vigorously under a hydrogen atmosphere (1 atm.) for 4 h. The mixture was filtered through a pad of diatomaceous earth (Celite®) and the filtercake was washed with acetic acid. The combined filtrates were evaporated in high vacuum and the residue was triturated with ethyl acetate to give 80 mg (39%) of the product as a beige powder. [0338]
  • MS (DCI/NH[0339] 3) m/z 486 (M+H). 1H NMR (DMSO-d6): δ 10.93 (s, 1H), 8.56 (s, 1H), 8.32 (d, 1H), 7.93-7.88 (m, 4H), 7.66 (s, 1H), 7.57 (d, 1H), 7.34 (d, 1H), 7.17 (s, 1H), 7.07-7.05 (m, 2H), 6.96 (t, 1H), 4.17-4.11 (m, 2H), 4.09-4.05 (m, 1H), 3.00 (dd, 1H), 2.92 (dd, 1H), 1.36 (s, 9H).
    • Example 72B 4-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-benzamidine Trifluoroacetic Acid Salt
  • The desired product was prepared by substituting Example 72A for Example 22A in Example 22B. MS (DCI/NH[0340] 3) m/z 386 (M+H). 1H NMR (DMSO-d6): δ 11.03 (s, 1H), 9.38 (s, 2H), 9.24 (s, 2H), 8.65 (d, 1H), 8.42 (d, 1H), 8.25 (bs, 2H), 8.00-7.94 (m, 4H), 7.74 (t, 1H), 7.62 (d, 1H), 7.38 (d, 1H), 7.29 (d, 1H), 7.10 (t, 1H), 7.01 (t, 1H), 4.36 (dd, 1H), 4.20 (dd, 1H), 3.90-3.82 (m, 1H), 3.17 (m, 2H).
    • EXAMPLE 73 3-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxyl]-6-(3-pyridinyl)-quinoline
  • The desired product was prepared by substituting pyridine-3-boronic acid for pyridine-4-boronic acid in Example 43. MS (DCI/NH[0341] 3) m/e 395 (M+1). 1H NMR (DMSO-d6): δ 10.89 (s; 1H), 9.02 (s; 1H), 8.72 (d; J=3.0 Hz, 1H), 8.62 (d; J=5.0 Hz, 1H), 8.20 (d; J=7.5 Hz, 1H), 8.15 (s; 1H), 8.06 (d; J=9.0 Hz, 1H), 7.95 (d; J=9.0 Hz, 1H), 7.70 (S; 1H), 7.59 (d; J=6.0 Hz, 1H), 7.57 (m; 1H), 7.35 (d; J=8.4 Hz, 1H), 7.22 (s; 1H), 7.06 (t; J=7.5 Hz, 1H), 6.95 (t; J=7.5 Hz, 1H), 4.05 (m; 2H), 3.53 (m; 1H), 3.01 (dd; J=6.3, 14.9 Hz, 1H), 2.87 (dd; J=6.9, 14.9 Hz, 1H)
    • EXAMPLE 74 3-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxyl]-6-(3-quinolinyl)-quinoline
  • The desired product was prepared by substituting quinoline-3-boronic acid for pyridine-4-boronic acid in Example 43. MS (DCI/NH[0342] 3) m/e 445 (M+1). 1H NMR (DMSO-d6): δ 0.89 (s; 1H), 9.49 (s; 1H), 8.80 (s; 1H), 8.74 (s; 1H), 8.31 (s; 1H), 8.10 (m; 4H), 7.82 (t; J=6.6 Hz, 1H), 7.73 (s; 1H), 7.69 (t; J=6.6 Hz, 1H), 7.49 (d; J=8.4 Hz, 1H), 7.35 (d; J=8.4 Hz, 1H), 7.23 (s; 1H), 7.06 (t; J=7.5 Hz, 1H), 6.95 (t; J=7.5 Hz, 1H), 4.05 (m; 2H), 3.52 (m; 1H), 3.01 (dd; J=6.3, 14.9 Hz, 1H), 2.87 (dd; J=6.9, 14.9 Hz, 1H).
    • EXAMPLE 75 3-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxyl]-5-[2-(2-amino-4-pyridinyl)vinyl]pyridine Trifluoroacetic Acid Salt Example 75A 2-Amino-4-iodopyridine
  • A mixture of 2-floro-4-iodopyridine (3.0 g, 13.5 mmol), acetylamide (15.8 g, 269 mmol) and potassium carbonate (9.2 g, 67 mmol) was stirred at 180° C. for 7 hours, poured into ice (100 g), extracted with ethyl acetate, washed with brine, dried (MgSO[0343] 4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 50% ethyl acetate/hexane to provide the title compound (1.1 g, 37%). MS (DCI/NH3) m/e 221 (M+H).
    • Example 75B N,N-Bis(tert-butyloxylcarbonyl)amino-4-iodopyridine
  • A solution of the product from Example 75A above (1.0 g, 4.5 mmol) in THF (25 mL) was treated dropwise with 1.0M LiHMDS (9.0 mL, 9.0 mmol), stirred for 30 minutes, treated with di-t-butyl dicarbonate(1.96 g, 9.0 mmol) and stirred for 1 hour. The mixture was quenched with water (10 mL), warmed to room temperature and extracted with ethyl acetate. The combined extracts were washed with brine, dried (MgSO[0344] 4), filtered, and concentrated. The concentrate was triturated with 1:1 hexanes/ethyl acetate to provide the desired product (1.0 g, 53%). MS (DCI/NH3) m/z 421 (M+H).
    • Example 75C N,N-Bis(tert-butyloxylcarbonyl)amino-4-vinylyridine
  • A mixture of the product from Example 75B above (0.7 g, 1.67 mmol), vinyltributyltin (0.83 g, 2.6 mmol) and tetrakis-(triphenylphosphine)-palladium(0) (0.12 g, 0.11 mmol) was heated at 100° C. for 6 hours, cooled to room temperature, treated with ethyl acetate (10 mL), washed with brine, dried (MgSO[0345] 4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 20% ethyl acetate/hexane to provide the title compound (0.4 g, 75%). MS (DCI/NH3) m/e 321 (M+H).
    • Example 75D 3-[(2S)-2-(N-tert-Butoxylcarbonyl)amino-3-(1H-3-indolyl)-propyloxyl]-5-{2-[2-(N,N-bis(tert-butoxylcarbonyl)amino]-4-pyridinyl)vinyl}pyridine
  • The desired product was prepared by substituting Example 75C for 4-vinylpyridine in Example 2B. Purification on silica gel eluting with 100% ethyl acetate provided the title compound (0.15 g, 49%). MS (DCI/NH[0346] 3) m/e 685 (M+H).
    • Example 75E 4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-ylamine
  • The desired product was prepared by substituting Example 75D for Example 2B in Example 2C. Purification on HPLC provided the title compound (0.06 g, 70%). MS (DCI/NH[0347] 3) m/e 386 (M+1). 1H NMR (DMSO-d6): δ 11.05 (s; 1H), 8.50 (s; 1H), 8.35 (s; 1H), 8.23 (bs; 2H), 8.13 (bs; 2H), 7.95 (d; J=6.3 Hz, 1H), 7.72 (s; 1H), 7.65 (d; J=15.9 Hz, 1H), 7.61 (d; J=6.3 Hz), 7.42 (d; J=15.9 Hz, 1H), 7.38 (d; J=6.9 Hz, 1H), 7.28 (s; 1H), 7.18 (d; J=6.9 Hz, 1H), 7.10 (t; J=6.9 Hz, 1H), 7.00 (t; J=6.9 Hz, 1H), 6.93 (s; 1H), 4.29 (m; 1H), 4.14 (m; 1H), 3.87 (m; 1H), 3.17 (m; 2H).
    • EXAMPLE 76 5-[(2S)-2-(Amino-3-(1H-3-indolyl)-propyloxyl]-3-[2-(2-amino-4-pyridinyl)vinyl]-2-chloro-pyridine Trifluoroacetic Acid Salt
  • The desired product was prepared by substituting 3-bromo-2-chloro-5-hydroxylpyridine for 3-bromo-5-hydroxylpyridine in Example 75. MS (DCI/NH[0348] 3) m/e 420 (M+1). 1H NMR (DMSO-d6): δ 11.05 (s; 1H), 8.21 (s; 1H), 8.21 (bs; 2H), 8.04 (bs; 2H), 7.95 (d; J=6.3 Hz, 1H), 7.93 (s; 1H), 7.61 (d; J=6.3 Hz, 1H), 7.58 (d; J=15.9 Hz, 1H), 7.39 (d; J=15.9 Hz, 1H), 7.39 (d; J=6.9 Hz, 1H), 7.28 (s; 1H), 7.18 (d; J=6.9 Hz, 1H), 7.10 (t; J=6.9 Hz, 1H), 7.00 (t; J=6.9 Hz, 1H), 6.99 (s; 1H), 4.32 (m; 1H), 4.16 (m; 1H), 3.87 (m; 1H), 3.17 (m; 2H).
    • EXAMPLE 77 (1S)-1-(1H-Indol-3-ylmethyl)-2-(5-naphthalen-2-yl-pyridin-3-yloxy)-ethylamine
  • The desired product was prepared by substituting 2-bromonaphthalene for 6-bromoisoquinoline in Example 27. [0349] 1H NMR (d6-DMSO, 500 MHz) δ: 11.02 (s, 1H), 8.74 (s, 1H), 8.38 (s, 1H), 8.30 (s, 1H), 8.18-8.21 (m, 2H), 8.04 (d, J=8 Hz, 1H), 7.97-8.01 (m, 2H), 8.85 (d, J=8 Hz, 1H), 7.81 (s, 1H), 7.62 (d, J=8 Hz, 1H), 7.50-7.58 (m, 1H), 7.35-7.39 (m, 1H), 7.23-7.31 (m, 1H), 7.08-7.12 (m, 1H), 6.96-7.03 (m, 2H), 4.18-4.41 (m, 2H), 3.82-3.87 (m, 1H), 3.17-3.21 (m, 2H). MS: (ESI) (M+H)+ m/z=394
    • EXAMPLE 78 (1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-5-yl-pyridin-3-yloxy)-ethylamine Example 78A 5-Bromoisoquinoline
  • To a solution of 5-aminoisoquinoline (2.0 g, 13.8 mmol) and 48% HBr (6 mL) in 20 mL water cooled to 0° C. was added a solution of sodium nitrite (0.95 g, 13.8 mmol) in 6 mL water. The solution was stirred at 0° C. for 20 minutes. The solution, while kept at 0° C., was added to a solution of CuBr (2.11 g, 15.9 mmol) in 48% HBr (4.77 mL) and water (10 mL). The reaction was stirred at room temperature for an additional 1 hr. The reaction was neutralized with NaOH (50%) and extracted with ethyl acetate (3×). The combined organic layer was concentrated in vacuo and chromatographed using 1:1 hexanes/ethyl acetate to yield 1.4 g product (50%). [0350]
    • Example 78B (1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-5-yl-pyridin-3-yloxy)-ethylamine
  • The desired product was prepared by substituting Example 78A for 6-bromoisoquinoline in Example 27. MS (ESI) m/z 395 (M+H)[0351] +; 1H NMR (d6-DMSO, 300 MHz) δ 11.02 (bs, 1H), 9.53 (s, 1H), 8.52 (d, J=8 Hz, 1H), 8.49 (d, J=4 Hz, 1H), 8.37 (d, J=3 Hz, 1H), 8.30-8.34 (m, 1H), 8.15-8.19 (m, 2H), 7.84-7.88 (m, 2H), 7.68 (d, J=8 Hz, 1H), 7.56-7.60 (m, 2H), 7.47 (d, J=8 Hz, 1H), 7.28 (d, J=4 Hz, 1H), 7.60-7.12 (m, 1H), 6.94-6.99 (m, 1H), 4.12-4.32 (m, 2H), 3.82-3.87 (m, 1H), 3.13-3.17 (m, 2H).
    • EXAMPLE 79 6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2H-isoquinolin-1-one
  • The desired product was prepared by substituting 2-hydroxylisoquinoline for 6-bromoisoquinoline in Example 27. MS (ESI) m/z 411 (M+H)[0352] +; 1H NMR (DMSO-d6, 300 MHz) δ 11.30 (bs, 1H), 11.04 (bs, 1H), 8.66-8.68 (m, 1H), 8.41 (d, J=3 Hz, 1H), 8.27 (d, J=8 Hz, 1H), 8.17-8.20 (m, 2H), 8.02-8.03 (m, 1H), 7.76-7.81 (m, 2H), 7.62 (d, J=8 Hz, 1H), 7.38 (d, J=8 Hz, 1H), 7.29-7.31 (m, 1H), 7.20-7.26 (m, 1H), 7.07-7.12 (m, 1H), 6.98-7.04 (m, 1H), 6.60 (d, J=8 Hz, 1H), 4.14-4.39 (m, 2H), 3.33-3.38 (m, 1H), 3.13-3.16 (m, 2H).
  • Anal. Calcd for C[0353] 25H22N4O.2TFA: C, 54.54; H, 3.78; N, 8.78; F, 17.86. Found: C, 54.54; H, 4.00; N, 8.56; F, 17.10.
    • EXAMPLE 80 (1S)-2-[5-(3-Chloro-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine Example 80A 6-Bromo-indan-1,2-dione 1-oxime
  • A solution of 5-bromo-1-indanone (1.8 g, 8.5 mmol) in ethanol (150 ml) was cooled to 0° C., treated with t-butylnitrite (2.1 ml), stirred at room temperature for 2 hours, filtrated and washed the desired product with ether. The yield is 76%. MS (DCI/NH[0354] 3) m/e 242 (M+1)+.
    • Example 80B 6-Bromo-1,3-dichloro-isoquinoline
  • A suspension solution of Example 80A (1.5 g, 6.2 mmol) in POCl[0355] 3 (40 ml) was treated with PCl5 (1.55 g, 7.4 mmol) and introduced HCl gas until solution was saturated. The reaction was stirred at 60° C. for 6 hours and concentrated under vacumm.
  • The residue was slowly hydrolysed by adding water, treated with ethyl acetate (200 mL), washed with brine, dried (MgSO[0356] 4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 10% ethyl acetate/hexane to provide the title compound (1.7 g, 100%). MS (DCI/NH3) m/e 278 (M+H)+.
    • Example 80C 6-Bromo-3-chloro-isoquinoline
  • A mixture of Example 80B (1.8 g, 6.5 mmol), P (0.48 g, 15.5 mmol) and HI (3 ml, 48%) in acetic acid (20 ml) was refluxed for 8 hours, filtrated under hot condition and concentrated under vacumm. The residue was basified by adding sodium hydroxide solution, treated with ethyl acetate (200 mL), washed with brine, dried (MgSO[0357] 4), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 30% ethyl acetate/hexane to provide the title compound (0.81 g, 50%). MS (DCI/NH3) m/e 244 (M+H)+.
    • Example 80D 3-Chloro-6-trimethylstannanyl-isoquinoline
  • The desired product was prepared by substituting Example 80C for 6-bromoisoquinoline in Example 27A. MS (DCI/NH[0358] 3) m/e 327 (M+H)+.
    • Example 80E (1S)-[2-[5-(3-Chloro-isoquinolin 6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting Example 80D for Example 27A in Example 27B. MS (DCI/NH[0359] 3) m/e 530 (M+H)+.
    • Example 80F (1S)-2-[5-(3-Chloro-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine
  • The desired product was prepared by substituting Example 80E for Example 27B in Example 27C. MS (DCI/NH[0360] 3) m/e 429 (M+1)+; 1H NMR (DMSO-d6, 300 MHz) δ 11.04 (s; 1H), 9.28 (s; 1H), 8.72 (s; 1H), 8.44 (s; 1H), 8.33 (s; 1H), 8.32 (d; 1H; J=8.4 Hz), 8.17 (s; 2H), 8.07 (s; 1H), 8.05 (d; 1H; J=8.4 Hz), 7.80 (s; 1H), 7.63 (d; 1H; J=7.5 Hz), 7.48 (d; 1H; J=7.5 Hz), 7.30 (s; 1H), 7.10 (t; 1H; J=7.2 Hz), 7!00 (t; 1H; J=7.2 Hz), 4.38 (m; 1H), 4.20 (m; 1H), 3.88 (m; 1H), 3.18 (m; 2H).
    • EXAMPLE 81 (1S)-2-([3,4′]Bipyridinyl-5-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine Trifluoroacetic Acid
  • The desired product was prepared by substituting 4-tributylstannylpyridine for Example 27A in Example 27. MS (APCI) m/z 345 (M+1)[0361] +; 1H NMR (CD3OD, 300 MHz) δ 8.85 (d, J=6.8 Hz, 2H), 8.73 (d, J=1.7 Hz, 1H), 8.53 (d, J=2.7 Hz, 1H), 8.20 (d, J=6.8 Hz, 2H), 7.84 (t, J=1.7 Hz, 1H), 7.59 (d, J=7.8 Hz, 1H), 7.38 (d, J=8.2 Hz, 1H), 7.24 (s, 1H), 7.12 (t, J=6.8 Hz, 1H), 7.01 (t, J=8.1 Hz, 1H), 4.44 (dd, J=10.8, 3.4 Hz, 1H), 4.30 (dd, J=10.5, 5.8 Hz, 1H), 4.01 (m, 1H), 3.33 (m, 2H); Anal. Calcd for C21H20N4O▪2.7 TFA: C, 48.61; H, 3.51; N, 8.59. Found: C, 48.69; H, 3.50; N, 8.46.
    • EXAMPLE 82 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(2-pyridin-2-yl-vinyl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared by substituting 2-vinylpyridine for 4-vinylpyridine in Example 2. MS (APCI) m/z 371 (M+1)[0362] +; 1H NMR (CD3OD, 300 MHz) δ 8.72 (d, J=5.5 Hz, 1H), 8.55 (s, 1H), 8.39 (d, J=2.4 Hz, 1H), 8.34 (td, J=7.8, 1.7 Hz, 1H), 8.12 (d, J=8.2 Hz, 1H), 7.88 (t, J=1.7 Hz, 1H), 7.82 (d, J=16.3 Hz, 1H), 7.74 (t, J=6.7 Hz, 1H), 7.59 (d, J=7.8 Hz, 1H), 7.53 (d, J=16.3 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.24 (s, 1H), 7.12 (td, J=7.1, 1.0 Hz, 1H), 7.03 (td, J=7.1, 1.0 Hz, 1H), 4.41 (tt, J=10.5, 3.4 Hz, 1H), 4.27 (dd, J=10.5, 5.5 Hz, 1H), 4.00 (m, 1H), 3.33 (m, 2H); Anal. Calcd for C23H22N4O▪3.8 TFA: C, 45.73; H, 3.24; N, 6.97. Found: C, 45.60; H, 3.34; N, 6.86.
    • EXAMPLE 83 (1S)-1-(1H-Indol-3-ylmethyl)-2-(5-pyridin-3-ylethynyl-pyridin-3-yloxy)-ethylamine Trifluoroacetic Acid Salt
  • The desired product was prepared by substituting 3-bromopyridine for 4-bromopyridine in Example 14. MS (APCI) m/z 367 (M−1)[0363] −; 1H NMR (CD3OD, 300 MHz) δ 8.80 (s, 1H), 8.62 (br d, J=4.7 Hz, 1H), 8.42 (s, 1H), 8.36 (d, J=2.7 Hz, 1H), 8.12 (dt, J=8.2, 1.7 Hz, 1H), 7.60 (m, 3H), 7.39 (d, J=8.1 Hz, 1H), 7.22 (s, 1H), 7.14 (td, J=7.1, 1.4 Hz, 1H), 7.04 (td, J=8.2, 1.1 Hz, 1H), 4.33 (dd, J=10.5, 3.0 Hz, 1H), 4.19 (dd, J=10.5, 5.4 Hz, 1H), 3.97 (m, 1H), 3.29 (m, 2H);
  • Anal. Calcd for C[0364] 23H20N4O▪3.0 TFA: C, 49.02; H, 3.26; N, 7.89. Found: C, 48.86; H, 3.14; N, 8.01.
    • EXAMPLE 84 (1S)-2-[5-(2-Fluoro-pyridin-4-ylethynyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine Trifluoroacetic Acid Salt
  • The desired product was prepared by substituting 4-iodo-2-fluoropyridine for 4-bromopyridine in Example 14. MS (APCI) m/z 385 (M−1)[0365] −; 1H NMR (CD3OD, 300 MHz) δ 8.42 (d, J=1.4 Hz, 1H), 8.38 (d, J=2.7 Hz, 1H), 8.26 (d, J=5.1 Hz, 1H), 7.61 (dd, J=2.7, 1.7 Hz, 1H), 7.58 (d, J=7.8 Hz, 1H), 7.43 (dt, J=5.1, 1.7 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.23 (m, 2H), 7.13 (td, J=7.1, 1.3 Hz, 1H), 7.04 (td, J=7.8, 1.3 Hz, 1H), 4.33 (dd, J=10.5, 3.4 Hz, 1H), 4.18 (dd, J=10.5, 5.8 Hz, 1H), 3.97 (m, 1H), 3.30 (m, 2H); Anal. Calcd for C23H19FN4O▪2.3 TFA: C, 51.10; H, 3.31; N, 8.64. Found: C, 51.06; H, 3.32; N, 8.69.
    • EXAMPLE 85 (1S)-4-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-ylethynyl}-pyridin-2-ol Trifluoroacetic Acid Salt
  • A solution of N-BOC protected Example 84 (45 mg, 0.093 mmol)) in acetic acid (5 mL) was heated at 80° C. for 15 h and at 100° C. for 5 h. The solution was concentrated and the residual oil was dissolved in CH[0366] 2Cl2 (5 mL). Trifluoroacetic acid (1.25 mL) was added at 0° C. The solution was stirred at 0° C. for 10 min and at rt for 30 min, and was concentrated. The residual material was purified on HPLC (Zorbax, C-18) to provide the title compound (15 mg, 33%). MS (APCI) m/z 383 (M−1)−; 1H NMR (CD3OD, 300 MHz) δ 8.40 (s, 1H), 8.36 (d, J=2.3 Hz, 1H), 7.58 (m, 2H), 7.46 (d, J=6.8 Hz, 1H), 7.39 (d, J=8.2 Hz, 1H), 7.22 (s, 1H), 7.14 (td, J=7.1, 1.0 Hz, 1H), 7.03 (td, J=8.2, 1.1 Hz, 1H), 6.69 (brs, 1H), 6.46 (dd, J=6.8, 1.7 Hz, 1H), 4.32 (dd, J=10.5, 3.4 Hz, 1H), 4.18 (dd, J=10.5, 5.8 Hz, 1H), 3.98 (m, 1H), 3.34 (m, 2H).
    • EXAMPLE 86 (1S)-2-[6-Chloro-5-(1-chloro-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine Trifluoroacetic Acid Salt
  • The title compound was prepared by substituting Example 13A for Example 2A and Example 80D for Example 27A in Example 27. MS (APCI) m/z 464 (M+1)[0367] +; 1H NMR (CD3OD, 300 MHz) δ 8.44 (d, J=8.8 Hz, 1H), 8.31 (d, J=5.8 Hz, 1H), 8.22 (d, J=3.1 Hz, 1H), 8.03 (d, J=1.7 Hz, 1H), 7.84 (m, 2H), 7.57 (dt, J=7.8, 1.0 Hz, 1H), 7.53 (d, J=3.0 Hz, 1H), 7.34 (d, J=7.2 Hz, 1H), 7.22 (s, 1H), 7.10 (td, J=7.2, 1.4 Hz, 1H), 7.01 (td, J=7.7, 1.0 Hz, 1H), 4.36 (dd, J=10.5, 3.0 Hz, 1H), 4.22 (dd, J=10.5, 5.7 Hz, 1H), 3.97 (m, 1H), 3.27 (m, 2H); Anal. Calcd for C25H20Cl2N4O▪2.05 TFA: C, 50.14; H, 3.19; N, 8.04. Found: C, 50.16; H, 3.03; N, 7.88.
    • EXAMPLE 87 Bis-[3-(4-Bromo-phenyl)-allyl]-{2-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yloxy]-ethyl}-amine Hydrochloride
  • The title compound was obtained from the less polar product in Example 19D (5.3 mg, 3%). MS (DCI/NH[0368] 3) m/z 630,632, 634 (M+H)+; 1H NMR (CDCl3, 300 MHz) δ 8.62 (m, 2H), 8.36 (s, 1H), 8.26 (d, J=2.7 Hz, 1HO, 7.0-7.5 (m, 13H0, 6.52 (m, 2H), 6.35 (m, 2H), 4.25 (m, 2H), 3.49 (m, 4H), 3.08 (m, 2H).
    • EXAMPLE 88 N4-[3-(2-Amino-ethoxy)-phenyl]-pyrimidine-2,4-diamine Hydrochloride
  • The title compound was prepared by substituting N-Boc-aminoethanol for BOC-tryptophanol in Example 20. MS (DCI/NH[0369] 3) m/z 246(M+1)+; 1H NMR (DMSO-d6, 300 mHz) δ 12.4 (br s, 1H), 11.0 (br s, 1H), 8.26 (br, 5H), 7.86 (d, J=7.1 Hz, 1H), 7.55 (m, 1H), 7.44 (m, 1H), 7.31 9t, J=8.1 Hz, 1h0, 6.79 (d, J=8.1 Hz, 1H), 6.46 (d, J=7.1 Ha, 1H), 4.22 (t, J=5.1 Hz, 2H), 3.22 (m, 2H).
    • EXAMPLE 89 trans-[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propylamino]-pyridin-3-yl}-vinyl)-pyrimidin-2-yl]-carbamic Acid Ethyl Ester Trifluoroacetic Acid Salt Example 89A trans-4-[(5-Bromo-pyridin-3-yl)-vinyl]-2-amino-pyrimidine
  • A solution of 5-bromo-pyridine-3-carbaldehyde (436 mg, 2.34 mmol) and 2-amino-4-methylpyrimidine (246 mg, 2.35 mmol) in formic acid (96%, 3 mL) was heated for 18 h. After cooling to rt, it was then diluted with water and basified to pH 13 with 1 N NaOH. The mixture was then extracted with methylene chloride. The combined extracts was washed with water (1×), dried over MgSO[0370] 4 and concentrated. The residue was chromatographed on silica gel eluting with CH2Cl2:MeOH:NH4OH (100:5:0.5) to give the title compound (463 mg, 71%). MS (DCI/NH3) m/z 277, 279(M+1)+.
    • Example 89B trans-4-[(5-Bromo-pyridin-3-yl)-vinyl]-2-[bis(tert-butoxycarbonyl)amino]-pyrimidine
  • A suspension of Example 89A (439 mg, 1.58 mmol), (BOC)[0371] 2O (1.040 g, 4.77 mmol), DMAP (50 mg, 0.41 mmol), and triethylamine (670 μL, 4.81 mmol) in THF (10 mL) was stirred at rt overnight. Reaction was concentrated and chromatographed on silica gel eluting with AcOEt:hexane (1:1) to give the title compound (511 mg, 68%). MS (DCI/NH3) m/z 477, 479(M+1).
    • Example 89C trans-4-[(5-amino-pyridin-3-yl)-vinyl-2-(tert-butoxycarbonyl)amino-pyrimidine
  • Example 89B was converted to the title compound according to the procedures described for Example 51, Steps 4 and 5. MS (DCI/NH[0372] 3) m/z 314(M+1)+.
    • Example 89D trans-[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propylamino]-pyridin-3-yl}-vinyl)-pyrimidin-2-yl]-carbamic Acid Ethyl Ester Trifluoroacetic Acid Salt
  • The title compound was prepared by substituting Example 89C for Example 11B in Example 11. (DCI/NH[0373] 3) m/z 458(M+1)+; NMR (DMSO-d6): δ 8.58 (d, J=5.3 Hz, 1H), 8.17 (s, 1H), 7.91 (d, J=2.2 Hz, 1H), 7.75 (d, J=15.9 Hz, 1H), 7.58 (m, 1H), 7.35 (m, 2H), 7.32 (s, 1H), 7.22 (d, J=5.3 Hz, 1H), 7.15 (d, J=15.9 Hz, 1H), 7.11 (m, 1H), 7.04 (m, 1H), 4.28 (q, J=7.2 Hz, 2H), 3.80 (m, 1H), 3.62 (dd, J=4.4, 14.7 Hz, 1H), 3.50 (dd, J=8.1, 14.7 Hz, 1H), 3.20 (m, 2H), 1.35 (t, J=7.2 Hz, 3H).
    • EXAMPLE 90 1-Amino-6-{5-[(2S)-2-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinoline Trifluoroacetic Acid Salt Example 90A 6-Bromo-1-chloroisoquinoline
  • A solution of 6-bromo-1-hydroxy]isoquinoline (9.205 g, 41.0 mmol) in POCl[0374] 3 (100 mL) was heated to 100° C. for 4 h. The reaction was concentrated to dryness. The residue was dissolved in ethyl acetate and the organic layer was washed with 5% NaHCO3, water, brine, dried over MgSO4 and concentrated. The residue was was chromatographed on silica gel eluting with CH2Cl2:hexane (3:7) to give the title compound (6.176 g, 62%). MS (DCI/NH3) m/z 241, 243 (M+1)+.
    • Example 90B 1-Amino-6-bromoisoquinoline
  • A mixture of the chloride from Example 90A (264 mg, 1.09 mmol), acetamide (1.3 g) and K[0375] 2CO3 (0.45 g) was heated to 180° C. for 5 h. After cooling to rt, the mixture was dissolved in ethyl acetate, which was washed with water, brine, dried over MgSO4, and concentrated. The residue was chromatographed on silica gel eluting with CH2Cl2:MeOH:NH4OH (100:5:0.5) to give the title compound (159 mg, 65%). MS (DCI/NH3) m/z 223, 225 (M+1)+.
    • Example 90C 1-[(Bis(tert-butoxycarbonyl)]amino-6-bromoisoquinoline
  • A solution of Example 90B (616 mg, 2.76 mmol), BOC[0376] 2O (1.81 g), DMAP (67 mg), and triethylamine (1.15 mL) in acetonitrile (15 mL) was stirred at rt for 2 h. The reaction was concentrated and the residue was chromatographed on silica gel eluting with AcOEt:hexane (3:7) to give the title compound (1.18 g, 71%). MS (DCI/NH3) m/z 423 (M+1)+.
    • Example 90D 1-Amino-6-{5-[(2S)-2-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinoline Trifluoroacetic Acid Salt
  • The title compound was prepared by substituting Example 90C for 6-bromophthalimide in Example 32. MS (DCI/NH[0377] 3) m/z 410(M+1)+; 1H NMR (DMSO-d6, 300 MHz) δ 8.77 (s, 1H), 8.55 (d, J=8.6 Hz, 1H), 8.45 (d, J=2.5 Hz, 1H), 8.20 (d, J=1.5 Hz, 1H), 8.05 (dd, J=1.8. 8.6 Hz, 1H), 7.83 (dd, J=1.8, 2.5 Hz, 1H), 7.61 (m, 2H), 7.38 (d, J=7.1 Hz, 1H), 7.24 (s, 1H), 7.12 (m, 1H), 7.02 (m, 1H), 4.44 (dd, J=3.1, 10.4 Hz, 1H), 4.30 (dd, J=5.8, 10.4 Hz, 1H), 4.01 (m, 1H), 3.32 (m, 2H).
    • EXAMPLE 91 6-{5-[(2S)-2-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1-chloro-isoquinoline Trifluoroacetic Acid Salt
  • The title compound was prepared by substituting Example 90A for 6-bromophthalimide in Example 32. MS (ESI) m/z 429, 431(M+1)[0378] +; 1HNMR (DMSO-d6, 300 MHz) δ 11.03 (br s, 1H), 8.75 (d, J=1.6 Hz, 1H), 8.47 (d, J=1.6 Hz, 1H), 8.45 (d, J=5.6 Hz, 1H), 7.84 (m, 1H), 7.62 (d, J=8.1 Hz, 1H), 7.39 (d, J=8.1 Hz, 1H), 7.31 (d, J=2.2 Hz, 1H), 7.10 (m, 1H), 7.01 (m, 1H), 4.38 (dd, J=3.1, 10.6 Hz, 1H), 4.22 (dd, J=6.2, 10.4 Hz, 1H), 3.88 (m, 1H), 3.18 (m, 2H).
    • EXAMPLE 92 (2S)-2-Amino-3-(1H-indol-3-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide
  • The title compound was prepared by substituting Boc-tryptophane for Boc-homnophenyalanine in Example 16. MS (DCI/NH[0379] 3) m/z 384 (M+1)+; 1H NMR (DMSO-d6, 300 MHz) δ 11.37 (s, 1H), 11.05 (s, 1H), 8.88 (d, J=6.44 Hz, 2H), 8.74 (m, 2H), 8.42 (m, 1H), 8.35 (s, 1H), 8.22 (d, J=6.10 Hz, 2H), 8.02 (d, J=16.61 Hz, 1H), 7.71 (d, J=7.80 Hz, 1H), 7.56 (d, J=16.27 Hz, 1H), 7.36 (d, J=7.80 Hz, 1H), 7.30 (m, 1H), 7.07 (m, 1H), 6.95 (m, 1H), 4.31 (m, 1H), 3.36 (m, 2H).
    • EXAMPLE 93 (2S)-2-Amino-3-(naphtha-1-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide Hydrochloride
  • The title compound was prepared by substituting Boc-3-(1-naphthyl)alanine for Boc-homnophenyalanine in Example 16. MS (DCI/NH[0380] 3) m/z 395 (M+1)+. 1H NMR (DMSO-d6, 500 MHz,) δ 11.86 (s, 1H), 8.90 (d, J=6.86 Hz, 2H), 8.78 (m, 1H), 8.85 (m, 1H), 8.58 (m, 1H), 8.45 (m, 1H), 8.26 (d, J=6.86 Hz, 2H), 8.04 (d, J=16.53 Hz, 1H), 7.89 (m, 2H) 7.84 (m, 1H), 7.60 (d, J=16.53 Hz, 1H), 7.58 (m, 1H), 7.49 (m, 2H), 4.53 (m, 1H), 3.49 (m, 1H), 3.36 (m, 1H).
    • EXAMPLE 94 (2S)-2-Amino-3-phenyl-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide Hydrochloride
  • The title compound was prepared by substituting Boc-phenylalanine for Boc-homnophenyalanine in Example 16. MS (DCI/NH[0381] 3) m/z 345 (M+1)+; 1H NMR (,DMSO-d6, 500 MHz) δ) 11.85 (s, 1H), 8.93 (m, 2H) 8.53 (m, 2H), 8.49 (m, 1H), 8.29 (m, 2H), 8.07 (d, J=16.22 Hz, 1H), 7.63 (d, J=16.53 Hz, 1H,) 7.32 (m, 5H), 4.44 (m, 1H), 3.24 (m, 2H)
    • EXAMPLE 95 S-2-Amino-3-(imidazol-4-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide Hydrochloride
  • The title compound was prepared by substituting bis(Boc)-histidine for Boc-homnophenyalanine in Example 16. MS (DCI/NH[0382] 3) m/z 335 (M+1)+, 1H NMR (DMSO-d6, 300 MHz) δ 10.95 (s, 1H), 9.04 (s, 1H), 8.74 (m, 1H), 8.70 (m, 1H), 8.52 (m, 2H) 8.32 (m, 1H) 8.08 (m, 2H), 7.93 (d, J=16.61 Hz, 1H), 7.50 (m, 2H), 4.50 (m, 1H), 3.33 (m, 2H).
    • EXAMPLE 96 (1R)-2-(1H-indol-3-yl)-1-[[(5-isoquinolin-6-ylpyridin-3-yl)oxy]methyl]ethylamine
  • The title compound was prepared as the trifluoroacetate salt by substituting R-Boc-tryptophanol for L-Boc-tryptophanol in Example 27. MS (ESI) m/e 395 (M+H)[0383] +; 1H NMR (DMSO-d6, 300 MHz) δ 11.02 (br s, 1H), 9.52 (s, 1H), 8.76 (d, J=3 Hz, 1H), 8.62 (d, J=8 Hz, 1H), 8.44-8.46 (m, 2H), 8.38 (d, J=9 Hz, 1H), 8.11-8.20 (m, 3H), 8.04-8.08 (m, 1H), 7.83-7.86 (m, 1H), 7.62 (d, J=9 Hz, 1H), 7.37-7.40 (m, 1H), 7.31 (d, J=3 Hz, 1H), 7.08-7.12 (m, 1H), 6.99-7.03 (m, 1H), 4.37-4.41 (m, 1H), 4.18-4.23 (m, 1H), 3.86-3.91 (m, 1H), 3.16-3.20 (m, 2H); Anal. Calcd for C25H22N4O.2.65 TFA: C, 52.24; H, 3.57; N, 8.04;. Found: C, 52.26; H, 3.70; N, 7.42.
    • EXAMPLE 97 (1S)-5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-ylamine Example 97A 2-Fluoro-5-(trimethylstannyl)benzonitrile
  • The desired product was prepared by substituting 5-bromo-2-fluorobenzonitrile for 6-bromoisoquinoline in Example 27A. [0384]
    • Example 97B (1S)-[2-[5-(3-Cyano-4-fluoro-phenyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting Example 97A for in Example 27A in Example 27B. [0385]
    • Example 97C (1S)-[2-[5-(3-Amino-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • A mixture of Example 97B (120 mg, 0.25 mmol) and 98% hydrazine (5 mL) was heated to reflux for 5 hours, poured over ice, diluted with brine, extracted with ethyl acetate, dried over MgSO[0386] 4, and concentrated. Purification by flash chromatography (7% MeOH/CH2Cl2) provided the desired product (103 mg, 84%).
    • Example 97D (1S)-5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-ylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 97C for Example 27B in Example 27C. MS (ESI) m/e 399 (M+H)[0387] +; 1H NMR (DMSO-d6, 300 MHz) δ 3.17(d,J=7.12 Hz, 2H) 3.84 (m, 1H) 4.18 (dd,J=10.51, 5.76 Hz, 1H) 4.36 (m, 1H) 7.12 (m, 4H) 7.30 (d, J=2.37 Hz, 1H) 7.38 (m, 1H) 7.42 (s, 1H) 7.63 (d, J=7.46 Hz, 1H) 7.66 (s, 1H) 8.18 (m, 4H) 8.32 (d,J=2.71 Hz, 1H) 8.57 (d,J=1.70 Hz, 1H) 11.04(s, 1H) 11.92 (bs, 1H); Anal. Calcd for C23H22N6O.2.9 TFA: C, 47.44; H, 3.44; N, 11.53;. Found: C, 47.87; H, 3.49; N, 11.19.
    • EXAMPLE 98 (1S)-6-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-ylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting 4-bromo-2-fluorobenzonitrile for 5-bromo-2-fluorobenzonitrile in Example 97. MS (ESI) m/e 399 (M+H)[0388] +; 1H NMR (DMSO-d6, 300 MHz) δ 3.16 (d, J=5.42 Hz, 2H) 3.91 (d, J=30.85 Hz, 1H) 4.19 (s, 1H) 4.35 (m, 1H) 7.07 (m, 2H) 7.34 (m, 3H) 7.63 (m, 2H) 7.71 (s, 1H) 7.88 (d, J=8.14 Hz, 1H) 8.17 (s, 4H) 8.37 (d, J=2.37 Hz, 1H) 8.60 (d, J=1.36 Hz, 1H) 11.03 (s, 1H) 11.93 (bs, 1H); Anal. Calcd for C23H22N6O.3.5 TFA: C, 45.18; H, 3.22; N, 10.54, F, 25.01; Found: C, 44.83; H, 3.19; N, 10.40, F, 25.01.
    • EXAMPLE 99 2-Amino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-acetamide Example 99A {[(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylcarbamoyl]-methyl}-carbamic Acid Tert-Butyl Ester
  • A solution of Example 27C (175 mg, 0.35 mmol), N-Boc-glycine (91 mg, 0.52 mmol), EDC (100 mg), iPr[0389] 2EtN (0.30 mL) and DMAP (10 mg) in CH2Cl2 (7 mL) was stirred at room temperature overnight, diluted with EtOAc, washed with water and brine, dried (MgSO4), filtered, and concentrated. The residue was purified by flash column chromatography on silica gel with 3% methanol/CH2Cl2 to provide the desired product (112 mg, 58%).
    • Example 99B 2-Amino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-acetamide
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 99A for Example 27B in Example 27C. MS (ESI) m/e 452 (M+H)[0390] +; 1H NMR (DMSO-d6, 300 MHz) δ ppm 3.07 (m, 2H) 3.58 (m, 2H) 4.22 (m, 2H) 4.48 (m, 1H) 6.97 (t, J=6.95 Hz, 1H) 7.06 (t, J=6.95 Hz, 1H) 7.21 (d, J=2.37 Hz, 1H) 7.34 (d, J=8.14 Hz, 1H) 7.64 (d, J=7.46 Hz, 1H) 7.86 (m, 1H) 7.99 (bs, 2H) 8.13 (d, J=6.10 Hz, 1H) 8.19 (dd, J=8.82, 1.70 Hz, 1H) 8.42 (m, 2H) 8.51 (s, 1H) 8.64 (d, J=6.10 Hz, 1H) 8.67 (d, J=7.80 Hz, 1H) 8.74 (d, J=1.70 Hz, 1H) 9.60 (s, 1H) 10.88 (s, 1H); Anal. Calcd for C27H25N5O2.2.9 TFA: C, 50.37; H, 3.60; N, 8.95;. Found: C, 50.59; H, 3.43; N, 8.83.
    • EXAMPLE 100 (2S)-2-Amino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-propionamide
  • The desired product was prepared by substituting L-Boc-alanine for N-Boc-glycine in Example 99. MS (ESI) m/e 466 (M+H)[0391] +; 1H NMR (DMSO-d6, 500 MHz) δ 1.36 (d, J=6.86 Hz, 3H) 3.09 (m, 2H) 3.88 (m, 1H) 4.35 (m, 2H) 4.46 (m, 1H) 6.97 (t, J=7.33 Hz, 1H) 7.05 (t, J=7.33 Hz, 1H) 7.29 (d, J=1.87 Hz, 1H) 7.35 (d, J=8.11 Hz, 1H) 7.66 (d, J=7.80 Hz, 1H) 8.30 (s, 1H) 8.34 (bs, 2H) 8.47 (dd, J=8.74, 1.56 Hz, 1H) 8.53 (d, J=6.55 Hz, 1H) 8.62 (d, J=1.87 Hz, 1H) 8.70 (d, J=6.74, 1H) 8.75 (d, J=6.24, 1H) 8.89 (s, 1H) 8.93 (s, 1H) 9.01 (d, J=8.11 Hz, 1H) 9.99 (s, 1H) 10.98 (s, 1H)
    • EXAMPLE 101 2-Dimethylamino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-acetamide
  • The desired product was prepared by substituting N,N-dimethylglycine for N-Boc-glycine in Example 99A. MS (ESI) m/e 480 (M+H)[0392] +; 1H NMR (DMSO-d6, 500 MHz) δ 2.71 (s, 3H) 2.77 (s, 3H) 3.10 (m, 2H) 3.95 (m, 2H) 4.40 (m, 2H) 4.52 (m, 1H) 6.97 (t, J=7.33 Hz, 1H) 7.05 (t, J=7.49 Hz, 1H) 7.28 (s, 1H) 7.34 (d, J=8.11 Hz, 1H) 7.67 (d, J=7.80 Hz, 1H) 8.38 (s, 1H) 8.50 (d, J=8.73 Hz, 1H) 8.55 (d, J=6.24 Hz, 1H) 8.67 (d, J=1.87 Hz, 1H) 8.71 (d, J=8.73 Hz, 1H) 8.75 (d, J=6.55 Hz, 1H) 8.92 (s, 1H) 8.98 (s, 1H) 9.34 (d, J=8.42 Hz, 1H) 10.00 (s, 1H) 11.02 (s, 1H).
    • EXAMPLE 102 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine Example 102A
  • A solution of 5-bromo-2-fluorobenzaldehyde (24.75 g; 122 mmol) in Et[0393] 2O (125 mL) at 0° C. was treated with 3.0 M MeMgBr in Et2O (43 mL, 129 mmol), stirred for 30 min., carefully diluted with water then acidified with 10% HCl (aq). The aqueous was extracted with Et2O, rinsed successively with 10% HCl (aq), water, and brine, dried (MgSO4), and evaporated to give the desired product (26.6 g; 99%) of sufficient purity to carry on to the next step.
    • Example 102B 1-(5-Bromo-2-fluoro-phenyl)-ethanone
  • A solution of Example 102A (26.6 g; 121 mmol) and manganese(IV) oxide (53 g; 610 mmol) in p-dioxane (500 mL) was heated at reflux for 4 hrs., cooled, filtered through Celite®, evaporated, and purified by flash chromatography (5-10% Et[0394] 2O/hexane) to yield the desired product as a nearly colorless oil that solidified upon standing (20.5 g; 78%).
    • Example 102C 5-Bromo-3-methyl-1H-indazole
  • A mixture of 102B (10 g, 46 mmol) and 98% hydrazine (25 mL) was heated to reflux for 9 hours, and poured over ice. The precipitate was collected and purified by flash chromatography (1:1 Et[0395] 2O:hexane) to give the desired product as a white solid (5.8 g, 60%).
    • Example 102D 3-Methyl-5-trimethylstannanyl-1H-indazole
  • A mixture of Example 102C (10.08 g, 47.8 mmol), hexamethyl-di-tin 2 (18 g, 55 mmol) and tetrakis(triphenylphosphine)palladium (5.5 g, 4.8 mmol) in toluene (100 ml) was stirred at 95° C. for 6 h. The mixture was then evaporated and the residue was taken into ethyl acetate (300 ml), washed with saturated sodium bicarbonate (100 ml), water (100 ml) and brine (100 ml). The ethyl acetate was evaporated off and the residue was purified by flash column chromatography on silica gel, eluting with 1:4 ethyl acetate/hexanes to give 11.2 g desired product (80%). MS: (ESI) m/z 409 (M+H)[0396] +.
    • Example 102E (1S)-{1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethyl}-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting Example Example 102D for Example 27A in Example 27B. [0397]
    • Example 102F (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 102E for Example 27B in Example 27C. MS (ESI) m/e 398 (M+H)[0398] +; 1H NMR (DMSO-d6, 300 MHz) δ 2.55 (s, 3H) 2.79 (dd, J=14.07, 7.29 Hz, 1H) 2.99 (dd, J=14.07, 7.29 1H) 3.32 (s, 2H) 3.40 (m, 1H) 4.03 (m, 2H) 6.95 (t, J=7.46 Hz, 1H) 7.05 (t, J=6.95 Hz, 1H) 7.21 (d, J=2.37 Hz, 1H) 7.34 (d, J=7.80 Hz, 1H) 7.56 (m, 2H) 7.67 (m, 2H) 8.08 (s, 1H) 8.26 (d, J=2.37 Hz, 1H) 8.54 (d, J=2.03 Hz, 1H) 10.85 (s, 1H) 12.73 (s, 1H); Anal. Calcd for C24H23N5O.2.25 HCl: C, 59.62; H, 5.31; N, 14.60;. Found: C, 59.62; H, 5.31; N, 14.28.
    • EXAMPLE 103 (1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(1H-pyrrol-2-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-ethylamine Example 103A 5-Bromo-2-fluoro-benzoic Acid
  • A mixture of 5-bromo-2-fluorobenzaldehyde (810 mg; 4.0 mmol), 15% NaOH (aq.) (3 mL), MeOH (5 mL), and 30% H[0399] 2O2 (5 mL) was stirred at r.t. for 2 hrs., then acidified with 10% HCl (aq.). The resulting white solid was collected, rinsed with water, and dried to give the desired product (670 mg; 77%).
    • Example 103B 5-Bromo-2-fluoro-benzoyl Chloride
  • Example 103A (665 mg; 3.0 mmol) in thionyl chloride (7 mL) was heated at reflux for 2 hrs., concentrated, and azeotroped with toluene to give a colorless oil that was carried on with no further purification. [0400]
    • Example 103C (5-Bromo-2-fluoro-phenyl)-(1H-pyrrol-2-yl)-methanone
  • A solution of 103B (720 mg; 3.0 mmol), and pyrrole (203 mg; 3.0 mmol) in 1,2-dichloroethane (10 mL) at 0° C. was treated portionwise with AlCl[0401] 3, stirred overnight while gradually warming to r.t., treated with ice and 1 N HCl, stirred for 1.5 hrs., and extracted with CH2Cl2. The extracts were rinsed with water and saturated NaHCO3 (aq.), dried over Na2SO4, concentrated, and isolated by flash chromatography (10% EtOAc/hexane) to give the desired product as a purple solid (252 mg; 31%).
    • Example 103D 5-Bromo-3-(1H-pyrrol-2-yl)-1H-indazole
  • The desired product was prepared by substituting Example 103C for Example 102B in Example 102C. [0402]
    • Example 103E (1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(1H-pyrrol-2-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 103D for 6-bromoisoquinoline in Example 27. MS (ESI) m/e 449 (M+H)[0403] +; 1H NMR (DMSO-d6, 300 MHz) δ 3.18 (m, 2H) 3.87 (m, 1H) 4.20 (dd,J=10.51, 5.76 Hz, 1H) 4.38 (m, 1H) 6.21 (m, 1H) 6.86 (m, 2H) 7.01 (t, J=7.46 Hz, 1H) 7.10 (t, J=7.46 Hz, 1H) 7.30 (d, J=2.03 Hz, 1H) 7.38 (d, J=8.14 Hz, 1H) 7.67 (m, 4H) 8.15 (bs, 2H) 8.26 (s, 1H) 8.35 (d, J=2.37 Hz, 1H) 8.68 (s, 1H) 11.03 (s, 1H) 11.38 (s, 1H) 13.10 (bs, 1H); Anal. Calcd for C21H24N6O.2.5 TFA: C, 52.39; H, 3.64; N, 11.46;. Found: C, 52.26; H, 3.67; N, 11.39.
    • EXAMPLE 104 (S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting phenyl magnesium bromide for methyl magnesium bromide in Example 102. MS (ESI) m/e 460 (M+H)[0404] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.17 (m, 2H) 3.87 (m, 1H) 4.19 (dd, J=10.51, 5.76 Hz, 1H) 4.38 (m, 1H) 7.00 (t, J=7.46 Hz, 1H) 7.09 (t, J=7.46 Hz, 1H) 7.30 (d, J=2.37 Hz, 1H) 7.39 (m, 1H) 7.44 (d, J=7.12 Hz, 1H) 7.54 (m, J=7.46, 7.46 Hz, 2H) 7.62 (d, J=7.46 Hz, 1H) 7.72 (s, 2H) 7.76 (m, 1H) 8.05 (s, 1H) 8.08 (s, 1H) 8.16 (m, 2H) 8.30 (s, 1H) 8.36 (d, J=2.71 Hz, 1H) 8.68 (d, J=1.70 Hz, 1H) 11.03 (s, 1H) 13.45 (bs, 1H); Anal. Calcd for C27H24N6O.3 TFA.2H2O: C, 53.24; H, 4.08; N, 8.87;. Found: C, 52.91; H, 3.68; N, 8.80.
    • EXAMPLE 105 (1S)-2-[5-(3-Cyclopropyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting cyclopropyl magnesium bromide for methyl magnesium bromide in Example 102. MS (ESI) m/e 424 (M+H)[0405] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 1.02 (m, 4H) 2.36 (m, 1H) 3.15 (m, 2H) 3.86 (m, 1H) 4.19 (dd, J=10.68, 5.93 Hz, 1H) 4.37 (dd, J=10.68, 3.22 Hz, 1H) 7.01 (t, J=7.46 Hz, 1H) 7.10 (t, J=6.95 Hz, 1H) 7.30 (d, J=2.37 Hz, 1H) 7.38 (d, J=8.14 Hz, 1H) 7.56 (d, J=8.48 Hz, 1H) 7.65 (m, 2H) 7.73 (m, 1H) 8.12 (s, 1H) 8.19 (m, 2H) 8.33 (d, J=2.37 Hz, 1H) 8.63 (d, J=1.36 Hz, 1H) 11.03 (d, J=2.03 Hz, 1H) 12.73 (m, 1H); Anal. Calcd for C26H21N5O.2.6 TFA: C, 52.05; H, 3.86; N, 9.73;. Found: C, 52.03; H, 3.89; N, 9.69.
    • EXAMPLE 106 (1S)-2-[5-(3-Ethyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting ethyl magnesium bromide for methyl magnesium bromide in Example 102. MS (ESI) m/e 412 (M+H)[0406] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 1.35 (t, J=7.63 Hz, 3H) 2.99 (q, J=7.57 Hz, 2H) 3.17 (m, 2H) 3.86 (m, 1H) 4.19 (dd, J=10.85, 6.10 Hz, 1H) 4.37 (m, 1H) 7.01 (t, J=7.46 Hz, 1H) 7.11 (t, J=7.46 Hz, 1H) 7.30 (d, J=2.37 Hz, 1H) 7.38 (d, J=7.80 Hz, 1H) 7.63 (m, 3H) 7.72 (m, 1H) 8.08 (s, 1H) 8.16 (m, 2H) 8.33 (d, J=2.71 Hz, 1H) 8.63 (d, J=1.70 Hz, 1H) 11.04 (d, J=2.03 Hz, 1H) 12.80 (m, 1H); Anal. Calcd for C25H25N5O.2.7 TFA: C, 50.76; H, 3.88; N, 9.74;. Found: C, 51.09; H, 3.88; N, 9.66.
    • EXAMPLE 107 (1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(1-methyl-1H-imidazol-2-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting N-methyl-2-imidazolyl lithium chloride for methyl magnesium bromide in Example 102. MS (ESI) m/e 464 (M+H)[0407] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 3.18 (m, 2H) 3.84 (s, 1H) 4.07 (s, 3H) 4.20 (dd, J=10.59, 5.98 Hz, 1H) 4.36 (m, 1H) 7.00 (t, J=7.36 Hz, 1H) 7.09 (t, J=7.36 Hz, 1H) 7.18 (s, 1H) 7.31 (d, J=2.15 Hz, 1H) 7.37 (m, 2H) 7.64 (m, 2H) 7.72 (s, 2H) 8.33 (m, 3H) 8.56 (d, J=1.53 Hz, 1H) 8.63 (s, 1H) 11.06 (s, 1H) 13.56 (s, 1H).
    • EXAMPLE 108 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-thiazol-2-yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting 2-thiozolyl lithium chloride for methyl magnesium bromide in Example 102. MS (ESI) m/e 467 (M+H)[0408] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.19 (d, J=7.18 Hz, 2H) 3.86 (m, 1H) 4.22 (dd, J=10.29, 5.93 Hz, 1H) 4.38 (dd, J=10.45, 2.65 Hz, 1H) 7.01 (t, J=7.49 Hz, 1H) 7.09 (t, J=7.49 Hz, 1H) 7.31 (d,J=1.56 Hz, 1H) 7.38 (d,J=8.11 Hz, 1H) 7.64 (d,J=7.80 Hz, 1H) 7.73 (s, 1H) 7.78 (s, 2H) 7.79 (d, J=3.12 Hz, 1H) 8.04 (d, J=3.43 Hz, 1H) 8.28 (s, 2H) 8.38 (d, J=2.18 Hz, 1H) 8.60 (s, 2H) 11.04(s, 1H) 13.74(s, 1H)
    • EXAMPLE 109 (1S)-2-15-[3-(1H-Imidazol-2-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-1-(1H-indol-3-ylmethyl)-ethylamine Example 109A (1S)-[1-(1H-Indol-3-ylmethyl)-2-(5-{3-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-1H-indazol-5-yl}-pyridin-3-yloxy)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared as the trifluoroacetate salt by substituting N-[2-trimethylsilanyl)ethoxy{methyl)-2-imidazolyl lithium chloride for methyl magnesium bromide in Example 102 without doing the last step. [0409]
    • Example 109B (1S)-2-{5-[3-(1H-Imidazol-2-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-1-(1H-indol-3-ylmethyl)-ethylamine
  • A solution of Example 109A (40 mg; 0.06 mmol) in MeOH (4 mL) was treated with conc. HCl (1 mL) and heated at reflux for 6 hrs., concentrated and purified by reverse phase HPLC on a C18 column with 0-100% CH[0410] 3CN/H2O/0.1% TFA to provide the desired product as the trifluoroacetate salt. MS (ESI) m/e 450 (M+H)+; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.19 (d, J=7.17 Hz, 2H) 3.86 (s, 1H) 4.22 (dd, J=10.45, 5.77 Hz, 1H) 4.37 (dd, J=10.45, 2.96 Hz, 1H) 7.00 (t, J=7.49 Hz, 1H) 7.09 (t, J=7.49 Hz, 1H) 7.30 (d, J=2.18 Hz, 1H) 7.38 (d, J=8.11 Hz, 1H) 7.63 (d, J=8.11 Hz, 1H) 7.76 (s, 1H) 7.83 (s, 1H) 7.86 (s, 2H) 8.26 (bs, 3H) 8.39 (d, J=2.50 Hz, 1H) 8.61 (s, 1H) 8.72 (s, 1H) 11.04 (s, 1H) 14.36 (s, 1H)
    • EXAMPLE 110 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-thiophen-2-yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared by substituting 2-thiophenyl lithium chloride for methylmagnesium bromide in Example 102. MS (ESI) m/e 466 (M+H)[0411] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 3.21 (d, J=7.06 Hz, 2H) 3.86 (bs, 1H) 4.23 (dd, J=10.43, 5.83 Hz, 1H) 4.38 (m, 1H) 7.00 (t, J=7.52 Hz, 1H) 7.10 (t, J=7.06 Hz, 1H) 7.23 (dd, J=5.22, 3.68 Hz, 1H) 7.31 (d, J=2.15 Hz, 1H) 7.39 (d, J=7.98 Hz, 1H) 7.59 (d, J=6.14 Hz, 1H) 7.64 (d, J=7.98 Hz, 1H) 7.73 (m, 3H) 7.91 (d, J=2.76 Hz, 1H) 8.34 (m, 4H) 8.67 (s, 1H) 11.06 (s, 1H) 13.39 (s, 1H)
    • EXAMPLE 111 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-morpholin-4-yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine Example 111A 5-Bromo-3-morpholin-4-yl-1H-indazole
  • The reaction between Example 35A and morpholine was carried out according to the procedure described by U. Wrzeciono, K. Majewska, J. Dudzinska-Usarewicz, M. Bemas, [0412] Pharmzie, 1986, 41, 472-474.
    • Example 111B (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-morpholin-4-yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared by substituting Example 111A for 6-bromoisoquinoline in Example 27. MS (ESI) m/e 469 (M+H)[0413] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.16 (d, J=7.12 Hz, 2H) 3.35 (m, 4H) 3.81 (m, 4H) 3.88 (m, 1H) 4.19 (dd, J=10.68, 5.93 Hz, 1H) 4.35 (m, 1H) 7.01 (t, J=7.46 Hz, 1H) 7.10 (t, J=7.46 Hz, 1H) 7.30 (d, J=2.37 Hz, 1H) 7.38 (d, J=7.80 Hz, 1H) 7.48 (d, J=8.82 Hz, 1H) 7.62 (m, 2H) 7.72 (m, 1H) 8.09 (s, 1H) 8.17 (m, 2H) 8.33 (d, J=2.71 Hz, 1H) 8.65 (d, J=1.70 Hz, 1H) 11.03 (s, 1H) 12.21 (s, 1H);
  • Anal. Calcd for C[0414] 27H28N6O2.3.4 TFA: C, 47.41; H, 3.70; N, 9.82;. Found: C, 47.10; H, 3.86; N, 9.95.
    • EXAMPLE 112 (1S)-2-[5-(1,3-Dimethyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine Example 112A 5-Bromo-1,3-dimethyl-1H-indazole
  • Example 102C (500 mg; 2.37 mmol) was added to a mixture of 60% NaH (115 mg; 2.84 mmol) in DMF (10 mL). After 15 min. at r.t. iodomethane (456 mg; 3.21 mmol) was added, the reaction was stirred for 2 hrs then diluted with water and extracted with EtOAc. The extracts were rinsed with water and brine, dried (MgSO[0415] 4), evaporated, and isolated by flash chromatography (1:1 Et2O:hexane) to give the desired product (360 mg; 67%).
    • Example 112B
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 112A for Example 6-bromoisoquinoline in Example 27. MS (ESI) m/e 412 (M+H)[0416] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.54 (s, 3H) 3.18 (m, 2H) 3.86 (s, 1H) 4.00 (s, 3H) 4.20 (dd, J=10.51, 6.10 Hz, 1H) 4.37 (m, 1H) 7.01 (t, J=7.46 Hz, 1H) 7.10 (t, J=7.12 Hz, 1H) 7.30 (d, J=2.37 Hz, 1H) 7.39 (d, J=7.80 Hz, 1H) 7.63 (d, J=7.80 Hz, 1H) 7.73 (m, 2H) 8.08 (s, 1H) 8.18 (m, 3H) 8.34 (d, J=2.71 Hz, 1H) 8.66 (d, J=1.70 Hz, 1H) 11.04 (s, 1H); Anal. Calcd for C25H25N5O.2.8 TFA: C, 50.29; H, 3.83; N, 9.58;. Found: C, 50.36; H, 3.84, N, 9.60.
    • EXAMPLE 113 (1S)-1-(1H-Indol-3-ylmethyl)-2-[3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting 3-bromophenol for 3-bromo-5-hydroxypyridine in Example 102. MS (ESI) m/e 397 (M+H)[0417] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.54 (s, 3H) 3.17 (m, 2H) 3.81 (m, 1H) 4.09 (dd, J=10.51, 5.76 Hz, 1H) 4.25 (dd, J=10.51, 3.05 Hz, 1H) 6.93 (m, 1H) 7.01 (t, J=7.46 Hz, 1H) 7.10 (t, J=7.46 Hz, 1H) 7.28 (m, 2H) 7.37 (m, 3H) 7.52 (d, J=8.48 Hz, 1H) 7.61 (m, 2H) 7.93 (s, 1H) 8.15 (bs, 2H) 11.03 (s, 1H) 12.62 (bs, 1H)
    • EXAMPLE 114 (1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(4-methyl-piperazin-1-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-ethylamine Example 114A 5-Bromo-3-(4-methyl-piperazin-1-yl)-1H-indazole
  • The reaction between Example 35A and N-methyl piperazine was carried out according to the procedure described by U. Wrzeciono, K. Majewska, J. Dudzinska-Usarewicz, M. Bemas, [0418] Pharmzie, 1986, 41, 472-474.
    • Example 114B (1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(4-methyl-piperazin-1-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-ethyl Amine
  • The desired product was prepared by substituting Example 114A for 6-bromoisoquinoline in Example 27. MS (ESI) m/e 482 (M+H)[0419] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.54 (s, 3H) 2.90 (m, 2H) 3.21 (m, 4H) 3.54 (m, 2H) 3.83 (m, 1H) 4.06 (m, 2H) 4.19 (dd, J=10.68, 5.93 Hz, 1H) 4.35 (dd, J=10.51, 2.71 Hz, 1H) 7.01 (t, J=6.95 Hz, 1H) 7.10(t, J=7.12 Hz, 1H) 7.30 (d, J=2.03 Hz, 1H) 7.38 (d, J=8.14 Hz, 1H) 7.51 (d, J=8.82 Hz, 1H) 7.65 (m, 3H) 8.15 (s, 1H) 8.21 (m, 2H) 8.33 (d, J=2.71 Hz, 1H) 8.66 (d, J=1.70 Hz, 1H) 11.04 (s, 1H) 12.36 (s, 1H); Anal. Calcd for C21H31N7O.4.45 TFA: C, 44.81; H, 3.61; N, 9.91;. Found: C, 44.83; H, 3.53, N, 9.97.
    • EXAMPLE 115 (1S)-(5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-yl)-dimethyl-amine Example 115A (5-Bromo-1H-indazol-3-yl)-dimethyl-amine
  • The reaction between Example 35A and dimethylamine was carried out according to the procedure described by U. Wrzeciono, K. Majewska, J. Dudzinska-Usarewicz, M. Bemas, [0420] Pharmzie, 1986, 41, 472-474.
    • Example 115B (1S)-(5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-yl)-dimethyl-amine
  • The desired product was prepared by substituting Example 115A for 6-bromoisoquinoline in Example 27. MS (ESI) m/e 427 (M+H)[0421] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.04 (s, 6H) 3.16 (m, 2H) 3.86 (s, 1H) 4.19 (m, 1H) 4.36 (m, 1H) 7.01 (t, J=6.95 Hz, 1H) 7.10 (t, J=7.12 Hz, 1H) 7.30 (d, J=2.37 Hz, 1H) 7.38 (d, J=8.14 Hz, 1H) 7.45 (d, J=8.82 Hz, 1H) 7.61 (m, 2H) 7.73 (s, 1H) 8.07 (s, 1H) 8.17 (m, 2H) 8.33 (d, J=2.37 Hz, 1H) 8.62 (d, J=1.36 Hz, 1H) 11.03 (s, 1H) 12.04 (s, 1H); Anal. Calcd for C25H26N6O.3.5 TFA: C, 46.55; H, 3.60; N, 10.18;. Found: C, 46.71; H, 3.65, N, 10.02.
    • EXAMPLE 116 (1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-benzyl)-phenyl-amine Example 116A (1S)-[2-[5-(4-Formyl-phenyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting 4-formylphenylboronic acid for 4-cyanophenylboronice acid in Example 22. MS: (ESI) m/z 472 (M+H)[0422] +.
    • Example 116B (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenylaminomethyl-phenyl)-pyridin-3-yloxy]-ethyl}-carbamic Acid Tert-Butyl Ester
  • A solution of Example 116A (0.03 g, 0.06 mmol) in 2 mL of MeOH was cooled to 0° C. then treated with aniline (0.018 g 0.2 mmol), NaBH[0423] 3CN (0.004 g, 0.06 mmol) and AcOH (1 ml). The mixture was allowed to warm to room temperature overnight. The mixture was diluted with ethyl acetate (20 ml), washed with water (10 ml) and brine (10 ml). The ethyl acetate was evaporated off and the residue was used without further purification.
    • Example 116C (1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-benzyl)-phenyl-amine
  • The desired product was prepared by substituting Example 116B for Example 27B in Example 27C. MS: (ESI) (M+H)[0424] + m/z=449. 1H NMR (500 MHz, DMSO-D6) δ ppm 3.82 (m, 7H) 4.18 (m, 1H) 4.32 (d, J=4.06 Hz, 2H) 6.55 (d, J=32.76 Hz, 1H) 6.59 (d, J=7.49 Hz, 1H) 6.89 (d, J=7.49 Hz, 1H) 7.04 (m, 3H) 7.18 (m, 1H) 7.29 (d, J=2.50 Hz, 1H) 7.37 (d, J=7.80 Hz, 1H) 7.48 (d, J=8.11 Hz, 1H) 7.62 (m, 3H) 8.31 (bs, 3H) 8.52 (d, J=1.56 Hz, 1H) 11.04 (d, J=1.87 Hz, 1H)
    • EXAMPLE 117 (1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-methanol Example 117A (1S)-{2-[5-(4-Hydroxymethyl-phenyl)-pyridin-3-yloxy]-1-phenyl-ethyl}-carbamic Acid Tert-Butyl Ester
  • Example 116A (0.03 g, 0.06 mmol) was dissolved in 2 mL of MeOH and cooled to 0° C., then treated with NaBH[0425] 4 (0.003 g, 0.08 mmol). The mixture was allowed to warm to room temperature over 2 h. The mixture was diluted with ethyl acetate (20 ml), washed with water (10 ml) and brine (10 ml). The ethyl acetate was evaporated off and the residue was used without further purification.
    • Example 117B (1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-methanol
  • The desired product was prepared by substituting Example 117A for Example 27B in Example 27C. MS: (ESI) m/z 374 (M+H)[0426] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.15 (m, 4H) 3.72 (m, 1H) 4.16 (dd, J=10.29, 5.93 Hz, 1H) 4.29 (m, 1H) 4.55 (s, 2H) 5.29 (s, 1H) 6.99 (t, J=7.02 Hz, 1H) 7.09 (t, J=7.02 Hz, 1H) 7.28 (d, J=2.18 Hz, 1H) 7.37 (d, J=8.11 Hz, 1H) 7.43 (d, J=8.42 Hz, 2H) 7.59 (m, 1H) 7.64 (dd, J=10.61, 8.42 Hz, 3H) 8.30 (d, J=2.81 Hz, 1H) 8.51 (d, J=1.56 Hz, 1H) 11.03 (s, 1H)
    • EXAMPLE 118 (1S)-2-(5-(4-Fluoro-phenyl)-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine
  • The desired product was prepared by substituting 4-fluorophenylboronic acid for 4-cyanophenylboronice acid in Example 22. MS: (ESI) m/z 362 (M+H)[0427] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.09 (m, 2H) 3.17 (d, J=4.68 Hz, 1H) 3.71 (s, 1H) 4.12 (dd, J=10.29, 6.24 Hz, 1H) 4.26 (dd, J=10.29, 3.43 Hz, 1H) 6.99 (t, J=7.49 Hz, 1H) 7.09 (m, 1H) 7.26 (d, J=2.18 Hz, 1H) 7.34 (m, 3H) 7.59 (m, 2H) 7.74 (m, 2H) 8.32 (d, J=2.50 Hz, 1H) 8.50 (d, J=1.87 Hz, 1H) 10.97 (s, 1H).
    • EXAMPLE 119 (1S)-4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-benzoic Acid
  • The desired product was prepared by substituting 4-hydroxycarbonylphenylboronic acid for 4-cyanophenylboronice acid in Example 22. MS (ESI) m/z 388 (M+H)[0428] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.17 (m, 1H) 3.84 (m, 1H) 4.20 (m, 1H) 4.35 (m, 1H) 7.00 (t, J=6.86 Hz, 1H) 7.10 (t, J=7.02 Hz, 1H) 7.30 (d, J=2.18 Hz, 1H) 7.38 (d, J=8.11 Hz, 1H) 7.63 (d, J=7.49 Hz, 1H) 7.68 (m, 1H) 7.83 (d, J=8.42 Hz, 1H) 8.04 (m, 2H) 8.26 (s, 3H) 8.38 (d, J=2.50 Hz, 1H) 8.59 (d, J=1.87 Hz, 1H) 11.02 (d, J=1.87 Hz, 1H)
    • EXAMPLE 120 (1S)-2-(3-Bromo-5-isoquinolin-6-yl-phenoxyoxy)-1-(1H-indol-3-ylmethyl)-ethylamine
  • Step 1. [0429]
    • Example 120A (2S)-[1-(3,5-Dibromo-phenoxymethyl)-2-(1H-indol-3-yl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • A solution of 3,5-dibromo-phenol (1 g, 4.1 mmol), (2-hydroxy-1-phenyl-ethyl)-carbamic acid tert-butyl ester (1.2 g, 4.1 mmol), and triphenylphosphine (1.6 g, 2 mmol) in THF (30 mL) was stirred at 0° C. for 30 min. To the mixture was added a solution of di-t-butyl azidodicarboxylate (1.45 g, 9.2 mmol) in 5 ml of THF. The mixture was allowed to warm to room temperature then stirred at room temperature for 20 h. The THF was evaporated off and the residue was taken into ethyl acetate (75 ml), washed with saturated sodium bicarbonate (50 ml) water (50 ml) and brine (50 ml). The ethyl acetate was evaporated of and the residue was purified by flash column chromatography on silica gel, eluting with a solvent gradient of 1:4 to 1:1 ethyl acetate/hexane. Recovered 1.33 g of product (64%). [0430]
    • Example 120B (2S)-[1-(3-Bromo-5-isoquinolin-6-yl-phenoxymethyl)-2-(1H-indol-3-yl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • A solution of Example 120A above (0.6 g, 01.1 mmol) and 6-trimethylstannanyl-isoquinoline (0.26 g, 1 mmol) in 5 mL of DMF was treated with Pd[0431] 2(dba)3 (0.1 g, 0.1 mmol), P(o-tol)3 (0.07 g, 0.2 mmol), and TEA (0.3 mL, 2.3 mmol). The reaction was heated to 95° C. for 6.5 h, then cooled and diluted with ethyl acetate (75 ml), washed with saturated sodium bicarbonate (50 ml) water (50 ml) and brine (50 ml). The ethyl acetate was evaporated off and the residue was purified by flash column chromatography on silica gel, eluting with a solvent gradient of 1:4 to 1:1 ethyl acetate/hexane.
  • 0.2 g of product (30%). MS (ESI) m/z 572 (M+H)[0432] +.
    • Example 120C (1S)-2-(3-Bromo-5-isoquinolin-6-yl-phenoxyoxy)-1-(1H-indol-3-ylmethyl)-ethylamine
  • The desired product was prepared by substituting Example 120B for Example 27B in Example 27C. MS (ESI) m/z 472 (M+H)[0433] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.87 (d, J=6.55 Hz, 1H) 3.00 (d, J=6.55 Hz, 1H) 3.47 (m, 2H) 3.99 (dd, J=9.67, 6.24 Hz, 1H) 4.07 (d, J=4.37 Hz, 1H) 6.96 (t, J=7.02 Hz, 1H) 7.06 (t, J=7.02 Hz, 1H) 7.22 (d, J=2.18 Hz, 1H) 7.24 (m, 1H) 7.35 (d, J=8.11 Hz, 1H) 7.41 (m, 1H) 7.58 (d, J=7.80 Hz, 1H) 7.62 (s, 1H) 7.89 (d, J=5.93 Hz, 1H) 8.00 (dd, J=8.42, 1.87 Hz, 1H) 8.21 (d, J=8.73 Hz, 1H) 8.32 (s, 1H) 8.54 (d, J=5.62 Hz, 1H) 9.35 (s, 1H) 10.87 (s, 1H)
    • EXAMPLE 121 N4-(3-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidine-2,4-diamine Example 121A (1S)-{2-[5-(3-Amino-phenyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl}-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting 3-aminophenylboronic acid for 4-cyanophenylboronice acid in Example 22. [0434]
    • Example 121B (S)-[2-{5-[3-(2-Amino-pyrimidin-4-ylamino)-phenyl]-pyridin-3-yloxy}-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • A mixture of Example 121A (0.07 g, 0.153 mmol) and 4-chloro-2-pyrimidinylamine (0.021 g, 0.163 mmol) was dissolved in EtOH (1 mL). The mixture was heated to 80° C. overnight then cooled and evaporated. The product was used without further purification. [0435]
    • EXAMPLE 121C (1S)-[2-[5-(3-Amino-phenyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting Example 121B for Example 27B in Example 27C. MS (ESI) m/z 452 (M+H)[0436] +. 1H NMR (500 MHz, DMSO-D6) δ ppm 3.17 (m, 2H) 3.85 (m, 1H) 3.97 (s, 1H) 4.19 (m, 1H) 4.35 (m, 1H) 6.35 (d, J=6.86 Hz, 1H) 7.00 (t, J=7.49 Hz, 1H) 7.10 (m, 1H) 7.29 (d, J=2.18 Hz, 1H) 7.38 (d, J=8.11 Hz, 1H) 7.52 (m, J=7.80 Hz, 2H) 7.62 (d, J=7.80 Hz, 1H) 7.66 (m, 1H) 7.88 (d, J=7.18 Hz, 1H) 8.25 (d, J=4.37 Hz, 2H) 8.38 (d, J=2.50 Hz, 1H) 8.58 (d, J=1.56 Hz, 1H) 10.73 (s, 1H) 11.02 (d, J=1.87 Hz, 1H).
    • EXAMPLE 122 (1S)-3-(2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-phenylamine Example 122A (1S)-[2-[3-(Benzhydrylidene-amino)-5-isoquinolin-6-yl-phenoxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • A solution of Example 120B (0.165 g, 0.29 mmol) and benzophenone imine (0.1 mL, 0.6 mmol) in 5 mL of toluene was treated with Pd[0437] 2 dba3 (0.026 g, 0.028 mmol), BINAP (0.036 g, 0.058 mmol) and sodium tbutoxide (0.042 g, 0.44 mmol). The reaction was heated to 80° C. overnight then to 95° C. for 24 h. The mixture was cooled and filtered through celite. The residue was purified by flash column chromatography on silica gel, eluting with 1:1 ethyl acetate/hexane. Recovered 0.175 g of product (90%). MS (ESI) m/z 673 (M+H)+.
    • Example 122B (1S)-3-(2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-phenylamine
  • A solution of Example 122A (0.175 g, 0.26 mmol) in 2 mL of THF was cooled to 0° C. then treated with 1 mL of 3N HCl. The mixture was stirred at 0° C. for 15 minutes then at room temperature for 4 h. The mixture was evaporated and the residue was purified by flash column chromatography on silica gel, eluting with 10% methanol in methylene chloride. Recovered 0.029 g of product (23%). MS (ESI) m/z 408 (M+H)[0438] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.20 (m, 2H) 3.77 (m, 1H) 4.12 (d, J=5.62 Hz, 1H) 4.21 (d, J=3.43 Hz, 1H) 6.58 (s, 1H) 6.86 (m, 1H) 6.95 (s, 1H) 7.01 (m, 1H) 7.08 (d, J=7.18 Hz, 1H) 7.29 (d, J=2.18 Hz, 1H) 7.37 (d, J=8.11 Hz, 1H) 7.66 (d, J=7.80 Hz, 1H) 8.13 (d, J=8.73 Hz, 1H) 8.38 (d, J=6.24 Hz, 1H) 8.43 (s, 1H) 8.52 (m, 3H) 8.65 (d, J=6.24 Hz, 1H) 9.78 (s, 1H) 11.06 (d, J=1.87 Hz, 1H)
    • EXAMPLE 123 4-(5-Isoquinolin-6-yl-pyridin-3-yl)-piperazine-1-carboxylic Acid Tert-Butyl Ester Example 123A 4-(5-Bromo-pyridin-3-yl)-piperazine-1-carboxylic Acid Tert-Butyl Ester
  • A solution of the 3,5-dibromo-pyridine (12.8 g, 68.8 mmol) and piperazine-1-carboxylic acid tert butyl ester (10 g, 42.4 mmol) in 200 mL of dioxane was treated with Pd[0439] 2(dba)3 (5 g, 5.5 mmol), 2-(di-tbutyl-phosphino)biphenyl (4 g, 13.4 mmol), and sodium t-butoxide (7.2 g, 75 mmol). The reaction was heated to 95° C. for 8 h then cooled and filtered through celite. The mixture was evaporated and the residue was purified by flash column chromatography on silica gel, eluting with a solvent gradient of 1:4 ethyl acetate/hexane to 100% ethyl acetate. Recovered 2.9 g of product (20%). MS (ESI) m/z 344 (M+H)+.
    • Example 123B 4-(5-Isoquinolin-6-yl-pyridin-3-yl)-piperazine-1-carboxylic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting Example 123A for Example 27A in Example 123B. MS (ESI) m/z 408 (M+H)[0440] +; 1H NMR (500 MHz, CHLOROFORM-D) δ ppm 1.50 (m, 9H) 3.29 (m, 4H) 3.65 (m, 4H) 7.46 (m, 1H) 7.72 (d, J=5.62 Hz, 1H) 7.83 (d, J=1.87 Hz, 1H) 7.99 (s, 1H) 8.09 (d, J=8.74 Hz, 1H) 8.37 (d, J=2.81 Hz, 1H) 8.46 (d, J=1.87 Hz, 1H) 8.59 (d, J=5.93 Hz, 1H) 9.31 (s, 1H).
    • EXAMPLE 124 6-(5-Piperazin-1-yl-pyridin-3-yl)-isoquinoline
  • The desired product was prepared by substituting Example 123 for Example 27B in Example 27C. MS (ESI) m/z 291 (M+H)[0441] +; 1H NMR (500 MHz, Solvent) δ ppm 3.47 (m, 4H) 3.79 (m, 4H) 8.30 (m, 1H) 8.39 (dd, J=8.58, 1.72 Hz, 1H) 8.49 (d, J=6.55 Hz, 1H) 8.57 (d, J=2.50 Hz, 1H) 8.63 (m, 2H) 8.70 (m, 2H) 9.78 (s, 1H).
    • EXAMPLE 125 ((2S)-2-Amino-5-(5-(2-amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl-(3-chloro-phenyl-methanone
  • The title compound was prepared by substituting 2-amino-5-iodo-3′-chloro benzophenone for Example 32A in Example 32. MS (ESI) m/z 291 (M+H)[0442] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.15 (m, 2H) 3.81 (m, 1H) 4.11 (m, 1H) 4.26 (m, 1H) 7.00 (m, 2H) 7.09 (m, 1H) 7.27 (m, 1H) 7.39 (m, 2H) 7.60 (m, 4H) 8.21 (m, 1H) 8.32 (m, 3H) 11.07 (m, 1H).
    • EXAMPLE 126 (1S)-N-6-(3-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-9H-purine-2,6-diamine
  • The title compound was prepared by substituting 6-Chloro-9H-purin-2-ylamine for 4-chloro-2-pyrimidinylamine in Example 121. MS (ESI) m/z 492 (M+H)[0443] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 3.18 (d, J=8.29 Hz, 2H) 3.83 (m, 1H) 4.01 (m, 1H) 4.19 (m, 1H) 4.36 (m, 1H) 7.01 (m, 2H) 7.09 (t, J=7.06 Hz, 1H) 7.16 (s, 1H) 7.30 (m, 2H) 7.38 (d, J=8.29 Hz, 1H) 7.63 (m, 2H) 8.18 (s, 2H) 8.30 (m, 2H) 8.35 (d, J=2.45 Hz, 1H) 8.56 (d, J=1.84 Hz, 1H) 11.02 (s, 1H).
    • EXAMPLE 127 (3-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidin-2yl-amine
  • The title compound was prepared by substituting 2-chloropyrimidine for 4-chloro-2-pyrimidinylamine in Example 121. MS (ESI) m/z 437 (M+H)[0444] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.17 (d, J=5.30 Hz, 1H) 4.06 (q, J=5.30 Hz, 5H) 6.86 (t, J=4.84 Hz, 2H) 6.96 (d, J=7.18 Hz, 1H) 7.05 (s, 1H) 7.26 (m, 1H) 7.34 (d, J=8.11 Hz, 1H) 7.40 (t, J=7.96 Hz, 1H) 7.54 (m, 1H) 7.55 (s, 1H) 7.85 (m, 2H) 8.07 (t, J=1.72 Hz, 1H) 8.30 (d, J=2.50 Hz, 1H) 8.44 (d, J=1.87 Hz, 1H) 8.50 (d, J=4.68 Hz, 2H) 9.68 (s, 1H) 10.85 (s, 1H).
    • EXAMPLE 128 (3-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-thiazol-2yl-amine
  • The title compound was prepared by substituting 2-chlorothiazole for 4-chloro-2-pyrimidinylamine in Example 121. MS (ESI) m/z 442 (M+H)[0445] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.16 (m, 3H) 4.16 (m, 1H) 4.34 (m, 1H) 6.94 (d, J=3.74 Hz, 1H) 7.01 (m, 1H) 7.10 (m, 1H) 7.22 (m, 1H) 7.28 (dd, J=7.96, 2.96 Hz, 2H) 7.38 (d, J=8.42 Hz, 1H) 7.42 (d, J=7.80 Hz, 1H) 7.57 (m, 1H) 7.62 (d, J=8.11 Hz, 1H) 8.02 (s, 1H) 8.14 (s, 2H) 8.35(d, J=2.50 Hz, 1H) 8.48 (d, J=1.87 Hz, 1H) 10.31 (s, 1H) 11.01 (s, 1H).
    • EXAMPLE 129 N-(3-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-acetamide Example 129A (1S)-[2-[5-(3-Acetylamino-phenyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • Example 121A (0.05 g, 0.11 mmol) was taken in methylene chloride (1.5 mL) and treated with acetic anhydride (0.2 mL, 2.1 mmol) and triethylamine (0.1 mL, 0.77 mmol). The mixture was stirred overnight at room temperature then diluted with methylene chloride (25 mL) and washed with water (15 mL) and brine (15 mL). The mixture was evaporated and used without further purification. [0446]
    • Example 129B N-(3-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-acetamide
  • The desired product was prepared by substituting Example 129A for Example 27B in Example 27C. MS (ESI) m/z 401 (M+H)[0447] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 2.07 (m, 3H) 3.16 (m, 3H) 4.16 (m, 1H) 4.33 (m, 1H) 7.01 (m, 1H) 7.10 (m, 1H) 7.29 (m, 1H) 7.38 (m, 3H) 7.55 (m, 2H) 7.62 (m, 1H) 7.99 (m, 1H) 8.14 (m, 2H) 8.35 (m, 1H) 8.48 (m, 1H) 10.06 (m, 1H) 11.01 (m, 1H).
    • EXAMPLE 130 6-(5-(4-(1H-Indol-3-ylmethyl)-piperazin-1-yl)-pyridin-3-yl)-isoquinoline
  • The title compound was prepared by substituting Example 124 for aniline, and 3-formylindole for Example 116A in example 116B. MS (ESI) (m/z 420M+H)[0448] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 1.89 (s, 2H) 2.50 (m, 4H) 2.60 (m, 4H) 7.02 (m, 2H) 7.27 (d, J=2.46 Hz, 1H) 7.36 (d, J=7.98 Hz, 1H) 7.68 (m, 2H) 7.87 (d, J=5.83 Hz, 1H) 8.05 (dd, J=8.59, 1.53 Hz, 1H) 8.22 (d, J=8.90 Hz, 1H) 8.34 (m, 2H) 8.44 (d, J=1.84 Hz, 1H) 8.54 (d, J=5.83 Hz, 1H) 9.35 (s, 1H) 10.93 (s, 1H).
    • EXAMPLE 131 3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-benzoic Acid Example 131A 3-[(2S)-2-tert-Butoxycarbonylamino-3-(1H-indol-3-yl)-propoxy]-5-isoquinolin-6-yl-benzoic Acid
  • A solution of Example 120 (0.2 g, 0.3 mmol) 6 mL of DMF was treated with Pd(dppf)[0449] 2Cl2 (0.039 g, 0.07 mmol), Pd(OAc)2 (0.016 g, 0.07 mmol), ammonium hydroxide (0.15 mL), and triethylamine (0.5 mL, 3.9 mmol). The reaction was heated to 80° C. after which CO was bubbled through for 30 minutes. The mixture was heated-to 80° C. overnight then cooled, neutralized with HCl and washed with ethyl acetate. The water was evaporated off to yield the product. MS (ESI) m/z 538 (M+H)+.
    • EXAMPLE 131B 3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-benzoic Acid
  • The desired product was prepared by substituting Example 131A for Example 27B in Example 27C. MS (ESI) m/z 438 (M+H)[0450] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.14 (m, 3H) 4.20 (m, 1H) 4.35 (d, J=2.81 Hz, 1H) 7.02 (m, 1H) 7.09 (d, J=8.11 Hz, 1H) 7.30 (d, J=2.50 Hz, 1H) 7.38 (d, J=8.11 Hz, 1H) 7.63 (m, 2H) 7.68 (s, 1H) 8.04 (s, 1H) 8.11 (m, 2H) 8.18 (s, 3H) 8.36 (d, J=8.73 Hz, 1H) 8.42 (s, 1H) 8.61 (d, J=5.93 Hz, 1H) 9.53 (s, 1H) 11.02 (d, J=1.56 Hz, 1H).
    Figure US20030187026A1-20031002-C00012
    • EXAMPLE 132 4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenylamine
  • The desired product was prepared by substituting 4-aminophenylboronic acid for 4-cyanophenylboronice acid in Example 22. MS (ESI) m/z 359 (M+H)[0451] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.16 (m, 2H) 3.90 (d, J=63.33 Hz, 3H) 4.16 (dd, J=10.61, 6.24 Hz, 1H) 4.33 (m, 1H) 6.77 (d, J=8.42 Hz, 1H) 7.01 (m, 1H) 7.11 (s, 1H) 7.29 (d, J=2.18 Hz, 1H) 7.38 (d, J=8.11 Hz, 1H) 7.47 (d, J=8.42 Hz, 1H) 7.61 (m, 2H) 8.17 (s, 2H) 8.24 (d, J=2.50 Hz, 1H) 8.50 (d, J=1.56 Hz, 1H) 11.02 (s, 1H).
    • EXAMPLE 133 N-(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-acetamide
  • The desired product was prepared by substituting Example 132 for Example 121A in Example 129. MS (ESI) m/z 401 (M+H)[0452] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.17 (d, J=6.86 Hz, 5H) 4.18 (d, J=5.93 Hz, 1H) 4.32 (d, J=3.12 Hz, 1H) 7.01 (m, 1H) 7.09 (d, J=7.18 Hz, 1H) 7.29 (d, J=2.18 Hz, 1H) 7.38 (d, J=8.11 Hz, 1H) 7.58 (d, J=2.18 Hz, 1H) 7.65 (m, 4H) 8.28 (m, 4H) 8.51 (d, J=1.25 Hz, 1H) 10.10 (s, 1H) 11.03 (d, J=1.25 Hz, 1H).
    • EXAMPLE 134 N6-(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-9H-purine-2,6-diamine
  • The title compound was prepared by substituting Example 132 for Example 121A in Example 126. MS (ESI) m/z 492 (M+H)[0453] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.51 (m, 3H) 3.16 (t, J=7.49 Hz, 1H) 3.91 (d, J=53.97 Hz, 2H) 4.19 (dd, J=10.76, 6.08 Hz, 1H) 4.35 (dd, J=10.76, 2.96 Hz, 1H) 7.01 (t, J=7.18 Hz, 1H) 7.11 (t, J=7.02 Hz, 1H) 7.30 (d, J=2.18 Hz, 1H) 7.39 (d, J=8.11 Hz, 1H) 7.64 (m, 2H) 7.74 (d, J=8.73 Hz, 1H) 8.02 (d, J=8.42 Hz, 1H) 8.20 (d, J=3.74 Hz, 2H) 8.26 (s, 1H) 8.34 (d, J=2.50 Hz, 1H) 8.58 (d, J=1.56 Hz, 1H) 10.52 (s, 1H) 11.03 (d, J=1.87 Hz, 1H).
    • EXAMPLE 135 N4-(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidine-2,4-diamine
  • The title compound was prepared by substituting Example 132 for Example 121A in Example 121. MS (ESI) m/z 452 (M+H)[0454] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.16 (d, J=7.18 Hz, 2H) 3.86 (m, 2H) 4.18 (m, 1H) 4.33 (d, J=3.12 Hz, 1H) 6.35 (d, J=7.18 Hz, 1H) 7.01 (t, J=7.33 Hz, 1H) 7.10 (t, J=7.02 Hz, 1H) 7.29 (d, J=2.18 Hz, 1H) 7.39 (d, J=8.11 Hz, 1H) 7.62 (dd, J=4.52, 2.03 Hz, 2H) 7.73 (d, J=8.73 Hz, 2H) 7.88 (d, J=7.49 Hz, 2H) 8.20 (s, 3H) 8.34 (d, J=2.81 Hz, 1H) 8.56 (d, J=1.87 Hz, 1H) 10.69 (s, 1H) 11.02 (d, J=1.87 Hz, 1H).
    • EXAMPLE 136 (4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidin-2-yl-amine
  • The title compound was prepared by substituting Example 132 for Example 121A in Example 127. MS (ESI) m/z 437 (M+H)[0455] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.94 (d, J=6.55 Hz, 1H) 3.04 (m, 1H) 3.17 (d, J=3.74 Hz, 1H) 3.55 (m, 1H) 4.04 (dd, J=9.83, 6.40 Hz, 1H) 4.16 (dd, J=9.98, 4.06 Hz, 1H) 6.88 (t, J=4.84 Hz, 1H) 6.98 (t, J=7.49 Hz, 1H) 7.08 (t, J=7.64 Hz, 1H) 7.24 (d, J=2.18 Hz, 1H) 7.36 (d, J=8.11 Hz, 1H) 7.55 (m, 1H) 7.59 (d, J=7.80 Hz, 1H) 7.64 (d, J=8.73 Hz, 2H) 7.90 (d, J=9.05 Hz, 2H) 8.25 (d, J=2.81 Hz, 1H) 8.49 (d, J=1.56 Hz, 1H) 8.52 (d, J=4.99 Hz, 2H) 9.78 (s, 1H).
    • EXAMPLE 137 3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-benzonitrile
  • [0456]
    Figure US20030187026A1-20031002-C00013
    • Example 137A (1S)-[2-(3-Cyano-5-isoquinolin-6-yl-phenoxy)-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • A solution of Example 120 (0.15 g, 0.3 mmol) 3 mL of dioxane and 1 mL of DMF was treated with Pd(PPh[0457] 3)4 (0.030 g, 0.026 mmol), and zinc cyanide (0.037 g, 0.3 mmol). The reaction was heated to 95° C. for 3 days. The mixture was diluted with ethyl acetate (25 mL) and washed with water (15 mL) and brine (15 mL). The mixture was evaporated and the residue was purified by flash column chromatography on silica gel, eluting 1:1 ethyl acetate/hexane. Recovered 0.108 g of product (79%). MS (ESI) m/z 519 (M+H)+.
    • Example 137B 3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-benzonitrile
  • The desired product was prepared by substituting Example 137A for Example 27B in Example 27C. MS (ESI) m/z 419 (M+H)[0458] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.95 (d, J=6.55 Hz, 1H) 3.05 (dd, J=14.35, 7.18 Hz, 1H) 3.57 (m, 1H) 4.07 (m, 1H) 4.16 (d, J=4.06 Hz, 1H) 6.96 (t, J=7.18 Hz, 1H) 7.06 (t, J=7.18 Hz, 1H) 7.23 (d, J=2.18 Hz, 1H) 7.34 (d, J=8.11 Hz, 1H) 7.50 (s, 1H) 7.58 (d, J=7.80 Hz, 1H) 7.73 (s, 1H) 7.87 (d, J=5.93 Hz, 1H) 7.93 (s, 1H) 8.04 (dd, J=8.58, 1.72 Hz, 1H) 8.23 (d, J=8.42 Hz, 1H) 8.36 (s, 1H) 8.55 (d, J=5.62 Hz, 1H) 9.36 (s, 1H) 10.91 (s, 1H).
    • EXAMPLE 138 5′-Benzyloxy-5-isoquinolin-6-yl-(3,3′)bipyridinyl Example 138A 6-(5-Bromo-pyridin-3-yl)-isoquinoline
  • The title compound was prepared by substituting 3,5-dibromopyridine for Example 2A in Example 27B. [0459]
    • Example 138B 3-Benzyloxy-5-trimethylstannanyl-pyridine
  • The title compound was prepared by substituting 3-benzyloxy-5-bromopyridine for 6-bromoisoquinoline in Example 27A. [0460]
    • Example 138C 5′-Benzyloxy-5-isoquinolin-6-yl-(3,3′)bipyridinyl
  • The title compound was prepared by substituting Example 138A for Example 2A, Example 138B for Example 27A in Example 27B. MS (ESI) m/z 390 (M+H)[0461] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 5.35 (s, 2H) 7.38 (d, J=7.36 Hz, 1H) 7.44 (t, J=7.21 Hz, 2H) 7.53 (d, J=6.75 Hz, 2H) 8.11 (m, 1H) 8.32 (d, J=6.14 Hz, 1H) 8.50 (m, 2H) 8.57 (m, 1H) 8.70 (d, J=6.14 Hz, 1H) 8.74 (t, J=2.15 Hz, 1H) 8.79 (m, 2H) 9.14 (d, J=2.15 Hz, 1H) 9.22 (d, J=1.84 Hz, 1H) 9.76 (s, 1H).
    • EXAMPLE 140 (7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)pyrimidin-4-yl)-phenyl-amine Example 140A 2-Amino-6-chloro-nicotinic Acid
  • A mixture of 2,6-dichloro-nicotonic acid (17.77 g, 92.6 mmol) in concenterated aqueous ammonia (173 mL) at 200 psi, was heated to 130° C. for 24 h. The mixture evaporated and the residue was taken into water (200 mL) and neuteralized with conc HCl then extracted into ether (200 ml). The ether was evaporated off to yield 12 g of product (75%). MS (DCI/NH[0462] 3) m/z 173 (M+1)+.
    • Example 140B 2-Amino-6-chloro-nicotinamide
  • To a mixture of Example 140A (11.9 g, 69.2 mmol) in 1,2-dichloroethane (100 mL) was added thionyl chloride (30 mL, 411 mmol) and DMF (catalytic). The mixture was refluxed for 4 h then evaporated. The residue was taken in ether (200 mL) and ammonia was bubbled through for 15 min. The mixture was stirred overnight at rt then washed with water (100 mL) and brine (100 ml). The ether was evaporated off to yield 9.2 g of product (78%). MS (DCI/NH3) m/z 172 (M+1)[0463] +.
    Figure US20030187026A1-20031002-C00014
    • Example 140C 7-Chloro-pyrido[2,3-d]pyrimidin-4-ol
  • A mixture of Example 140B (1 g, 5.8 mmol) in triethylorthoformate (30 mL) was refluxed for 6 h then cooled. Hexane (150 mL) was added and the solid formed was filtered and washed with water and hexane to yield 0.27 g of product (26%). MS: (DCI/NH[0464] 3) m/z=182 (M+1)
    Figure US20030187026A1-20031002-C00015
    • Example 140D 4,7-Dichloro-pyrido[2,3-d]pyrimidine
  • A mixture of Example 140C (1 g, 5.5 mmol) in phosphorus oxychloride (40 mL) was refluxed for 2 h then cooled and evaporated. The residue was taken into ethyl acetate (75 ml), washed with saturated sodium bicarbonate (50 ml) water (50 ml) and brine (50 ml). The ethyl acetate was evaporated to yield 0.8 g of product (73%). [0465]
    Figure US20030187026A1-20031002-C00016
    • Example 140E (7-Chloro-pyrido[2,3-d]pyrimidin-4-yl)-phenyl-amine
  • A solution of Example 140D (0.5 g, 2.5 mmol), and aniline (0.23 mL, 2.5 mmol) in THF (25 mL) and 2-propanol (2.5 mL) was stirred at 0° C. for 1 h then at room temperature for 2 days. The THF was evaporated off and the residue was taken into ethyl acetate (75 ml), washed with water (50 ml) and brine (50 ml). The ethyl acetate was evaporated off and the residue was purified by flash column chromatography on silica gel, eluting with 1:1 ethyl acetate/hexane. Recovered 0.15 g of product (23%). MS (ESI) m/z 390 (M+H)[0466] +.
    Figure US20030187026A1-20031002-C00017
    • Example 140F (7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)pyrimidin-4-yl)-phenyl-amine
  • The title compound was prepared by substituting Example 140E for 6-bromoisoquinoline in Example 27. MS (ESI) m/z 257 (M+H)[0467] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.15 (m, 3H) 3.38 (s, 4H) 4.06 (dd, J=10.29, 5.93 Hz, 4H) 4.21 (dd, J=10.45, 2.96 Hz, 1H) 6.99 (t, J=7.18 Hz, 1H) 7.09 (t, J=7.18 Hz, 1H) 7.26 (d, J=2.18 Hz, 1H) 7.35 (m, 4H) 8.21 (d, J=4.37 Hz, 3H) 11.02 (s, 1H)
    Figure US20030187026A1-20031002-C00018
    • EXAMPLE 141 (7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)pyrimidin-4-yl)-ethyl-amine
  • The title compound was prepared by substituting ethylamine for aniline in Example 140. MS (ESI) m/z 440 (M+H)[0468] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 1.30 (m, 3H) 3.19 (m, 2H) 3.78 (m, 2H) 4.05 (s, 2H) 4.21 (dd, J=10.45, 5.77 Hz, 1H) 4.38 (dd, J=10.45, 2.96 Hz, 1H) 7.00 (t, J=7.49 Hz, 1H) 7.09 (t, J=7.49 Hz, 1H) 7.30 (d, J=2.18 Hz, 1H) 7.38 (d, J=7.80 Hz, 1H) 7.61 (d, J=7.80 Hz, 1H) 8.15 (s, 1H) 8.24 (d, J=4.06 Hz, 2H) 8.51 (d, J=8.42 Hz, 1H) 8.56 (d, J=1.56 Hz, 1H) 8.96 (s, 1H) 9.01 (d, J=8.74 Hz, 1H) 9.12 (s, 1H) 11.03, (d, J=1.56 Hz, 1H).
    Figure US20030187026A1-20031002-C00019
    • EXAMPLE 142 (7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)pyrimidin-4-yl)-benzyl-amine
  • The title compound was prepared by substituting benzylamine for aniline in Example 140. MS (ESI) m/z 502 (M+H)[0469] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 3.19 (m, J=6.60, 6.60 Hz, 2H) 3.89 (m, 1H) 4.22 (dd, J=10.43, 5.52 Hz, 1H) 4.38 (m, 1H) 5.00 (d, J=5.52 Hz, 2H) 7.00 (m, 1H) 7.09 (m, 1H) 7.34 (m, 5H) 7.45 (m, 1H) 7.62 (d, J=7.98 Hz, 1H) 8.17 (m, 1H) 8.31 (d, J=3.68 Hz, 2H) 8.54 (m, 2H) 8.97 (s, 1H) 9.07 (d, J=8.90 Hz, 1H) 9.12 (d, J=1.84 Hz, 1H) 10.81 (s, 1H) 11.05 (d, J=2.15 Hz, 1H).
    Figure US20030187026A1-20031002-C00020
    • EXAMPLE 143 (1S)-1-(1H-Indol-3-ylmethyl)-2-(6-isoquinolin-6-yl-pyrazin-2-yloxy)-ethylamine
  • The title compound was prepared by substituting 6-chloro-pyrazin-2-ol for 3-bromo-5-hydroxypyridine in Example 27. MS (ESI) m/z 396 (M+H)[0470] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 3.20 (m, 1H) 3.95 (m, 1H) 4.52 (m, J=7.36 Hz, 1H) 4.76 (m, 1H) 7.02 (m, J=7.06 Hz, 1H) 7.11 (m, J=7.98 Hz, 1H) 7.34 (d, J=2.15 Hz, 1H) 7.41 (d, J=8.29 Hz, 1H) 7.65 (d, J=7.98 Hz, 1H) 7.99 (d, J=5.83 Hz, 1H) 8.17 (s, 3H) 8.28 (m, 2H) 8.41 (s, 1H) 8.62 (m, 1H) 8.72 (s, 1H) 9.10 (s, 1H) 11.05 (s, 1H).
    Figure US20030187026A1-20031002-C00021
    • (1S)-[2-(5-Bromo-pyridin-3-yloxy)-1-phenyl-ethyl]-carbamic Acid Tert-Butyl Ester
  • A solution of 5-bromo-pyridin-3-ol (0.3 g, 1.7 mmol), (2-hydroxy-1-phenyl-ethyl)-carbamic acid tert-butyl ester (0.41 g 1.7 mmol), and triphenylphosphine (0.52 g, 2 mmol) in THF (15 mL) was stirred at 0° C. for 30 min. To the mixture was added a solution of di-t-butyl azidodicarboxylate (0.46 g, 2 mmol) in 5 ml of THF. The mixture was allowed to warm to room temperature then stirred at room temperature for 20 h. The THF was evaporated off and the residue was taken into ethyl acetate (75 ml), washed with saturated sodium bicarbonate (50 ml) water (50 ml) and brine (50 ml). The ethyl acetate was evaporated off and the residue was purified by flash column chromatography on silica gel, eluting with a solvent gradient of 1:4 to 1:2 ethyl acetate/hexane. Recovered 0.82 g of a mixture of product and di-tert-butyl azidodicarboxylate. MS (ESI) m/z 395 (M+H)[0471] +.
    Figure US20030187026A1-20031002-C00022
    • Example 144B 5 (1S)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-1-phenyl-ethylamine
  • The title compound was prepared by substituting Example 144A for Example 2A in Example 27. MS (ESI) m/z 342 (M+H)[0472] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 4.51 (m, J=18.74 Hz, 1H) 4.57 (m, 1H) 4.87 (m, 1H) 7.49 (m, 3H) 7.63 (d, J=7.18 Hz, 2H) 7.90 (d, J=5.62 Hz, 1H) 7.93 (m, 1H) 8.10 (dd, J=8.73, 1.56 Hz, 1H) 8.26 (d, J=8.73 Hz, 1H) 8.39 (s, 1H) 8.45 (d, J=2.50 Hz, 1H) 8.56 (d, J=5.62 Hz, 1H) 8.69 (m, 2H) 8.74 (d, J=1.56 Hz, 1H) 9.39 (s, 1H).
    Figure US20030187026A1-20031002-C00023
    • EXAMPLE 145 (1S)-1-(1H-Indol-3-ylmethyl)-2-(6-(3-methyl-1H-indazol-5-yl)-pyrazin-2-yloxy)-ethylamine
  • The title compound was prepared by substituting 102C for 6-bromoisoquinoline in Example 143. MS (ESI) m/z 399 (M+H)[0473] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 2.54 (s, 3H) 3.18 (m, 2H) 3.92 (m, 1H) 4.47 (d, J=7.06 Hz, 1H) 4.70 (m, 1H) 7.02 (d, J=7.06 Hz, 1H) 7.10 (m, 1H) 7.32 (d, J=2.15 Hz, 1H) 7.39 (d, J=8.29 Hz, 1H) 7.49 (d, J=8.59 Hz, 1H) 7.64 (d, J=8.29 Hz, 1H) 7.92 (dd, J=8.75, 1.69 Hz, 1H) 8.15 (m, 2H) 8.24 (s, 1H) 8.46 (s, 1H) 8.95 (s, 1H) 11.04 (d, J=1.53 Hz, 1H).
  • The following compounds were made according the procedures used in Example 27 or 102, using the appropriate Boc protected N-Boc-aminoethanols. [0474]
    Figure US20030187026A1-20031002-C00024
    • EXAMPLE 146 (1S)-1-Cyclohexylmethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 362 (M+H)[0475] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 0.92 (s, 2H) 1.24 (m, 3H) 1.64 (m, 6H) 3.52 (s, 2H) 4.23 (dd, J=10.61, 6.55 Hz, 1H) 4.40 (dd, J=10.61, 3.12 Hz, 1H) 7.91 (m, 1H) 7.96 (d, J=5.93 Hz, 1H) 8.13 (dd, J=8.58, 1.72 Hz, 4H) 8.32 (d, J=8.73 Hz, 1H) 8.43 (m, 2H) 8.59 (m, J=5.62 Hz, 1H) 8.74 (d, J=1.56 Hz, 1H) 9.44 (s, 1H).
    Figure US20030187026A1-20031002-C00025
    • EXAMPLE 147 (1S)-1-Benzyl-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 359 (M+H)[0476] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (m, 3H) 3.05 (m, 1H) 3.38 (m, 1H) 3.87 (m, 1H) 4.12 (dd, J=10.76, 5.77 Hz, 1H) 4.28 (dd, J=10.76, 2.96 Hz, 1H) 7.33 (m, 4H) 7.57 (d, J=8.73 Hz, 1H) 7.67 (m, 2H) 8.06 (s, 1H) 8.21 (s, 2H) 8.31 (d, J=1.56 Hz, 1H) 8.61 (s, 1H) 12.74 (s, 1H).
    Figure US20030187026A1-20031002-C00026
    • EXAMPLE 148 (1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-phenyl-ethylamine
  • MS (ESI) m/z 345 (M+H)[0477] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 2.55 (m, 3H) 4.01 (s, 1H) 4.31 (m, 1H) 4.39 (m, 1H) 4.57 (m, 1H) 7.36 (m, 1H) 7.43 (t, J=7.36 Hz, 2H) 7.55 (t, J=7.67 Hz, 4H) 7.70 (m, 1H) 8.08 (s, 1H) 8.29 (d, J=2.76 Hz, 1H) 8.57 (d, J=1.84 Hz, 1H) 12.72 (s, 1H).
    Figure US20030187026A1-20031002-C00027
    • EXAMPLE 149 (1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-phenyl-ethylamine
  • MS (ESI) m/z 365 (M+H)[0478] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 0.90 (d, J=14.12 Hz, 2H) 1.16 (m, 3H) 1.44 (m, 3H) 1.69 (m, 3H) 2.55 (d, J=5.22 Hz, 3H) 3.37 (m, 3H) 4.03 (m, 1H) 4.17 (dd, J=9.97, 4.14 Hz, 1H) 7.56 (d, J=8.59 Hz, 1H) 7.71 (m, 2H) 8.08 (s, 1H) 8.28 (d, J=2.76 Hz, 1H) 8.57 (d, J=1.53 Hz, 1H) 12.73 (s, 1H).
    Figure US20030187026A1-20031002-C00028
    • EXAMPLE 150 4-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)propyl)-benzonitrile
  • MS (ESI) m/z 384 (M+H)[0479] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 3.14 (d, J=7.06 Hz, 2H) 3.94 (m, 1H) 4.15 (dd, J=10.74, 5.52 Hz, 1H) 4.32 (dd, J=10.74, 3.07 Hz, 1H) 7.57 (t, J=8.13 Hz, 2H) 7.69 (m, 1H) 7.73 (t, J=1.99 Hz, 1H) 7.85 (d, J=7.98 Hz, 2H) 8.07 (s, 1H) 8.24 (m, 2H) 8.32 (d, J=2.45 Hz, 1H) 8.64 (d, J=1.53 Hz, 1H).
    Figure US20030187026A1-20031002-C00029
    • EXAMPLE 151 (1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-napthalen-2-ylmethyl-ethylamine
  • MS: (ESI) m/z 409 (M+H)[0480] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 2.54 (s, 3H) 3.23 (d, J=7.06 Hz, 2H) 4.00 (s, 1H) 4.21 (dd, J=10.74, 5.52 Hz, 1H) 4.37 (dd, J=10.74, 3.07 Hz, 1H) 7.51 (m, 3H) 7.56 (d, J=8.29 Hz, 1H) 7.67 (dd, J=8.59, 1.84 Hz, 1H) 7.78 (m, 1H) 7.86 (m, 2H) 7.91 (m, 2H) 8.07 (s, 1H) 8.26 (m, 2H) 8.36 (d, J=2.76 Hz, H) 8.65 (d, J=1.84 Hz, 1H).
    Figure US20030187026A1-20031002-C00030
    • EXAMPLE 152 4-((2S)-2-Amino-3-(5-isoquinolin-6-yl-pyridin-3-yloxy-propyl)-benzonitrile
  • MS (ESI) m/z 381 (M+H)[0481] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 3.16 (m, 2H) 3.97 (s, 1H) 4.26 (m, 2H) 7.56 (d, J=8.29 Hz, 2H) 7.84 (d, J=8.29 Hz, 2H) 7.90 (m, 1H) 8.24 (m, 2H) 8.33 (m, 2H) 8.48 (m, 2H) 8.55 (s, 1H) 8.67 (d, J=6.14 Hz, 1H) 8.79 (d, J=1.84 Hz, 1H) 9.67 (s, 1H).
    Figure US20030187026A1-20031002-C00031
    • EXAMPLE 153 (1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-nanpthalen-2-ylmethyl)-ethylamine
  • MS: (ESI) m/z 406 (M+H)[0482] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 3.24 (m, 2H) 4.03 (s, 1H) 4.31 (m, 2H) 7.50 (m, 3H) 7.89 (m, 5H) 8.22 (m, 2H) 8.33 (s, 3H) 8.48 (m, 2H) 8.54 (s, 1H) 8.66 (m, J=6.14 Hz, 1H) 8.78 (d, J=1.84 Hz, 1H).
    Figure US20030187026A1-20031002-C00032
    • EXAMPLE 154 (1S)-1-Benzyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 356 (M+H)[0483] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.05 (m, 2H) 3.88 (s, 1H) 4.16 (dd, J=10.61, 5.62 Hz, 1H) 4.32 (dd, J=10.76, 2.96 Hz, 1H) 7.29 (m, 1H) 7.35 (m, 3H) 7.85 (m, 1H) 7.99 (d, J=5.62 Hz, 1H) 8.12 (dd, J=8.58, 1.72 Hz, 1H) 8.27 (m, 3H) 8.33 (d, J=8.74 Hz, 1H) 8.43 (m, 2H) 8.60 (d, J=5.93 Hz, 1H) 8.75 (d, J=1.87 Hz, 1H) 9.47 (s, 1H).
    Figure US20030187026A1-20031002-C00033
    • EXAMPLE 155 (1S)-1-(4-Fluoro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 377 (M+H)[0484] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 3.04 (d, J=7.18 Hz, 2H) 3.85 (m, 1H) 4.14 (dd, J=10.76, 5.77 Hz, 1H) 4.30 (m, 1H) 7.19 (m, J=8.89, 8.89 Hz, 2H) 7.37 (dd, J=8.58, 5.46 Hz, 2H) 7.58 (d, J=8.73 Hz, 1H) 7.69 (dd, J=8.74, 1.56 Hz, 1H) 7.75 (s, 1H) 8.08 (s, 1H) 8.23 (s, 3H) 8.34 (s, 1H) 8.65 (s, 1H)
    Figure US20030187026A1-20031002-C00034
    • EXAMPLE 156 (1S)-1-(4-Fluoro-benzyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 374 (M+H)[0485] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.05 (m, 2H) 3.88 (s, 1H) 4.17 (dd, J=10.92, 5.62 Hz, 1H) 4.34 (dd, J=10.76, 2.96 Hz, 1H) 7.18 (m, 2H) 7.38 (dd, J=8.58, 5.46 Hz, 2H) 7.90 (m, 1H) 8.24 (m, 5H) 8.47 (d, J=8.73 Hz, 2H) 8.53 (d, J=9.98 Hz, 1H) 8.79 (s, 1H) 9.67 (s, 1H).
    Figure US20030187026A1-20031002-C00035
    • EXAMPLE 157 2-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-propyl)-benzonitrile
  • MS (ESI) m/z 384 (M+H)[0486] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.54 (d, J=4.06 Hz, 3H) 3.34 (m, 2H) 4.03 (m, 1H) 4.11 (dd, J=10.61, 4.99 Hz, 1H) 4.33 (dd, J=10.92, 3.12 Hz, 1H) 7.50 (t, J=7.64 Hz, 1H) 7.65 (m, 7H) 7.85 (d, J=7.80 Hz, 1H) 8.06 (s, 1H) 8.37 (s, 2H) 8.65 (s, 1H).
    Figure US20030187026A1-20031002-C00036
    • EXAMPLE 158 2-((2S)-2-Amino-3-(5-isoquinolin-6-yl)-pyridin-3-yloxy)-propyl)-benzonitrile
  • MS (ESI) m/z 381 (M+H)[0487] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.32 (m, 2H) 4.04 (m, 1H) 4.16 (m, 1H) 4.37 (dd, J=10.76, 3.28 Hz, 1H) 7.50 (t, J=7.64 Hz, 1H) 7.64 (d, J=7.49 Hz, 1H) 7.71 (d, J=7.49 Hz, 1H) 7.84 (m, 2H) 8.00 (d, J=5.62 Hz, 1H) 8.12 (dd, J=8.73, 1.87 Hz, 1H) 8.34 (d, J=8.73 Hz, 1H) 8.40 (m, 2H) 8.54 (s, 2H) 8.60 (d, J=5.61 Hz, 1H) 8.74 (d, J=1.56 Hz, 1H) 9.48 (s, 1H).
    Figure US20030187026A1-20031002-C00037
    • EXAMPLE 159 (1S)-2-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-pyridin-4-ylmethyl-ethylamine
  • MS (ESI) m/z 360 (M+H)[0488] +; 1H NMR (500 MH1H N z, DMSO-D6) δ ppm 2.50 (s, 3H) 3.24 (d, J=6.86 Hz, 2H) 4.05 (m, 1H) 4.12 (m, 1H) 4.25 (m, J=3.43 Hz, 1H) 7.49 (m, J=4.68 Hz, 2H) 7.53 (d, J=1.87 Hz, 1H) 7.59 (m, 1H) 7.71 (m, 1H) 7.80 (m, 3H) 8.09 (s, 1H) 8.30 (d, J=4.06 Hz, 1H) 8.40 (s, 2H) 8.78 (m, J=4.99 Hz, 1H).
    Figure US20030187026A1-20031002-C00038
    • EXAMPLE 160 (1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-pyridin-4-ylmethyl-ethylamine
  • MS (ESI) m/z 357 (M+H)[0489] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.24 (d, J=7.17 Hz, 1H) 3.28 (d, J=7.18 Hz, 1H) 4.04 (m, 1H) 4.26 (m, 1H) 4.40 (d, J=3.43 Hz, 1H) 7.83 (dd, J=14.66, 6.24 Hz, 3H) 7.93 (m, 1H) 8.26 (m, 2H) 8.38 (m, 1H) 8.47 (d, J=2.81 Hz, 2H) 8.51 (d, J=8.42 Hz, 1H) 8.58 (s, 1H) 8.68 (d, J=6.24 Hz, 1H) 8.80 (m, 2H) 9.71 (s, 1H).
    Figure US20030187026A1-20031002-C00039
    • EXAMPLE 161 (1S)-1-(4-Methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 373 (M+H)[0490] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.28 (m, 3H) 2.55 (s, 3H) 2.98 (m, 2H) 3.81 (s, 1H) 4.11 (dd, J=10.45, 6.08 Hz, 1H) 4.27 (dd, J=10.76, 2.96 Hz, 1H) 7.16 (m, 3H) 7.21 (m, 1H) 7.57 (d, J=8.73 Hz, 1H) 7.69 (m, 2H) 8.07 (s, 1H) 8.21 (m, 3H) 8.31 (d, J=2.18 Hz, 1H) 8.62 (s, 1H).
    Figure US20030187026A1-20031002-C00040
    • EXAMPLE 162 (1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(4-methyl-benzyl)-ethylamine
  • MS (ESI) m/z 370 (M+H)[0491] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.28 (m, 3H) 3.01 (m, 2H) 3.83 (s, 1H) 4.14 (dd, J=10.76, 5.77 Hz, 1H) 4.30 (m, 1H) 7.18 (m, 6H) 7.84 (m, 1H) 7.97 (d, J=5.93 Hz, 1H) 8.10 (dd, J=8.58, 1.72 Hz, 1H) 8.24 (m, 2H) 8.31 (d, J=8.74 Hz, 1H) 8.59 (d, J=5.93 Hz, 1H) 8.74 (d, J=1.87 Hz, 1H) 9.45 (s, 1H)
    Figure US20030187026A1-20031002-C00041
    • EXAMPLE 163 (1S)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-quinolin-3-ylmethyl-ethylamine
  • MS (ESI) m/z 410 (M+H)[0492] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.56 (m, 3H) 3.29 (m, 2H) 4.12 (m, 1H) 4.29 (m, 1H) 4.42 (dd, J=10.76, 3.28 Hz, 1H) 7.56 (d, J=8.73 Hz, 1H) 7.66 (m, 2H) 7.78 (m, 2H) 7.97 (t, J=7.18 Hz, 2H) 8.05 (m, 2H) 8.36 (m, 4H) 8.91 (m, 2H)
    Figure US20030187026A1-20031002-C00042
    • EXAMPLE 164 (1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-quinolin-3-ylmethyl-ethylamine
  • MS (ESI) m/z 407 (M+H)[0493] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.27 (m, 2H) 4.09 (d, J=5.62 Hz, 1H) 4.27 (dd, J=10.92, 5.62 Hz, 1H) 4.43 (dd, J=10.61, 3.43 Hz, 1H) 5.75 (s, 1H) 7.62 (m, 1H) 7.76 (m, 1H) 7.86 (m, 1H) 7.94 (m, 2H) 8.06 (m, 1H) 8.30 (m, 5H) 8.46 (d, J=2.81 Hz, 1H) 8.59 (d, J=5.93 Hz, 1H) 8.74 (m, J=1.87 Hz, 1H) 8.89 (dd, J=20.28, 2.18 Hz, 1H) 9.43 (s, 1H).
    Figure US20030187026A1-20031002-C00043
    • EXAMPLE 165 (1R)-1-Benzyl-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 358 (M+H)[0494] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.49 (s, 3H) 2.99 (m, 2H) 3.79 (s, 1H) 4.07 (dd, J=10.61, 5.93 Hz, 1H) 4.23 (dd, J=10.76, 2.96 Hz, 1H) 7.22 (m, 2 H) 7.29 (m, 3H) 7.51 (d, J=8.73 Hz, 1H) 7.62 (dd, J=8.73, 1.56 Hz, 1H) 7.64 (m, 1H) 8.00 (s, 1H) 8.19 (s, 3H) 8.26 (m, 1H) 8.56 (s, 1H).
    Figure US20030187026A1-20031002-C00044
    • EXAMPLE 166 (1R)-1-Benzyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine
  • MS (ESI m/z 356) (M+H)[0495] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.86 (m, 1H) 2.95 (m, 1H) 3.58 (m, 1H) 4.08 (m, 1H) 4.18 (m, 1H) 7.28 (m, 5H) 7.81 (m, 1H) 7.88 (m, 1H) 8.06 (m, 1H) 8.25 (m, 1H) 8.36 (m, 1H) 8.39 (m, 1H) 8.55 (m, 1H) 8.69 (m, 1H) 9.37 (m, 1H)
    Figure US20030187026A1-20031002-C00045
    • EXAMPLE 167 4-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-propyl)-phenol
  • MS (ESI) m/z 374 (M+H)[0496] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 3.50 (m, 8H) 6.73 (dd, J=8.44, 2.92 Hz, 1H) 7.09 (m, 1H) 7.59 (m, 2H) 7.69 (m, 2H) 7.87 (s, 1H) 8.14 (m, 2H) 8.23 (d, J=1.84 Hz, 1H) 8.62 (s, 1H).
    Figure US20030187026A1-20031002-C00046
    • EXAMPLE 168 (1S)-1-(4-Benzyloxy-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
  • MS m/z 465 (ESI) (M+H)[0497] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 2.97 (m, 2H) 3.82 (m, 1H) 4.13 (m, 1H) 4.28 (m, 1H) 5.07 (s, 2H) 6.99 (d, J=8.59 Hz, 3H) 7.24 (d, J=8.59 Hz, 2H) 7.32 (m, J=7.06 Hz, 1H) 7.40 (m, 4H) 7.69 (dd, J=8.75, 1.69 Hz, 1H) 7.73 (m, 1H) 8.08 (s, 1H) 8.19 (m, 3H) 8.33 (m, J=2.46 Hz, 1H) 8.64 (d, J=1.53 Hz, 1H).
    Figure US20030187026A1-20031002-C00047
    • EXAMPLE 169 (1S)-1-(3-Methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 373 (M+H)[0498] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.28 (s, 3H) 2.56 (s, 3H) 3.01 (m, 2H) 4.15 (dd, J=10.92, 5.62 Hz, 1H) 4.30 (m, J=2.81 Hz, 1H) 7.11 (m, J=17.00, 7.64 Hz, 3H) 7.23 (m, J=7.49 Hz, 1H) 7.58 (d, J=8.73 Hz, 1H) 7.70 (dd, J=8.73, 1.56 Hz, 1H) 7.80 (m, 1H) 8.10 (s, 1H) 8.26 (s, 3H) 8.35 (d, J=2.81 Hz, 1H) 8.67 (d, J=1.56 Hz, 1H).
    Figure US20030187026A1-20031002-C00048
    • EXAMPLE 170 (1S)-1-(2-Methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 373 (M+H)[0499] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.30 (d, J=7.80 Hz, 1H) 2.33 (s, 3H) 2.56 (m, 3H) 3.07 (d, J=7.80 Hz, 1H) 3.80 (s, 1H) 4.12 (dd, J=10.76, 4.84 Hz, 1H) 4.26 (dd, J=10.61, 2.81 Hz, 1H) 7.19 (m, 4H) 7.57 (d, J=8.73 Hz, 1H) 7.68 (dd, J=11.07, 2.03 Hz, 2H) 8.06 (s, 1H) 8.31 (s, 3H) 8.62 (s, 1H).
    Figure US20030187026A1-20031002-C00049
    • EXAMPLE 171 (1S)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-(4-nitro-benzyl)-ethylamine
  • MS (ESI) m/z 404 (M+H)[0500] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 3.19 (m, 2H) 3.97 (s, 1H) 4.18 (dd, J=10.92, 5.62 Hz, 1H) 4.34 (dd, J=10.76, 3.28 Hz, 1H) 7.57 (d, J=8.74 Hz, 1H) 7.64 (m, J=8.73 Hz, 2H) 7.69 (dd, J=8.58, 1.72 Hz, 1H) 7.77 (m, 1H) 8.08 (s, 1H) 8.23 (d, J=8.73 Hz, 2H) 8.29 (m, 2H) 8.34 (d, J=2.50 Hz, 1H) 8.66 (d, J=1.25 Hz, 1H).
    Figure US20030187026A1-20031002-C00050
    • EXAMPLE 172 (1S)-1-(4-Methoxy-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 389 (M+H)[0501] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.56 (s, 3H) 2.98 (dd, J=15.13, 6.08 Hz, 2H) 3.73 (m, 3H) 3.80 (m, 1H) 4.16 (dd, J=10.76, 5.77 Hz, 1H) 4.32 (dd, J=10.61, 3.12 Hz, 1H) 6.91 (m, 2H) 7.21 (dd, J=8.58, 2.65 Hz, 1H) 7.25 (d, J=8.73 Hz, 2H) 7.59 (d, J=8.73 Hz, 1H) 7.71 (dd, J=8.73, 1.87 Hz, 1H) 7.84 (m, 1H) 8.11 (s, 1H) 8.28 (m, 2H) 8.37 (d, J=2.81 Hz, 1H) 8.69 (d, J=1.56 Hz, 1H).
    Figure US20030187026A1-20031002-C00051
    • EXAMPLE 173 (1S)-1-Biphenyl-4-ylmethyl-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 435 (M+H)[0502] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 3.10 (m, 2H) 3.92 (s, 1H) 4.21 (dd, J=10.92, 5.62 Hz, 1H) 4.36 (dd, J=10.76, 2.96 Hz, 1H) 7.36 (t, J=7.49 Hz, 1H) 7.44 (m, 4H) 7.57 (d, J=8.73 Hz, 1H) 7.65 (dd, J=10.29, 7.80 Hz, 4H) 7.70 (dd, J=8.73, 1.56 Hz, 1H) 7.82 (s, 1H) 8.10 (s, 1H) 8.30 (d, J=2.81 Hz, 3H) 8.37 (d, J=2.50 Hz, 1H) 8.67 (d, J=1.25 Hz, 1H).
    Figure US20030187026A1-20031002-C00052
    • EXAMPLE 174 (1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-napthalen-1-ylmethyl-ethylamine
  • MS (ESI) m/z 409 (M+H)[0503] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 3.44 (dd, J=14.04, 6.86 Hz, 2H) 3.93 (s, 1H) 4.17 (dd, J=10.61, 4.99 Hz, 1H) 4.32 (m, 1H) 7.48 (m, 2H) 7.59 (m, 3H) 7.66 (dd, J=8.58, 1.72 Hz, 1H) 7.69 (m, 1H) 7.89 (dd, J=6.24, 3.12 Hz, 1H) 7.98 (d, J=8.11 Hz, 1-H) 8.05 (s, 1H) 8.21 (d, J=8.42 Hz, 1H) 8.29 (m, 2H) 8.32 (d, J=2.81 Hz, 1H) 8.63 (d, J=1.56 Hz, 1H).
    Figure US20030187026A1-20031002-C00053
    • EXAMPLE 175 (1S)-1-(3-Chloro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 393 (M+H)[0504] +, 1H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 3.06 (d, J=7.49 Hz, 2H) 3.92 (m, 1H) 4.16 (m, 1H) 4.33 (dd, J=10.92, 3.12 Hz, 1H) 7.31 (d, J=7.49 Hz, 1H) 7.37 (m, J=14.51, 7.02 Hz, 2H) 7.45 (s, 1H) 7.58 (d, J=8.73 Hz, 1H) 7.70 (dd, J=8.73, 1.56 Hz, 1H) 7.77 (s, 1H) 8.08 (s, 1H) 8.23 (s, 3H) 8.34 (d, J=2.50 Hz, 1H) 8.65 (s, 1H).
    Figure US20030187026A1-20031002-C00054
    • EXAMPLE 176 3-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-propyl)-benzonitrile
  • MS (ESI) m/z 384 (M+H)[0505] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 3.12 (d, J=7.49 Hz, 2H) 3.96 (s, 1H) 4.17 (dd, J=110.76, 5.77 Hz, 1H) 4.33 (m, 1H) 7.57 (dd, J=8.11, 6.55 Hz, 2H) 7.69 (dd, J=8.42, 1.56 Hz, 2H) 7.76 (m, 2H) 7.84 (s, 1H) 8.08 (s, 1H) 8.23 (s, 3H) 8.33 (d, J=2.81 Hz, 1H) 8.64 (d, J=1.56 Hz, 1H).
    Figure US20030187026A1-20031002-C00055
    • EXAMPLE 177 (1S)-1-(3,4-Difluoro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 395 (M+H)[0506] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.56 (s, 3H) 3.05 (d, J=7.18 Hz, 2H) 3.90 (m, 1H) 4.17 (dd, J=10.92, 5.93 Hz, 1H) 4.34 (dd, J=110.61, 3.12 Hz, 1H) 7.19 (m, J=2.18 Hz, 1H) 7.44 (m, 2H) 7.58 (d, J=8.73 Hz, 1H) 7.70 (dd, J=8.73, 1.56 Hz, 1H) 7.77 (d, J=2.50 Hz, 1H) 8.08 (s, 1H) 8.23 (s, 3H) 8.34 (d, J=2.50 Hz, 1H) 8.65 (d, J=1.56 Hz, 1H).
    Figure US20030187026A1-20031002-C00056
    • EXAMPLE 178 (1S)-1-(3,4-Dimethoxy-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 419 (M+H)[0507] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 2.98 (m, 2H) 3.70 (s, 3H) 3.71 (s, 3H) 3.82 (s, 1H) 4.14 (dd, J=10.61, 5.62 Hz, 1H) 4.31 (dd, J=10.76, 2.96 Hz, 1H) 6.82 (d, J=8.11 Hz, 1H) 6.91 (m, 2H) 7.57 (d, J=8.42 Hz, 1H) 7.68 (m, 1H) 7.71 (s, 1H) 8.07 (s, 1H) 8.28 (s, 3H) 8.32 (s, 1H) 8.62 (s, 1H).
    Figure US20030187026A1-20031002-C00057
    • EXAMPLE 179 (1S)-1-(3-Fluoro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 377 (M+H)[0508] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 3.08 (m, 2H) 3.91 (s, 1H) 4.15 (dd, J=10.61, 5.93 Hz, 1H) 4.32 (dd, J=10.61, 3.12 Hz, 1H) 7.12 (m, 1H) 7.20 (m, 2H) 7.40 (m, 1H) 7.57 (d, J=8.73 Hz, 1H) 7.69 (dd, J=8.42, 1.56 Hz, 1H) 7.71 (d, J=1.87 Hz, 1H) 8.07 (s, 1H) 8.29 (s, 3H) 8.31 (d, J=2.81 Hz, 1H) 8.62 (s, 1H).
    Figure US20030187026A1-20031002-C00058
    • EXAMPLE 180 (1S)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-(3-trifluoromethyl-benzyl)-ethylamine
  • MS (ESI) m/z 427. (M+H)[0509] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 3.16 (dd, J=7.33, 2.34 Hz, 2H) 3.97 (s, 1H) 4.16 (dd, J=10.61, 5.62 Hz, 1H) 4.34 (dd, J=10.76, 3.28 Hz, 1H) 7.58 (d, J=8.42 Hz, 1H) 7.61 (d, J=7.49 Hz, 1H) 7.65 (s, 1H) 7.66 (s, 1H) 7.69 (dd, J=8.74, 1.56 Hz, 1H) 7.73 (s, 1H) 7.75 (m, 1H) 8.07 (s, 1H) 8.22 (s, 3H) 8.33 (d, J=2.50 Hz, 1H) 8.64 (d, J=1.56 Hz, 1H).
    Figure US20030187026A1-20031002-C00059
    • EXAMPLE 181 (1S)-1-(4-Ethoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (ESI) m/z 403 (M+H)[0510] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 1.30 (t, J=7.02 Hz, 3H) 2.55 (s, 3H) 2.97 (m, 2H) 3.79 (s, 1H) 3.98 (q, J=6.86 Hz, 2H) 4.13 (dd, J=10.76, 5.77 Hz, 1H) 4.29 (dd, J=10.76, 2.96 Hz, 1H) 6.89 (d, J=8.42 Hz, 1H) 7.22 (d, J=8.42 Hz, 1H) 7.57 (d, J=8.42 Hz, 2H) 7.61 (m, J=11.85 Hz, 1H) 7.69 (dd, J=8.73, 1.56 Hz, 1H) 7.75 (s, 1H) 8.08 (s, 1H) 8.18 (s, 3H) 8.33 (d, J=2.50 Hz, 1H) 8.65 (d, J=1.56 Hz, 1H).
    Figure US20030187026A1-20031002-C00060
    • EXAMPLE 182 (1S)-1-(4-tert-Butyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 415 (M+H)[0511] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 1.26 (m, 9H) 2.55 (s, 3H) 2.80 (dd, J=13.73, 6.86 Hz, 1H) 2.92 (m, 1H) 3.55 (m, 1H) 4.06 (dd, J=9.98, 5.93 Hz, 1H) 4.15 (m, 1H) 7.21 (d, J=8.11 Hz, 2H) 7.34 (d, J=8.42 Hz, 2H) 7.56 (d, J=8.42 Hz, 1H) 7.69 (m, 2H) 8.08 (s, 1H) 8.28 (d, J=2.50 Hz, 1H) 8.57 (d, J=1.56 Hz, 1H) 12.73 (s, 1H).
    Figure US20030187026A1-20031002-C00061
    • EXAMPLE 183 (1S)-1-(4-Methoxy-3-methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/z 403 (M+H)[0512] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.11 (s, 3H) 2.55 (s, 3H) 2.71 (m, 1H) 2.83 (dd, J=13.73, 6.86 Hz, 1H) 3.17 (d, J=3.74 Hz, 2H) 3.47 (m, 1H) 3.74 (m, 3H) 4.07 (m, 2H) 6.86 (d, J=8.11 Hz, 1H) 7.05 (m, 2H) 7.56 (m, J=8.73 Hz, 1H) 7.67 (m, 2H) 8.07 (s, 1H) 8.27 (d, J=2.81 Hz, 1H) 8.57 (d, J=1.56 Hz, 1H) 12.72 (s, 1H).
    Figure US20030187026A1-20031002-C00062
    • EXAMPLE 184 2-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-propyl)-4-methyl-phenol
  • MS (ESI) m/z 403 (M+H)[0513] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.18 (s, 3H) 2.55 (s, 3H) 2.98 (d, J=7.49 Hz, 2H) 3.73 (d, J=3.74 Hz, 3H) 3.79 (m, 1H) 4.12 (dd, J=10.61, 5.62 Hz, 1H) 4.27 (dd, J=10.61, 3.12 Hz, 1H) 6.90 (d, J=8.11 Hz, 1H) 7.02 (s, 1H) 7.07 (d, J=8.42 Hz, 1H) 7.57 (d, J=8.73 Hz, 1H) 7.68 (dd, J=8.73, 1.56 Hz, 1H) 7.71 (s, 1H) 8.07 (s, 1H) 8.17 (s, 3H) 8.31 (d, J=2.50 Hz, 1H) 8.64 (d, J=1.56 Hz, 1H).
    Figure US20030187026A1-20031002-C00063
    • EXAMPLE 185 (1S)-1-Methyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (ESI) m/e 283 (M+H)[0514] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 1.32 (d, J=6.78 Hz 3H) 2.56 (s, 3H) 3.66 (m, 1H) 4.16 (dd, J=10.51, 7.12 Hz, 1H) 4.35 (dd, J=10.51, 3.73 Hz, 1H) 7.57 (d, J=8.81 Hz, 1H) 7.72 (m, 1H) 7.78 (m, 1H) 8.01 (m, 2H) 8.10 (m, 1H) 8.33 (d, J=2.71 Hz, 1H) 8.63 (d, J=1.70 Hz, 1H) 12.70 (bs, 1H); Anal. Calcd for C16H18N4O.2.2 TFA: C, 45.95; H, 3.82; N, 10.51; Found: C, 46.11; H, 3.76; N, 10.55.
    Figure US20030187026A1-20031002-C00064
    • EXAMPLE 186 (1)-1-(1H-Benzoimidazol-2-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/e 396 (M+H)[0515] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.51 (m, 2H) 4.32 (m, 1H) 4.44 (m, 1H) 4.55 (m, 1H) 7.36 (dd, J=6.24, 3.12 Hz, 2H) 7.68 (dd, J=5.93, 3.12 Hz, 2H) 7.88 (d, J=2.18 Hz, 1H) 8.12 (d, J=6.24 Hz, 1H) 8.19 (dd, J=8.58, 1.40 Hz, 1H) 8.42 (m, 2H) 8.49 (s, 1H) 8.64 (d, J=5.93 Hz, 1H) 8.77 (d, J=1.56 Hz, 1H) 9.60 (s, 1H).
    Figure US20030187026A1-20031002-C00065
    • EXAMPLE 187 (±)-1-(1H-Indazol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine
  • MS (ESI) m/e 396 (M+H)[0516] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 3.21 (m, 2H) 3.84 (m, 1H) 4.21 (dd, J=9.97, 5.98 Hz, 1H) 4.31 (dd, J=9.97, 5.98 Hz, 1H) 7.08 (t, J=7.21 Hz, 1H) 7.33 (t, J=7.21 Hz, 1H) 7.49 (d, J=8.59 Hz, 1H) 7.80 (m, 2H) 7.89 (d, J=5.83 Hz, 1H) 8.06 (dd, J=8.59, 1.84 Hz, 1H) 8.25 (d, J=8.59 Hz, 1H) 8.36 (s, 1H) 8.39 (d, J=2.76 Hz, 1H) 8.56 (d, J=5.83 Hz, 1H) 8.69 (d, J=1.84 Hz, 1H) 9.37 (s, 1H) 12.87 (s, 1H).
    Figure US20030187026A1-20031002-C00066
    • EXAMPLE 188 (1S)-1-(2-Fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (ESI) m/e 377 (M+H)[0517] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 3.11 (d, J=7.12 Hz, 2H) 3.86 (m, 1H) 4.15 (m, 1H) 4.31 (dd, J=10.85, 3.39 Hz, 1H) 7.20 (m, 2H) 7.37 (m, 2H) 7.57 (d, J=9.49 Hz, 1H) 7.71 (m, 2H) 8.08 (s, 1H) 8.29 (s, 2H) 8.31 (d, J=2.71 Hz, 1H) 8.64 (d, J=1.69 Hz, 1H) 12.74 (bs, 1H).
    Figure US20030187026A1-20031002-C00067
    • EXAMPLE 189 (1S)-1-(2-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (ESI) m/e 393 (M+H)[0518] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 3.22 (m, 2H) 3.89 (m, 1H) 4.15 (m, 1H) 4.31 (m, 1H) 7.35 (m, 2H) 7.48 (m, 3H) 7.58 (d, J=8.82 Hz, 1H) 7.70 (m, 2H) 8.08 (s, 1H) 8.31 (d, J=2.71 Hz, 2H) 8.64 (d, J=1.70 Hz, 1H) 12.84 (bs, 1H).
    Figure US20030187026A1-20031002-C00068
    • EXAMPLE 190 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-thiophen-2-ylmethyl-ethylamine
  • MS (ESI) m/e 365 (M+H)[0519] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 3.28 (m, 2H) 3.90 (m, 1H) 4.20 (m, 1H) 4.35 (m, 1H) 7.03 (m, 2H) 7.46 (m, 1H) 7.58 (d, J=8.82 Hz, 1H) 7.70 (m, 1H) 7.75 (m, 1H) 8.09 (s, 1H) 8.26 (m, 2H) 8.33 (d, J=2.71 Hz, 1H) 8.64 (d, J=1.70 Hz, 1H) 12.53 (bs, 1H).
    Figure US20030187026A1-20031002-C00069
    • EXAMPLE 191 (1R)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (ESI) m/e 398 (M+H)[0520] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 3.16 (m, 2H) 3.86 (d, J=1.70 Hz, 1H) 4.19 (dd, J=10.51, 6.10 Hz, 1H) 4.36 (dd, J=10.85, 3.39 Hz, 1H) 7.01 (t, J=7.46 Hz, 1H) 7.10 (t, J=6.95 Hz, 1H) 7.30 (d, J=2.37 Hz, 1H) 7.38 (d, J=8.14 Hz, 1H) 7.65 (m, 5H) 8.07 (s, 1H) 8.16 (s, 2H) 8.33 (d, J=2.71 Hz, 1H) 8.63 (d, J=1.70 Hz, 1H) 11.04 (bs, 1H); Anal. Calcd for C24H23N5O.2.9 TFA: C, 49.16; H, 3.59; N, 9.62;. Found: C, 49.36; H, 3.66; N, 9.78.
    Figure US20030187026A1-20031002-C00070
    • EXAMPLE 192 1-(4-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (ESI) m/e 393 (M+1)[0521] +; 1H NMR (300 MHz, Solvent) δ ppm 2.63 (s, 3H) 3.16 (m, 2H) 3.98 (m, 1H) 4.29 (m, 1H) 4.44 (m, 1H) 7.34 (m, 2H) 7.39 (m, 2H) 7.63 (d, J=8.82 Hz, 1H) 7.74 (dd, J=8.82, 1.70 Hz, 1H) 8.09 (m, 1H) 8.11 (m, 1H) 8.42 (br. s., 1H) 8.73 (br. s., 1H).
    Figure US20030187026A1-20031002-C00071
    • Example 193 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-pyrrol-1-yl-benzyl)-ethylamine
  • MS (ESI) m/e 424 (M+1)[0522] +; 1H NMR (300 MHz, Solvent) δ ppm 2.61 (m, 3H) 3.19 (m, 2H) 4.10 (m, 1H) 4.30 (m, 1H) 4.44 (m, 1H) 6.27 (t, J=2.03 Hz, 2H) 7.16 (t, J=2.03 Hz, 2H) 7.41 (d, J=8.48 Hz, 1H) 7.49 (d, J=8.48 Hz, 2H) 7.59 (d, J=8.48 Hz, 1H) 7.70 (m, 1H) 7.94 (m, 1H) 8.07 (m, 1H) 8.38 (br. s., 1H) 8.66 (br. s., 1H).
    Figure US20030187026A1-20031002-C00072
    • EXAMPLE 194 (1S)-1-(4-Methyl-benzylsulfanylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (ESI) m/e 419 (M+1)[0523] +; 1H NMR (300 MHz, MeOH) δ ppm 2.26 (s, 3H) 2.62 (s, 3H) 2.88 (m, 2H) 3.67 (m, 1H) 3.82 (s, 2H) 4.38 (m, 2H) 7.18 (m, 6H) 7.62 (d, J=8.81 Hz, 1H) 7.72 (dd, J=8.81, 1.70 Hz, 1H) 7.85 (dd, J=2.71, 1.70 Hz, 1H) 8.06 (m, 1H) 8.30 (d, J=2.71 Hz, 1H) 8.62 (d, J=1.70 Hz, 1H).
    Figure US20030187026A1-20031002-C00073
    • EXAMPLE 195 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-trifluoromethyl-benzyl)-ethylamine
  • MS m/z 427 (M+H)[0524] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.57 (s, 3H) 3.30 (m, 2H) 3.93 (s, 1H) 4.32 (dd, J=10.85, 5.42 Hz, 1H) 4.45 (m, 1H) 7.53 (td, J=8.22, 3.90 Hz, 1H) 7.61 (dd, J=8.82, 0.68 Hz, 1H) 7.68 (m, 2H) 7.77 (m, 2H) 8.14 (s, 1H) 8.23 (d, J=0.68 Hz, 1H) 8.46 (d, J=2.03 Hz, 1H) 8.65 (s, 3H) 8.83 (s, 1H).
    Figure US20030187026A1-20031002-C00074
    • EXAMPLE 196 (1R)-1-Benzyl-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propylamine
  • MS m/z 373 (M+H)[0525] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.05 (m, 2H) 2.57 (s, 3H) 2.91 (dd, J=13.73, 8.65 Hz, 1H) 3.11 (m, 1H) 3.63 (m, 1H) 4.41 (m, 2H) 7.25 (m, 1H) 7.33 (m, 4H) 7.61 (dd, J=8.81, 0.68 Hz, 1H) 7.81 (dd, J=8.81, 1.70 Hz, 1H) 8.21 (s, 1H) 8.28 (s, 2H) 8.47 (d, J=2.37 Hz, 1H) 8.82 (s, 1H).
    Figure US20030187026A1-20031002-C00075
    • EXAMPLE 197 (1R)-1-Benzyl-4-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-butylamine
  • MS m/z 387 (M+H)[0526] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 1.70 (q, J=7.23 Hz, 2H) 1.91 (m, 2H) 2.57 (s, 3H) 2.82 (dd, J=13.56, 8.48 Hz, 1H) 3.06 (dd, J=13.73, 5.26 Hz, 1H) 3.47 (s, 1H) 4.27 (m, 2H) 7.27 (m, 5H) 7.61 (d, J=8.48 Hz, 1H) 7.84 (dd, J=8.81, 1.70 Hz, 1H) 8.29 (s, 2H) 8.33 (s, 1H) 8.49 (d, J=2.37 Hz, 1H) 8.87 (s, 1H).
    Figure US20030187026A1-20031002-C00076
    • EXAMPLE 198 (1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-3-phenyl-propylamine
  • MS m/z 373 (M+H)[0527] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.04 (m, 2H) 2.57 (s, 3H) 2.80 (m, 2H) 3.57 (m, 1H) 4.44 (dd, J=10.68, 6.61 Hz, 1H) 4.59 (m, 1H) 7.24 (m, 5H) 7.62 (d, J=8.82 Hz, 1H) 7.82 (dd, J=8.65, 1.53 Hz, 1H) 8.27 (s, 2H) 8.50 (s, 2H) 8.54 (d, J=2.71 Hz, 1H) 8.86 (s, 1H).
    Figure US20030187026A1-20031002-C00077
    • EXAMPLE 199 (1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(1-methyl-1H-indol-3-ylmethyl)-ethylamine Trifloroacetic Acid Salt
  • MS (DCI/NH[0528] 3) m/z 409(M+1)+; 1HNMR (500 MHz, MeOD) δ ppm 3.28 (m, 1H) 3.33 (m, 1H) 3.77 (s, 3H) 4.00 (m, 1H) 4.33 (dd, J=10.61, 5.93 Hz, 1H) 4.46 (dd, J=10.61, 3.12 Hz, 1H) 7.04 (m, 1H) 7.17 (m, 1H) 7.17 (s, 1H) 7.36 (d, J=8.42 Hz, 1H) 7.59 (d, J=7.80 Hz, 1H) 7.93 (m, 1H) 8.28 (dd, J=8.73, 1.87 Hz, 1H) 8.49 (m, 2H) 8.59 (m, 3H) 8.76 (s, 1H) 9.77 (s, 1H).
    Figure US20030187026A1-20031002-C00078
    • EXAMPLE 199 (1S)-[1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-dimethyl-amine
  • [0529] 1HNMR (400 MHz, MeOD) δ ppm 3.16 (s, 6H) 3.44 (m, 2H) 4.11 (m, 1H) 4.46 (m, 1H) 4.55 (m, 1H) 7.00 (m, 1H) 7.09 (m, 1H) 7.26 (m, 1H) 7.35 (d, J=8.29 Hz, 1H) 7.60 (d, J=7.98 Hz, 1H) 7.81 (m, 1H) 8.22 (dd, J=8.59, 1.53 Hz, 1H) 8.42 (m, 2H) 8.50 (m, 1H) 8.55 (d, J=8.90 Hz, 1H) 8.61 (m, 1H) 8.72 (m, 1H) 9.73 (s, 1H)
    Figure US20030187026A1-20031002-C00079
    • EXAMPLE 200 (1S)-1-Benzo[b]thiophen-3-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0530] 3) m/z 415 (M+1); 1HNMR (400 MHz, MeOD) δ ppm 2.62 (s, 3H) 3.41 (dd, J=14.73, 6.75 Hz, 1H) 3.50 (dd, J=14.42, 8.59 Hz, 1H) 4.12 (m, 1H) 4.32 (dd, J=10.43, 5.22 Hz, 1H) 4.45 (dd, J=10.74, 3.07 Hz, 1H) 7.40 (m, 2H) 7.55 (m, 1H) 7.61 (d, J=8.90 Hz, 1H) 7.68 (dd, J=8.59, 1.53 Hz, 1H) 7.91 (m, 3H) 8.03 (s, 1H) 8.35 (s, 1H) 8.64,(s, 1H).
    Figure US20030187026A1-20031002-C00080
    • EXAMPLE 201 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-thiophen-3-ylmethyl-ethylamine
  • MS (DCI/NH[0531] 3) m/z 365 (M+1)+; 1HNMR (500 MHz, MeOD) δ ppm 2.63 (s, 3H) 3.43 (m, 2H) 3.98 (m, 1H) 4.40 (dd, J=10.61, 5.62 Hz, 3H) 4.52 (dd, J=10.61, 3.12 Hz, 1H) 7.03 (dd, J=8.42, 3.43 Hz, 1H) 7.06 (m, 1H) 7.36 (dd, J=4.99, 1.25 Hz, 1H) 7.64 (d, J=8.73 Hz, 1H) 7.75 (dd, J=8.73, 1.87 Hz, 1H) 8.14 (s, 1H) 8.21 (m, 1H) 8.47 (brs, 1H) 8.77 (s, 1H).
    Figure US20030187026A1-20031002-C00081
    • EXAMPLE 202 (1S)-1-Benzyloxymethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine
  • [0532]
    Figure US20030187026A1-20031002-C00082
    • Example 202A (1S)-[1-Benzyloxymethyl-2-(5-bromo-pyridin-3-yloxy)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The product was prepared by substituting Boc-serinol(Bn) for Boc-tryptophanol in Example 2A. MS m/z 437, 439 (M+H)[0533] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 1.37 (s, 9H) 3.50 (d, J=6.10 Hz, 2H) 3.97 (m, 1H) 4.11 (m, 2H) 4.50 (s, 2H) 6.99 (d, J=7.80 Hz, 1H) 7.29 (m, 5H) 7.70 (m, 1H) 8.28 (dd, J=4.75, 2.37 Hz, 2H).
    Figure US20030187026A1-20031002-C00083
    • Example 202B (1S)-[1-Benzyloxymethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting 202A for Example 2A in Example 27B. [0534] 1H NMR (300 MHz, DMSO-D6) δ ppm 1.38 (s, 9H) 3.56 (d, J=6.10 Hz, 2H) 4.04 (m, 1H) 4.22 (d, J=5.43 Hz, 2H) 4.52 (s, 2H) 7.05 (d, J=8.14 Hz, 1H) 7.28 (m, 5H) 7.87 (m, 2H) 8.10 (dd, J=8.65, 1.53 Hz, 1H) 8.25 (d, J=8.82 Hz, 1H) 8.35 (d, J=2.71 Hz, 1H) 8.40 (s, 1H) 8.56 (d, J=5.76 Hz, 1H) 8.68 (d, J=1.70 Hz, 1H) 9.37 (s, 1H).
    Figure US20030187026A1-20031002-C00084
    • Example 202C (1S)-1-Benzyloxymethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine
  • The desired product was prepared by substituting Example 202B for Example 27A in Example 202. in Example 27C. MS m/z 386 (M+1)[0535] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.76 (m, 3H) 3.97 (s, 2H) 4.44 (m, 2H) 4.60 (s, 2H) 7.35 (m, 5H) 8.00 (m, 1H) 8.33 (m, 2H) 8.48 (d, J=2.71 Hz, 1H) 8.54 (d, J=8.81 Hz, 1H) 8.66 (s, 1H) 8.68 (d, J=6.10 Hz, 1H) 8.81 (d, J=1.70 Hz, 1H) 9.75 (s, 1H).
    Figure US20030187026A1-20031002-C00085
    • EXAMPLE 203 (1S)-1-Benzyloxymethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • [0536]
    Figure US20030187026A1-20031002-C00086
    • Example 203A 5-Bromo-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • A solution of Example 102C (1.0 g; 4.7 mmol), TEA (526 mg; 5.2 mmol), DMAP (200 mg; 1.6 mmol) and di-tert-butyldicarbonate (1.1 g; 5.0 mmol) in CH[0537] 3CN (15 mL) was stirred at r.t. for 3 hrs, evaporated, and isolated by flash chromatography (30% Et2O/hexane) to give the desired product as a white solid (1.4 g; 95%).
    Figure US20030187026A1-20031002-C00087
    • Example 203B 3-Methyl-5-trimethylstannanyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • A solution of Example 203A (1.35 g; 4.3 mmol), hexamethylditin (1.56 g; 4.8 mmol), and Pd(PPh[0538] 3)4 (250 mg, 0.22 mmol) in toluene (15 mL) was stirred overnight at 85° C., evaporated and purified by flash chromatography (20% Et2O/hexane) to provide the desired product (1.32 g; 77%).
    Figure US20030187026A1-20031002-C00088
    • Example 203C (2S)-5-[5-(3-Benzyloxy-2-tert-butoxycarbonylamino-propoxy)-pyridin-3-yl]-3-methylindazole-1-carboxylic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting 203B for Example 27A in Example 202B. MS m/z 589 (M+H)[0539] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 1.38 (s, 9H) 1.66 (s, 9H) 2.59 (s, 3H) 3.32 (m, 1H) 3.56 (d, J=6.10 Hz, 2H) 4.20 (d, J=5.76 Hz, 2H) 4.52 (s, 2H) 7.03 (d, J=8.14 Hz, 1H) 7.27 (m, 1H) 7.32 (m, 4H) 7.78 (s, 1H) 8.00 (dd, J=8.82, 1.70 Hz, 1H) 8.12 (m, 1H) 8.26 (d, J=1.02 Hz, 1H) 8.29 (d, J=2.71 Hz, 1H) 8.61 (d, J=1.70 Hz, 1H).
    Figure US20030187026A1-20031002-C00089
    • Example 203D (1S)-1-Benzyloxymethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared by substituting 203C for Example 27B in Example 27C. MS m/z 389 (M+H)[0540] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.57 (s, 3H) 3.79 (m, 3H) 4.51 (m, 2H) 4.60 (s, 2H) 4.90 (br s, 2H) 7.34 (m, 5H) 7.61 (d, J=8.81 Hz, 1H) 7.80 (dd, J=8.81, 1.70 Hz, 1H) 8.23 (s, 1H) 8.27 (s, 1H) 8.52 (m, 2H) 8.85 (d, J=1.70 Hz, 1H).
    Figure US20030187026A1-20031002-C00090
    • EXAMPLE 204 (1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(naphthalen-2-yloxymethyl)-ethylamine
  • [0541]
    Figure US20030187026A1-20031002-C00091
    • Example 204A (1S)-l 1-Hydroxymethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-carbamic Acid Tert-Butyl Ester
  • To Example 202B (290 mg, 0.60 mmol) was added sequentially: ammonium formate (377 mg, 5.97 mmol), MeOH (wet) (15 mL), and 10% Pd/C (320 mg). The resulting black reaction mixture was warmed to 70° C. for 6 d and then cooled to room temperature and filtered through Celite. K[0542] 2CO3 (50 mg) and silica gel were added and the volatiles removed on a rotary evaporator. Flash chromatography (2-3-5-7% MeOH/CH2Cl2) gave 40 mg (14%) recovered starting material and 89 mg (38%) of as a colorless waxy solid. Rf=0.32 (10% MeOH/CH2Cl2); 1H NMR (300 MHz, DMSO-D6) δ ppm 1.38 (s, 9H) 3.51 (td, J=5.76, 2.71 Hz, 2H) 3.84 (m, 1H) 4.19 (m, 2H) 4.84 (t, J=5.76 Hz, 1H) 6.82 (d, J=8.14 Hz, 1H) 7.89 (m, 2H) 8.11 (dd, J=8.65, 1.53 Hz, 1H) 8.25 (d, J=8.82 Hz, 1H) 8.36 (d, J=2.71 Hz, 1H) 8.41 (s, 1H) 8.56 (d, J=5.76 Hz, 1H) 8.68 (d, J=1.70 Hz, 1H) 9.37 (s, 1H).
    Figure US20030187026A1-20031002-C00092
    • Example 204B (1S)-[2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(naphthalen-2-yloxymethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • 2-Napthol (15 mg, 101 μmol), Example 204A (20 mg, 51 μmol), DBAD (17 mg, 76 μmol), and PPh[0543] 3-polymer (3 mmol/g) (34 mg, 101 μmol) were combined in a 10 mL round bottom flask. THF (2 mL) was added and the reaction mixture stirred 2 d at 23° C. and then rotavapped with silica gel. Flash chromatography (2-3-5-10% MeOH/CH2Cl2) gave 19 mg (73%) of as a colorless waxy solid. Rf=0.47 (10% MeOH/CH2Cl2); 1H NMR (300 MHz, DMSO-D6) δ ppm 1.41 (s, 9H) 4.24 (m, 3H) 4.37 (m, 2H) 7.19 (dd, J=8.82, 2.71 Hz, 1H) 7.34 (m, 3H) 7.45 (td, J=7.54, 1.19 Hz, 1H) 7.78 (s, 1H) 7.81 (s, 1H) 7.84 (s, 1H) 7.88 (d, J=5.76 Hz, 1H) 7.92 (s, 1H) 8.10 (dd, J=8.48, 1.70 Hz, 1H) 8.24 (d, J=8.48 Hz, 1H) 8.40 (m, 2H) 8.56 (d, J=5.76 Hz, 1H) 8.69 (d, J=1.70 Hz, 1H) 9.37 (s, 1H).
    Figure US20030187026A1-20031002-C00093
    • Example 204C (1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(naphthalen-2-yloxymethyl)-ethylamine
  • The desired product was prepared by substituting Example 204B for Example 27B in Example 27C. LCMS m/z 422 (M+1)[0544] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.54 (dt, J=11.44, 5.64 Hz, 1H) 4.23 (m, 4H) 7.20 (dd, J=8.98, 2.54 Hz, 1H) 7.34 (m, 2H) 7.45 (ddd, J=8.05, 6.87, 1.36 Hz, 1H) 7.81 (m, 3H) 7.88 (m, 2H) 8.09 (m, 1H) 8.24 (d, J=8.48 Hz, 1H) 8.38 (s, 1H) 8.42 (d, J=2.71 Hz, 1H) 8.55 (d, J=5.76 Hz, 1H) 8.67 (d, J=1.70 Hz, 1H) 9.37 (s, 1H).
    • EXAMPLE 205 (1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(pyridin-3-yloxymethyl)-ethylamine
  • The desired product was prepared as tri-TFA salt by substituting 3-hydroxypyridine for 2-naphthol in Example 204. MS m/z 373 (M+1)[0545] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 4.10 (m, 1H) 4.48 (m, 4H) 7.44 (dd, J=8.65, 4.92 Hz, 1H) 7.54 (m, 1H) 7.96 (t, J=2.03 Hz, 1H) 8.09 (d, J=6.78 Hz, 1H) 8.21 (dd, J=8.65, 1.53 Hz, 1H) 8.27 (d, J=4.75 Hz, 1H) 8.41 (m, 2H) 8.49 (m, 4H) 8.63 (d, J=5.76 Hz, 1H) 8.79 (d, J=1.70 Hz, 1H) 9.56 (s, 1H).
    • EXAMPLE 206 (1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(quinolin-7-yloxymethyl)-ethylamine
  • The desired product was prepared as trifluoroacedic acid salt by substituting 7-hydroxyquinoline for 2-naphthol in Example 204. [0546] 1H NMR (300 MHz, DMSO-D6) δ ppm 4.24 (m, 4H) 7.45 (m, 3H) 7.90 (m, 3H) 8.09 (dd, J=8.48, 1.70 Hz, 1H) 8.23 (s, 1H) 8.25 (s, 1H) 8.39 (s, 1H) 8.42 (d, J=2.71 Hz, 1H) 8.56 (d, J=5.43 Hz, 1H) 8.67 (d, J=1.70 Hz, 1H) 8.73 (dd, J=4.41, 1.70 Hz, 1H) 9.37 (s, 1H).
    • EXAMPLE 207 (2S)-4-[2-Amino-3-(5-isoquinolin-6-yl-pyridin-3-yloxy)-propoxy]-benzonitrile
  • The desired product was prepared as trifluoroacedic acid salt by substituting 4-cyanophenol for 2-naphthol in Example 204. [0547] 1H NMR (300 MHz, DMSO-D6) δ ppm 2.27 (br s, 2H) 3.49 (m, 1H) 4.18 (m, 4H) 7.16 (m, 2H) 7.76 (m, 2H) 7.86 (dd, J=2.71, 2.03 Hz, 1.H) 7.89 (d, J=5.76 Hz, 1H) 8.09 (dd, J=8.65, 1.86 Hz, 1H) 8.25 (d, J=8.82 Hz, 1H) 8.39 (m, 2H) 8.56 (d, J=5.76 Hz, 1H) 8.68 (d, J=1.69 Hz, 1H) 9.37 (s, 1H).
    • EXAMPLE 208 (2S)-N′-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl)-3-phenyl-propane-1,2-diamine Example 208A (2S)-{1-[(5-Bromo-pyridin-3-ylamino)-methyl]-2-phenyl-ethyl}-carbamic Acid Tert-Butyl Ester
  • A solution of Example 23B (0.4 g, 2.3 mmol), (1-formyl-2-phenyl-ethy)-carbamic acid tert-butyl ester (0.7 g, 2.8 mmol), and Ti(iPrO)[0548] 4 (10 ml) in CH2Cl2 (15 mL) was stirred at room temperature for 2 h. The solvent was evaporated off and the residue was dissolved in 15 ml of EtOH. The solution was treated with NaBH3CN (0.5 g, 4.9 mmol) then stirred overnight at room temperature. The mixture was diluted with ethyl acetate (50 ml), washed with water (25 ml) and brine (25 ml). The ethyl acetate was evaporated off and the residue was purified by flash column chromatography on silica gel, eluting with a solvent gradient of 1:4 to 1:1 ethyl acetate/hexane to give 0.28 g of product (30%). MS: (ESI) m/z 408 (M+H)+.
    • Example 208B (2S)-5-[5-(2-tert-Butoxycarbonylamino-3-phenyl-propylamino)-pyridin-3-yl]-3-methylindazole-1-carboxylic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting Example 208A for Example 202A in Example 203C. [0549]
    • Example 208C (2S)-N′-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl)-3-phenyl-propane-1,2-diamine
  • The desired product was prepared by substituting Example 208B for Example 27B in Example 27C. MS: (ESI) m/z 358 (M+H)[0550] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.56 (d, J=3.74 Hz, 3H) 3.00 (m, 2H) 3.42 (d, J=5.30 Hz, 3H) 6.89 (m, 1H) 7.27 (m, 2H) 7.35 (m, 3H) 7.57 (s, 1H) 7.62 (d, J=4.06 Hz, 2H) 8.01 (s, 1H) 8.07 (m, 1H) 8.13 (s, 2H) 8.38 (s, 1H).
    • EXAMPLE 209 (2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl-methanesulfonamide
  • Example 208B (500 mg, 0.90 mmol) in pyridine (8 ml) was added dropwise with methyl sulfonyl chloride (308 mg, 2.7 mmol) in an ice-bath. The reaction mixture was allowed to warm up to rt and stirred for 12 hrs. The solvent was removed by bubbling nitrogen to the reaction flask. The residue was chromatographed on silica gel eluting with EtOAc to give the Boc protected product, which was deprotected according to the procedure described in Example 27C to give the title compound as trifluoroacetic acid salt (21.2 mg, 4%). MS (DCI/NH[0551] 3) m/z 436 (M+1)+; 1HNMR (500 MHz, MeOD) δ ppm 2.62 (s, 3H) 2.89 (dd, J=14.35, 9.36 Hz, 1H) 3.03 (s, 3H) 3.05 (dd, J=14.35, 5.62 Hz, 1H) 3.59 (m, 1H) 4.06 (d, J=5.93 Hz, 2H) 7.07 (s, 1H) 7.09 (s, 1H) 7.18 (d, J=7.18 Hz, 1H) 7.24 (m, 2H) 7.60 (s, 1H) 7.60 (s, 1H) 7.95 (s, 1H) 8.10 (t, J=1.87 Hz, 1H) 8.59 (s, 1H) 8.87 (s, 1H).
    • EXAMPLE 210 (2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-benzenesulfonamide
  • The desired product was prepared as trifluoroacetic acid salt by substituting benzenesulfonyl chloride for methanesulfonyl chloride in Example 209. MS (DCI/NH[0552] 3) m/z 498 (M+1)+; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 2.84 (dd, J=14.04, 8.42 Hz, 1H) 2.97 (dd, J=14.04, 5.62 Hz, 1H) 3.45 (m, 1H) 3.78 (m, 2H) 7.17 (s, 1H) 7.19 (s, 1H) 7.24 (d, J=7.18 Hz, 1H) 7.30 (m, 2H) 7.43 (s, 1H) 7.44 (d, J=0.62 Hz, 1H) 7.50 (dd, J=8.73, 1.56 Hz, 1H) 7.57 (d, J=8.42 Hz, 1H) 7.62 (m, 3H) 7.78 (t, J=7.49 Hz, 1H) 7.82 (s, 1H) 8.11 (s, 3H) 8.25 (d, J=2.18 Hz, 1H) 8.92 (d, J=1.87 Hz, 1H).
    • EXAMPLE 211 (2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-benzamide
  • The desired product was prepared as trifluoroacetic acid salt by substituting benzoyl chloride for methanesulfonyl chloride in Example 209. MS (DCI/NH[0553] 3) m/z 462 (M+1)+; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.54 (s, 3H) 2.90 (dd, J=14.04, 9.05 Hz, 1H) 3.03 (dd, J=14.04, 5.30 Hz, 1H) 3.65 (m, 1H) 4.09 (dd, J=14.97, 4.06 Hz, 1H) 4.28 (dd, J=14.97, 8.42 Hz, 1H) 7.19 (m, 3H) 7.27 (m, 4H) 7.33 (m, 2H) 7.44 (dd, J=8.73, 1.56 Hz, 1H) 7.54 (d, J=8.73 Hz, 1H) 7.75 (s, 1H) 7.86 (m, 1H) 8.09 (s, 3H) 8.22 (d, J=2.18 Hz, 1H) 8.69 (d, J=1.87 Hz, 1H).
    • EXAMPLE 212 (2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-acetamide
  • The desired product was prepared as trifluoroacetic acid salt by substituting acetyl chloride for methanesulfonyl chloride in Example 209. MS (DCI/NH[0554] 3) m/z 400 (M+1)+; 1H NMR (400 MHz, MeOD) δ ppm 1.98 (s, 3H) 2.63 (s, 3H) 2.90 (dd, J=14.12, 8.90 Hz, 1H) 3.02 (dd, J=13.81, 5.83 Hz, 1H) 3.68 (m, 1H) 3.76 (dd, J=15.04, 2.46 Hz, 1H) 4.31 (dd, J=15.04, 7.98 Hz, 1H) 7.25-7.11 (m, 6H) 7.64 (m, 2H) 8.00 (s, 1H) 8.03 (s, 1H) 8.46 (s, 1H) 8.93 s, 1H)
    • EXAMPLE 213 (2S)-3-[2-Amino-3-(1H-indol-3-yl)-propylidene]-5-isoquinolin-6-yl-1,3-dihydro-indol-2-one
  • The desired product was prepared as trifluoroacetic acid salt by substituting 5-bromooxindole for 5-bromo-7 aza-oxindole in Example 44. MS (DCI/NH[0555] 3) m/z 431 (M+1)+; 1HNMR (500 MHz, MeOD) δ ppm 3.26 (dd, J=14.35, 9.67 Hz, 1H) 3.57 (dd, J=14.66, 4.06 Hz, 1H) 5.05 (dt, J=19.34, 4.06 Hz, 1H) 6.71 (m, 1H) 6.83 (d, J=9.98 Hz, 1H) 6.85 (m, 1H) 6.98 (d, J=8.42 Hz, 1H) 7.03 (m, 1H) 7.06 (d, J=8.11 Hz, 1H) 7.14 (d, J=1.56 Hz, 1H) 7.55 (dd, J=8.73, 1.87 Hz, 1H) 7.64 (dd, J=8.11, 1.56 Hz, 1H) 7.69 (d, J=8.11 Hz, 1H) 7.94 (s, 1H) 8.18 (d, J=6.24 Hz, 1H) 8.31 (d, J=8.73 Hz, 1H) 8.52 (s, 1H) 9.55 (s, 1H).
    • EXAMPLE 214 (1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(1-methyl-1H-indol-3-ylmethyl)-ethylamine
  • The title compound was prepared as trifluoroacetic acid salt by substituting 5-bromo-7-azaindole (D. Mazeas, et al., [0556] Heterocycles 1990, 50, 1065) for 6-bromophthalimide in Example 32. MS (DCI/NH3) m/z 384 (M+1)+; 1HNMR (500 MHz, MeOD) δ ppm 3.29 (m, 1H) 3.33 (dd, J=8.11, 2.81 Hz, 1H) 4.03 (m, 1H) 4.36 (dd, J=10.61, 5.62 Hz, 1H) 4.49 (dd, J=10.61, 3.12 Hz, 1H) 6.69 (d, J=3.12 Hz, 1H) 7.02 (m, 1H) 7.10 (t, J=7.49 Hz, 1H) 7.25 (s, 1H) 7.36 (d, J=8.11 Hz, 1H) 7.57 (m, 2H) 8.08 (s, 1H) 8.45 (s, 2H) 8.58 (s, 1H) 8.80 (s, 1H).
    • EXAMPLE 215 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(1H-pyrrolo[2,3-b]pyridin-5-yl)-pyridin-3-yloxy]-ethylamine Example 215A (1S)-N-[1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-2-nitro-benzenesulfonamide
  • To a solution of Example 27 (400 mg, 1.01 mmol) and DIEA (1.06 mL, 6.06 mmol) in THF (30 mL) in ice-bath cooling was added 2-nitrobenzylsulfonyl chloride (896 mg, 4.04 mmol). The reaction was allowed to warm up to rt for 12 hrs. The reaction mixture was concentrated and the resulting crude oil was purified by flash column chromatography eluting with EtOAc/Hex (1:1), EtOAc, and EtOAc/MeOH (20:1) to give the title compound (267 mg, 46%). MS (DCI/NH[0557] 3) m/z 580(M+1)+.
    • Example 215B (1S)-N-[11-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-N-methyl-2-nitro-benzenesulfonamide
  • To a solution of Example 215A (260 mg, 0.45 mmol), MeOH (16 uL, 4.5 mmol), and Ph[0558] 3P (591 mg, 2.25 mmol) in THF (10 mL) in an ice-bath was added dropwise DEAD (392 mg, 2.25 mmol). The reaction was allowed to ward up to rt for 12 hrs. The reaction mixture was concentrated and the resulting crude oil was purified by flash column chromatography eluting with EtOAc, and EtOAc/MeOH (40:3) to give the title compound (47 mg, 18%). MS (DCI/NH3) m/z 594(M+1)+.
    • Example 215C (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(1H-pyrrolo[2,3-b]pyridin-5-yl)-pyridin-3-yloxy]-ethylamine
  • A mixture of Example 215B (47 mg, 0.08 mmol), PhSH (9.7 uL, 0.095 mmol), and K[0559] 2CO3 (33 mg, 0.237 mmol) in DMF (5 mL) was stirred at rt for 2 hrs. The reaction was Concentrated to dryness. The resulting residue was purified on C18 HPLC to afford the title compound (34.2 mg, 58%). MS (DCI/NH3) m/z 409(M+1)+; 1H NMR (500 MHz, MeOD) δ ppm 2.91 (s, 3H) 2.99 (brs, 1H) 3.37 (dd, J=14.66, 9.36 Hz, 1H) 3.43 (dd, J=14.66, 5.93 Hz, 1H) 3.96 (m, 1H) 4.38 (dd, J=10.92, 4.37 Hz, 1H) 4.52 (dd, J=10.92, 2.81 Hz, 1H) 6.99 (dt, J=8.11, 0.94 Hz, 1H) 7.10(dt, J=8.11, 0.94 Hz, 1H) 7.25 (s, 1H) 7.36(d, J=8.11 Hz, 1H) 7.58 (d, J=8.11 Hz, 1H) 7.92 (m, 1H) 8.29 (dd, J=8.73, 1.87 Hz, 1H) 8.49 (d, J=6.55 Hz, 1H) 8.50 (s, 1H) 8.56 (s, 1H) 8.60 (d, J=8.73 Hz, 1H) 8.63 (d, J=6.55 Hz, 1H) 8.77 (s, 1H) 9.78 (s, 1H).
    • EXAMPLE 216 (1S)-2-{5-[2-(2-Fluoro-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-1-(1H-indol-3-ylmethyl)-ethylamine Example 216A 2-Fluoro-4-vinylpyridine
  • A mixture of 2-fluoro-4-iodopyridine (2.23 g, 10.0 mmol), tributyl vinyl tin (3.8 g, 12 mmol), and Pd[0560] 2Cl2(PPh3)2 (703 mg, 1.0 mmol) in dioxane (20 mL) was heated under nitrogen at 80° C. overnight. After cooled, ethyl acetate (40 ml) and saturated KF aqueous solution were added to the reaction mixture. The mixture was stirred for 30 min. The organic layer was separated and washed with water, dried (MgSO4), and concentrated. The resulting residue was purified by flash column chromatography eluting with hexane/ethyl acetate (20:1) to provide the title compound (463 mg, 38%). 1HNMR (500 MHz, CDCl3) δ ppm 5.55 (d, J=10.92 Hz, 1H) 5.99 (d, J=17.47 Hz, 1H) 6.67 (dd, J=17.47, 10.61 Hz, 1H) 6.88 (m, 1H) 7.17 (dt, J=5.30, 1.56 Hz, 1H) 8.16 (d, J=5.30 Hz, 1H).
    Figure US20030187026A1-20031002-C00094
    • Example 216B (1S)-[2-{5-[2-(2-Fluoro-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared as a trifluoroacetic acid salt by substituting Example 216A for 4-vinylpyridine in Example 2 (1.067 g, 84%). MS (DCI/NH[0561] 3) m/z 489 (M+1)+; 1HNMR (400 MHz, MeOD) δ ppm 1.42 (m, 9H) 2.98 (m, 1H) 3.04 (m, 1H) 3.14 (m, 1H) 4.09 (m, 2H) 4.25 (m, 1H) 6.96 (t, J=7.36 Hz, 1H) 7.07 (t, J=7.07 Hz, 1H) 7.09 (m, 1H) 7.20 (m, 1H) 7.29 (m, 2H) 7.45 (m, 2H) 7.59 (m, 2H) 8.16 (d, J=5.52 Hz, 1H) 8.19 (s, 1H) 8.32 (s, 1H).
    • EXAMPLE 217 (1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-methoxy-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethylamine Example 217A (1S)-(1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-methoxy-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethyl)-carbamic Acid Tert-Butyl Ester
  • A mixture of Example 216B (100 mg, 0.2 mmol), NaOMe (25% in MeOH) (1 mL) in MeOH (10 mL) was refluxed for 8 hrs. The mixture was concentrated to give the crude product. [0562]
    • Example 217B (1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-methoxy-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethylamine
  • Example 217A was treated with TFA (1 mL) at rt for 10 min. Upon Removal of the TFA, the crude product was purified on C18 HPLC to give the title compound (101.8 mg, 69%). MS (DCI/NH[0563] 3) m/z 401 (M+1)+; 1HNMR (400 MHz, MeOD) δ ppm 3.31 (m, 2H) 3.99 (s, 3H) 4.00 (m, 1H) 4.29 (dd, J=10.43, 5.52 Hz, 1H) 4.41 (dd, J=10.43, 3.07 Hz, 1H) 7.03 (m, 1H) 7.06 (s, 1H) 7.13 (m, 1H) 7.24 (s, 1H) 7.27 (dd, J=5.52, 1.23 Hz, 1H) 7.34 (d, J=16.26 Hz, 1H) 7.39 (d, J=8.29 Hz, 1H) 7.48 (d, J=16.57 Hz, 1H) 7.59 (d, J=7.98 Hz, 1H) 7.87 (s, 1H) 8.16 (d, J=5.22 Hz, 1H) 8.40 (brs, 1H) 8.57 (brs, 1H).
    • EXAMPLE 218 (1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-phenoxy-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethylamine
  • A mixture of Example 216B (50 mg, 0.1 mmol), phenol (94 mg, 1.0 mmol) and KOH (11.2 mg, 0.2 mmol) was heated at 140 C in a sealed bottle for 2 hrs. The mixture was concentrated to dryness. The residue was then treated with TFA (1 mL) at rt for 10 min. Upon Removal of TFA, the crude product was purified on C18 HPLC to give rhe title compound (4.3 mg, 5.3%). MS (DCI/NH[0564] 3) m/z 463 (M+1)+; 1HNMR (400 MHz, MeOD) δ ppm 3.30 (m, 1H) 3.48 (dd, J=13.81, 7.06 Hz, 1H) 4.00 (m, 1H) 4.27 (dd, J=10.43, 5.83 Hz, 1H) 4.40 (dd, J=10.43, 3.07 Hz, 1H) 7.15-7.01 (m, 5H) 7.26-7.23 (m, 2H) 7.48-7.32 (m, 6H) 7.59 (d, J=7.98 Hz, 1H) 7.87 (m, 1H) 8.16 (d, J=5.52 Hz, 1H) 8.35 (s, 1H) 8.53 (s, 1H).
    • EXAMPLE 219 (1S)-2-{5-[2-(2-Benzylsulfanyl-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-1-(1H-indol-3-ylmethyl)-ethylamine
  • The title compound was prepared as trifloroacetic acid salt by substituting benzylthiol for phenol in Example 218. MS (DCI/NH[0565] 3) m/z 493(M+1)+; 1HNMR (500 MHz, MeOD) δ ppm 3.31 (m, 1H) 3.35 (m, 1H) 4.00 (m, 1H) 4.26 (dd, J=10.61, 5.62 Hz, 1H) 4.39 (dd, J=10.61, 3.43 Hz, 1H) 4.48 (m, 2H) 7.03 (m, 1H) 7.13 (m, 1H) 7.27 (m, 6H) 7.40 (m, 4H) 7.47 (d, J=16.53 Hz, 1H) 7.52 (m, 1H) 7.59 (d, J=7.80 Hz, 1H) 7.78 (s, 1H) 8.43 (d, J=5.30 Hz, 1H) 8.56 (s, 1H).
    • EXAMPLE 220 [4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-cyclopropyl-amine
  • A mixture of Example 216 (100 mg, 0.2 mmol) and cyclopropyl amine (1.5 mL) was heated at 125° C. for 36 hrs. The mixture was concentrated to dryness. The residue was then treated with TFA (1 mL) at rt for 10 min. Upon removal of TFA, the crude product was purified on C18 HPLC to give the title compound (4.1 mg, 3%). MS (DCI/NH[0566] 3) m/z 426(M+1)+;
  • [0567] 1HNMR (500 MHz, MeOD) δ ppm 0.74 (m, 2H) 1.03 (m, 2H) 2.71 (m, 1H) 3.29 (m, 1H) 3.34 (m, 1H) 4.00 (m, 1H) 4.27 (dd, J=10.61, 5.62 Hz, 1H) 4.39 (dd, J=10.61, 3.43 Hz, 1H) 7.03 (m, J=15.91 Hz, 1H) 7.10 (s, 1H) 7.13 (m, 1H) 7.23 (s, 1H) 7.26 (dd, J=6.86, 1.56 Hz, 1H) 7.39-7.34 (m, 2H) 7.58 (d, J=5.30 Hz, 1H) 7.60 (d, J=3.12 Hz, 1H) 7.83 (m, 1H) 7.87 (d, J=6.86 Hz, 1H) 8.37 (s, 1H) 8.52 (s, 1H).
    • EXAMPLE 221 [4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-benzyl-amine
  • The title compound was prepared as trifloroacetic acid salt by substituting benzylamine for cyclopropylamine in Example 220 (38.2 mg, 23%). MS (DCI/NH[0568] 3) m/z 476 (M+1)+; 1HNMR 1H NMR (500 MHz, MeOD) δ ppm 3.30 (m, 1H) 3.34 (m, 1H) 3.99 (m, 1H) 4.24 (dd, J=10.61, 5.62 Hz, 1H) 4.37 (dd, J=10.61, 3.12 Hz, 1H) 4.63 (s, 2H) 7.02 (m, 1H) 7.10 (m, 1H) 7.12 (m, 1H) 7.22 (m, 2H) 7.41 (m, 3H) 7.39-7.29(m, 4H) 7.57 (d, J=9.05 Hz, 1H) 7.59 (m, 1H) 7.73 (s, 1H) 7.82 (d, J=6.86 Hz, 1H) 8.37 (s, 1H) 8.52 (s, 1H).
    • EXAMPLE 222 [4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-ethyl-amine
  • The title compound was prepared as trifloroacetic acid salt by substituting ethylamine for cyclopropylamine in Example 220 (16 mg, 15%). MS (DCI/NH[0569] 3) m/z 414(M+1)+; 1HNMR (400 MHz, MeOD) δ ppm 1.36 (t, J=7.06 Hz, 3H) 3.98 (m, 4H) 4.24 (dd, J=10.43, 5.52 Hz, 1H) 4.37 (dd, J=10.74, 3.38 Hz, 1H) 7.02 (m, 2H) 7.12 (d, J=8.29 Hz, 1H) 7.18 (d, J=8.29 Hz, 1H) 7.23 (s, 1H) 7.30 (d, J=16.26 Hz, 1H) 7.38 (d, J=8.90 Hz, 1H) 7.56 (d, J=11.97 Hz, 1H) 7.59 (d, J=3.68 Hz, 1H) 7.72 (s, 1H) 7.77 (d, J=7.06 Hz, 1H) 7.87 (m, 2H) 8.33 (s, 1H) 8.48 (s, 1H).
    • EXAMPLE 223 [4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-methyl-amine
  • The title compound was prepared as trifloroacetic acid salt by substituting methylamine for cyclopropylamine in Example 220 (11.9 mg, 8%). MS (DCI/NH[0570] 3): m/z 400 (M+1)+; 1HNMR (400 MHz, MeOD) δ ppm ppm 3.05 (s, 3H) 3.32 (m, 2H) 3.99 (m, 1H) 4.24 (dd, J=10.43, 5.52 Hz, 1H) 4.37 (dd, J=10.74, 3.38 Hz, 1H) 7.03 (m, 1H) 7.05 (m, 1H) 7.13 (m, 1H) 7.19 (d, J=7.06 Hz, 1H) 7.23 (m, 1H) 7.31 (d, J=16.57 Hz, 1H) 7.39 (d, J=7.36 Hz, 1H) 7.57 (d, J=7.06 Hz, 1H) 7.60 (m, 1H) 7.74 (s, 1H) 7.80 (d, J=7.06 Hz, 1H) 8.41 (brs, 1H) 8.57 (brs, 1H).
    • EXAMPLE 224 (1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-indol-1-yl-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethylamine
  • A mixture of Example 216 (100 mg, 0.2 mmol), indole (48 mg, 0.4 mmol), and NaH (60%) (29 mg, 0.72 mmol) in DMF (5 mL) was heated at 125° C. for 1.5 hrs. The mixture was concentrated to dryness. The residue was then treated with TFA (1 mL) at rt for 10 min. Upon removal of TFA, the crude product was purified on C18 HPLC to give the title compound (8.1 mg, 5%). MS (DCI/NH[0571] 3) m/z 486(M+1)+; 1HNMR (500 MHz, MeOD) δ ppm 3.29 (m, 1H) 3.35 (m, 1H) 4.00 (m, 1H) 4.26 (dd, J=10.61, 5.93 Hz, 1H) 4.39 (dd, J=10.29, 3.12 Hz, 1H) 6.73 (d, J=3.43 Hz, 1H) 7.05 (m, 1H) 7.11-7.18 (m, 2H) 7.24 (s, 1H) 7.26 (m, 1H) 7.63-7.38 (m, 6H) 7.75 (m, 1H) 7.80 (m, 1H) 7.84 (d, J=3.43 Hz, 1H) 8.22 (dd, J=8.42, 0.62 Hz, 1H) 8.32 (s, 1H) 8.52 (s, 1H) 8.53 (s, 1H).
    • EXAMPLE 225 (±)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-methyl-1H-indol-3-ylmethyl)-ethylamine Example 225A 3-Bromo-2-hydroxyimino-propionic Acid Ethyl Ester
  • Ethyl bromopyruvate (5.0 mL, 39.8 mmol) was added to hydroxylamine hydrochloride (2.52 g, 36.2 mmol) in H[0572] 2O (10 mL) and CHCl3 (10 mL). The reaction mixture was capped and stirred overnight at 23° C. at which time CH2Cl2 and H2O were added, the layers separated, the organics dried over Na2SO4, and the volatiles removed on a rotary evaporator to yield 7.58 g (100%) of as a white solid. 1H NMR (300 MHz, DMSO-D6) δ ppm 1.26 (t, J=7.12 Hz, 3H) 4.20 (s, 2H) 4.24 (m, 2H) 13.19 (s, 1H).
    • Example 225B 2-Hydroxyimino-3-(2-methyl-1H-indol-3-yl)-propionic Acid Ethyl Ester
  • The desired compound was prepared by a reference method ([0573] J. Chem. Soc. Chem. Comm. 1979, 1089). To 2-methylindole (1.28 g, 9.76 mmol) and Na2CO3 (1.24 g, 11.7 mmol) in CH2Cl2 was added Example 225A (2.05 g, 9.76 mmol). The resulting reaction mixture was stirred overnight at 23° C. at which time H2O was added, the layers separated, and the organics dried over Na2SO4. Flash chromatography (20-30-50-70% EtOAc/hexanes) gave 1.41 g (56%) of as a green solid. Rf=0.30 (50% EtOAc/hexanes); MS m/z 261 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 1.13 (t, J=7.12 Hz, 3H) 2.35 (s, 3H) 3.84 (s, 2H) 4.08 (q, J=7.12 Hz, 2H) 6.92 (m, 2H) 7.19 (d, J=7.80 Hz, 1H) 7.44 (d, J=7.46 Hz, 1H) 10.74 (s, 1H) 12.34 (s, 1H).
    • Example 225C (±)-2-tert-Butoxycarbonylamino-3-(2-methyl-1H-indol-3-yl)-propionic Acid Ethyl Ester
  • The desired compound was prepared by a reference method ([0574] Angew. Chem. Int. Ed. Engl. 1979, 78, and Tet. Lett. 1988, p447). Aluminum foil (1.18 g, 43.8 mmol) was cut into long thin (1 cm) strips then dipped into a 2% aqueous HgCl2 solution (30 sec each strip). Each strip was immediately washed successively with H2O, MeOH, then Et2O. Each strip was then immediately cut into small pieces (˜1×0.5 cm) into a solution of Example 225B (1.14 g, 4.38 mmol) in THF (60 mL) and H2O (6 mL) which was kept at room temperature with a water bath. The mixture was stirred vigorously at 23° C. After a short time fine black solids began to form and much bubbling was observed. The reaction mixture was stirred 3 h then filtered through Celite, and the filter cake washed with Et2O. All volatiles were removed on a rotary evaporator. MeOH (50 mL) was added followed by Na2CO3 (0.51 g, 4.82 mmol) and Boc2O (1.00 g, 4.60 mmol). The resulting reaction mixture was stirred 30 min at 23° C. and then silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (10-30-40-50% EtOAc/hexanes) gave 1.33 g (88%) of as an off-white solid. Rf=0.68 (70% EtOAc/hexanes); MS m/z 345 (M−H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 1.02 (t, J=7.12 Hz, 3H) 1.33 (s, 9H) 2.28 (s, 3H) 3.00 (m, 2H) 3.97 (q, J=7.12 Hz, 2 H) 4.10 (m, 1H) 6.94 (m, 2H) 7.14 (d, J=8.14 Hz, 1H) 7.21 (d, J=7.12 Hz, 1H) 7.38 (d, J=7.12 Hz, 1H) 10.73 (s, 1H).
    • Example 225D (±)-[2-Hydroxy-1-(2-methyl-1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • To Example 225C (1.30 g, 3.75 mmol) and CaCl[0575] 2 (anhydrous) (0.83 g, 7.51 mmol) in a 500 mL round bottom flask equipped with a stirbar was added sequentially: EtOH (wet) (30 mL), THF (20 mL) and NaBH4 (0.57 g, 15.0 mmol). The resulting cloudy reaction mixture was stirred 1 h at 23° C. and then poured onto 1 M citric acid and extracted with EtOAc. The organic extracts were washed with brine and dried over MgSO4. Silica gel and NaHCO3 (100 mg) were added and the volatiles removed on a rotary evaporator. Flash chromatography (35-50-60% EtOAc/hexanes) gave 1.08 g (95%) of as a white solid. Rf=0.51 (70% EtOAc/hexanes); MS m/z 303 (M−H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 1.35 (s, 9H) 2.31 (s, 3H) 2.71 (m, 2H) 3.29 (t, J=5.42 Hz, 2H) 3.57 (m, 1H) 4.54 (t, J=5.42 Hz, 1H) 6.45 (d, J=8.48 Hz, 1H) 6.92 (m, 2H) 7.19 (dd, J=6.78, 1.02 Hz, 1H) 7.48 (d, J=7.12 Hz, 1H) 10.64 (s, 1H).
    • Example 225E (±)-[2-(5-Bromo-pyridin-3-yloxy)-1-(2-methyl-1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desried product was prepared by substituting Example 225D for Boc-tryptophanol in Example 2A. R[0576] f=0.41 (50% EtOAc/hexanes); MS m/z 460, 462 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 1.35 (s, 9H) 2.30 (s, 3H) 2.86 (m, 2H) 3.97 (s, 2H) 6.93 (m, 3H) 7.21 (d, J=7.80 Hz, 1H) 7.46 (d, J=7.46 Hz, 1H) 7.59 (s, 1H) 8.13 (dd, J=3.56, 2.20 Hz, 1H) 8.25 (dd, J=5.09, 2.03 Hz, 2H) 10.72 (s, 1H).
    • Example 225F (±)-[1-(2-Methyl-1H-indol-3-ylmethyl)-2-(5-trimethylstannanyl-pyridin-3-yloxy)-ethyl]-carbamic Acid Tert-Butyl Ester
  • Example 225D (350 mg, 0.76 mmol), Pd(PPh[0577] 3)4 (88 mg, 0.08 mmol) and hexamethylditin (300 mg, 0.92 mmol) were combined in a 25 mL round bottom flask with a stirbar. The atmosphere of the flask was evacuated and replaced with argon. Toluene (4 mL) was added and the resulting reaction mixture warmed to 100° C. for 2 h and then cooled to room temperature. EtOAc and silica gel were added and the volatiles removed on a rotary evaporator. Flash chromatography (30-40-50-60% EtOAc/hexanes gave 294 mg (71%) of as a yellow solid. Rf=0.43 (70% EtOAc/hexanes); MS m/z 546 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 0.28 (s, 9H) 1.36 (s, 9H) 2.30 (s, 3H) 2.86 (m, 2H) 3.95 (s, 3H) 6.93 (m, 3H) 7.21 (d, J=7.80 Hz, 1H) 7.33 (d, J=2.03 Hz, 1H) 7.44 (d, J=7.46 Hz, 1H) 8.14 (s, 2H) 10.72 (s, 1H).
    • Example 225G (±)-[2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-methyl-]H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • Bromo-methylindazole (71 mg, 0.33 mmol), Example 225F (200 mg, 367 mmol), Pd[0578] 2 dba3 (61 mg, 0.7 mmol), and P(o-tol)3 (41 mg, 0.14 mmol) were combined in a 10 mL round bottom flask with a stirbar. DMF (2 mL) was added and the atmosphere of the flask evacuated and replaced with argon twice. Et3N (0.09 mL, 0.67 mmol) was added and the reaction mixture warmed to 80° C. for 5 h and then cooled to room temperature. EtOAc was added and the resulting mixture filtered through Celite. The filtrate was washed twice with H2O and once with brine. Silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (70-85-100% EtOAc/hexanes) gave 48 mg (28%) of as a yellow solid. Rf=0.30 (EtOAc); MS m/z 512 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 1.36 (s, 9H) 2.31 (s, 3H) 2.54 (s, 3H) 2.90 (m, 2H) 4.05 (m, 3H) 6.93 (m, 3H) 7.20 (m, 2H) 7.58 (m, 3H) 8.06 (s, 1H) 8.20 (d, J=2.71 Hz, 1H) 8.53 (d, J=1.70 Hz, 1H) 10.72 (s, 1H) 12.72 (s, 1H).
    • Example 225H (±)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-methyl-1H-indol-3-ylmethyl)-ethylamine
  • The title compound was prepared as trifluoroacetic acid salt by substituting Example 225G for Example 27B in Example 27C (31.9 mg, 84%). MS m/z 412 (M+H)[0579] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.33 (s, 3H) 2.55 (s, 3H) 2.75 (dd, J=14.41, 6.61 Hz, 1H) 2.92 (m, 1H) 3.18 (s, 2H) 3.99 (m, 2H) 4.09 (q, J=5.43 Hz, 1H) 6.89 (m, 1H) 6.96 (td, J=7.46, 1.02 Hz, 1H) 7.22 (d, J=7.80 Hz, 1H) 7.46 (d, J=7.46 Hz, 1H) 7.54 (d, J=8.82 Hz, 1H) 7.63 (m, 1H) 7.67 (m, 1H) 8.08 (s, 1H) 8.25 (d, J=2.37 Hz, 1H) 8.54 (d, J=1.70 Hz, 1H) 10.75 (s, 1H) 12.73 (s, 1H).
    • EXAMPLE 226 7-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-quinazolin-2-ylamine Example 226A 7-Bromo-quinazolin-2-ylamine
  • The 4-Bromo-2-fluoro-benzaldehyde (0.61 g, 3 mmol), guanidine (1.05 g, 5.83 mmol) and DMF were heated at 140° C. for 2.5 hours. 50 ml water was added to the mixture. The orange precipitate was filtered and washed with water. The solid was dissolved in 2N HCl. and filtered. The HCl solution was neutralized by ammonia hydroxyl. The off white solid was filtered and dried under vacuum to afforded the desired product (91 mg, 14%). MS (ESI) m/c 224 (M+1)[0580] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 7.00 (br. s., 2H) 7.36 (d, J=8.82 Hz, 1H) 7.77 (dd, J=9.16, 2.37 Hz, 1H) 8.05 (d, J=2.37 Hz, 1H) 9.09 (br. s., 1H).
    • Example 226B 7-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-quinazolin-2-ylamine
  • The desired product was prepared by substituting Example 226A for 6-bromophthalimide in Example 32 as the tri-TFA salt. MS m/z 11 (M+H)[0581] +, (M−H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.85 (m, 1H) 3.01 (m, 1H) 3.32 (m, 1H) 4.06 (m, 2H) 6.96 (m, 3H) 7.05 (m, 1H) 7.22 (d, J=2.03 Hz, 1H) 7.34 (d, J=8.14 Hz, 1H) 7.54 (m, 1H) 7.68 (m, 1H) 8.05 (dd, J=8.99, 2.20 Hz, 1H) 8.19 (d, J=2.03 Hz, 1H) 8.30 (d, J=2.71 Hz, 1H) 8.57 (d, J=2.03 Hz, 1H) 9.16 (s, 1H) 10.88 (s, 1H).
    • EXAMPLE 227 2-Phenyl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-ethylamine Example 227A (2,6-Difluoro-pyridin-3-yl)-pyridin-4-yl-methanol
  • To diisopropylamine (9.3 mL, 66.1 mmol) in THF (100 mL) at −78° C. was added n-BuLi (23.1 mL of a 2.5 M solution in hexanes, 57.8 mmol) dropwise via syringe. 2,6-difluoropyridine (5.0 mL, 55.1 mmol) in THF (100 mL) at −78° C. was added to the above prepared LDA solution dropwise via canula to give a clear yellow-green solution. isonicotinaldehyde (6.3 mL, 66.1 mmol) was added causing a white precipitate to form. The reaction mixture was warmed to room temperature and then glacial acetic acid (3.3 mL, 57.8 mmol) was added. Silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (80-100% EtOAc/hexanes-3-5-7% MeOH/EtOAc) gave 8.48 g (69%) of as an off white solid. R[0582] f=0.38 (5% MeOH/EtOAc); MS m/z 223 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 5.91 (d, J=4.41 Hz, 1H) 6.49 (d, J=4.41 Hz, 1H) 7.20 (dd, J=8.31, 2.54 Hz, 1H) 7.36 (m, 2H) 8.19 (m, 1H) 8.53 (m, 2H); Found: 223, 221; Anal calcd for C11H8F2N2O: C, 59.46; H, 3.63; N, 12.61. Found: C: 59.45, H: 3.66, N: 12.62.
    • Example 227B (2,6-Difluoro-pyridin-3-yl)-pyridin-4-yl-methanone
  • Example 227A (7.36 g, 33.1 mmol) and MnO[0583] 2 (8.64 g, 99.4 mmol) were combined in a 500 mL round bottom flask with a stirbar. 1,4-dioxane (120 mL) was added and the resulting black mixture warmed to 110° C. MnO2 (˜22 g) was added in 2 g amounts every couple of hours over the next 2 days. The reaction mixture was cooled to room temperature and filtered through Celite. The filter cake was washed with EtOAc and then all volatiles were removed on a rotary evaporator. Flash chromatography (50-70-80% EtOAc/hexanes) gave 4.61 g (63%) of as a green solid. Rf=0.58 (5% MeOH/EtOAc); MS m/z 221. (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 7.41 (ddd, J=8.14, 2.37, 0.68 Hz, 1H) 7.72 (m, 2H) 8.47 (dt, J=9.41, 8.01 Hz, 1H) 8.85 (m, 2H); Anal calcd for C11H6F2N2O: C, 60.01; H, 2.75; N, 12.72. Found: C: 60.05, H: 2.87, N: 12.97.
    • Example 227C 6-Fluoro-3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridine
  • To Example 227B (4.20 g, 19.1 mmol) in 1,4-dioxane (100 mL) was added hydrazine hydrate (0.93 mL, 19.1 mmol). The resulting yellow reaction mixture was stirred 20 min at 23° C. and then silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (60-80-100% EtOAc/hexanes-1-5% MeOH/EtOAc) gave 2.49 g (61%) of as a white solid. R[0584] f=0.40 (5% MeOH/EtOAc); MS m/z 215 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 7.14 (dd, J=8.65, 0.85 Hz, 1H) 8.02 (m, 2H) 8.71 (m, 2H) 8.87 (dd, J=8.48, 7.80 Hz, 1H) 14.25 (s, 1H); Anal calcd for C11H7FN4: C, 61.68; H, 3.29; N, 26.16. Found: C: 61.35, H: 3.35, N: 25.81.
    • Example 227D Phenyl-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-acetonitrile
  • To a stirred mixture of Example 227C (0.96 g, 4.48 mmol) in DMF (20 mL) at −35° C. was added benzyl cyanide (1.55 mL, 13.4 mmol) and then NaH (0.57 g of 95% NaH, 22.4 mmol). The resulting dark red mixture was stirred 15 min while being slowly warmed to ˜−20° C. At this time most of the bubbling had stopped and the reaction mixture was then quickly warmed to room temperature and then to 100° C. overnight. The reaction mixture was cooled to room temperature and saturated aqueous NH[0585] 4Cl was added. The mixture was extracted with EtOAc and the organic extracts washed twice with H2O and once with brine. Silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (60-80-100% EtOAc-3% MeOH/EtOAc) gave 1.14 g (82%) of as an orange solid. Rf=0.40 (5% MeOH/EtOAc); MS m/z 312 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 6.17 (s, 1H) 7.40 (m, 4H) 7.52 (m, 2H) 8.00 (m, 2H) 8.70 (m, 2H) 8.74 (d, J=8.48 Hz, 1H) 14.36 (s, 1 H); Anal Calcd for C19H13N5: C, 73.30; H, 4.21; N, 22.49. Found: C: 73.09, H: 4.10, N: 22.58.
    • Example 227E 2-Phenyl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-ethylamine
  • The desire product was prepared by substituting Example 227D for Example 41C in Example 41D (84 mg, 27%). R[0586] f=0.33 (20% MeOH/CH2Cl2); MS m/z 316 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.23 (m, 1H) 3.34 (br s, 3H) 3.52 (m, 1H) 4.34 (m, 1H) 7.27 (m, 6H) 7.99 (d, J=6.10 Hz, 2H) 8.57 (d, J=8.48 Hz, 1H) 8.68 (d, J=6.10 Hz, 2H).
    • EXAMPLE 228 Naphthalen-2-yl-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-acetonitrile
  • The desired product was obtained by substituting 2-napthyl acetonitrile for benzyl nitrile in Example 227D (244 mg, 42%). R[0587] f=0.46 (EtOAc); MS m/z 362 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 6.36 (s, 1H) 7.44 (d, J=8.48 Hz, 1H) 7.57 (m, 3H) 7.98 (m, 6H) 8.09 (d, J=1.36 Hz, 1H) 8.69 (m, 2H) 8.75 (d, J=8.48 Hz, 1H).
    • EXAMPLE 229 2-Naphthalen-2-yl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-ethylamine
  • The desire product was prepared by substituting Example 228 for Example 41C in Example 41D. MS m/z 366 (M+H)[0588] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.96 (m, 2H) 4.82 (t, J=7.46 Hz, 1H) 7.39 (d, J=8.48 Hz, 1H) 7.52 (m, 3H) 7.89 (m, 4H) 8.20 (d, J=6.10 Hz, 2H) 8.68 (d, J=8.48 Hz, 1H) 8.80 (m, 3H).
    • EXAMPLE 230 (3-Isoquinolin-6-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-phenyl-acetonitrile Example 230A Isoquinoline-6-carbaldehyde
  • A solution of 6-bromoisoquinoline (19.9 g, 95.6 mmol), PdCl[0589] 2(dppf).CH2Cl2 (1.8 g), and triethylamine (30 mL) in toluene (50 mL) was heated to 130° C. under 850 psi of H2/CO (1:1) for 4 h. After cooling to rt, the reaction mixture was filtered. The filtrate was concentrated and the residue was purified by flash chromatography eluting with 70-80-90-100% EtOAc/hexanes to give 6.11 g (41%) of the aldehyde as a yellow solid. Rf=0.55 (EtOAc); 1H NMR (300 MHz, DMSO-D6) δ ppm 8.07 (m, 2H) 8.30 (dd, J=8.48, 0.68 Hz, 1H) 8.64 (s, 1H) 8.67 (d, J=5.76 Hz, 1H) 9.47 (s, 1H) 10.23 (s, 1H).
    • Example 230B (3-Isoquinolin-6-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-phenyl-acetonitrile
  • The desired product (244 mg, 42%) was obtained by substituting Example 230A for isonicotinaldehyde in Example 227. R[0590] f=0.46 (EtOAc); MS m/z 362 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 6.18 (s, 1H) 7.40 (m, 4H) 7.54 (m, 2H) 7.99 (d, J=5.76 Hz, 1H) 8.25 (d, J=8.48 Hz, 1H) 8.36 (m, 1H) 8.56 (d, J=5.42 Hz, 1H) 8.63 (s, 1H) 8.87 (d, J=8.48 Hz, 1H) 9.35 (s, 1H) 14.27 (s, 1H).
    • EXAMPLE 231 2-(3-Isoquinolin-6-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-2-phenyl-ethylamine
  • The desire product was prepared by substituting Example 230 for Example 41C in Example 41D. MS m/z 366 (M+H)[0591] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.11 (m, 1H) 3.90 (m, 1H) 4.66 (dd, J=9.16, 6.10 Hz, 1H) 7.31 (m, 8H) 8.28 (d, J=6.10 Hz, 1H) 8.42 (d, J=8.82 Hz, 1H) 8.54 (d, J=8.48 Hz, 1H) 8.63 (d, J=6.44 Hz, 1H) 8.78 (s, 1H) 8.82 (d, J=8.48 Hz, 1H) 9.59 (s, 1H) 14.26 (s, 1H).
    • EXAMPLE 232 (1S)-1-Benzyl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-5-yloxy)-ethylamine Example 232B 5-(tert-Butyl-dimethyl-silanyloxy)-2-fluoro-pyridine
  • A mixture of 2-fluoro-5-hydroxypyridine (1.00 g, 8.84 mmol) and BDCS reagent (0.5M TBSCl, 1.0M imidazole in DMF) (35.4 mL, 17.7 mmol) was stirred at rt for 1 h. The reaction was poured into satd. aqueous NaHCO[0592] 3 solution. The aqueous layer was extracted with ether. The combined extracts were washed with water, brine, dried over MgSO4, and concentrated. The residue was purified by flash column chromatography on silica gel eluting with 10% ethyl acetate/hexanes to give the title compound (1.96 g, 98%).
    • Example 232B 5-(tert-Butyl-dimethyl-silanyloxy)-3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridine
  • The desired product was prepared according to the procedures used for Example 227C by substituting Example 232A for 2,6-difluoropyridine in Example 227A. [0593]
    • Example 232C 5-(tert-Butyl-dimethyl-silanyloxy)-3-pyridin-4-yl-pyrazolo[3,4-b]pyridine-1-carboxylic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting Example 232B for Example 102C in Example 203A (75%). [0594]
    • Example 232D 5-Hydroxy-3-pyridin-4-yl-pyrazolo[3,4-b]pyridine-1-carboxylic Acid Tert-Butyl Ester
  • A mixture of Example 232C (91 mg, 0.213 mmol) and TBAF (IM in THF, 213 μL, 0.213 mmol) in THF (10 mL) was stirred at rt for 5 min. Reaction was concentrated. Flash column chromatography eluting with 5% methanol/CH[0595] 2Cl2 to give the dedired product purified the residue (75%).
    • Example 232E 5-((2S)-2-tert-Butoxycarbonylamino-3-phenyl-propoxy)-3-pyridin-4-yl-pyrazolo[3,4-bipyridine-1-carboxylic Acid Tert-Butyl Ester
  • The title compound was prepared by substituting Example 232D for Example 238A and Boc-phenylalaminol for Boc-4′-bromophenylalaminol in Example 238B. [0596]
    • Example 232F (1S)-1-Benzyl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-5-yloxy)-ethylamine
  • To Example 232E (39 mg, 71 μmol) in CH[0597] 2Cl2 (4 mL) was added 4-methoxybenzyl mercaptan (30 μL, 214 μmol) and then TFA (1 mL). The resulting yellow reaction mixture was stirred 50 min at 23° C. at which time all volatiles were removed on a rotary evaporator. K2CO3 (excess) and MeOH (5 mL) were added and the resulting mixture stirred 1 h at 23° C. at which time silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (EtOAc-5-10-12% MeOH/CH2Cl2) gave a light yellow waxy product which was dissolved in 20% MeOH/CH2Cl2 and stirred for 1 h with 1 N HCl (1 mL of a 1 N solution in Et2O, 1 mmol). The volatiles were removed to give 111 mg (17%, two steps) of a yellow solid which was the bis-HCl salt. MS m/z 346 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.92 (dd, J=13.73, 8.98 Hz, 1H) 3.12 (dd, J=14.24, 5.09 Hz, 1H) 4.14 (dd, J=5.59, 1.86 Hz, 1H) 4.74 (t, J=5.93 Hz, 2H) 7.20 (m, 5H) 7.97 (d, J=2.37 Hz, 1H) 8.38 (m, 5H) 8.90 (d, J=6.78 Hz, 2H) 10.31 (s, 1H).
    • EXAMPLE 233 2-Benzyl-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propylamine
  • The desired product was prepared as trifluoroacetic acid by substituting (2-Benzyl-3-hydroxy-propyl)-carbamic acid tert-butyl ester (Khumtaveepom, K.; Ullmann, A.; Matsumoto, K.; Davis, B. G.; Jones, J. B. [0598] Tetrahedron: Asymmetry 2001, 12, 249) for Example Boc-tryptophanol in Example 102. MS m/z 373 (M+H)+, (M−H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 2.81 (dd, J=7.29, 3.56 Hz, 2H) 2.92 (m, 1H) 3.05 (m, 1H) 4.09 (dd, J=10.17, 5.76 Hz, 2H) 4.16 (m, 2H) 7.28 (m, 5H) 7.57 (dd, J=8.48, 0.68 Hz, 1H) 7.69 (m, 1H) 7.74 (m, 1H) 7.82 (s, 2H) 8.09 (m, 1H) 8.30 (d, J=2.71 Hz, 1H) 8.62 (d, J=1.70 Hz, 1H).
    • EXAMPLE 234 (1S)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphthyridin-5-yloxy)-ethylamine Example 234A 3-Bromo-5-(4-methoxy-benzyloxy)-pyridine
  • 3-Bromo-5-hydroxypyridine (14.7 g, 84.3 mmol), tetrabutylammonium iodide (0.3 g, 0.8 mmol), and K[0599] 2CO3 (14.0 g, 101 mmol) were combined in a dry 500 mL round bottom flask with a stirbar. DMF (170 mL) was added followed by PMBCl (12.0 mL, 88.5 mmol). The resulting brown colored mixture was stirred 3.5 days at 23° C. and then silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (10-20-40% EtOAc/hexanes) gave 14.1 g (57%) of as an orange solid. Rf=0.52 (50% EtOAc/hexanes) 1H NMR (300 MHz, DMSO-D6) δ ppm 3.32 (s, 3H) 5.12 (s, 2H) 6.96 (m, 2H) 7.39 (m, 2H) 7.79 (m, 1H) 8.28 (d, J=2.03 Hz, 1H) 8.34 (d, J=2.71 Hz, 1H). 13C NMR (100 MHz, DMSO-D6) δ ppm 55.0, 69.8, 113.8, 119.9, 124.0, 127.8, 129.8, 137.1, 142.1, 155.1, 159.2; Anal Calcd for C12H10BrNO: C, 53.08; H, 4.11; N, 4.76. Found: C: 53.00, H: 3.98, N: 4.66.
    • Example 234B 3-Amino-5-(4-methoxy-benzyloxy)-pyridine
  • Example 234A (16.15 g, 54.9 mmol), Pd[0600] 2 dba3 (0.50 g, 0.55 mmol), rac-BINAP (1.03 g, 1.65 mmol), and sodium tert-butoxide (7.39 g, 76.9 mmol) were combined in a 500 mL round bottom flask with a stirbar. Benzophenone imine (11.1 mL, 65.9 mmol) was added followed by toluene (180 mL). The resulting reaction mixture was warmed to 80° C. for 3 h and then allowed to cool to room temperature, diluted with Et2O, and filtered through Celite. The volatiles were removed on a rotary evaporator. Flash chromatography (30-40-50% EtOAc/hexanes) yielded an impure orange oil which was dissolved in THF (180 mL) and 1 N HCl (60 mL). The resulting orange mixture was stirred 15 min and then partitioned between 30% EtOAc/hexanes and 0.5 M HCl. The layers were separated and the organic layer washed once with 0.5 M HCl. The combined HCl layers were washed once with 30% EtOAc/hexanes and then cooled to 0° C. 50% aqueous NaOH was added until the mixture was basic on litmus paper and then the mixture was extracted twice with CH2Cl2. The combined organic extracts were dried over Na2SO4 and the volatiles removed on a rotary evaporator to yield 8.92 g (71%, two steps) of as a yellow solid. 1H NMR (300 MHz, DMSO-D6) δ ppm 3.75 (s, 3H) 4.97 (s, 2H) 4.97 (s, 2H) 5.29 (s, 2H) 6.54 (t, J=2.37 Hz, 1H) 7.35 (m, 2H) 7.50 (d, J=2.37 Hz, 1H) 7.54 (d, J=2.37 Hz, 1H), 13C NMR (100 MHz, DMSO-D6) δ ppm 55.0, 68.9, 105.6, 113.8, 125.3, 128.7, 129.3, 129.4, 145.7, 155.1, 159.0.
    • Example 234C [5-(4-Methoxy-benzyloxy)-pyridin-3-yl]-carbamic Acid Tert-Butyl Ester
  • To a stirred solution of Example 234B (8.92 g, 38.7 mmol) in THF (240 mL) at 23° C. was added NaHMDS (129 mL of a 0.6 M solution in toluene, 77.5 mmol) dropwise via syringe. The resulting cloudy yellow-brown mixture was stirred 5 min and then Boc[0601] 2O (8.45 g, 38.7 mmol) was added all at once. The cloudiness of the mixture disappeared leaving a clear yellow-brown solution. 0.1 M HCl was added and the resulting aqueous and organic layers separated. The pH of the aqueous layer was 8. The organic layer was washed with brine and then combined with silica gel before the volatiles were removed on a rotary evaporator. Flash chromatography (30-40-50-70% EtOAc/hexanes-5-10% MeOH/CH2Cl2) gave 1.69 (10%) of bis-Boc protected as an orange solid, 7.04 g (55%) of the desired mono-Boc protected as a yellow solid, and 1.51 g (17%) of starting amine as an orange solid. Data for bis-Boc: Rf=0.38 (50% EtOAc/hexanes) 1H NMR (300 MHz, DMSO-D6) δ ppm 1.35 (s, 18H) 3.75 (s, 3H) 5.11 (s, 2H) 6.94 (m, 2H) 7.39 (m, 2H) 7.43 (dd, J=2.71, 2.03 Hz, 1H) 8.02 (d, J=2.03 Hz, 1H) 8.28 (d, J=2.37 Hz, 1H). Data for mono-Boc: Rf=0.30 (50% EtOAc/hexanes) 1H NMR (300 MHz, DMSO-D6) δ ppm 1.48 (s, 9H) 3.76 (s, 3H) 5.04 (s, 2H) 6.95 (m, 2H) 7.39 (m, 2H) 7.60 (t, J=2.20 Hz, 1H) 7.96 (d, J=2.71 Hz, 1H) 8.22 (d, J=2.03 Hz, 1H) 9.57 (s, 1H). 13C NMR (100 MHz, DMSO-D6) δ ppm 28.0, 55.0, 69.3, 79.6, 110.8, 113.8, 128.3, 129.6, 131.1, 132.3, 136.9, 152.7, 154.4, 159.1, Anal Calcd for C18H22N2O4: C, 65.44; H, 6.71; N, 8.48. Found: C: 65.40, H: 6.66, N: 8.40.
    • Example 234D [4-Formyl-5-(4-methoxy-benzyloxy)-pyridin-3-yl]-carbamic Acid Tert-Butyl Ester
  • To Example 234C (2.50 g, 7.54 mmol) in THF (125 mL) at −78° C. was added dropwise via syringe n-BuLi (6.64 mL of a 2.5 M solution in hexanes, 16.6 mmol). The resulting dark orange reaction mixture was slowly warmed to −10° C. over 45 min and then recooled to −78° C. Methyl formate (1.40 mL, 22.6 mmol) was added dropwise via syringe and the reaction was stirred an additional 10 min at −78° C. Saturated aqueous NH[0602] 4Cl was added and the quenched reaction mixture warmed to room temperature. H2O and Et2O were added and the layers separated. The organics were washed with brine and dried over MgSO4. Flash chromatography (20-40-60-80% EtOAc/hexanes gave 0.3 g (12%) of recovered starting material, and 1.7 g (63%) of as a yellow solid. (1H NMR (400 MHz, DMSO-D6) δ ppm 1.47 (s, 9H) 3.75 (s, 3H) 5.28 (s, 2H) 6.95 (d, J=8.59 Hz, 2H) 7.43 (d, J=8.59 Hz, 2H) 8.38 (s, 1H) 9.07 (s, 1H) 10.17 (s, 1H) 10.35 (s, 1H), 13C NMR (100 MHz, DMSO-D6) δ ppm 27.7, 55.0, 70.8, 81.1, 113.9, 114.6, 127.7, 129.6, 130.0, 133.3, 134.6, 151.7, 154.7, 159.2, 192.8, Anal Calcd for C19H22N2O5: C, 63.67; H, 6.19; N, 7.82. Found: C: 63.59, H: 6.21, N: 7.64.
    • Example 234E 5-(4-Methoxy-benzyloxy)-[1,7naphthyridin-2-ol
  • To Bis(2,2,2-trifluoroethyl)(methoxycarbonylmethyl)phosphonate (1.27 mL, 5.99 mmol) in THF (45 mL) at −78° C. was added KHMDS (11.I mL of a 0.5 M solution in toluene, 5.53 mmol) dropwise via syringe. The resulting clear, light yellow solution was added dropwise via canula to Example 234D (1.65 g, 4.60 mmol) in THF (60 mL) at −78° C. The resulting cloudy yellow reaction mixture was stirred 20 min at −78° C. at which time saturated aqueous NH[0603] 4Cl was added and the quenched reaction mixture warmed to room temperature. H2O and Et2O were added and the layers separated. The organics were washed with brine and dried over MgSO4. Flash chromatography (40-50-60-70% EtOAc/hexanes) gave 1.98 g of impure product which was a 5:1 mixture of Z:E olefin isomers. To the crude product in THF (150 mL) was added NaHMDS (11.6 mL of a 0.6 M solution in toluene, 6.95 mmol). The resulting reaction mixture was stirred 30 min at 23° C. at which time silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (60-100% EtOAc/hexanes-5-10% MeOH/CH2Cl2) gave 0.23 g (12%) of E-olefin as a yellow solid and the desired product 0.98 g (75%, two steps) of as a white solid. Rf=0.32 (10% MeOH/CH2Cl2), 1H NMR (400 MHz, DMSO-D6) δ ppm 3.77 (s, 3H) 5.27 (s, 2H) 6.68 (d, J=9.51 Hz, 1H) 6.98 (m, 2H) 7.46 (m, 2H) 8.00 (d, J=9.82 Hz, 1H) 8.18 (s, 1H) 8.31 (s, 1H) 11.98 (s, 1H), 13C NMR (100 MHz, DMSO-D6) δ ppm 55.0, 70.2, 113.7, 113.9, 125.7, 125.8, 128.1, 129.5, 131.0, 132.7, 134.9, 149.3, 159.2, 161.2, Anal Calcd for C16H14N2O3: C, 68.07; H, 5.00; N, 9.92. Found: C: 67.75, H: 4.89, N: 9.88.
    • Example 234F 2-Chloro-5-(4-methoxy-benzyloxy)-[1,7]naphthyridine
  • To a suspension of Example 234D (2.21 g, 7.83 mmol) in DMF (50 mL) at 23° C. was added POCl[0604] 3 (2.2 mL, 23.5 mmol). All the solid starting material dissolved and the resulting yellow reaction mixture was warmed to 45° C. for 6 h. The color of the reaction changed from yellow to dark red-brown. The reaction was poured onto NaHCO3 (13.2 g 157 mmol) in ice water (250 mL) in a 1 L Ehrlenmeyer flask with vigorous stirring. The product was extracted with EtOAc and Et2O and the organic extracts washed twice with H2O and once with brine. Silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (20-30-45-50% EtOAc/hexanes) gave 1.86 g (79%) of as an off-white solid. Rf=0.65 (10% MeOH/CH2Cl2), 1H NMR (400 MHz, DMSO-D6) δ ppm 3.79 (s, 3H) 5.35 (s, 2H) 6.99 (d, J=8.59 Hz, 2H) 7.51 (d, J=8.90 Hz, 2H) 7.77 (d, J=8.90 Hz, 1H) 8.47 (s, 1H) 8.52 (dd, J=8.90, 0.61 Hz, 1H) 8.96 (s, 1H), 13C NMR (100 MHz, DMSO-D6) δ ppm 55.0, 70.4, 113.9, 121.8, 125.9, 126.5, 127.9, 129.6, 133.7, 142.4, 144.0, 148.5, 151.7, 159.2; Anal Calcd for C16H13ClN2O2: C, 63.90; H, 4.36; N, 9.31. Found: C: 63.54, H: 4.17, N: 9.14.
    • Example 234G 5-(4-Methoxy-benzyloxy)-2-pyridin-4-yl-[1,7]naphthyridine
  • Example 234F (164 mg, 0.55 mmol), 4-tributylstannylpyridine (401 mg, 1.09 mmol), Pd[0605] 2 dba3 (50 mg, 0.06 mmol), and 2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl (43 mg, 0.11 mmol) were combined in a 10 mL round bottom flask with a stirbar. The atmosphere of the flask was evacuated and replaced with argon twice. DMF (2 mL) and Et3N (0.5 mL, 3.27 mmol) were added and the reaction mixture warmed to 100° C. for 5 h. The reaction mixture was cooled to room temperature, diluted with EtOAc and Et2O, and filtered through Celite. The filtrate was washed twice with H2O and once with brine. Silica gel was added and the volatiles removed by rotary evaporation. Flash chromatography (70-100% EtOAc/hexanes-2-5% MeOH/CH2Cl2 gave 92 mg (49%) of as a yellow solid. Rf=0.39 (10% MeOH/CH2Cl2), 1H NMR (400 MHz, DMSO-D6) δ ppm 3.79 (s, 3H) 5.37 (s, 2H) 7.01 (m, 2H) 7.53 (m, 2H) 8.21 (d, J=5.83 Hz, 2H) 8.43 (m, 2H) 8.64 (d, J=8.59 Hz, 1H) 8.80 (d, J=4.30 Hz, 2H) 9.13 (s, 1H), 13C NMR (100 MHz, DMSO-D6) δ ppm 55.1, 70.3, 113.9, 121.3, 122.1, 122.6, 126.0, 128.1, 129.6, 131.3, 142.7, 144.6, 145.8, 148.4, 150.5, 155.5, 159.2; Anal Calcd for C21H17N3O2: C, 73.45; H, 4.99; N, 12.24. Found: C: 73.32, H: 5.10, N: 12.17.
    • Example 234I 2-Pyridin-4-yl-[1,7]naphthyridin-5-ol
  • To Example 234H (108 mg, 0.32 mmol) in a 50 mL round bottom flask with a stirbar was added a mixture of 1 N HCl (1.6 mL, 1.57 mmol) in EtOH (8 mL). The resulting reaction mixture was warmed to 90° C. for 2 h, cooled to room temperature, and then poured onto K[0606] 2CO3 (120 mg, 0.87 mmol) in a 100 mL round bottom flask. MeOH (10 mL) was added and the mixture was stirred vigorously for 1 h at which time silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (3-5-7-12% MeOH/CH2Cl2) gave 52 mg (74%) of as an off-white solid. Rf=0.24 (10% MeOH/CH2Cl2); MS m/z 224 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 8.20 (s, 1H) 8.24 (m, 2H) 8.44 (d, J=8.82 Hz, 1H) 8.69 (d, J=8.82 Hz, 1H) 8.80 (m, 2H) 9.01 (s, 1H) 10.91 (Br S, 1H).
    • Example 234J 5 (1S)-[1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphthyridin-5-yloxy)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting Example 2321 for 3-bromo-5-hydroxypyridine in Example 27A. R[0607] f=0.41 (10% MeOH/CH2Cl2); 1H NMR (300 MHz, DMSO-D6) δ ppm 1.37 (s, 9H) 3.07 (m, 1H) 3.38 (m, 1H) 4.25 (m, 3H) 6.93 (m, 1H) 7.05 (td, J=7.54, 1.19 Hz, 1H) 7.15 (d, J=2.03 Hz, 1H) 7.21 (d, J=7.80 Hz, 1H) 7.33 (d, J=7.80 Hz, H) 7.56 (d, J=7.80 Hz, 1H) 8.27 (m, 3H) 8.51 (d, J=8.82 Hz, 1H) 8.82 (m, 3H) 9.13 (s, 1H) 10.82 (s, 1H).
    • Example 234K (1S)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphthyridin-5-yloxy)-ethylamine
  • The desire product was prepared as trifluoroacetic acid salt by substituting Example 234K for Example 232D in Example 232E. MS m/z 396 (M+H)[0608] +; 1H NMR (300 MHz, DMSO-D6) (of the free base) δ ppm 2.96 (m, 1H) 3.11 (m, 1H) 3.24 (m, 1H) 3.61 (s, 1H) 4.09 (q, J=5.09 Hz, 1H) 4.16 (dd, J=9.49, 6.10 Hz, 1H) 4.26 (m, 1H) 6.93 (m, 1H) 7.06 (td, J=7.46, 1.02 Hz, 1H) 7.22 (d, J=2.37 Hz, 1H) 7.34 (d, J=8.14 Hz, 1H) 7.58 (d, J=8.14 Hz, 1H) 8.27 (m, 3H) 8.51 (d, J=8.82 Hz, 1H) 8.82 (m, 2H) 8.89 (d, J=8.82 Hz, 1H) 9.14 (s, 1H) 10.88 (s, 1H).
    • EXAMPLE 235 (1R)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphthyridin-5-yloxy)-ethylamine
  • The desired product was prepared by substituting Boc-R-Tryptophanol for Boc-L-tryptophanol in Example 234. MS m/z 396 (M+H)[0609] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.31 (m, 2H) 4.34 (dd, J=10.51, 5.42 Hz, 1H) 4.50 (dd, J=10.68, 2.54 Hz, 1H) 6.95 (m, 1H) 7.08 (m, 1H) 7.29 (d, J=2.03 Hz, 1H) 7.37 (d, J=8.14 Hz, 1H) 7.63 (d, J=7.80 Hz, 1H) 8.30 (s, 1H) 8.65 (m, 6H) 8.99 (d, J=5.76 Hz, 2H) 9.23 (s, 1H) 9.29 (m, 1H) 11.04 (d, J=1.70 Hz, 1H).
    • EXAMPLE 236 (1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-ylsulfanyl)-ethylamine Example 236A 3-Bromo-5-(4-methoxy-benzylsulfanyl)-pyridine
  • To a suspension of sodium hydride (370 mg, 60% in mineral oil, 9.25 mmol) in DMF (30 ml) (4-Methoxy-phenyl)-methanethiol (1.25 ml, 9 mmol) was added. The resulting solution was stirred at room temperature for 1 hour and added to 3.5-dibromopyridine (2.13 g, 8.99 mmol) in DMF (30 ml). The mixture was stirred at room temperature for 48 hours. The reaction solution was partitioned between ether and water. The organic layer was washed (brine), dried (Na[0610] 2SO4), filtered and concentrated under vacuum. Purification on silica gel eluting with 5% ethyl acetate/hexane provides the title compound (1.75 g, 63%). MS (DCI/NH3) m/e 310 (M+1)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.72 (s, 3H) 4.30 (s, 2H) 6.85 (d, J=2.03 Hz, 1H) 6.89 (d, J=2.37 Hz, 1H) 7.26 (d, J=2.37 Hz, 1H) 7.29 (d, J=2.03 Hz, 1H) 8.04 (dd, J=2.03 Hz, 1H) 8.45 (d, J=2.03 Hz, 1H) 8.48 (d, J=2.03 Hz, 1H).
    • Example 236B 5-Bromo-pyridine-3-thiol
  • A mixture of Example 236A (1.43 g, 4.6 mmol), m-cresol (4.9 ml, 47 mmol) and TFA (4 ml) was refluxed for 24hours. After cooled to room temperature, the solution was dried by vacuum. Purification on silica gel eluted with 5% ethyl acetate in hexanes to provide the crude title compound (contaminated with disulfide). [0611]
    • Example 236C (1S)-[2-(5-Bromo-pyridin-3-ylsulfanyl)-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • A 100 ml RBF was charged with Example 236B (0.620 mg, 3.26 mmol), 2-Hydroxy-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic acid tert-butyl ester (1.077 g, 3.71 mmol), Ph[0612] 3P (1.23 g, 4.69 mmol) and DBAD (1.0968 g, 4.763 mmol). THF (10 ml) was added at 0° C. The reaction mixture was stirred at 0° C. for 1 h and at room temperature for 22 hours. The reaction mixture was concentrated and the residue was separated by flash chromatography (30% EtOAc in hexane) to provide 0.614 g product with DBAD.
    • Example 236D (1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-ylsulfanyl)-ethylamine
  • The desired compound was prepared by substituting Example 236C for Example 2A in Example 27. MS (ESI) m/e 411 (M+1)[0613] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.13 (m, 2H) 3.37 (m, 2H) 3.57 (m, 1H) 6.90 (t, J=8.14 Hz, 1H) 7.02 (t, J=8.14 Hz, 1H) 7.25 (d, J=2.37 Hz, 1H) 7.31 (d, J=8.14 Hz, 1H) 7.47 (m, 1H) 8.06 (br. s., 2H) 8.18 (m, 2H) 8.28 (t, J=2.03 Hz, 1H) 8.46 (m, 1H) 8.52 (br. s., 1H) 8.67 (d, J=6.10 Hz, 1H) 8.69 (d, J=2.03 Hz, 1H) 8.97 (d, J=2.03 Hz, 1H) 9.66 (br. s., 1H) 11.03 (br. s., 1H).
    • EXAMPLE 237 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylsulfanyl]-ethylamine
  • The title compound was prepared by substituting Example 102C for 6-bromoisoquinoline in Example 236. MS (ESI) m/e 414 (M+1)[0614] +; 1H NMR (300 MHz, MeOH) δ ppm 3.20 (d, J=6.78 Hz, 2H) 3.25 (m, 1H) 3.50 (m, 1H) 3.69 (m, 1H) 6.91 (td, J=8.14, 6.10, 1.02 Hz, 1H) 7.02 (td, J=8.14, 6.10, 1.02 Hz, 1H) 7.15 (br. s., 1H) 7.26 (d, J=8.14 Hz, 1H) 7.40 (d, J=8.14 Hz, 1H) 7.53 (t, J=8.82 Hz, 1H) 7.60 (d, J=8.82 Hz, 1H) 7.93 (m, 1H) 8.12 (t, J=2.03 Hz, 1H) 8.51 (br. s., 1H) 8.74 (br. s., 1H).
    • EXAMPLE 238 (1S)-1-(4-Bromo-benzyl)-2-[5-(3-methyl-1 H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine Example 238A 5-(5-Hydroxy-pyridin-3-yl)-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting 3-bromo-5-hydroxypyridine for Example 203B in Example 203C. [0615]
    • Example 238B (1S)-{1-(4-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethyl}-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared according to the procedures described for Example 2A, substituting Example 238A for 3-bromo-5-hydroxypyridine, and 3′-bromo-Boc-phenylalaminol for Boc-tryptophanol in Example 2A. [0616]
    • Example 238C (1S)-1-(4-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared as trifluoroacetic acid salt by substituting Example 238B for Example 27B in Example 27. MS (ESI) m/e 437 (M+1); [0617] 1H NMR (300 MHz, TRIFLUOROACETIC ACID-D) δ ppm 3.16 (s, 3H) 3.46 (m, 2H) 4.48 (m, 1H) 4.86 (m, 2H) 7.34 (m, 2H) 7.70 (m, 2H) 8.24 (m, 2H) 8.57 (m, 2H) 8.86 (m, 1H) 9.07 (m, 1H).
    • EXAMPLE 239 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(2-methyl-quinazolin-7-yl)-pyridin-3-yloxy]-ethylamine Example 239A 7-Bromo-2-methyl-quinazoline
  • The 4-Bromo-2-fluoro-benzaldehyde (1 g, 4.9 mmol), acetamidine and DMA were mixed and heated to 140° C. for 5 hours. The mixture was cooled to room temperature and dried under vacuum. The mixture was purified by flash column afforded 47 mg product in 4% yield. MS (ESI) m/e 223 (M+1)[0618] +.
    • Example 239B (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(2-methyl-quinazolin-7-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared by substituting Example 239A for 6-bromophthalimide in Example 32. MS (ESI) m/e 410 (M+1)[0619] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.57 (s, 3H) 3.10 (m, 2H) 3.85 (m, 1H) 4.29 (m, 1H) 4.46 (m, 1H) 7.39 (m, 5H) 7.62 (dd, J=8.81, 0.68 Hz, 1H) 7.80 (dd, J=8.81, 1.70 Hz, 1H) 8.28 (d, J=0.68 Hz, 2H) 8.56 (m, 5H) 8.89 (d, J=1.70 Hz, 1H).
    • EXAMPLE 240 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(1H-indol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared by substituting 5-bromoindole for 6-bromophthalimide in Example 32. MS (ESI) m/e 383 (M+1)[0620] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.58 (m, 1H) 4.09 (m, 3H) 4.18 (m, 1H) 6.67 (br. s., 2H) 6.98 (m, 1H) 7.08 (m, 1H) 7.27 (m, 3H) 7.38 (m, 4H) 7.50 (m, 1H) 7.60 (m, 2H) 7.88 (br. s., 1H) 8.23 (br. s., 1H) 8.51 (br. s., 1H).
    • EXAMPLE 241 (1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[4-(1H-tetrazol-5-yl)-phenyl]-pyridin-3-yloxy}-ethylamine
  • The desired product was prepared by substituting 5-(4-bromo-phenyl)-1H-tetrazole for 6-bromophthalimide in Example 32. MS (ESI) m/e 412 (M+1)[0621] +; 1H NMR (300 MHz, Solvent) δ ppm 3.24 (m, 2H) 3.99 (m, 1H) 4.29 (m, 1H) 4.44 (m, 1H) 7.04 (m, 1H) 7.14 (m, 1H) 7.24 (m, 1H) 7.39 (m, 1H) 7.61 (m, 1H) 7.79 (m, 1H) 7.86 (m, 2H) 8.17 (br. s., 1H) 8.20 (br. s., 1H) 8.39 (br. s., 1H) 8.61 (br. s., 1H).
    • EXAMPLE 242 (1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyrimidin-4-yloxy)-ethylamine Example 242A 5-Bromo-pyrimidin-4-ol
  • The Pyrimidin-4-ol (366 mg, 3.8 mmol) and AcOH were cooled to 0° C. Br[0622] 2 (0.27 ml) was added slowly via syringe. The mixture was stirred at room temperature for 3 hours. The AcOH was removed under pressure. The residue was dissolved in CH2Cl2, washed with saturated NaHCO3, brine, and dried over MgSO4. The solvent was removed and the product was purified by flash column chromatography to afforded the desired product (605 mg, 91%). MS (ESI) m/e 175 (M+1)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 8.23 (br. s., 1H) 8.33 (br. s., 1H) 13.08 (br. s., 1H).
    • Example 242B (1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyrimidin-4-yloxy)-ethylamine
  • The title compound was prepared by substituting Example 242A for 3-bromo-5-hydroxypyridine in Example 27. MS (ESI) m/e 396 (M+1)[0623] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.10 (m, 2H) 4.35 (m, 1H) 4.48 (m, 1H) 4.72 (m, 1H) 6.96 (m, 2H) 7.31 (m, 3H) 8.26 (m, 3H) 8.50 (m, 3H) 8.68 (m, 1H) 8.88 (s, 2H) 9.74 (br. s., 1H) 10.99 (br. s., 1H)
    • EXAMPLE 243 (1S)-1-Benzyl-2-[3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethylamine Example 243A [1-Benzyl-2-(3-bromo-phenoxy)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting 3-bromophenol for 3-bromo-5-hydroxypyridine and L-Boc-phenylalaminol for L-Boc-tryptophanol in Example 2A. [0624]
    • Example 243B 5-[3-((2S)-2-tert-Butoxycarbonylamino-3-phenyl-propoxy)-phenyl]-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting Example 243A for Example 2A in Example 102E. [0625]
    • Example 243C (1S)-1-Benzyl-2-[3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 243B for Example 27B in Example 27C. MS (ESI) m/e 358 (M+H)[0626] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.54 (s, 3H) 3.06 (m, 2H) 3.82 (m, 1H) 4.02 (dd, J=10.61, 5.62 Hz, 1H) 4.18 (dd, J=0.61, 3.12 Hz, 1H) 6.93 (dd, J=7.80, 1.56 Hz, 1H) 7.28 (d, J=2.18 Hz, 1H) 7.36 (m, 7H) 7.53 (d, J=8.42 Hz, 1H) 7.62 (m, 1H) 7.94 (s, 1H) 8.27 (s, 2H) 12.68 (bs, 1H); Anal. Calcd for C23H23N3O.1.45 TFA: C, 59.50; H, 4.71; N, 8.04;. Found: C, 59.46; H, 4.69, N, 8.25.
    • EXAMPLE 244 (1S)-1-Benzyl-2-[6-(3-methyl-1H-indazol-5-yl)-pyridin-2-yloxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 3-bromo-6-hydroypyridine for 3-bromophenol in Example 243. MS (ESI) m/e 359 (M+H)[0627] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.54 (s, 3H) 3.05 (m, 2H) 3.90 (m, 1H) 4.33 (dd, J=11.70, 6.27 Hz, 1H) 4.60 (dd, J=11.87, 3.39 Hz, 1H) 6.80 (d, J=8.14 Hz, 1H) 7.33 (m, 5H) 7.49 (d, J=7.80 Hz, 1H) 7.68 (d, J=7.12 Hz, 1H) 7.83 (m, 1H) 7.96 (dd, J=8.81, 1.70 Hz, 1H) 8.20 (s, 2H) 8.35 (s, 1H) 12.69 (bs, 1H); Anal. Calcd for C22H22N4O.1.4 TFA.1H2O: C, 55.56; H, 4.78; N, 10.45;. Found: C, 55.45; H, 4.51, N, 10.50.
    • EXAMPLE 245 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-thiophen-3-yl-benzyl)-ethylamine Example 245A (1S)-[2-Hydroxy-1-(4-iodo-benzyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The material was prepared from L-Boc-(4-iodophenyl)alanine according to the procedure described by M. Rodriguez, M. Llinares, S. Doulut, A. Heitz, J. Martinez [0628] Tetrahedron Letters 1991, 32 (7), 923-926.
    • Example 245B (1S)-[2-(5-Bromo-pyridin-3-yloxy)-1-(4-iodo-benzyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting Example 245A for L-Boc-tryptophanol in Example 2A. [0629]
    • Example 245C (1S)-[2-(5-Bromo-pyridin-3-yloxy)-1-(4-thiophen-3-yl-benzyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • A solution of Example 245B (200 mg; 0.37 mmol), 3-thiopheneboronic acid (50 mg; 0.39 mmol), Pd(PPh[0630] 3)4 (25 mg; 0.02 mmol) and CsF (115 mg; 0.76 mmol) in 1:2 MeOH:DME (5 mL) was heated at reflux for 4 hrs, cooled, diluted with water, and extracted with EtOAc. The extracts were rinsed with brine, dried (MgSO4), evaporated, and purified by flash chromatography (30% Et2O/hexane) to provide the desired product (145 mg, 79%).
    • Example 245D (1S)-[2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-thiophen-3-yl-benzyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting Example 245C for Example 2A in Example 102E. [0631]
    • Example 245E (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-thiophen-3-yl-benzyl)-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 245D for Example 27B in Example 27C. MS (ESI) m/e 441 (M+H)[0632] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.54 (s, 3H) 3.06 (d, J=7.12 Hz, 2H) 3.89 (m, 1H) 4.16 (dd, J=10.68, 5.59 Hz, 1H) 4.33 (dd, J=10.68, 2.88 Hz, 1H) 7.37 (d, J=8.48 Hz, 2H) 7.55 (m, 2H) 7.63 (m, 1H) 7.70 (m, 3H) 7.76 (m, 1H) 7.85 (dd, J=3.05, 1.36 Hz, 1H) 8.08 (s, 1H) 8.22 (m, 2H) 8.35 (d, J=2.71 Hz, 1H) 8.64 (d, J=1.70 Hz, 1H) 12.47 (bs, 1H).
    • EXAMPLE 246 (1S)-1-(4-Iodo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Boc-3′-bromophenylalaminol for Example 245A in Example 238. MS (ESI) m/e 485 (M+H)[0633] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 3.00 (d, J=7.12 Hz, 2H) 3.85 (m, 1H) 4.13 (m, 1H) 4.30 (m, 1H) 7.16 (d, J=8.14 Hz, 2H) 7.58 (d, J=8.82 Hz, 1H) 7.70 (m, 3H) 8.08 (s, 1H) 8.19 (d, J=3.05 Hz, 2H) 8.32 (d, J=2.71 Hz, 1H) 8.63 (d, J=1.70 Hz, 1H) 8.97 (s, 1H) 12.72 (bs, 1H).
    • EXAMPLE 247 [4-((2S)-2-Amino-3-phenyl-propoxy)-2-(3-methyl-1H-indazol-5-yl)-phenyl]-methanol Example 247A (1S)-[1-Benzyl-2-(3-chloro-4-formyl-phenoxy)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting 2-chloro-4-hydroxybenzaldehyde for 3-bromo-5-hydroxypyridine and L-Boc-phenylalaminol for L-Boc-tryptophanol in Example 2A. [0634]
    • Example 247B (1S)-{1-Benzyl-2-[4-formyl-3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethyl}-carbamic Acid Tert-Butyl Ester
  • A solution of Example 102D (230 mg; 0.78 mmol) and Example 247A (300 mg; 0.77 mmol) in DMF (4 mL) was treated with Pd2(dba)[0635] 3 (73 mg; 0.0.08 mmol),2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl (61 mg; 0.15 mmol), and triethylamine (97 mg; 0.96 mmol), heated at 110° C. for 4 hrs., partitioned between brine and EtOAc, filtered through Celite®, and extracted with EtOAc. The extracts were rinsed with brine, dried (MgSO4), concentrated, and purified by flash chromatography (40% EtOAc/hexane) to provide the desired product (235 mg; 63%).
    • Example 247C (1S)-{1-Benzyl-2-[4-hydroxymethyl-3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethyl}-carbamic Acid Tert-Butyl Ester
  • A solution of Example 247B (225 mg; 0.46 mmol) in EtOH (4 mL) was treated portionwise with NaBH[0636] 4 (26 mg; 0.70 mmol) and stirred for 30 min., diluted with water, and extracted into EtOAc. The extracts were rinsed with brine, dried (MgSO4), concentrated, and purified by flash chromatography (60% EtOAc/hexane) to provide the desired product (150 mg; 66%).
    • Example 247D [4-((2S)-2-Amino-3-phenyl-propoxy)-2-(3-methyl-1H-indazol-5-yl)-phenyl]-methanol
  • Example 247C (115 mg; 0.23 mmol) was heated neat at 190° C. for 45 min. then purified by flash chromatography on silica gel eluting with 10% MeOH/CH[0637] 2Cl2 to provide the desired product (17 mg; 19%). MS (ESI) m/e 388 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.50 (s, 3H) 2.60 (dd, J=13.22, 7.80 Hz, 1H) 2.83 (dd, J=13.22, 5.76 Hz, 1H) 3.25 (m, 1H) 3.82 (t, J=5.59 Hz, 2H) 4.33 (d, J=5.09 Hz, 2H) 4.99 (t, J=5.26 Hz, 1H) 6.81 (d, J=2.37 Hz, 1H) 6.93 (dd, J=8.48, 2.37 Hz, 1H) 7.23 (m, 5H) 7.36 (d, J=8.48 Hz, 1H) 7.46 (m, 3H) 7.69 (s, 2H) 12.66 (s, 1H).
    • EXAMPLE 248 (1S)-2-[5-(1H-Benzotriazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine Example 248A 4-Bromo-benzene-1,2-diamine
  • A mixture of 4-bromo-2-nitroaniline (1 g; 4.6 mmol) and SnCl[0638] 2.2H2O (6.2 g; 27.6 mmol) in MeOH (30 mL) with 5-6 drops of conc. HCl was heated at reflux for 5 hrs., concentrated, suspended in sat'd NaHCO3 (aq.) and extracted with EtOAc. The extracts were rinsed with brine, dried (MgSO4), and concentrated to provide the product of sufficient purity to carry on.
    • Example 248B 5-Bromo-1H-benzotriazole
  • A mixture of Example 248A (262 mg; 1.4 mmol) in 10% H[0639] 2SO4 (4 mL) was treated with NaNO2 (120 mg; 1.7 mmol) in water (1 mL), stirred for 30 min., diluted with water, and extracted with EtOAc. The extracts were rinsed with brine, dried (Na2SO4), concentrated and purified by flash chromatography (5% MeOH/CH2Cl2) to provide the desired product.
    • Example 248C 5-Bromo-benzotriazole-1-carboxylic Acid Tert-Butyl Ester
  • A solution of Example 248B (770 mg; 5 mmol) in THF (5 mL) was added to a solution of 20% phosgene in toluene (10 mL) at −20° C., stirred for 1 hr. at −20° C. then 2 hrs. at r.t., evaporated and dissolved in THF (4 mL). This solution was added to a solution of tBuOH (1 mL), and pyridine (426 mg; 5.4 mmol) in THF (3 mL) at −20° C. then stirred overnight at r.t. The solids were removed by filtration and rinsed with EtOAc. The filtrate was rinsed with water and brine, dried (MgSO[0640] 4), concentrated, and isolated by flash chromatography (1:1 Et2O:hexane) to provide the desired product (970 mg; 76%).
    • Example 248D (1S)-2-[5-(1H-Benzotriazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 248C for 6-bromophthalimide in Example 32. MS (ESI) m/e 385 (M+H)[0641] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.17 (d, J=7.12 Hz, 2H) 3.86 (m, 1H) 4.21 (dd, J=110.68, 6.27 Hz, 1H) 4.38 (dd, J=10.68, 2.88 Hz, 1H) 7.01 (t, J=6.95 Hz, 1H) 7.10 (t, J=7.12 Hz, 1H) 7.30 (d, J=2.37 Hz, 1H) 7.38 (d, J=8.14 Hz, 1H) 7.63 (d, J=7.80 Hz, 1H) 7.78 (m, 1H) 8.01 (m, 1H) 8.18 (m, 3H) 8.27 (m, 1H) 8.38 (d, J=2.71 Hz, 1H) 8.66 (d, J=1.36 Hz, 1H) 11.03 (s, 1H).
    • EXAMPLE 249 (1S)-2-[5-(1H-Benzotriazol-5-yl)-pyridin-3-yloxy]-1-benzyl-ethylamine Example 249A (1S)-[1-Benzyl-2-(5-bromo-pyridin-3-yloxy)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting L-Boc-phenylalaminol for L-Boc-tryptophanol in Example 2A. [0642]
    • Example 249B (1S)-[1-Benzyl-2-(5-trimethylstannanyl-pyridin-3-yloxy)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting Example 249A for Example 2A in Example 32A. [0643]
    • Example 249C 5-[5-((2S)-2-tert-Butoxycarbonylamino-3-phenyl-propoxy)-pyridin-3-yl]-benzotriazole-1-carboxylic Acid Tert-Butyl Ester
  • A solution of Example 249B (400 mg; 0.81 mmol) and Example 73C (255 mg; 0.85 mmol) in DMF (6 mL) was treated with Pd[0644] 2(dba)3 (111 mg; 0.12 mmol),tri-o-tolylphosphine (74 mg; 0.24 mmol), and triethylamine (102 mg; 1.0 mmol), heated at 110° C. for 4 hrs., partitioned between brine and EtOAc, filtered through Celite®, and extracted with EtOAc. The extracts were rinsed with brine, dried (MgSO4), concentrated, and purified by flash chromatography (80% EtOAc/CH2Cl2) to provide the desired product (110 mg; 25%).
    • Example 249D (1S)-2-[5-(1H-Benzotriazol-5-yl)-pyridin-3-yloxy-1-benzyl-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 249C for Example 27B in Example 27C. MS (ESI) m/e 346 (M+H)[0645] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.04(m, 2H) 3.86 (m, 1H) 4.14 (m, 1H) 4.30 (m, 1H) 7.32 (m, 5H) 7.78 (m, 2H) 8.02 (m, 1H) 8.22 (m, 3H) 8.38 (d, J=2.37 Hz, 1H) 8.66 (d, J=2.03 Hz, 1H); Anal. Calcd for C21H19N5O.2.6 TFA: C, 47.16; H, 3.39; N, 10.91;. Found: C, 46.90; H, 3.26; N, 11.01.
    • EXAMPLE 250 (1S)-1-Benzyl-2-[5-(3-morpholin-4-yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 111A for Example 249A in Example 249. MS (ESI) m/e 430 (M+H)[0646] +; 1H NMR (400 MHz, DMSO-D6) δ ppm 3.04 (m, 2H) 3.36 (m, 4H) 3.81 (m, 4H) 3.87 (m, 1H) 4.13 (dd, J=10.74, 5.83 Hz, 1H) 4.29 (dd, J=10.74, 2.76 Hz, 1H) 7.30 (m, 5H) 7.49 (d, J=8.90 Hz, 1H) 7.64 (d, J=8.59 Hz, 1H) 7.71 (s, 1H) 8.09 (s, 1H) 8.26 (bs, 2H) 8.32 (d, J=2.15 Hz, 1H) 8.64 (s, 1H) 12.20 (bs, 1H).
    • EXAMPLE 251 (1S)-1-Benzyl-2-{5-[3-(4-methyl-piperazin-1-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 114A for Example 249A in Example 249. MS (ESI) m/e 443 (M+H)[0647] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.53 (s, 3H) 2.90 (m, 4H) 3.04 (m, 2H) 3.17 (m, 2H) 3.53 (m, 2H) 3.84 (m, 1H) 4.10 (m, 1H) 4.27 (dd, J=11.02, 3.22 Hz, 1H) 7.32 (m, 5H) 7.52 (d, J=8.82 Hz, 1H) 7.66 (m, 2H) 8.15 (s, 1H) 8.24 (m, 2H) 8.32 (d, J=2.71 Hz, 1H) 8.66 (d, J=1.70 Hz, 1H) 12.36 (s, 1H); Anal. Calcd for C26H30N6O.3 TFA: C, 48.98; H, 4.21; N, 10.71;. Found: C, 48.60; H, 4.39; N, 11.05.
    • EXAMPLE 252 (1S)-{5-[5-(2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-dimethyl-amine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 115A for Example 249A in Example 249. MS (ESI) m/e 388 (M+H)[0648] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.03 (m, 8H) 3.83 (m, 1H) 4.13 (m, 1H) 4.29 (m, 1H) 7.34 (m, 5H) 7.46 (d, J=8.81 Hz, 1H) 7.63 (dd, J=8.65, 1.53 Hz, 1H) 7.75 (m, 1H) 8.08 (s, 1H) 8.21 (m, 2H) 8.33 (d, J=2.71 Hz, 1H) 8.64 (d, J=1.70 Hz, 1H) 12.01 (bs, 1H); Anal. Calcd for C23H25N5O.3 TFA: C, 47.74; H, 3.87; N, 9.60;. Found: C, 47.76; H, 3.76; N, 9.52.
    • EXAMPLE 253 (1S)-{5-[5-(2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-methoxy-ethyl)-amine Example 253A (5-Bromo-1H-indazol-3-yl)-(2-methoxy-ethyl)-amine
  • The reaction between Example 35A and O-methyl ethanolamine was carried out according to the procedure described by U. Wrzeciono, K. Majewska, J. Dudzinska-Usarewicz, M. Bemas, [0649] Pharmzie, 1986, 41, 472-474.
    • Example 253A (1S)-{5-[5-(2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-methoxy-ethyl)-amine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 253A for Example 249A in Example 249. MS (ESI) m/e 418 (M+H)[0650] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.04 (m, 2H) 3.30 (s, 3H) 3.46 (m, 2H) 3.57 (m, 2H) 3.83 (m, 1H) 4.11 (dd, J=10.68, 5.60 Hz, 1H) 4.28 (m, 1H) 7.34 (m, 5H) 7.64 (dd, J=10.68, 1.87 Hz, 3H) 8.21 (s, 3H) 8.30 (d, J=2.37 Hz, 1H) 8.58 (d, J=1.70 Hz, 1H) 11.67 bs, 1H); Anal. Calcd for C24H27N5,2-3 TFA: C, 46.34; H, 4.15; N, 9.01. Found: C, 46.54; H, 4.34; N, 8.79.
    • EXAMPLE 254 {5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-morpholin-4-yl-ethyl)-amine Example 254A (5-Bromo-1H-indazol-3-yl)-(2-morpholin-4-yl-ethyl)-amine
  • The reaction between Example 35A and 4-(2-aminoethyl)morpholine was carried out according to the procedure described by U. Wrzeciono, K. Majewska, J. Dudzinska-Usarewicz, M. Bernas, [0651] Pharmzie, 1986, 41, 472-474.
    • Example 254B {5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-morpholin-4-yl-ethyl)-amine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 254A for Example 249A in Example 249. MS (ESI) m/e 473 (M+H)[0652] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.50 (m, 8H) 3.04 (m, 2H) 3.43 (m, 2H) 3.68 (m, 2H) 3.87 (m, 1H) 4.10 (m, 1H) 4.28 (m, 1H) 7.36 (m, 7H) 7.65 (m, 2H) 8.07 (s, 1H) 8.21 (m, 2H) 8.31 (d, J=2.71 Hz, 1H) 8.55 (d, J=1.70 Hz, 1H) 11.83 (bs, 1H)
    • EXAMPLE 255 5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-ylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 249A for Example 2A in Example 97. MS (ESI) m/e 360 (M+H)[0653] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.04 (m, 2H) 3.85 (m, 1H) 4.11 (dd, J=10.68, 5.59 Hz, 1H) 4.28 (dd, J=110.68, 2.88 Hz, 1H) 7.35 (m, 6H) 7.65 (m, 2H) 8.14 (s, 1H) 8.21 (m, 4H) 8.31 (d, J=2.71 Hz, 1H) 8.56 (d, J=2.03 Hz, 1H) 11.87 (bs, 1H); Anal. Calcd for C21H21N5O.3.1 TFA: C, 45.83; H, 3.41; N, 9.82;. Found: C, 45.58; H, 3.34; N, 9.57.
    • EXAMPLE 256 N-{5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-2,2,2-trifluoro-acetamide Example 256A 5-Bromo-1H-indazol-3-ylamine
  • The desired product was prepared by substituting 5-bromo-2-fluorobenzonitrile for 5-bromo-2-fluorobenzaldehyde in Example 35A. [0654]
    • Example 256B N-(5-Bromo-1H-indazol-3-yl)-2,2,2-trifluoro-acetamide
  • A solution of 256A (2.5 g; 12 mmol) and trifluoroacetic anhydride (3.4 mL; 24 mmol) in pyridine (50 mL) was stirred at r.t. for 2 days, acidified with 10% HCl (aq), and extracted with EtOAc. The extracts were rinsed with water and brine, dried (MgSO[0655] 4), concentrated and purified by flash chromatography (1:1 EtOAc:hexane) to provide the desired product (3.0 g; 84%).
    • Example 256C N-{5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-2,2,2-trifluoro-acetamide
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 256B for Example 249A in Example 249. MS (ESI) m/e 454 (M−H)[0656] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.04 (m, 2H) 3.84 (m, 1H) 4.11 (dd, J=10.85, 5.76 Hz, 1H) 4.28 (dd, J=10.68, 2.88 Hz, 1H) 7.35 (m, 6H) 7.68 (m, 2H) 8.16 (s, 1H) 8.22 (m, 3H) 8.32 (d, J=2.71 Hz, 1H) 8.57 (d, J=1.70 Hz, 1H) 11.87 (bs, 1H).
    • EXAMPLE 257 (2S)-2-Amino-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-3-phenyl-propionamide Example 257A 5-(5-Amino-pyridin-3-yl)-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting Example 203B for Example 27A and Example 23B for Example 2A in Example 27B. [0657]
    • Example 257B 5-15-((2S)-2-tert-Butoxycarbonylamino-3-phenyl-propionylamino)-pyridin-3-yl]-3-methylindazole-1-carboxylic acid tert-butyl Ester
  • The desired product was prepared by substituting Example 257A for Example 25E and L-Boc-phenylalanine for Boc-tryptophane in Example 25G. [0658]
    • Example 257C (2S)-2-Amino-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-3-phenyl-propionamide
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 257B for Example 27B in Example 27C. MS (ESI) m/e 372 (M+H)[0659] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.55 (s, 3H) 3.19 (m, 2H) 4.23 (m, 1H) 7.32 (m, 6H) 7.62 (s, 1H) 8.01 (s, 1H) 8.19 m, 1H) 8.36 (s, 2H) 8.68 (d, J=2.03 Hz, 1H) 8.74 (d, J=2.03 Hz, 1H) 10.70 (s, 1H) 12.85 (bs, 1H); Anal. Calcd for C22H21N5O.2.6 TFA: C, 48.91; H, 3.56; N, 10.49;. Found: C, 48.96; H, 3.71; N, 10.64.
    • EXAMPLE 258 (1S)-2-[5-(3-Benzyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting benzyl magnesium chloride for methyl magnesium bromide in Example 102. MS (ESI) m/e 474 (M+H)[0660] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.17 (m, 2H) 3.86 (m, 1H) 4.17 (dd, J=10.68, 5.93 Hz, 1H) 4.35 (s, 2H) 4.42 (dd, J=110.68, 5.93 Hz, 1H) 7.02 (t, J=7.12 Hz, 1H) 7.08 (m, 1H) 7.29 (m, 7H) 7.61 (m, 4H) 7.98 (s, 1H) 8.15 (m, 3H) 8.32 (d, J=2.71 Hz, 1H) 8.55 (d, J=1.70 Hz, 1H) 11.03 (s, 1H); Anal. Calcd for C30H27N5O.3.9 TFA: C, 49.44; H, 3.39; N, 7.63;. Found: C, 49.07; H, 3.75; N, 7.42.
    • EXAMPLE 259 (1S)-1-Benzyl-2-[5-(3-benzyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting 249B for Example 2A in Example 258. MS (ESI) m/e 435 (M+H)[0661] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.03 (m, 2H) 3.86 (m, 1H) 4.11 (dd, J=10.85, 5.76 Hz, 1H) 4.28 (dd, J=10.68, 2.88 Hz, 1H) 5.72 (s, 2H) 7.30 (m, 8H) 7.72 (m, 3H) 7.84 (m, 1H) 8.13 (s, 1H) 8.21 (m, 3H) 8.33 (d, J=2.71 Hz, 1H) 8.60 (d, J=1.70 Hz, 1H)
    • EXAMPLE 260 (1S)-2-[5-(3-Benzyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-methyl-ethylamine Example 260A (1S)-[2-(5-Bromo-pyridin-3-yloxy)-1-methyl-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting Boc-alaminol for Boc-tryprophanol in Example 2A. [0662]
    • Example 260B (1S)-[1-Methyl-2-(5-trimethylstannanyl-pyridin-3-yloxy)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desire product was prepared by substituting Example 260A for Example 249A in Example 249B. [0663]
    • Example 260C (1S)-2-[5-(3-Benzyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-methyl-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting 260B for Example 32A in Example 258. MS (ESI) m/e 359 (M+H)[0664] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 1.31 (m, 3H) 4.10 (m, 1H) 4.30 (m, 1H) 4.35 (s, 2H) 4.41 (m, 1H) 7.17 (m, 1H) 7.29 (m, 2H) 7.36 (m, 2H) 7.61 (s, 2H) 7.69 (s, 2H) 8.02 (bs, 2H) 8.33 (d, J=2.37 Hz, 1H) 8.56 (s, 1H) 12.71 (bs, 1H); Anal. Calcd for C22H22N4O.3.2 TFA: C, 47.16; H, 3.51; N, 7.75;. Found: C, 47.27; H, 3.60; N, 7.60.
    • EXAMPLE 261 (6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl)-phenyl-amine Example 261A (6-Bromo-cinnolin-4-yl)-phenyl-amine
  • A solution of Example 34D (500 mg; 2.5 mmol) and aniline (1.5 mL) in MeOH (11 mL) was stirred at r.t. for 2.5 hrs, the resulting precipitate was collected, rinsed with water and dried under vacuum to provide the desired product (400 mg; 62%). [0665]
    • Example 261B (6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl)-phenyl-amine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 261A for Example 27A in Example 27. MS (ESI) m/e 487 (M+H)[0666] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.18 (m, 2H) 3.86 (m, 1H) 4.25 (dd, J=10.61, 5.93 Hz, 1H) 4.39 (m, 1H) 6.99 (t, J=7.49 Hz, 1H) 7.09 (t, J=7.02 Hz, 1H) 7.31 (d, J=2.50 Hz, 1H) 7.38 (d, J=8.11 Hz, 1H) 7.45 (t, J=7.33 Hz, 1H) 7.60 (m, 6H) 7.90 (m, 1H) 8.19 (d, J=9.05 Hz, 1H) 8.35 (bs, 2H) 8.44 (m, 2H) 8.64 (s, 1H) 8.81 (d, J=1.56 Hz, 1H) 9.08 (s, 1H) 11.04 (d, J=1.87 Hz, 1H).
    • EXAMPLE 262 (1S)-2-[5-(1H-Indazol-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting 4-bromo-2-fluorobenzaldehyde for 5-bromo-2-fluorobenzaldehyde in Example 35. MS (ESI) m/e 384 (M+H)[0667] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.97 (m, 2H) 3.60 (m, 1H) 4.13 (m, 2H) 6.99 (m, 2H) 7.24 (m, 1H) 7.38 (m, 2H) 7.61 (m, 3H) 7.84 (m, 3H) 8.11 (m, 1H) 8.31 (m, 1H) 8.55 (m, 1H) 11.03 (m, 1H) 12.98 (m, 1H)
    • EXAMPLE 263 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2,3-dihydro-isoindol-1-one Example 263A 4-Bromo-2-methyl-benzoic Acid Methyl Ester
  • A solution of 4-bromo-2-methyl benzoic acid (1.0 g; 4.7 mmol) in MeOH (24 mL) with 20 drops conc. HCl was heated at reflux for 6 hrs. the concentrated to provide the desired product (1.1 g; 100%). [0668]
    • Example 263B 4-Bromo-2-bromomethyl-benzoic acid methyl Ester
  • A solution of Example 263A (1.02 g; 4.5 mmol) in CCl[0669] 4 (22 mL) was treated with AIBN (65 mg; 0.4 mmol), heated at reflux for 4 hrs., washed with water, dried (Na2SO4) and concentrated to provide the desired product (1.1 g; 79%).
    • Example 263C 5-Bromo-2,3-dihydro-isoindol-1-one Example 263D 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2,3-dihydro-isoindol-1-one
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 263C for 5-bromooxindole in Example 36. MS (ESI) m/e 399 (M+H)[0670] +; 1H NMR (d6-DMSO, 300 MHz) δ: 11.03 (bs, 1H), 8.63 (s, 1H), 8.57 (s, 1H), 8.35 (bs, 3H), 7.90 (s, 1H), 7.78 (s, 2H), 7.67 (s, 1H), 7.61 (d, J=8 Hz, 1H), 7.37 (d, J=8 Hz, 1H), 7.79 (d, J=2 Hz, 1H), 7.03-7.10 (m, 1H), 6.96-7.01 (m, 1H), 4.32-4.36 (m, 1H), 4.17-4.22 (m, 1H), 3.80-3.83 (m, 1H), 3.18 (d, J=8 Hz, 2H), 2.50 (s, 2H).
    • EXAMPLE 264 6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-cinnolin-4-one
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 34A for 6-bromophthalimide in Example 32. MS (ESI) m/e 412 (M+H)[0671] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.19 (d, J=7.18 Hz, 2H) 3.84 (m, 1H) 4.24 (dd, J=10.61, 5.93 Hz, 1H) 4.39 (dd, J=10.61, 3.12 Hz, 1H) 7.01 (t, J=7.02 Hz, 1H) 7.10 (t, J=7.18 Hz, 1H) 7.31 (d, J=2.50 Hz, 1H) 7.38 (d, J=8.11 Hz, 1H) 7.64 (d, J=7.80 Hz, 1H) 7.76 (d, J=8.73 Hz, 1H) 7.80 (m, 2H) 7.96 (s, 1H) 8.17 (dd, J=8.73, 2.18 Hz, 1H) 8.32 (d, J=2.18 Hz, 2H) 8.40 (d, J=2.81 Hz, 1H) 8.65 (d, J=1.87 Hz, 1H) 11.05 (d, J=1.56 Hz, 1H) 13.72 (bs, 1H); Anal. Calcd for C24H21N5O2.3 TFA: C, 47.82; H, 3.21; N, 9.29. Found: C, 47.88; H, 3.41; N, 9.35.
    • EXAMPLE 265 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-cinnolin-6-yl)-pyridin-3-yloxy]-ethylamine Example 265A 1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-cinnolin-6-yl)-pyridin-3-yloxy]-ethylamine
  • A solution of Example 34C (200 mg; 0.8 mmol) in THF (10 mL) was treated with 3.0 M phenylmagnesium bromide in Et[0672] 2O (1.6 mL; 4.8 mmol), stirred at r.t. for 4 hrs., sat;d NH4Cl (aq) was added, and extracted with EtOAc. The extracts were rinsed with brine, dried (MgSO4), concentrated and purified by flash chromatography (30% EtOAc/hexane) to provide the desired product (67 mg; 29%).
    • Example 265B (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-cinnolin-6-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 265A for 6-bromophthalimide in Example 32. MS (ESI) m/e 472 (M+H)[0673] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.15 (d, J=7.18 Hz, 2H) 3.84 (m, 1H) 4.17 (dd, J=10.61, 5.93 Hz, 1H) 4.33 (dd, J=10.61, 3.12 Hz, 1H) 6.98 (t, J=7.49 Hz, 1H) 7.08 (t, J=7.49 Hz, 1H) 7.28 (d, J=2.18 Hz, 1H) 7.37 (d, J=8.11 Hz, 1H) 7.64 (m, 5H) 7.70 (d, J=1.87 Hz, 1H) 7.78 (d, J=6.55 Hz, 2H) 8.16 (bs, 2H) 8.30 (dd, J=8.89, 1.72 Hz, 1H) 8.42 (d, J=2.50 Hz, 1H) 8.61 (d, J=1.56 Hz, 1H) 8.69 (d, J=9.05 Hz, 1H) 9.41 (s, 1H) 11.01 (s, 1H); Anal. Calcd for C30H25N5O.1.9 TFA: C, 58.99; H, 3.94; N, 10.18; Found: C, 58.87; H, 3.85; N, 10.08.
    • EXAMPLE 266 (6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl)-benzyl-amine Example 266A Benzyl-(6-bromo-cinnolin-4-yl)-amine
  • A solution of 34D (100 mg; 0.41 mmol) and benzylamine (0.5 mL) in MeOH (3 mL) was stirred at r.t. for 24 hrs., concentrated, suspended in Et[0674] 2O, and the precipitate was collected to provide the desired product (100 mg; 78%).
    • Example 266B (6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl-cinnolin-4-yl)-benzyl-amine
  • The desired product was prepared as the trifluoroacetate salt by substituting Example 266A for 6-bromophthalimide in Example 32. MS (ESI) m/e 501 (M+H)[0675] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.18 (d, J=7.18 Hz, 2H) 3.87 (m, 1H)-4.23 (dd, J=10.61, 5.62 Hz, 1H) 4.38 (dd, J=10.45, 2.96 Hz, 1H) 5.00 (d, J=5.62 Hz, 2H) 7.00 (t, J=7.49 Hz, 1H) 7.09 (t, J=7.18 Hz, 1H) 7.30 (d, J=2.50 Hz, 1H) 7.37 (m, 4H) 7.50 (d, J=7.49 Hz, 2H) 7.62 (d, J=8.11 Hz, 1H) 7.83 (d, J=2.18 Hz, 1H) 8.10 (d, J=9.05 Hz, 1H) 8.29 (bs, 2H) 8.40 (dd, J=8.89, 1.40 Hz, 1H) 8.45 (d, J=2.50 Hz, 1H) 8.78 (d, J=1.56 Hz, 1H) 8.80 (s, 1H) 8.98 (s, 1H) 10.35 (bs, 1H) 11.03 (s, 1H); Anal. Calcd for C31H28N6O.3.1 TFA: C, 52.31; H, 3.67; 30 N, 9.84;. Found: C, 52.36; H, 3.47; N, 9.67.
    • EXAMPLE 267 (6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl)-methyl-amine
  • The desired product was prepared as the trifluoroacetate salt by substituting methylamine for benzylamine in Example 266. MS (ESI) m/e 425 (M+H)[0676] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.50 (d, J=1.87 Hz, 3H) 3.19 (m, 2H) 3.85 (m, 1H) 4.26 (dd, J=10.92, 5.93 Hz, 1H) 4.40 (dd, J=10.61, 3.12 Hz, 1H) 6.99 (t, J=7.49 Hz, 1H) 7.09 (t, J=7.33 Hz, 1H) 7.32 (d, J=1.87 Hz, 1H) 7.37 (d, J=8.11 Hz, 1H) 7.63 (d, J=8.11 Hz, 1H) 7.87 (s, 1H) 8.10 (d, J=9.05 Hz, 1H) 8.37 (m, 3H) 8.43 (d, J=2.81 Hz, 1H) 8.72 (s, 1H) 8.76 (d, J=1.56 Hz, 1H) 8.93 (s, 1H) 10.00 (bs, 1H) 11.04 (d, J=1.25 Hz, 1H)
    • EXAMPLE 268 6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-ylamine
  • The desired product was prepared as the trifluoroacetate salt by substituting ammonia for benzylamine in Example 266. MS (ESI) m/e 411 (M+H)[0677] +; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.18 m, 2H) 3.86 (m, 1H) 4.27 (m, 1H) 4.41 (m, 1H) 6.99 (m, 1H) 7.08 (m, 1H) 7.36 (m, 2H) 7.64 (d, J=6.55 Hz, 1H) 7.89 (s, 1H) 8.10 (d, J=8.42 Hz, 1H) 8.46 (m, 4H) 8.59 (s, 1H) 8.76 (s, 1H) 9.00 (s, 1H) 10.06 (s, 2H) 11.08 (s, 1H)
    • EXAMPLE 269 [(3S)-3-(5-Isoquinolin-6-yl-pyridin-3-yloxymethyl)-1,2,3,4-tetrahydro-b-carbolin-9-yl]-methanol
  • A solution of Example 27 (100 mg; 0.19 mmol) and 37% formaldehyde (aq) (18 μL) in water (1 mL) with 2 drops conc. H[0678] 2SO4 was heated at reflux for 3 hrs., evaporated and purified by reverse phase HPLC on a C18 column with 0-100% CH3CN/H2O/0.1% TFA to provide the desired product as the trifluoroacetate salt. MS (ESI) m/e 412 (M+H)+; 1H NMR (400 MHz, DMSO-D6) δ ppm 3.04 (m, 1H) 3.20 (m, 3H) 4.19 (bs, 1H) 4.53 (m, 6.75 Hz, 1H) 4.64 (m, 1H) 4.70 (m, 1H) 5.52 (m, 2H) 7.12 ((t, J=7.67 Hz, 1H) 7.22 (t, J=7.67 Hz, 1H) 7.52 (d, J=7.98 Hz, 1H) 7.58 (d, J=8.29 Hz, 1H) 8.05 (s, 1H) 8.26 (d, J=6.44 Hz, 1H) 8.33 (d, J=8.59 Hz, 1H) 8.53 (m, 2H) 8.63 (s, 1H) 8.68 (d, J=5.83 Hz, 1H) 8.83 (s, 1H) 9.71 (s, 1H) 9.94 (bs, 1H)
    • EXAMPLE 270 3-(5-Isoquinolin-6-yl-pyridin-3-yloxymethyl)-2,3,4,9-tetrahydro-1H-β-carboline
  • A solution of Example 27 (100 mg; 0.19 mmol) and 37% formaldehyde (aq) (17 μL) in water (1 mL) with conc. H[0679] 2SO4 (6 μL) was stirred overnight at r.t., neutralized with NH3/MeOH, concentrated and purified by flash chromatography (10% MeOH/CH2Cl2) to provide the desired product. MS (ESI) m/e 407 (M+H)+; 1H NMR (500 MHz, DMSO-D6) δ ppm 2.58 (dd, J=14.66, 9.98 Hz, 1H) 2.85 (dd, J=14.97, 3.74 Hz, 1H) 3.38 (m, 2H) 4.02 (d, J=4.99 Hz, 1H) 4.33 (m, 2H) 6.95 (t, J=7.02 Hz, 1H) 7.02 (t, J=7.49 Hz, 1H) 7.29 (d, J=8.11 Hz, 1 H) 7.39 (d, J=8.11 Hz, 1H) 7.91 (m, 2H) 8.12 (dd, J=8.42, 1.56 Hz, 1H) 8.25 (d, J=8.42 Hz, 1H) 8.41 (s, 1H) 8.45 (t, J=2.65 Hz, 1H) 8.56 (d, J=5.62 Hz, 1H) 8.69 (d, J=1.56 Hz, 1H) 9.37 (s, 1H) 10.72 (s, 1H).
    • EXAMPLE 271 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazole-3-carboxylic Acid Example 271A 1H-Indazole-3-carboxylic Acid Methyl Ester
  • A solution of 3-carboxyindazole (2.0 g; 12.3 mmol) and conc.HCl (2 mL) in MeOH (50 mL) was heated at reflux overnight, concentrated, diluted with 2N NaOH (aq), and extracted with EtOAc. The extracts were rinsed with brine, dried (MgSO[0680] 4), and concentrated to provide the desired product.
    • Example 271B 5-Iodo-1H-indazole-3-carboxylic Acid Methyl Ester
  • A solution of Example 271A (300 mg; 1.7 mmol), bis(trifluoroacetoxy)iodobenzene (800 mg; 1.9 mmol), and iodine (253 mg; 1.0 mmol) in CH[0681] 2Cl2 (10 mL) was stirred overnight at r.t., and treated with sodium bisulfite (aq). The precipitate was collected, rinsed with water and hexane, and dried under vacuum to provide the desired product (180 mg; 36%).
    • Example 271C 5-{5-[(2S)-2-tert-Butoxycarbonylamino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazole-3-carboxylic Acid Methyl Ester
  • The desired product was prepared by substituting Example 271B for 6-bromophthalimide in Example 32B. [0682]
    • Example 271D 5-5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazole-3-carboxylic Acid Methyl Ester
  • The desired product was prepared by substituting Example 271C for Example 27B in Example 27C. [0683]
    • Example 271E 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazole-3-carboxylic Acid
  • A solution of Example 271D (150 mg; 0.34 mmol) and 1N NaOH (5 mL) in MeOH (1 mL) was heated at reflux for 6 hrs., concentrated, and purified by reverse phase HPLC on a C18 column with 0-100% CH[0684] 3CN/H2O/0.1% TFA to provide the desired product as the trifluoroacetate salt. MS (ESI) m/e 428 (M+H)+; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.18 (d, J=7.49 Hz, 2H) 3.86 (m, 1H) 4.21 (dd, J=10.29, 5.93 Hz, 1H) 4.37 (dd, J=10.29, 2.50 Hz, 1H) 7.01 (t, J=7.33 Hz, 1H) 7.10 (t, J=7.33 Hz, 1H) 7.30 (d, J=1.87 Hz, 1H) 7.38 (d, J=8.11 Hz, 1H) 7.63 (d, J=7.80 Hz, 1H) 7.71 (s, 1H) 7.77 (m, 2H) 8.26 (s, 3H) 8.32 (s, 1H) 8.37 (s, 1H) 8.59 (s, 1H) 11.03 (s, 1H) 13.64 (m, 1H).
    • EXAMPLE 272 5-[5-((2S)-2-tert-Butoxycarbonylamino-3-hydroxy-propoxy)-pyridin-3-yl]-3-methylindazole-1-carboxylic Acid Tert-Butyl Ester
  • Example 203 (719 mg, 1.22 mmol) was dissolved in 30 mL EtOAc in a 100 mL round bottom flask with a stirbar. A combination vacuum/Ar/H[0685] 2 manifold was attached and the flask evacuated and filled with Ar twice. Pd/C (800 mg, 10 wt. % (dry basis)) was added and the flask evacuated and filled with H2 twice. The resultant black mixture was stirred vigorously and warmed to 50° C. for 20 h at which time TLC indicated ˜70% consumption of starting material. Another 480 mg of the Pd/C was added and a fresh H2 balloon attached. The reaction was stirred another 26 h at 50° C. at which time it was cooled to room temperature and the flask evacuated and filled with Ar. The cooled reaction mixture was filtered through Celite and the filter cake washed with EtOAc. The filtrate was subjected to rotary evaporation and then dried with house vacuum to yield the desired product (540 mg, 89%) as a colorless foam/solid. Rf=0.26 (EtOAc); MS m/z 499 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 1.39 (s, 9H) 1.66 (s, 9H) 2.60 (s, 3H) 3.50 (m, 2H) 3.82 (m, 1H) 4.17 (m, 2H) 4.83 (t, J=5.59 Hz, 1H) 6.82 (d, J=8.14 Hz, 1H) 7.79 (s, 1H) 8.02 (dd, J=8.65, 1.53 Hz, 1H) 8.12 (m, 1H) 8.27 (d, J=1.02 Hz, 1H) 8.29 (d, J=2.71 Hz, 1H) 8.61 (d, J=2.03 Hz, 1H).
    • EXAMPLE 273 5-[5-((2S)-Aziridin-2-ylmethoxy)-pyridin-3-yl]-3-methyl-1H-indazole Example 273A (1R)-[2-(5-Bromo-pyridin-3-yloxy)-1-(tert-butyl-dimethyl-silanyloxymethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • A 100 mL RBF was charged with 3-bromo-5-hydroxypyridine (1.20 g, 6.87 mmol), (R)-[1-(tert-butyl-dimethyl-silanyloxymethyl)-2-hydroxy-ethyl]-carbamic acid tert-butyl ester (2.1 g, 6.87 mmol) and Ph[0686] 3P (2.34 g, 8.93 mmol), and was purged with nitrogen. THF (30 mL) was added at 0° C. After stirring at 0° C. for 10 min, DEAD (1.41 mL, 8.93 mmol) was added via syringe. The reaction mixture was stirred at 0° C. for 0.5 h and at rt for 2 h. The reaction mixture was concentrated and the residue was separated by flash chromatography (5-25% EtOAc in hexane) to provide the desired product (3.14 g, 99%). MS (DCI) m/z 461, 463 (M+1)+.
    • Example 273B (1S)-12-(5-Bromo-pyridin-3-yloxy)-1-hydroxymethyl-ethyl]-carbamic Acid Tert-Butyl Ester
  • To a solution of Example 273A (3.14 g, 6.8 mmol) in THF (40 mL) was added TBAF (7.14 mL, 7.14 mmol) at rt. The solution was stirred at rt for 1 h and was concentrated. The residual oil was purified by flash chromatography (40-80% EtOAc in hexane) to give the desired product (2.19 g, 93%). MS (DCI) m/z 347, 349 (M+1)[0687] +.
    • Example 273C (2S)-2-(5-Bromo-pyridin-3-yloxymethyl)-aziridine-1-carboxylic Acid Tert-Butyl Ester
  • Ph[0688] 3P (1.13 g, 4.32 mmol) was dissolved in 9:1 THF/CH3CN (30 mL) and cooled to 4° C. with an ice/water bath. DIAD (850 μL, 4.32 mmol) was added slowly. After stirring 15 min, a solution of Example 273B (1.0 g, 2.88 mmol) in THF (4 mL) was added slowly. The solution was allowed to warm to rt and stirred for over night. The solution was concentrated and the residual oil was purified by flash chromatography (20-40% EtOAc in hexane) to give the desired product (1.0 g, 75%). MS (DCI) m/z 329, 331 (M+1)+.
    • Example 273D 5-[5-((2S)-1-tert-Butoxycarbonyl-aziridin-2-ylmethoxy)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • Method 1. A 100 mL RBF was charged with Example 273C (950 mg, 2.88 mmol), Example 203B (1.14 g, 2.88 mmol), Pd[0689] 2(dba)3 (263 mg, 0.288 mmol), and tri-o-tolylphosphine (263 mg), and was purged with N2. Anhydrous DMF (35 mL) and Et3N (1.2 mL) were added via syringe. The solution was purged with N2 again and was heated at 72° C. for 4 h. After cooled, ethyl acetate (150 mL) was added. The mixture was washed with brine (200 mL) and water (200 mL). The ethyl acetate solution was concentrated and the residual oil was separated by flash chromatography (50-80% EtOAc in hexane) to give the desired product (634 mg, 65%). MS (APCI) m/z 481 (M+1)+.
  • Method 2. To a stirred solution of PPh[0690] 3 (2.16 g, 8.24 mmol) in THF (130 mL) and CH3CN (20 mL) at 0° C. was added DIAD (1.62 mL, 8.24 mmol) slowly via syringe. After 20 min the resulting light yellow solution was canulated onto Example 272 (2.74 g, 5.50 mmol) in THF (150 mL). The reaction mixture was stirred 6 h at 23° C. and then silica gel was added and the volatiles removed on a rotary evaporator. Flash chromatography (50-60-70-80% EtOAc/hexanes) gave 3.72 g of a white solid which was a 1.33:1 mixture of triphenylphosphine oxide:aziridine. Rf=0.50 (EtOAc). This was used without further purification.
    • Example 273E 5-[5-((2S)-Aziridin-2-ylmethoxy)-pyridin-3-yl]-3-methyl-1H-indazole
  • The desired product was prepared as the trifluoroacetate by substituting Example 273D for Example 27B in Examples 27C. MS (APCI) m/z 281 (M+1)[0691] +; 1H NMR (300 MHz, CD3OD) δ 2.63 (s, 3H), 3.31 (dd, J=3.30, 1.83 Hz, 2H), 3.62 (dd, J=6.23, 1.83 Hz, 2H), 3.89 (m, 1H), 4.60 (m, 2H), 7.64 (d, J=8.79 Hz, 1H), 7.77 (d, J=8.79 Hz, 1H), 8.15 (s, 1H), 8.22 (s, 1H).
    • EXAMPLE 274 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3-trifluoromethoxy-benzyl)-ethylamine Example 274A 5-{5-[(2S)-2-tert-Butoxycarbonylamino-3-(3-trifluoromethoxy-phenyl)-propoxy]-pyridin-3-yl}-3-methyl-indazole-1-carboxylic acid tert-butyl Ester
  • To a suspension of CuBr—SMe[0692] 2(25 mg, 0.12 mmol) and Example 273D (100 mg, 0.21 mmol) in THF (6 mL) was added 3-trifluoromethoxyphenylmagnesium bromide (0.5 M solution in THF, 1.6 mL, 0.8 mmol) at approximately −35° C. The formed clear solution was allowed to warm up to −20° C. within 40 min and was partitioned between ether and water. The organic layer was concentrated and the residue was separated by flash chromatography (40-65% EtOAc in hexane) to give the desired product (88 mg, 66%). MS (APCI) m/z 643 (M+1)+.
    • Example 274B (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3-trifluoromethoxy-benzyl)-ethylamine
  • The desired product was prepared as the trifluoroacetate by substituting Example 274A for Example 27B in Examples 27C. MS (APCI) m/z 444 (M+1)[0693] +; 1H NMR (300 MHz, CD3OD) δ 2.62 (s, 3H), 3.22 (dd, J=7.29, 5.26 Hz, 2H), 4.00 (m, 1H), 4.26 (dd, J=10.51, 5.09 Hz, 1H), 4.43 (dd, J=10.85, 3.05 Hz, 1H), 7.25 (d, J=8.48 Hz, 1H), 7.30 (s, 1H), 7.36 (d, J=7.46 Hz, 1H), 7.49 (t, J=7.97 Hz, 1H), 7.62 (d, J=8.48 Hz, 1H), 7.72 (dd, J=8.82, 1.70 Hz, 1H), 8.00 (s, 1H), 8.08 (s, 1H), 8.40 (d, J=2.03 Hz, 1H), 8.68 (s, 1H). Anal. Calcd for C23H21F3N4O2▪2.6 TFA: C, 45.84; H, 3.22; N, 7.58. Found: C, 45.87; H, 3.17; N, 7.28.
  • The following compounds were prepared by substituting the appropriate Grignard reagents for 3-trifluoromethoxyphenylmagnesium bromide in Example 274. [0694]
    • EXAMPLE 275 (1S)-1-(3,5-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 427 (M+1)[0695] +; 1H NMR (300 MHz, CD3OD) δ 2.63 (s, 3H), 3.18 (dd, J=7.32, 3.30 Hz, 2H), 4.02 (m, 1H), 4.32 (dd, J=10.44, 5.31 Hz, 1H), 4.47 (dd, J=10.62, 2.93 Hz, 1H), 7.37 (s, 1H), 7.39 (d, J=8.06 Hz, 1H), 7.63 (d, J=8.79 Hz, 1H), 7.74 (d, J=8.06 Hz, 1H), 8.10 (s, 3H), 8.44 (s, 1H), 8.73 (s, 1H); Anal. Calcd for C22H20Cl2N4O▪3.2 TFA: C, 43.38; H, 2.98; N, 7.18. Found: C, 43.49; H, 3.18; N, 6.92.
    • EXAMPLE 276 (1S)-1-(2,3-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 427 (M+1)[0696] +; 1H NMR (300 MHz, CD3OD) δ 2.63 (s, 3H), 3.40 (dd, J=7.32, 5.13 Hz, 2H), 4.10 (m, 1H), 4.33 (dd, J=10.62, 4.76 Hz, 1H), 4.47 (dd, J=10.99, 2.93 Hz, 1H), 7.30 (t, J=7.69 Hz, 1H), 7.39 (d, J=7.32 Hz, 1H), 7.52 (d, J=7.69 Hz, 1H), 7.63 (d, J=8.79 Hz, 1H), 7.74 (d, J=8.79 Hz, 1H), 8.11 (s, 2H), 8.45 (s, 1H), 8.75 (s, 1H); Anal. Calcd for C22H20Cl2N4O▪3.5TFA: C, 42.15; H, 2.87; N, 6.78. Found: C, 41.86; H, 3.05; N, 6.60.
    • EXAMPLE 277 (1S)-1-Biphenyl-3-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 435 (M+1)[0697] +; 1H NMR (300 MHz, CD3OD) δ 2.61 (s, 3H), 3.25 (d, J=7.69 Hz, 2H), 4.05 (m, 1H), 4.33 (dd, J=10.62, 5.13 Hz, 1H), 4.46 (d, J=10.25 Hz, 1H), 7.36 (m, 4H), 7.46 (t, J=7.14 Hz, 1H), 7.57 (m, 6H), 8.06 (s, 2H), 8.42 (s, 1H), 8.69 (s, 1H); Anal. Calcd for C28H26N4O▪3.2 TFA: C, 51.68; H, 3.68; N, 7.01. Found: C, 51.94; H, 3.66; N, 6.85.
    • EXAMPLE 278 (1S)-1-(3-Chloro-4-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 411 (M+1)[0698] +; 1H NMR (300 MHz, CD3OD) δ 2.62 (s, 3H) 3.15 (t, J=7.12 Hz, 2H) 3.98 (m, 1H) 4.28 (dd, J=10.51, 5.42 Hz, 1H) 4.44 (dd, J=10.51, 3.05 Hz, 1H) 7.23 (d, J=8.48 Hz, 1H) 7.30 (m, 1H) 7.51 (dd, J=7.12, 2.03 Hz, 1H) 7.62 (d, J=8.81 Hz, 1H) 7.72 (dd, J=8.48, 1.36 Hz, 1H) 7.99 (s, 1H) 8.08 (s, 1H) 8.39 (s, 1H) 8.68 (s, 1H); Anal. Calcd for C22H20ClFN4O▪2.7 TFA: C, 45.79; H, 3.18; N, 7.80. Found: C, 45.86; H, 3.44; N, 7.66.
    • EXAMPLE 279 (1S)-1-(4-Chloro-3-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 411 (M+1)[0699] +; 1H NMR (300 MHz, CD3OD) δ 2.63 (s, 3H), 3.17 (t, J=6.95 Hz, 2H), 4.00 (m, 1H), 4.28 (dd, J=10.51, 5.43 Hz, 1H), 4.44 (dd, J=10.51, 3.05 Hz, 1H), 7.17 (dd, J=8.14, 1.70 Hz, 1H), 7.29 (dd, J=10.00, 1.87 Hz, 1H), 7.49 (t, J=7.97 Hz, 1H), 7.62 (d, J=8.82 Hz, 1H), 7.73 (d, J=7.12 Hz, 1H), 8.01 (m, 1H), 8.09 (s, 1H), 8.40 (d, J=2.37 Hz, 1H), 8.68 (d, J=1.70 Hz, 1H); Anal. Calcd for C22H20ClFN4O▪2.7 TFA: C, 45.79; H, 3.18; N, 7.80. Found: C, 45.86; H, 3.44; N, 7.66.
    • EXAMPLE 280 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-trifluoromethoxy-benzyl)-ethylamine
  • MS (APCI) m/z 443 (M+1)[0700] +; 1H NMR (300 MHz, CD3OD) δ 2.62 (s, 3H) 3.20 (t, J=6.95 Hz, 2H) 3.98 (m, 1H) 4.28 (dd, J=10.51, 5.42 Hz, 1H) 4.43 (dd, J=10.51, 2.71 Hz, 1H) 7.30 (d, J=7.80 Hz, 2H) 7.45 (d, J=8.48 Hz, 2H) 7.62 (d, J=8.48 Hz, 1H) 7.73 (d, J=8.81 Hz, 1H) 8.00 (s, 1H) 8.08 (s, 1H) 8.40 (s, 1H) 8.68 (s, 1H). Anal. Calcd for C23H21F3N4O2▪2.4 TFA: C, 46.63; H, 3.29; N, 7.82. Found: C, 46.57; H, 3.30; N, 7.80.
    • EXAMPLE 281 (1S)-1-(2-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 445 (M+1)[0701] +; 1H NMR (300 MHz, CD3OD) δ 2.62 (s, 3H), 3.31 (m, 2H), 4.04 (m, 1H), 4.29 (dd, J=10.85, 5.09 Hz, 1H), 4.45 (dd, J=10.85, 3.39 Hz, 1H), 7.54 (d, J=8.81 Hz, 1H), 7.55 (s, 1H), 7.60 (dd, J=4.07, 3.39 Hz, 1H), 7.63 (s, 1H), 7.72 (dd, J=8.81, 1.70 Hz, 1H), 7.96 (s, 1H), 8.07 (s, 1H), 8.39 (s, 1H), 8.67 (s, 1H).
    • EXAMPLE 282 (1S)-1-(3-Fluoro-5-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 445 (M+1)[0702] +; 1H NMR (300 MHz, CD3OD) δ 2.62 (s, 3H), 3.30 (m, 2H), 4.06 (m, 1H), 4.29 (dd, J=10.51, 5.09 Hz, 1H), 4.45 (dd, J=10.85, 3.05 Hz, 1H), 7.45 (dd, J=7.80, 5.76 Hz, 2H), 7.55 (s, 1H), 7.62 (d, J=8.81 Hz, 1H), 7.73 (d, J=8.48 Hz, 1H), 7.98 (s, 1H), 8.07 (s, 1H), 8.42 (br s, 1H), 8.73 (br s, 1H).
    • EXAMPLE 283 (1S)-1-(2-Methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-,3-yloxy]-ethylamine
  • MS (APCI) m/z 389 (M+1)[0703] +; 1H NMR (300 MHz, CD3OD) δ 2.62 (s, 3H), 3.16 (d, J=7.46 Hz, 2H), 3.85 (s, 3H), 3.99 (m, 1H), 4.23 (dd, J=10.51, 5.76 Hz, 1H), 4.39 (dd, J=10.85, 3.39 Hz, 1H), 6.94 (t, J=7.46 Hz, 1H), 7.03 (d, J=8.14 Hz, 1H), 7.23 (d, J=7.46 Hz, 1H), 7.32 (dd, J=8.14, 7.46 Hz, 1H), 7.62 (d, J=8.48 Hz, 1H), 7.71 (d, J=8.82 Hz, 1H), 7.91 (d, J=2.03 Hz, 1H), 8.06 (s, 1H), 8.34 (d, J=2.71 Hz, 1H), 8.65 (s, 1H).
    • EXAMPLE 284 (3-{(2S)-2-Amino-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propyl}-phenyl)-dimethyl-amine
  • MS (DCI/NH[0704] 3) m/e 402 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.73 (s; 1H), 8.43 (s; 1H), 8.10 (m; 2H), 7.74 (d; 1H; J=7.5 Hz), 7.63 (d; 1H; J=7.5 Hz), 7.38(t; 1H; J=7.5 Hz), 7.09 (s; 1H), 7.08 (d; 1H; J=7.5 Hz), 7.04 (d; 1H; J=7.5 Hz), 4.45 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.31 (dd; 1H; J=10.8 Hz; J=6.0 Hz), 4.00 (m; 1H), 3.17 (m; 2H), 3.05 (s; 6H), 2.64 (s; 3H).
    • EXAMPLE 285 (1S)-1-(4-Chloro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0705] 3) m/e 407 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.71 (s; 1H), 8.41 (s; 1H), 8.10 (s; 1H), 8.04 (s; 1H), 7.73 (d; 1H; J=8.1 Hz), 7.62 (d; 1H; J=8.1 Hz), 7.28 (s; 1H), 7.22 (m; 2H), 4.40 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.26 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.94 (m; 1H), 3.17 (m; 2H), 2.62 (s; 3H), 2.39 (s; 3H).
    • EXAMPLE 286 (1S)-1-(3-Iodo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0706] 3) m/e 485 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.65 (s; 1H), 8.36 (s; 1H), 8.07 (s; 1H), 7.92 (s; 1H), 7.75 (s; 1H), 7.72 (d; 1H; J=8.1 Hz), 7.68 (d; 1H; J=7.8 Hz), 7.62 (d; 1H; J=8.1 Hz), 7.35 (d; 1H; J=7.8 Hz), 7.16 (d; 1H; J=7.8 Hz), 4.40 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.24 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.96 (m; 1H), 3.12 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 287 (1S)-(1S)-1-(3-Fluoro-4-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0707] 3) m/e 391 (M+1)4; 1H NMR (300 MHz, CD3OD) δ=8.73 (s; 1H), 8.42 (s; 1H), 8.12 (s; 1H), 8.10 (s; 1H), 7.74 (d; 1H; J=8.1 Hz), 7.63 (d; 1H; J=8.14 Hz), 7.24 (t; 1H; J=8.4 Hz), 7.05 (m; 2H), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.97 (m; 1H), 3.13 (m; 2H), 2.62 (s; 3H), 2.23 (s; 3H).
    • EXAMPLE 288 (1S)-1-(3-Fluoro-4-methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0708] 3) m/e 407 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.73 (s; 1H), 8.42 (s; 1H), 8.12 (s; 1H), 8.10 (s; 1H), 7.74 (d; 1H; J=8.1 Hz), 7.63 (d; 1H; J=8.1 Hz), 7.24 (t; 1H; J=8.4 Hz), 7.05 (m; 2H), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.97 (m; 1H), 3.13 (m; 2H), 2.62 (s; 3H), 2.23 (s; 3H).
    • EXAMPLE 289 (1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3,4-dichloro-benzyl)-ethylamine
  • MS (DCI/NH[0709] 3) m/e 462 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.16 (s; 1H), 7.78 (s; 1H), 7.54 (m; 4H), 7.48 (d; 1H; J=8.1 Hz), 7.25 (d; 1H; J=8.1 Hz), 4.32 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.15 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.93 (m; 1H), 3.12 (m; 2H), 2.58 (s; 3H).
    • EXAMPLE 290 (1S)-1-(2-Fluoro-6-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0710] 3) m/e 445 (M+1)+; 1H NMR (300 MHz, CD3OD) δ 8.69 (s; 1H), 8.36 (s; 1H), 8.08 (s; 1H), 7.96 (s; 1H), 7.73 (d; 1H; J=8.1 Hz), 7.63 (m; 3H), 7.50 (t; 1H; J=9.0 Hz), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.32 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.08 (m; 1H), 3.48 (m; 1H), 3.35 (m; 1H), 2.62 (s; 3H).
    • EXAMPLE 291 (1S)-1-(4-Fluoro-3-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0711] 3) m/e 445 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.70 (s; 1H), 8.41 (s; 1H), 8.09 (s; 1H), 8.04 (s; 1H), 7.74 (d; 1H; J=8.1 Hz), 7.68 (m; 1H), 7.62 (d; 1H; J=8.1 Hz), 7.36 (t; 1H; J=9.0 Hz), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.02 (m; 1H), 3.23 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 292 (1S)-1-Furan-2-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0712] 3) m/e 349 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.68 (s; 1H), 8.39 (s; 1H), 8.09 (m; 1H), 8.00 (s; 1H), 7.73 (d; 1H; J=9.0 Hz), 7.62 (d; 1H; J=9.0 Hz), 7.50 (s; 1H), 6.42 (m; 1H), 6.33 (m; 1H), 4.49 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.31 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.02 (m; 1H), 3.24 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 293 (1S)-1-Benzofuran-2-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0713] 3) m/e 398 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.72 (s; 1H), 8.42 (s; 1H), 8.09 (m; 2H), 7.72 (d; 1H; J=9.0 Hz), 7.62 (d; 1H; J=9.0 Hz), 7.55 (d; 1H; J=8.4 Hz), 7.45 (d; 1H; J=8.4 Hz), 7.44 (m; 2H), 6.78 (s; 1H), 4.58 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.44 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.18 (m; 1H), 3.41 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 294 (1S)-1-(3-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethyl Amine
  • MS (DCI/NH[0714] 3) m/e 445 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.74 (s; 1H), 8.44 (s; 1H), 8.13 (m; 2H), 7.75 (d; 1H; J=8.1 Hz), 7.70 (t; 1H; J=8.4 Hz), 7.43 (d; 1H; J=8.4 Hz), 7.40 (d; 1H; J=12.0 Hz), 7.38 (d; 1H; J=8.1 Hz), 4.48 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.32 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.08 (m; 1H), 3.28 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 295 (1S)-1-(4-Chloro-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0715] 3) m/e 407 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.71 (s; 1H), 8.41 (s; 1H), 8.10 (s; 1H), 8.05 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.36 (d; 1H; J=8.4 Hz), 7.27 (s; 1H), 7.15 (d; 1H; J=8.4 Hz), 4.44 (dd; 1H; J=10.8 Hz, J=3.0 Hz), 4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.96 (m; 1H), 3.11 (m; 2H), 2.62 (s; 3H), 2.34 (s; 3H).
    • EXAMPLE 296 (1S)-1-Furan-3-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0716] 3) m/e 349 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.73 (s; 1H), 8.43 (s; 1H), 8.12 (m; 2H), 7.74 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.53 (m; 2H), 6.47 (m; 1H), 4.49 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.33 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.91 (m; 1H), 3.00 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 297 (1S)-1-(2-Fluoro-5-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0717] 3) m/e 391 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.65 (s; 1H), 8.36 (s; 1H), 8.05 (s; 1H), 7.90 (s; 1H), 7.70 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.09 (s; 1H), 7.27 (d; 1H; J=8.1 Hz) 7.18 (t; 1H; J=8.1 Hz), 4.39 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.25 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.04 (m; 1H), 3.28 (m; 2H), 2.62 (s; 3H), 2.30 (s; 3H).
    • EXAMPLE 298 (1S)-1-(3-Chloro-5-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0718] 3) m/e 411 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.71 (s; 1H), 8.41 (s; 1H), 8.10 (s; 1H), 8.06 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.26 (s; 1H), 7.18 (d; 1H; J=8.4 Hz), 7.12 (d; 1H; J=8.4 Hz), 4.46 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.30 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.02 (m; 1H), 3.18 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 299 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3,4,5-trifluoro-benzyl)-ethylamine
  • MS (DCI/NH[0719] 3) m/e 413 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.73 (s; 1H), 8.44 (s; 1H), 8.10 (m; 2H), 7.74 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.17 (t; 2H; J=9.0 Hz), 4.47 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.32 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.00 (m; 1H), 3.15 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 300 (1S)-1-(4-Fluoro-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0720] 3) m/e 391 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.73 (s; 1H), 8.42 (s; 1H), 8.12 (s; 1H), 8.08 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.18 (m; 2H), 7.03 (t; 1H; J=9.0 Hz), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.94 (m; 1H), 3.10 (m; 2H), 2.62 (s; 3H), 2.24 (s; 3H).
    • EXAMPLE 301 (1S)-1-(2,4-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0721] 3) m/e 428 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.69 (s; 1H), 8.40 (s; 1H), 8.10 (s; 1H), 8.00 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.56 (s; 1H), 7.41 (d; 1H; J=8.1 Hz), 7.36 (d; 1H; J=8.1), 4.43 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.05 (m; 1H), 3.31 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 302 (1S)-1-(4-Chloro-3-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0722] 3) m/e 461 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.69 (s; 1H), 8.39 (s; 1H), 8.08 (s; 1H), 8.00 (s; 1H), 7.79 (s; 1H), 7.72 (d; 1H; J=8.4 Hz), 7.62 (m; 3H), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.02 (m; 1H), 3.26 (m; 2H), 2.62 (s; 3H).
    Figure US20030187026A1-20031002-C00095
    • EXAMPLE 303 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-trifluoromethoxy-benzyl)-ethylamine
  • MS (DCI/NH[0723] 3) m/e 443 (M+1)+; 1H NMR (300 MHz, CD3OD) δ 8.70 (s; 1H), 8.39 (s; 1H), 8.09 (s; 1H), 8.01 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.42 (m; 4H), 4.40 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.24 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.00 (m; 1H), 3.28 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 304 (1S)-1-(2,5-Dimethoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0724] 3) m/e 419 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.71 (s; 1H), 8.40 (s; 1H), 8.10 (s; 1H), 8.04 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 6.95 (d; 1H; J=9.0 Hz), 6.85 (m; 2H), 4.43 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.27 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.00 (m; 1H), 3.80 (s; 3H), 3.69 (s; 3H), 3.13 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 305 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-methylsulfanyl-benzyl)-ethylamine
  • MS (DCI/NH[0725] 3) m/e 405 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.73 (s; 1H), 8.62 (s; 1H), 8.12 (s; 1H), 8.08 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.28 (s; 4H), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.29 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.95 (m; 1H), 3.12 (m; 2H), 2.62 (s; 3H), 2.44 (s; 3H).
    • EXAMPLE 306 (1S)-1-(2-Cyclohexyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0726] 3) m/e 441 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.70 (s; 1H), 8.40 (s; 1H), 8.07 (s; 1H), 8.01 (s; 1H), 7.71 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.34 (d; 1H; J=7.8 Hz), 7.25 (m; 2H), 7.16 (t; 1H; J=7.8 Hz), 4.37 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.23 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.38 (m; 1H), 3.27 (m; 2H), 2.77 (m; 1H), 2.62 (s; 3H), 1.85 (m; 1H), 1.74 (m; 4H), 1.48 (m; 3H), 1.29 (m, 2H).
    • EXAMPLE 307 (1S)-1-(2,5-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0727] 3) m/e 428 (M+)+; 1H NMR (300 MHz, CD3OD) δ=8.71 (s; 1H), 8.41 (s; 1H), 8.10 (s; 1H), 8.04 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.48 (m; 2H), 7.36 (d; 1H; J=8.4 Hz), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.07 (m; 1H), 3.36 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 308 (1S)-1-(2,5-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0728] 3) m/e 387 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.74 (s; 1H), 8.2 (s; 1H), 8.11 (s; 1H), 8.08 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.11 (d; 1H; J=8.1 Hz), 7.03 (m; 2H), 4.41 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.94 (m; 1H), 3.14 (m; 2H), 2.62 (s; 3H), 2.34 (s; 3H), 2.23 (s; 3H).
    • EXAMPLE 309 (1S)-1-(2,3-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0729] 3) m/e 387 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.65 (s; 1H), 8.35 (s; 1H), 8.05 (s; 1H), 7.90 (s; 1H), 7.70 (d; 1H; J=8.4 Hz), 7.60 (d; 1H; J=8.4 Hz), 7.07 (m; 3H), 4.35 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.22 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.88 (m; 1H), 3.21 (m; 2H), 2.62 (s; 3H), 2.31 (s; 3H), 2.28 (s; 3H).
    • EXAMPLE 310 (1S)-1-(3,4-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0730] 3) m/e 428 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.68 (s; 1H), 8.39 (s; 1H), 8.08 (s; 1H), 7.98 (s; 1H), 7.72 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.56 (s; 1H), 7.54 (d; 1H; J=8.4 Hz), 7.28 (d; 1H; J=8.4 Hz), 4.43 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.27 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.99 (m; 1H), 3.16 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 311 (1S)-1-(2,4-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0731] 3) m/e 387 (M+1)+; 1H NMR (300 MHz, CD3OD) δ 8.68 (s; 1H), 8.37 (s; 1H), 8.08 (s; 1H), 7.96 (s; 1H), 7.71 (d; 1H; J=8.4 Hz), 7.61 (d; 1H; J=8.4 Hz), 7.10 (d; 1H; J=7.5 Hz), 7.06 (s; 1H), 6.98 (d; 1H; J=7.5 Hz), 4.37 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.24 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.90 (m; 1H), 3.14 (m; 2H), 2.62 (s; 3H), 2.35 (s; 3H), 2.26 (s; 3H).
    • EXAMPLE 312 (1S)-1-(3-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0732] 3) m/e 445 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.68 (s; 1H), 8.39 (s; 1H), 8.08 (s; 1H), 7.98 (s; 1H), 7.72 (d; 1H; J=8.4 Hz), 7.70 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.39 (d; 1H; J=12.0 Hz), 7.35 (d; 1H; J=8.4 Hz), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.05 (m; 1H), 3.28 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 313 (1S)-1-(3,5-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0733] 3) m/e 387 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.68 (s; 1H), 8.38 (s; 1H), 8.08 (s; 1H), 7.97 (s; 1H), 7.71 (d; 1H; J=8.4 Hz), 6.94 (m; 3H), 4.41 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.25 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.92 (m; 1H), 3.07 (m; 2H), 2.62 (s; 3H), 2.26 (s; 6H).
    • EXAMPLE 314 (1S)-1-Biphenyl-2-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0734] 3) m/e 435 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.64 (s; 1H), 8.11 (s; 1H), 8.05 (s; 1H), 7.70 (d; 1H; J=8.4 Hz), 7.68 (s; 1H), 7.63 (d; 1H; J=8.4 Hz), 7.34 (m; 9H), 4.12 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 3.89 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.64 (m; 1H), 3.39 (dd; 1H; J=14.4 Hz; J=9.3 Hz), 3.16 (dd; 1H; J=14.4 Hz, J=4.5 Hz), 2.62 (s; 3H).
    • EXAMPLE 315 (1S)-1-(3,4-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0735] 3) m/e 387 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.69 (s; 1H), 8.38 (s; 1H), 8.08 (s; 1H), 7.99 (s; 1H), 7.72 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.08 (m; 3H), 4.41 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.26 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.91 (m; 1H), 3.08 (m; 2H), 2.62 (s; 3H), 2.29 (s; 3H), 2.23 (s; 3H).
    • EXAMPLE 316 (1S)-1-(2,3-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0736] 3) m/e 395 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.74(s; 1H), 8.44 (s; 1H), 8.12 (s; 2H), 7.74 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.19 (m; 3H), 4.48 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.32 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.03 (m; 1H), 3.30 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 317 (1S)-1-(2,5-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0737] 3) m/e 395 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.77 (s; 1H), 8.46 (s; 1H), 8.18 (s; 1H), 8.13 (s; 1H), 7.75 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.17 (m; 3H), 4.49 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.33 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.02 (m; 1H), 3.12 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 318 (1S)-1-(2,6-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0738] 3) m/e 428 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.64 (s; 1H), 8.33 (s; 1H), 8.05 (s; 1H), 7.88 (s; 1H), 7.70 (d; 1H; J=8.4 Hz), 7.61 (d; 1H; J=8.4 Hz), 7.48 (d; 2H; J=7.2 Hz), 7.33 (t; 1H; J=7.2 Hz), 4.40 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.29 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.10 (m; 1H), 3.67 (dd; 1H; J=15.0 Hz; J=9.6 Hz), 3.43 (dd; 1H; J=15.0 Hz; J=5.4 Hz), 2.62 (s; 3H).
    • EXAMPLE 319 (1S)-1-(2,4-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0739] 3) m/e 395 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.67 (s; 1H), 8.37 (s; 1H), 8.08 (s; 1H), 7.94 (s; 1H), 7.71 (d; 1H; J=8.4 Hz), 7.61 (d; 1H; J=8.4 Hz), 7.40(m; 1H), 7.01 (m; 2H), 4.43 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.27 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.96 (m; 1H), 3.10 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 320 (1S)-1-(2,6-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0740] 3) m/e 387 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.62 (s; 1H), 8.32 (s; 1H), 8.03 (s; 1H), 7.83 (s; 1H), 7.69 (d; 1H; J=8.4 Hz), 7.60 (d; 1H; J=8.4 Hz), 7.70 (m; 3H), 4.29 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.16 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.92 (m; 1H), 3.37 (dd; 1H; J=15.0 Hz; J=10.5 Hz), 3.15 (dd; 1H; J=15.0 Hz; J=5.4 Hz), 2.62 (s; 3H), 2.38 (s; 6H).
    • EXAMPLE 321 (1S)-1-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0741] 3) m/e 417 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.64 (s; 1H), 8.36 (s; 1H), 8.07 (s; 1H), 7.91 (s; 1H), 7.71 (d; 1H; J=8.4 Hz), 7.61 (d; 1H; J=8.4 Hz), 6.80(m; 3H), 4.40 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.23 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.20 (s; 4H), 3.88 (m; 1H), 3.03 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 322 (1S)-1-(3,5-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0742] 3) m/e 395 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.67 (s; 1H), 8.39 (s; 1H), 8.08 (s; 1H), 7.98 (s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.61 (d; 1H; J=8.4 Hz), 6.97(m; 3H), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.29 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.01 (m; 1H), 3.19 (m; 2H), 2.62 (s; 3H).
    • EXAMPLE 323 (1S)-1-(2,6-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0743] 3) m/e 395 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.41 (s; 1H), 8.31 (s; 1H), 8.04 (s; 1H), 7.84 (s; 1H), 7.70 (d; 1H; J=8.4 Hz), 7.60 (d; 1H; J=8.4 Hz), 7.40(m; 1H), 7.06 (m; 2H), 4.42 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.24 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.97 (m; 1H), 3.31 (m; 2H), 2.62 (s; 3H).
    Figure US20030187026A1-20031002-C00096
    • EXAMPLE 324 (1S)-1-Benzo[1,3]dioxol-5-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 404 (M+1)[0744] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.63 (s, 3H), 3.08 (dd, J=7.64, 2.65 Hz, 2H), 3.92 (m, 1H), 4.32 (dd, J=10.45, 5.77 Hz, 1H), 4.46 (dd, J=10.61, 2.81 Hz, 1H), 5.92 (d, J=1.87 Hz, 2H), 6.80 (d, J=1.87 Hz, 2H), 6.85 (s, 1H), 7.64 (d, J=8.73 Hz, 1H), 7.74 (dd, J=8.73, 1.56 Hz, 1H), 8.12 (s, 1H), 8.14 (d, J=1.87 Hz, 1H), 8.45 (d, J=1.87 Hz, 1H), 8.74 (s, 1H); Anal. Calcd for C23H22N4O3: C, 48.46; H, 3.55; N, 8.02. Found: C, 48.59; H, 3.65; N, 8.13.
    • EXAMPLE 325 (S)-1-(4-Fluoro-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 392 (M+1)[0745] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.24 (s, 3H), 2.63 (s, 3H), 3.11 (dd, J=7.64, 3.90 Hz, 2H), 3.94 (m, 1H), 4.29 (dd, J=10.61, 5.62 Hz, 1H), 4.44 (dd, J=10.61, 2.81 Hz, 1H), 7.03 (m, 1H), 7.16 (m, 1H), 7.21 (d, J=7.18 Hz, 1H), 7.63 (d, J=8.73 Hz, 1H), 7.74 (d, J=1.87 Hz, 1H), 8.06 (s, 1H), 8.10 (s, 1H), 8.42 (s, 1H), 8.71 (s, 1H); Anal. Calcd for C23H23FN4O: C, 50.79; H, 3.91; N, 8.58. Found: C, 51.10; H, 4.02; N, 8.43.
    • EXAMPLE 326 (S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,4,6-trimethyl-benzyl)-ethylamine
  • MS (APCI) m/z 402 (M+1)[0746] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.21 (s, 3H), 2.34 (s, 6H), 2.62 (s, 3H), 3.14 (dd, J=14.19, 5.46 Hz, 2H), 3.92 (m, J=8.73, 4.99 Hz, 1H), 4.26 (dd, J=10.45, 4.84 Hz, 1H), 4.36 (m, 1H), 6.89 (s, 2H), 7.63 (d, J=8.74 Hz, 1H), 7.72 (dd, J=8.73, 1.56 Hz, 1H), 8.11 (s, 2H), 8.42 (s, 1H), 8.75 (s, 1H); Anal. Calcd for C25H21N4O: C, 52.56; H, 4.48; N, 8.17. Found: C, 52.49; H, 4.41; N, 8.06.
    • EXAMPLE 327 (1S)-1-(2,4-Dimethoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 419 (M+1)[0747] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.63 (s, 3H), 3.08 (dd, J=7.33, 2.96 Hz, 2H), 3.77 (s, 3H), 3.83 (s, 3H), 3.94 (m, 1H), 4.26 (dd, J=10.45, 5.77 Hz, 1H), 4.41 (dd, J=10.61, 3.12 Hz, 1H), 6.50 (dd, J=8.27, 2.34 Hz, 1H), 6.59 (d, J=2.50 Hz, 1H), 7.12 (d, J=8.42 Hz, 1H), 7.63 (d, J=8.73 Hz, 1H), 7.72 (m, 1H), 8.00 (s, 1H), 8.09 (s, 1H), 8.40 (s, 1H), 8.71 (s, 1H).
    • EXAMPLE 328 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-trifluoromethyl-benzyl)-ethylamine
  • MS (APCI) m/z 428 (M+1)[0748] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.63 (s, 3H), 3.28 (m, 2H), 4.05 (m, 1H), 4.32 (dd, J=10.61, 5.30 Hz, 1H), 4.47 (dd, J=10.61, 2.81 Hz, 1H), 7.56 (d, J=7.80 Hz, 2H), 7.63 (d, J=8.74 Hz, 1H), 7.69 (d, J=8.11 Hz, 2H), 7.74 (dd, J=8.74, 1.56 Hz, 1H), 8.12 (d, J=6.55 Hz, 2H), 8.45 (br s, 1H), 8.74 (br s, 1H); Anal. Calcd for C23H21F3N4O: C, 46.45; H, 3.25; N, 7.63. Found: C, 46.55; H, 3.30; N, 7.64.
    • EXAMPLE 329 (1S)-1-(5-Fluoro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 391 (M+1)[0749] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.36 (s, 3H), 2.62 (s, 3H), 3.16 (dd, J=14.19, 6.71 Hz, 1H), 3.23 (m, 1H), 3.97 (m, 1H), 4.29 (dd, J=10.45, 4.84 Hz, 1H), 4.42 (dd, J=10.61, 3.12 Hz, 1H), 6.95 (td, J=8.42, 2.81 Hz, 1H), 7.04 (dd, J=9.67, 2.81 Hz, 1H), 7.25 (dd, J=8.42, 5.93 Hz, 1H), 7.63 (d, J=8.74 Hz, 1H), 7.73 (dd, J=8.73, 1.56 Hz, 1H), 8.05 (s, 1H), 8.09 (s, 1H), 8.42 (s, 1H), 8.71 (s, 1H); Anal. Calcd for C23H23FN4O: C, 49.31; H, 3.76; N, 8.16. Found: C, 49.28; H, 3.61; N, 8.10.
    • EXAMPLE 330 (1S)-1-(3,5-Bis-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 495 (M+1)[0750] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.62 (s, 3H), 3.35 (m, 1H), 3.42 (m, 1H), 4.12 (m, 1H), 4.31 (dd, J=10.61, 5.30 Hz, 1H), 4.49 (dd, J=10.61, 3.12 Hz, 1H), 7.63 (d, J=8.73 Hz, 1H), 7.73 (dd, J=8.74, 1.87 Hz, 1H), 7.94 (s, 1H), 8.01 (s, 2H), 8.05 (s, 1H), 8.08 (s, 1H), 8.43 (s, 1H), 8.72 (s, 1H); Anal. Calcd for C24H20F6N4O: C, 43.69; H, 2.82; N, 6.89. Found: C, 43.70; H, 2.65; N, 6.82.
    • EXAMPLE 331 (1S)-1-(4-Fluoro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 392 (M+1)[0751] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.40 (s, 3H), 2.62 (s, 3H), 3.15 (dd, J=14.19, 6.40 Hz, 1H), 3.22 (m, 1H), 3.94 (m, 1H), 4.29 (dd, J=10.61, 4.99 Hz, 1H), 4.42 (dd, J=10.61, 2.81 Hz, 1H), 6.91 (td, J=8.42, 2.50 Hz, 1H), 7.00 (dd, J=9.83, 2.34 Hz, 1H), 7.26 (dd, J=8.42, 5.93 Hz, 1H), 7.63 (d, J=8.74 Hz, 1H), 7.73 (dd, J=8.74, 1.25 Hz, 1H), 8.08 (s, 1H), 8.10 (s, 1H), 8.43 (s, 1H), 8.72 (s, 1H); Anal. Calcd for C23H23FN4O: C, 48.40; H, 3.66; N, 7.89. Found: C, 48.59; H, 3.85; N, 7.90.
    • EXAMPLE 332 (1S)-1-(5-Fluoro-2-methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 408 (M+1)[0752] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.63 (s, 3H), 3.16 (d, J=7.18 Hz, 2H), 3.84 (s, 3H), 4.02 (m, 1H), 4.30 (dd, J=10.61, 5.93 Hz, 1H), 4.45 (dd, J=10.45, 2.96 Hz, 1H), 7.04 (m, 3H), 7.64 (d, J=8.73 Hz, 1H), 7.74 (d, J=8.74 Hz, 1H), 8.12 (s, 2H), 8.43 (s, 1H), 8.74 (s, 1H); Anal. Calcd for C23H23FN4O2: C, 44.73; H, 3.32; N, 6.96. Found: C, 44.77; H, 3.46; N, 6.83.
    • EXAMPLE 333 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-methyl-naphthalen-1-ylmethyl)-ethylamine
  • MS (APCI) m/z 424 (M+1)[0753] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.58 (s, 3H), 2.61 (s, 3H), 3.61 (dd, J=14.19, 4.84 Hz, 1H), 3.84 (dd, J=14.19, 10.76 Hz, 1H), 4.06 (m, J=9.20, 4.21 Hz, 1H), 4.14 (dd, J=10.29, 3.74 Hz, 1H), 4.28 (dd, J=10.45, 2.65 Hz, 1H), 7.41 (m, 3H), 7.60 (d, J=8.42 Hz, 1H), 7.65 (m, 1H), 7.75 (d, J=8.42 Hz, 1H), 7.84 (m, 2H), 8.01 (s, 1H), 8.12 (d, J=8.11 Hz, 1H), 8.33 (s, 1H), 8.66 (s, 1H); Anal. Calcd for C27H26N4O: C, 52.30; H, 3.87; N, 7.44. Found: C, 52.56; H, 4.00; N, 7.38.
    • EXAMPLE 334 (1S)-1-(2,2-Difluoro-benzo[1,3]dioxol-4-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 437 (M−1)[0754] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.63 (s, 3H), 3.28 (m, 2H), 4.07 (m, 1H), 4.34 (dd, J=10.61, 4.99 Hz, 1H), 4.51 (dd, J=10.61, 2.81 Hz, 1H), 7.17 (m, 3H), 7.64 (d, J=8.73 Hz, 1H), 7.75 (d, J=8.73 Hz, 1H), 8.12 (s, 1H), 8.16 (s, 1H), 8.46 (s, 1H), 8.76 (s, 1H); Anal. Calcd for C23H20F2N4O3: C, 44.63; H, 2.97; N, 7.18. Found: C, 44.74; H, 3.08; N, 7.23.
    • EXAMPLE 335 (1S)-1-(4-Fluoro-naphthalen-1-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 428 (M+1)[0755] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.62 (s, 3H), 3.60 (dd, J=14.04, 6.55 Hz, 1H), 3.66 (m, 1H), 4.09 (m, 1H), 4.29 (dd, J=10.61, 4.99 Hz, 1H), 4.42 (dd, J=10.61, 3.12 Hz, 1H), 7.19 (dd, J=10.29, 7.80 Hz, 1H), 7.47 (dd, J=7.80, 5.30 Hz, 1H), 7.61 (d, J=8.73 Hz, 2H), 7.64 (d, J=7.18 Hz, 1H), 7.68 (t, J=8.11 Hz, 1H), 7.96 (s, 1H), 8.05 (s, 1H), 8.15 (d, J=8.11 Hz, 1H), 8.18 (d, J=8.42 Hz, 1H), 8.38 (s, 1H), 8.68 (s, 1H).
    • EXAMPLE 336 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,2,3,3-tetrafluoro-2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-ethylamine
  • MS (APCI) m/z 487 (M−1)[0756] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.63 (s, 3H), 3.18 (dd, J=14.19, 7.02 Hz, 1H), 3.24 (m, 1H), 4.02 (m, J=5.15, 2.65 Hz, 1H), 4.33 (dd, J=10.45, 5.46 Hz, 1H), 4.47 (dd, J=10.61, 3.12 Hz, 1H), 7.29 (m, 2H), 7.34 (s, 1H), 7.63 (d, J=8.73 Hz, 1H), 7.74 (dd, J=8.74, 1.25 Hz, 1H), 8.11 (s, 2H), 8.44 (s, 1H), 8.72 (s, 1H); Anal. Calcd for C23H20F2N4O3: C, 43.08; H, 2.77; N, 6.65. Found: C, 42.94; H, 2.79; N, 6.64.
    • EXAMPLE 337 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-methyl-naphthalen-1-ylmethyl)-ethylamine
  • MS (APCI) m/z 421 (M−1)[0757] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.61 (d, J=8.11 Hz, 3H), 2.67 (s, 3H), 3.62 (m, 2H), 4.09 (m, 1H), 4.28 (dd, J=10.61, 4.99 Hz, 1H), 4.40 (dd, J=10.61, 3.12 Hz, 1H), 7.32 (d, J=7.49 Hz, 1H), 7.38 (m, 1H), 7.58 (m, 2H), 7.62 (d, J=8.73 Hz, 1H), 7.68 (m, 1H), 7.97 (s, 1H), 8.06 (s, 1H), 8.10 (m, 1H), 8.15 (m, 1H), 8.37 (d, J=2.50 Hz, 1H), 8.68 (s, 1H); Anal. Calcd for C27H26N4O: C, 52.79; H, 3.91; N, 7.55. Found: C, 52.64; H, 3.85; N, 7.53.
    • EXAMPLE 338 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,4,6-trifluoro-benzyl)-ethylamine
  • MS (APCI) m/z 411 (M−1)[0758] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.63 (s, 3H), 3.19 (m, 2H), 3.97 (m, 1H), 4.32 (dd, J=10.61, 4.99 Hz, 1H), 4.49 (dd, J=10.61, 3.12 Hz, 1H), 6.95 (t, J=8.27 Hz, 2H), 7.63 (d, J=8.73 Hz, 1H), 7.74 (dd, J=8.74, 1.56 Hz, 1H), 8.08 (d, J=2.18 Hz, 1H), 8.10 (s, 1H), 8.41 (s, 1H), 8.72 (s, 1H);Anal. Calcd for C22H19F3N4O: C, 44.57; H, 2.94; N, 7.43. Found: C, 44.47; H, 2.78; N, 7.46.
    • EXAMPLE 339 (1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,3,4-trifluoro-benzyl)-ethylamine
  • [0759] 1H NMR (500 MHz, CD3OD) δ ppm 2.62 (s, 3H), 3.23 (m, 2H), 4.00 (m, 1H), 4.31 (dd, J=10.61, 5.30 Hz, 1H), 4.46 (dd, J=10.61, 3.12 Hz, 1H), 7.17 (m, 2H), 7.62 (d, J=8.73 Hz, 1H), 7.73 (dd, J=8.74, 1.56 Hz, 1H), 8.02 (s, 1H), 8.08 (s, 1H), 8.40 (s, 1H), 8.69 (s, 1H); Anal. Calcd for C22H19F3N4O: C, 45.31; H, 3.00; N, 7.66. Found: C, 45.59; H, 2.73; N, 7.84.
    • EXAMPLE 340 (1S)-1-(4-Bromo-2-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • [0760] 1H NMR (500 MHz, CD3OD) δ ppm 2.63 (s, 3H), 3.22 (m, 2H), 4.00 (m, 1H), 4.34 (dd, J=10.61, 5.30 Hz, 1H), 4.49 (dd, J=10.61, 3.12 Hz, 1H), 7.33 (t, J=8.11 Hz, 1H), 7.37 (d, J=1.56 Hz, 1H), 7.41 (m, 1H), 7.64 (d, J=8.73 Hz, 1H), 7.75 (dd, J=8.74, 1.56 Hz, 1H), 8.13 (s, 1H), 8.19 (s, 10H), 8.46 (s, 1H), 8.77 (s, 1H); Anal. Calcd for C22H20BrFN4O: C, 42.80; H, 2.97; N, 7.23. Found: C, 42.73; H, 3.17; N, 7.02.
    • EXAMPLE 341 (1S)-1-(4-Bromo-3-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (ESI) m/z 456 (M+1)[0761] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.63 (s, 3H), 3.18 (m, 2H), 4.01 (m, 1H), 4.32 (dd, J=10.61, 5.62 Hz, 1H), 4.46 (dd, J=10.61, 2.81 Hz, 1H), 7.11 (dd, J=8.11, 1.56 Hz, 1H), 7.26 (dd, J=9.36, 1.87 Hz, 1H), 7.62 (d, J=7.18 Hz, 1H), 7.63 (d, J=8.42 Hz, 1H), 7.74 (dd, J=8.73, 1.56 Hz, 1H), 8.10 (d, J=4.06 Hz, 2H), 8.43 (s, 1H), 8.72 (s, 1H);Anal. Calcd for C22H20BrFN4O: C, 43.46; H, 3.03; N, 7.45. Found: C, 43.52; H, 3.07; N, 7.43.
    • EXAMPLE 342 (1S)-1-(2-Bromo-4,6-difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • [0762] 1H NMR (500 MHz, CD3OD) δ ppm 2.63 (s, 3H), 3.32 (m, 1H), 3.48 (m, 1H), 4.03 (m, 1H), 4.34 (dd, J=10.45, 4.84 Hz, 1H), 4.48 (dd, J=10.61, 3.43 Hz, 1H), 7.13 (t, J=8.11 Hz, 1H), 7.40 (d, J=8.11 Hz, 1H), 7.63 (d, J=8.73 Hz, 1H), 7.74 (dd, J=8.73, 1.56 Hz, 1H), 8.09 (s, 1H), 8.11 (s, 1H), 8.42 (s, 1H), 8.73 (s, 1H); Anal. Calcd for C22H19BrF2N4O: C, 41.24; H, 2.72; N, 6.87. Found: C, 41.35; H, 2.68; N, 6.76.
    • EXAMPLE 343 (1S)-1-(4-Bromo-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (ESI) m/z 452 (M+1)[0763] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.37 (s, 3H), 2.63 (s, 3H), 3.11 (m, 2H), 3.97 (m, 1H), 4.29 (dd, J=10.61, 5.62 Hz, 1H), 4.44 (dd, J=10.61, 3.12 Hz, 1H), 7.07 (dd, J=8.11, 1.87 Hz, 1H), 7.27 (s, 1H), 7.54 (d, J=8.11 Hz, 1H), 7.63 (d, J=8.73 Hz, 1H), 7.73 (d, J=8.73 Hz, 1H), 8.06 (s, 1H), 8.10 (s, 1H), 8.41 (s, 1H), 8.71 (s, 1H);Anal. Calcd for C23H23BrN4O: C, 44.93; H, 3.41; N, 7.38. Found: C, 45.11; H, 3.36; N, 7.28.
    • EXAMPLE 344 (1S)-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • [0764] 1H NMR (500 MHz, CD3OD) δ ppm 2.62 (s, 3H), 3.37 (m, 2H), 4.10 (m, 1H), 4.30 (dd, J=10.61, 4.99 Hz, 1H), 4.43 (dd, J=10.61, 3.12 Hz, 1H), 7.25 (t, J=6.71 Hz, 1H), 7.37 (t, J=6.86 Hz, 1H), 7.42 (m, 1H), 7.63 (d, J=8.74 Hz, 1H), 7.66 (d, J=8.11 Hz, 1H), 7.73 (dd, J=8.73, 1.56 Hz, 1H), 8.03 (d, J=1.87 Hz, 1H), 8.09 (s, 1H), 8.40 (s, 1H), 8.70 (s, 1H); Anal. Calcd for C22H21BrN4O: C, 43.48; H, 3.14; N, 7.30. Found: C, 43.67; H, 3.06; N, 7.10.
    • EXAMPLE 345 (1S)-1-(3-Methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS m/z 389 (M+H)[0765] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.57 (s, 3H) 3.00 (dd, J=13.56, 9.16 Hz, 1H) 3.12 (m, 1H) 3.73 (s, 3H) 4.28 (dd, J=10.85, 5.43 Hz, 1H) 4.44 (m, 2H) 6.85 (dd, J=8.48, 2.37 Hz, 1H) 6.91 (m, 2H) 7.27 (t, J=7.80 Hz, 1H) 7.61 (d, J=8.82 Hz, 1H) 7.79 (dd, J=8.82, 1.70 Hz, 1H) 8.23 (s, 1H) 8.26 (s, 1H) 8.53 (d, J=2.37 Hz, 4H) 8.86 (s, 1H).
    • EXAMPLE 346 (1S)-1-(3-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS m/z 437, 439 (M+H)[0766] +; 1H NMR (300 MHz, DMSO-D6) δ ppm 2.57 (s, 3H) 3.08 (m, 2H) 4.27 (dd, J=10.85, 5.43 Hz, 1H) 4.43 (m, 1H) 7.34 (m, 2H) 7.49 (dt, J=7.54, 1.65 Hz, 1H) 7.61 (m, 2H) 7.77 (dd, J=8.65, 1.53 Hz, 1H) 8.14 (s, 1H) 8.22 (s, 1H) 8.49 (s, 2H) 8.82 (s, 1H).
    • EXAMPLE 347 (1S)-1-(2-Methoxy-naphthalen-1-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (ESI) m/e 439 (M+1)[0767] +; 1H NMR (300 MHz, Solvent) δ ppm 2.62 (s, 3H) 3.55 (m, 1H) 3.74 (m, 1H) 3.97 (s, 3H) 4.03 (m, 1H) 4.23 (m, 1H) 4.39 (m, 1H) 7.33 (m, 1H) 7.46 (m, 2H) 7.64 (m, 2H) 7.84 (m, 1H) 7.92 (m, 2H) 8.03 (m, 2H) 8.34 (br. s., 1H) 8.67 (br. s., 1H).
    • EXAMPLE 348 (1R)-1-(4-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine Example 348A 5-[5-((2R)-1-tert-Butoxycarbonyl-aziridin-2-ylmethoxy)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting (S)-[1-(tert-Butyl-dimethyl-silanyloxymethyl)-2-hydroxy-ethyl]-carbamic acid tert-butyl ester for (R)-[1-(tert-Butyl-dimethyl-silanyloxymethyl)-2-hydroxy-ethyl]-carbamic acid tert-butyl ester in Example 273D. MS (APCI) m/z 481 (M+1)[0768] +.
    • Example 348B (1R)-1-(4-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate by substituting Example 348A for Example 273D and 4-chlorophenylmagnesium bromide for 3-trifluoromethoxyphenyl-mangnesium bromide in Example 274. MS (APCI) m/z 393 (M+1)[0769] +; 1H NMR (300 MHz, CD3OD) δ 2.63 (s, 3H), 3.16 (dd, J=7.63, 2.54 Hz, 2H), 3.98 (m, 1H), 4.30 (dd, J=10.51, 5.42 Hz, 1H), 4.45 (dd, J=10.51, 3.05 Hz, 1H), 7.34 (d, J=8.81 Hz, 2H), 7.39 (d, J=8.81 Hz, 2H), 7.63 (d, J=8.81 Hz, 1H), 7.74 (dd, J=8.81, 1.70 Hz, 1H), 8.11 (m, 2H), 8.43 (d, J=2.03 Hz, 1H), 8.73 (s, 1H); Anal. Calcd for C22H21ClN4O▪3 TFA: C, 45.76; H, 3.29; N, 7.62. Found: C, 45.86; H, 3.28; N, 7.72.
  • The following compounds were prepared by substituting appropriate Girgnard reagents for 3-trifluoromethoxyphenyl-mangnesium bromide in Example 348. [0770]
    • EXAMPLE 349 (1R)-1-Benzo[1,3]dioxol-5-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 403 (M+1)[0771] +; 1H NMR (300 MHz, CD3OD) δ 2.63 (s, 3H), 3.08 (dd, J=8.14, 2.03 Hz, 2H), 3.92 (m, 1H), 4.31 (dd, J=10.51, 5.76 Hz, 1H), 4.46 (dd, J=10.51, 3.05 Hz, 1H), 5.92 (s, 2H), 6.79 (d, J=8.14 Hz, 1H), 6.81 (d, J=8.14 Hz, 1H), 6.85 (s, 1H), 7.64 (d, J=8.81 Hz, 1H), 7.75 (d, J=8.81 Hz, 1H), 8.14 (m, 2H), 8.44 (d, J=2.37 Hz, 1H), 8.75 (d, J=1.70 Hz, 1H); Anal. Calcd for C23H22N4O3▪3.3 TFA: C, 45.65; H, 3.27; N, 7.19. Found: C, 45.71; H, 3.15; N, 7.21.
    • EXAMPLE 350 (1R)-1-(3-Fluoro-4-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 391 (M+1)[0772] +; 1H NMR (300 MHz, CD3OD) δ 2.24 (d, J=1.70 Hz, 3H), 2.63 (s, 3H), 3.11 (d, J=8.14 Hz, 2H), 3.96 (m, 1H), 4.31 (dd, J=10.51, 5.76 Hz, 1H), 4.46 (dd, J=10.85, 3.05 Hz, 1H), 7.03 (t, J=8.48 Hz, 1H), 7.15 (m, 1H), 7.21 (d, J=7.46 Hz, 1H), 7.64 (d, J=8.48 Hz, 1H), 7.74 (dd, J=8.81, 1.70 Hz, 1H), 8.14 (m, 2H), 8.45 (d, J=2.37 Hz, 1H), 8.75 (d, J=1.36 Hz, 1H); Anal. Calcd for C23H23FN4O▪2.9 TFA: C, 47.97; H, 3.62; N, 7.77. Found: C, 48.09; H, 3.75; N, 7.87.
    • EXAMPLE 351 (1S)-1-Benzyl-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine Example 351A 5-(2-Chloro-5-hydroxy-pyridin-3-yl)-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • A 250 mL RBF was charged with Example 12B (1.58 g, 7.59 mmol), Example 203B (3.0 g, 7.59 mmol), Pd[0773] 2(dba)3 (696 mg, 0.76 mmol), and tri-o-tolylphosphine (696 mg), and was purged with N2. Anhydrous DMF (60 mL) and Et3N (3.17 mL) were added via syringe. The solution was purged with N2 again and was heated at 70° C. for 15 h. After cooled, ethyl acetate (300 mL) was added. The mixture was washed with brine (500 mL) and water (500 mL). The ethyl acetate solution was concentrated and the residual oil was separated by flash chromatography (40-65% EtOAc in hexane) to give the desired produc. (1.86 g, 68%). MS (APCI) m/z 360 (M+1)+.
    • Example 351B 5-[5-((2S)-2-tert-Butoxycarbonylamino-3-phenyl-propoxy)-2-chloro-pyridin-3-yl]-3-methylindazole-1-carboxylic Acid Tert-Butyl Ester
  • A 25 mL RBF was charged with Example 351A (150 mg, 0.417 mmol), Boc-phenylalaminol (157 mg, 0.625 mmol), DBAD (144 mg, 0.625 mmol) and Ph[0774] 3P (163 mg, 0.625 mmol), and was purged with nitrogen. THF (8 mL) was added at 0° C. After stirring at 0° C. for 30 min the ice-H2O bath was removed and the reaction mixture was stirred at rt overnight. The reaction mixture was concentrated and the residue was separated by flash chromatography (20-40% EtOAc in hexane) to provide the desired product (215.0 mg, 87%). MS (APCI) m/z 593 (M+1)+.
    • Example 351C (1S)-1-Benzyl-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate by substituting Example 351B for Example 27B in Examples 27C. MS (APCI) m/z 393 (M+1)[0775] +; 1H NMR (300 MHz, CD3OD) δ 2.58 (s, 3H), 3.12 (d, J=7.46 Hz, 2H), 3.91 (m, 1H), 4.14 (dd, J=10.51, 5.43 Hz, 1H), 4.30 (dd, J=10.51, 3.05 Hz, 1H), 7.34 (m, 5H), 7.47 (dd, J=8.65, 1.53 Hz, 1H), 7.52 (d, J=3.05 Hz, 1H), 7.56 (d, J=8.82 Hz, 1H), 7.78 (s, 1H), 8.14 (d, J=2.71 Hz, 1H); Anal. Calcd for C22H21ClN4O▪1.6 TFA: C, 52.61; H, 3.96; N, 9.74. Found: C, 52.87; H, 3.90; N, 9.81.
  • The following compounds were prepared by substituting the appropriate Boc-aminoalcohol for Boc-phenylalaminol in Example 351. [0776]
    • EXAMPLE 352 (1S)-1-(4-Bromo-benzyl)-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 471, 473 (M+1)[0777] +; 1H NMR (300 MHz, CD3OD) δ 2.59 (s, 3H), 3.10 (dd, J=7.63, 2.88 Hz, 2H), 3.90 (m, 1H), 4.15 (dd, J=10.85, 5.43 Hz, 1H), 4.30 (dd, J=10.51, 3.05 Hz, 1H), 7.24 (d, J=8.48 Hz, 2H), 7.47 (dd, J=8.65, 1.53 Hz, 1H), 7.51 (s, 1H), 7.54 (s, 1H), 7.56 (d, J=8.48 Hz, 2H), 7.79 (s, 1H), 8.15 (d, J=3.05 Hz, 1H); Anal. Calcd for C22H20BrClN4O▪1.5 TFA: C, 46.71; H, 3.37; N, 8.72. Found: C, 46.62; H, 3.29; N, 8.64.
    • EXAMPLE 353 (1S)-1-(4-Chloro-benzyl)-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • MS (APCI) m/z 427 (M+1)[0778] +; 1H NMR (300 MHz, CD3OD) δ 2.59 (s, 3H), 3.12 (dd, J=7.63, 2.54 Hz, 2H), 3.91 (m, 1H), 4.15 (dd, J=10.51, 5.43 Hz, 1H), 4.30 (dd, J=10.51, 3.05 Hz, 1H), 7.30 (d, J=8.48 Hz, 2H), 7.37 (d, J=8.82 Hz, 2H), 7.47 (dd, J=8.65, 1.53 Hz, 1H), 7.53 (d, J=3.05 Hz, 1H), 7.56 (d, J=8.48 Hz, 1H), 7.79 (s, 1H), 8.15 (d, J=3.05 Hz, 1H); Anal. Calcd for C22H20Cl2N4O▪1.6 TFA: C, 49.64; H, 3.57; N, 9.19. Found: C, 49.99; H, 3.56; N, 9.22.
    • EXAMPLE 354 (1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-cyclohexylmethyl-ethylamine
  • MS (APCI) m/z 399 (M+1)[0779] +; 1H NMR (300 MHz, CD3OD) δ 1.01 (m, 2H), 1.31 (m, 4H), 1.49 (m, 1H), 1.65 (q, J=6.89 Hz, 2H), 1.78 (m, 4H), 2.59 (s, 3H), 3.74 (m, 1H), 4.18 (dd, J=10.51, 6.44 Hz, 1H), 4.37 (dd, J=10.51, 3.39 Hz, 1H), 7.49 (dd, J=8.82, 1.70 Hz, 1H), 7.56 (dd, J=8.48, 0.68 Hz, 1H), 7.59 (d, J=3.05 Hz, 1H), 7.80 (s, 1H), 8.17 (d, J=3.05 Hz, 1H); Anal. Calcd for C22H27ClN4O▪1.75 TFA: C, 51.18; H, 4.84; N, 9.36. Found: C, 51.13; H, 4.75; N, 9.20.
    • EXAMPLE 355 (1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,6-dimethyl-benzyl)-ethylamine
  • MS (DCI/NH[0780] 3) m/e 421 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.10 (d; 1H; J=8.4 Hz), 7.75 (d; 1H; J=8.4 Hz), 7.55 (s; 1H), 7.53 (s; 1H), 7.44 (m; 3H), 7.04 (s; 1H), 4.30 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.09 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.87 (m; 1H), 3.30 (m; 2H), 2.62 (s; 3H), 2.36 (s; 6H).
    • EXAMPLE 356 (1S)-1-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-2-phenyl-propylamine
  • The desired product was prepared by substituting Example 12B for 3-bromo-5-hydroxypyridine and Boc-3-methyl-phenylalaminol for Boc-tryptophanol in Example 102. MS (DCI/NH[0781] 3) m/e 407 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.20 (d; 1H; J=3.0 Hz), 7.81 (s; 1H), 7.61 (d; 1H; J=3.0 Hz), 7.57 (d; 1H; J=8.4 Hz), 7.40 (m; 6H), 4.44 (d; 2H; J=4.5 Hz), 3.88 (m; 1H), 3.28 (m; 1H), 2.59 (s; 3H), 1.42 (d; 3H; J=7.5 Hz).
    • EXAMPLE 357 (1S)-1-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-2,2-diphenyl-ethylamine
  • The desired product was prepared by substituting Example 12B for 3-bromo-5-hydroxypyridine and Boc-3,3-diphenylalaminol for Boc-tryptophanol in Example 102. MS (DCI/NH[0782] 3) m/e 469 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.08 (d; 1H; J=3.0 Hz), 7.74 (s; 1H), 7.55 (m; 3H), 7.43 (m; 5H), 7.31 (m; 3H), 7.21 (m; 2H), 4.65 (d; 1H; J=11.1 Hz), 4.44 (d; 1H; J=11.1 Hz), 4.31 (d; 1H; J=11.1 Hz), 4.09 (d; 1H; J=11.1 Hz), 2.59 (s; 3H).
    • EXAMPLE 358 (1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-2-phenyl-propylamine
  • The desired product was prepared by substituting Boc-3-methyl-phenylalaminol for Boc-tryptophanol in Example 102. MS (DCI/NH[0783] 3) m/e 373 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.11 (s; 2H), 8.05 (s; 2H), 7.74 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.40(m; 1H), 7.39 (m; 5H), 4.56 (m; 2H), 3.92 (m; 2H), 2.62 (s; 3H), 1.6 (d; 3H; J=7.5 Hz).
    • EXAMPLE 359 (1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-2,2-diphenyl-ethylamine
  • The desired product was prepared by substituting Boc-3,3-diphenylalaminol for Boc-tryptophanol in Example 102. MS (DCI/NH[0784] 3) m/e 435 (M+1)+; 1H NMR (300 MHz, CD3OD) δ=8.62 (s; 1H), 8.31 (s; 1H), 8.02 (s; 1H), 7.82 (s; 1H), 7.67 (d; 1H; J=8.4 Hz), 7.60 (d; 1H; J=8.4 Hz), 7.58 (d; 1H; J=6.9 Hz), 7.43(m; 4H), 7.30 (m; 5H), 4.61 (d; 1H; J=12.0 Hz), 4.48 (d; 1H; J=12 Hz), 4.40 (dd; 1H; J=11.4 Hz; J=3.0 Hz), 4.00 (dd; 1H; J=11.4 Hz), 2.62 (s; 3H).
    • EXAMPLE 360 (1S)-3-Methyl-1-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-butylamine
  • The desired product was prepared by substituting Example 12B for 3-bromo-5-hydroxypyridine and Boc-leucinol for Boc-tryptophanol in Example 102. MS (APCI) m/z 357 (M−1)[0785] +; 1H NMR (500 MHz, CD3OD) δ ppm 1.02 (m, J=6.40, 3.90 Hz, 6H), 1.67 (m, 2H), 1.80 (dd, J=13.57, 6.71 Hz, 1H), 2.59 (s, 3H), 3.71 (m, J=6.86, 3.12 Hz, 1H), 4.20 (dd, J=10.61, 6.55 Hz, 1H), 4.38 (dd, J=10.45, 3.28 Hz, 1H), 7.49 (dd, J=8.58, 1.72 Hz, 1H), 7.56 (d, J=8.11 Hz, 1H), 7.59 (d, J=3.12 Hz, 1H), 7.80 (s, 1H), 8.17 (d, J=3.12 Hz, 1H); Anal. Calcd for C19H23ClN4O: C, 49.56; H, 5.21; N, 10.88. Found: C, 49.86; H, 4.83; N, 10.49.
    • EXAMPLE 361 (1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine
  • The desired product was prepared by substituting Example 12B for 3-bromo-5-hydroxypyridine in Example 102. MS (APCI) m/z 533 (M+1)[0786] +; 1H NMR (500 MHz, CD3OD) δ ppm 2.58 (s, 3H), 3.28 (m, 2H), 3.96 (m, 1H), 4.20 (dd, J=10.45, 5.77 Hz, 1H), 4.34 (dd, J=10.61, 3.12 Hz, 1H), 7.02 (t, J=7.49 Hz, 1H), 7.12 (t, J=7.64 Hz, 1H), 7.22 (s, 1H), 7.37 (d, J=8.42 Hz, 1H), 7.44 (dd, J=8.42, 1.56 Hz, 1H), 7.47 (d, J=3.12 Hz, 1H), 7.54 (d, J=8.42 Hz, 1H), 7.57 (d, J=8.11 Hz, 1H), 7.74 (s, 1H), 8.12 (d, J=2.81 Hz, 1H); Anal. Calcd for C24H22ClN5O: C, 52.08; H, 4.12; N, 11.61. Found: C, 52.45; H, 4.08; N, 11.24.
    • EXAMPLE 362 (1S)-2-(6-Chloro-5-thieno[2,3-c]pyridin-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine Example 362A (1S)-[2-(6-Chloro-5-thieno[2,3-c]pyridin-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The title compound was prepared by substituting Example 13A for Example 2A and Example 38A for Example 27A in Example 27B. [0787]
    • Example 362B (1S)-2-(6-Chloro-5-thieno[2,3-c]pyridin-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine
  • The title compound was prepared by substituting Example 362A for Example 27B in Example 27C. MS (APCI) m/z 436 (M+1)[0788] +; 1H NMR (300 MHz, CD3OD) δ 3.29 (m, 2H), 4.00 (m, 1H), 4.26 (dd, J=10.51, 5.76 Hz, 1H), 4.40 (dd, J=10.51, 3.05 Hz, 1H), 7.02 (t, J=7.63 Hz, 1H), 7.10 (t, J=6.95 Hz, 1H), 7.23 (s, 1H), 7.36 (d, J=8.14 Hz, 1H), 7.58 (d, J=7.80 Hz, 1H), 7.74 (d, J=3.05 Hz, 1H), 8.05 (s, 1H), 8.29 (d, J=3.05 Hz, 1H), 8.35 (d, J=6.10 Hz, 1H), 8.64 (d, J=6.10 Hz, 1H), 9.57 (s, 1H); Anal. Calcd for C23H19ClN4OS▪2.6 TFA: C, 46.31; H, 2.98; N, 7.66. Found: C, 46.22; H, 2.94; N, 7.52.
    • EXAMPLE 363 5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-isoquinolin-6-yl-pyridine-2-carbonitrile Example 363A (1S)-[2-(6-Chloro-5-isoquinolin-6-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The title compound was prepared by substituting Example 13A for Example 2A in Example 27B. MS (APCI) m/z 529 (M+1)[0789] +.
    • Example 363B (1S)-[2-(6-Cyano-5-isoquinolin-6-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • A 10 mL RBF was charged with Example 363A (100 mg, 0.189 mmol), zinc cyanide (56 mg, 0.47 mmol) and Pd(PPh[0790] 3)4 (44 mg, 0.0378 mmol), and was purged with nitrogen. Anhydrous DMF (3 mL) was added and the solution was purged with nitrogen again. The reaction mixture was stirred at 90° C. for 70 h. After cooled, the mixture was partitioned between ethyl acetate and brine, and the organic phase was washed with water. The Organic layer was concentrated and the residue was separated by flash chromatography (40-100% EtOAc in hexane) to give the desired product (87.4 mg, 89%). MS (APCI) m/z 520 (M+1)+.
    • Example 363C 5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-isoquinolin-6-yl-pyridine-2-carbonitrile
  • The desired product was prepared as the trifluoroacetate by substituting Example 363B for Example 27B in Examples 27C. MS (APCI) m/z 421 (M+1)[0791] +; 1H NMR (300 MHz, CD3OD) δ 3.31 (m, 2H), 4.03 (m, 1H), 4.34 (dd, J=10.85, 5.76 Hz, 1H), 4.48 (dd, J=10.85, 3.39 Hz, 1H), 7.00 (t, J=7.46 Hz, 1H), 7.10 (t, J=6.95 Hz, 1H), 7.23 (s, 1H), 7.35 (d, J=8.14 Hz, 1H), 7.57 (d, J=7.80 Hz, 1H), 7.64 (d, J=2.71 Hz, 1H), 8.08 (dd, J=8.48, 1.69 Hz, 1H), 8.39 (d, J=7.46 Hz, 1H), 8.37 (d, J=6.44 Hz, 1H), 8.55 (d, J=7.12 Hz, 1H), 8.56 (m, 1H), 8.65 (d, J=6.10 Hz, 1H), 9.72 (s, 1H); Anal. Calcd for C26H21N5O▪2.9 TFA: C, 50.92; H, 3.21; N, 9.34. Found: C, 50.98; H, 3.23; N, 9.48.
    • EXAMPLE 364 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine Example 364A (1S)-{1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethyl}-carbamic Acid Tert-Butyl Ester
  • To a solution of Example 80E (150 mg, 0.28 mmol), (1,1,1-tributylstannyl)benzene (137 mg, 0.57 mmol), tris(dibenzylideneacetone)-dipalladium (27 mg, 0.028 mmol) and 2-dicyclohexylphosphino-2′-dimethylamino-1,1′-biphenyl (22 mg, 0.057 mmol) in dry DMF (10 ml) triethyl amine was added under N[0792] 2. The resulting solution was stirred 3 hours at 100° C. The reaction solution was partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na2SO4), filtered and concentrated under vacumm. Purification on silica gel with 60% ethyl acetate/hexane to provide the title compound (70 mg, 47%). MS (DCI/NH3) m/e 571 (M+1)+.
    • Example 364B (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine
  • The title compound was prepared as trifluoroacetic acid salt by substituting Example 354A for Example 27B in Example 27C. MS (DCI/NH[0793] 3) m/e 471 (M+1)+;. 1H NMR (300 MHz, D6-DMSO) δ 11.04 (s; 1H), 9.49 (s; 1H), 8.74 (s; 1H), 8.45 (s; 1H), 8.44 (s; 1H), 8.39 (s; 1H), 8.28 (d; 1H; J=8.4 Hz), 8.23 (d; 1H; J=7.5 Hz), 8.08 (s; 2H), 8.02 (d; 1H; J=8.4 Hz), 7.83 (s; 1H), 7.63 (d; 1H; J=8.4 Hz), 7.55 (t; 3H; J=7.5 Hz), 7.47 (d; 1H; J=7.5 Hz), 7.37 (d; 1H; J=8.4 Hz), 7.31 (s; 1H), 7.10 (t; 1H; J=7.2 Hz), 7.00 (t; 1H; J=7.2 Hz), 4.40 (m; 1H), 4.23 (m; 1H), 3.88 (m; 1H), 3.18 (m; 2H) The following compounds were prepared by substituting the appropriate tributylsannyl reagents for (1,1,1-tributylstannyl)benzene in Example 364.
    • EXAMPLE 365 (1S)-2-[5-(3-Ethyl-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine
  • MS (DCI/NH[0794] 3) m/e 423 (M+1)+;. 1H NMR (300 MHz, D6-DMSO) δ=11.04 (s; 1H), 9.61 (s; 1H), 8.77 (s; 1H), 8.47 (s; 1H), 8.45 (s; 1H), 8.42 (d; 1H; J=9.0 Hz), 8.20 (s; 2H), 8.14 (d; 2H; J=9.0 Hz), 8.03 (s; 2H), 7.85 (s; 1H), 7.63 (d; 1H; J=7.5 Hz), 7.38 (d; 1H; J=7.5 Hz), 7.30 (s; 1H), 7.10 (t; 1H; J=7.5 Hz), 7.00 (t; 1H; J=7.5 Hz), 4.40 (m; 1H), 4.22 (m; 1H), 3.88 (m; 1H), 3.18 (m; 2H), 3.04 (q; 2H; J=7.5 Hz), 1.37 (t; 3H; J=7.5 Hz).
    • EXAMPLE 366 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-pyridin-4-yl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0795] 3) m/e 472 (M+1)+;. 1H NMR (300 MHz, D6-DMSO) δ=11.04 (s; 1H), 9.54 (s; 1H), 8.93 (d; 2H; J=7.5 Hz), 8.87 (d; 2H; J=7.5 Hz), 8.83 (s; 1H), 8.70 (s; 1H), 8.43 (s; 2H), 8.35 (d; 1H; J=8.4 Hz), 8.09 (d; 2H; J=8.4 Hz), 7.84 (s; 1H), 7.61 (d; 1H; J=8.4 Hz), 7.38 (d; 1H; J=8.4 Hz), 7.25 (s; 1H), 7.12 (t; 1H; J=8.4 Hz), 7.03 (t; 1H; J=8.4 Hz), 4.45 (m; 1H), 4.30 (m; 1H), 4.00 (m; 1H), 3.30 (m; 2H)
    • EXAMPLE 367 (1S)-2-[5-(3-Furan-2-yl-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine
  • MS (DCI/NH[0796] 3) m/e 461 (M+1)+;. 1H NMR (300 MHz, D6-DMSO) δ=11.04 (s; 1H), 9.39 (s; 1H), 8.74 (s; 1H), 8.44 (s; 1H), 8.41 (s; 1H), 8.25 (d; 1H; J=8.4 Hz), 8.18 (m; 3H), 8.00 (d; 2H; J=8.4 Hz), 7.89 (s; 1H), 7.83 (s; 1H), 7.63 (d; 1H; J=8.4 Hz), 7.39 (d; 1H; J=8.4 Hz), 7.31 (s; 1H), 7.18 (s; 1H), 7.11 (t; 1H; J=8.4 Hz), 7.01 (t; 1H; J=8.4 Hz), 6.71 (s; 1H), 4.40 (m; 1H), 4.21 (m; 1H), 3.88 (m; 1H), 3.18 (m; 2H)
    • EXAMPLE 368 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenylethynyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0797] 3) m/e 495 (M+1)+;. 1H NMR (300 MHz, D6-DMSO) δ=11.04 (s; 1H), 9.41 (s; 1H), 8.73 (s; 1H), 8.45 (s; 1H), 8.35 (s; 1H), 8.31 (d; 1H; J=5.4 Hz), 8.24 (s; 2H), 8.21 (s; 1H), 8.07 (d; 1H; J=5.4 Hz), 7.82 (s; 1H), 7.65 m; 4H), 7.48 (m; 2H), 7.39 (d; 1H; J=5.4 Hz), 7.30 (s; 1H), 7.10 (t; 1H; J=5.4 Hz), 7.00 (t; 1H; J=5.4 Hz), 4.40 (m; 1H), 4.22 (m; 1H), 4.13 (m; 1H), 3.18 (m; 2H).
    • EXAMPLE 369 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-prop-1-ynyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0798] 3) m/e 433 (M+1)+; 1H NMR (300 MHz, D6-DMSO) δ=11.04 (s; 1H), 9.32 (s; 1H), 8.71 (s; 1H), 8.43 (s; 1H), 8.28 (s; 1H), 8.25 (d; 1H; J=8.4 Hz), 8.18 (s; 2H), 8.02 (d; 1H; J=8.4 Hz), 7.99 (s; 1H), 7.80 (s; 1H), 7.62 (d; 1H; J=8.4 Hz), 7.38 (d; 1H; J=8.4 Hz), 7.30 (s; 1H), 7.10 (t; 1H; J=8.4 Hz), 7.00 (t; 1H; J=8.4 Hz), 4.40 (m; 1H), 4.21 (m; 1H), 3.88 (m; 1H), 3.18 (m; 2H), 2.13 (s; 3H).
    • EXAMPLE 370 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-vinyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine
  • MS (DCI/NH[0799] 3) m/e 421 (M+1)+; 1H NMR (300 MHz, D6-DMSO) δ=11.04 (s; 1H), 9.36 (s; 1H), 8.71 (s; 1H), 8.42 (s; 1H), 8.28 (s; 1H), 8.25 (d; 1H; J=9.0 Hz), 8.18 (s; 2H), 8.00 (d; 1H; J=9.0 Hz), 7.85 (s; 1H), 7.81 (s; 1H), 7.63 (d; 1H; J=8.4 Hz), 7.38 (d; 1H; J=8.4 Hz), 7.29 (s; 1H), 7.10 (t; 1H; J=8.4 Hz), 7.01 (t; 1H; J=8.4 Hz), 6.98 (dd; 1H; J=17.4 Hz; J=12.0 Hz), 6.40 (d; 1H; J=17.4 Hz), 5.50 (d; 1H; J=12.0 Hz), 4.40 (m; 1H), 4.21 (m; In), 3.88 (m; 1H), 3.18 (m; 2H).
    • EXAMPLE 371 (1S)-6-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinoline-3-carbonitrile Example 371A (1S)-[2-[5-(3-Cyano-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was obtained by substituting Example 80E for example 363A in Example 363B. [0800]
    • Example 371B (1S)-6-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinoline-3-carbonitrile
  • The desired product was obtained as trifluoroacetic acid salt by substituting Example 371A for Example 27B in Example 27C. MS (DCI/NH[0801] 3) m/e 420 (M+1)+;. 1H NMR (300 MHz, D6-DMSO) δ=11.04 (s; 1H), 9.52 (s; 1H), 8.75 (s; 1H), 8.64 (s; 1H), 8.47 (s; 2H), 8.42 (d; 1H; J=6.0 Hz), 8.26 (m; 3H), 7.84 (s; 1H), 7.62 (d; 1H; J=6.0 Hz), 7.38 (d; 1H; J=6.0 Hz), 7.31 (s; 1H), 7.10 (t; 1H; J=6.0 Hz), 7.00 (t; 1H; J=6.0 Hz), 4.40 (m; 1H), 4.22 (m; 1H), 3.88 (m; 1H), 3.18 (m; 2H).
    • EXAMPLE 372 (1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-6-vinyl-pyridin-3-yloxy)-ethylamine
  • The desired product was prepared as the trifluoroacetate by substituting tributylvinyltin for tributylphenyltin and Example 363A for Example 80E in Example 364. MS (APCI) m/z 420 (M+1)[0802] +; 1H NMR (300 MHz, CD3OD) δ 3.30 (m, 2H), 3.98 (m, 1H), 4.24 (dd, J=10.51, 5.76 Hz, 1H), 4.38 (dd, J=10.51, 3.05 Hz, 1H), 5.39 (dd, J=10.85, 1.70 Hz, 1H), 6.24 (dd, J=16.95, 1.70 Hz, 1H), 6.66 (dd, J=17.12, 10.68 Hz, 1H), 7.00 (dd, J=6.78, 6.10 Hz, 1H), 7.09 (t, J=7.63 Hz, 1H), 7.22 (s, 1H), 7.35 (d, J=8.14 Hz, 1H), 7.40 (d, J=2.71 Hz, 1H), 7.57 (d, J=7.80 Hz, 1H), 7.95 (dd, J=8.48, 1.70 Hz, 1H), 8.22 (s, 1H), 8.45 (d, J=7.46 Hz, 1H), 8.45 (s, 1H), 8.56 (d, J=8.81 Hz, 1H), 8.64 (d, J=6.44 Hz, 1H), 9.79 (s, 1H); Anal. Calcd for C27H24N4O▪4 TFA: C, 47.96, 3.22; N, 6.39. Found: C, 48.02; H, 3.00; N, 6.07.
    • EXAMPLE 373 (1S)-2-(6-Ethynyl-5-isoquinolin-6-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine
  • The desired product was prepared as the trifluoroacetate by substituting tributylethynyltin for tributylphenyltin and Example 363A for Example 80E in Example 364. MS (APCI) m/z 419 (M+1)[0803] +; 1H NMR (300 MHz, CD3OD) δ 3.31 (m, 2H), 3.67 (s, 1H), 3.99 (m, 1H), 4.28 (dd, (J=10.74, 5.83 Hz, 1H), 4.42 (dd, J=10.74, 3.07 Hz, 1H), 7.00 (t, J=7.06 Hz, 1H), 7.09 t, J=7.21 Hz, 1H), 7.23 (s, 1H), 7.35 (d, J=8.29 Hz, 1H), 7.55 (m, 1H), 7.56 (d, J=7.98 Hz, 1H), 8.19 (dd, J=8.59, 1.53 Hz, 1H), 8.42 (s, 2H), 8.47 (d, J=6.44 Hz, 1H), 8.56 (d, J=8.59 Hz, 1H), 8.63 (d, J=6.44 Hz, 1H), 9.79 (s, 1H); Anal. Calcd for C27H22N4O▪2.9 TFA: C, 52.59; H, 3.35; N, 7.48. Found: C, 52.52; H, 3.44; N, 7.01.
    • EXAMPLE 374 (1S)-2-(6-Furan-2-yl-5-isoquinolin-6-yl-pyridin-3-yloxy)-(1H-indol-3-ylmethyl)-ethylamine
  • The desired product was prepared as the trifluoroacetate by substituting tributylethynyltin for tributylstannylfuran and Example 363A for Example 80E in Example 364. MS (APCI) m/z 461 (M+1)[0804] +; 1H NMR (300 MHz, CD3OD) δ 3.30 (m, 2H), 3.98 (m, 1H), 4.25 (dd, J=10.51, 5.76 Hz, 1H), 4.40 (dd, J=10.51, 3.05 Hz, 1H), 6.39 (dd, J=3.39, 1.70 Hz, 1H), 6.44 (d, J=4.41 Hz, 1H), 7.00 (dd, J=7.80, 7.12 Hz, 1H), 7.09 (t, J=6.78 Hz, 1H), 7.21 (s, 1H), 7.28 (d, J=1.70 Hz, 1H), 7.37 (d, J=8.14 Hz, 1H), 7.47 (d, J=2.71 Hz, 1H), 7.57 (d, J=7.80 Hz, 1H), 7.80 (dd, J=8.65, 1.53 Hz, 1H), 8.21 (s, 1H), 8.42 (d, J=6.78 Hz, 1H), 8.46 (d, J=7.12 Hz, 1H), 8.48 (s, 1H), 8.62 (d, J=6.44 Hz, 1H), 9.77 (s, 1H); Anal. Calcd for C29H24N4O2.3.9 TFA: C, 48.83; H, 3.11; N, 6.19. Found: C, 48.86; H, 3.31; N, 6.18.
    • EXAMPLE 375 (1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-6-phenylethynyl-pyridin-3-yloxy)-ethylamine
  • The desired product was prepared as the trifluoroacetate by substituting tributyl(phenylethynyl)tin tributylphenyltin and Example 363A for Example 80E in Example 364. MS (APCI) m/z 495 (M+1)[0805] +; 1H NMR (300 MHz, CD3OD) δ 3.30 (m, 2H), 4.02 (m, 1 H), 4.30 (dd, J=10.51, 5.76 Hz, 1H), 4.44 (dd, J=10.51, 3.05 Hz, 1H), 7.01 (t, J=7.46 Hz, 1H), 7.11 (t, J=7.46 Hz, 1H), 7.24 (s, 1H), 7.29 (m, 5H), 7.36 (d, J=8.14 Hz, 1H), 7.61 (d, J=2.71 Hz, 1H), 7.59 (d, J=7.80 Hz, 1H), 8.24 (dd, J=8.65, 1.53 Hz, 1H), 8.38 (d, J=6.44 Hz, 1H), 8.46 (d, J=2.71 Hz, 1H), 8.46 (s, 1H), 8.55 (d, J=8.81 Hz, 1H), 8.62 (d, J=6.44 Hz, 1H), 9.72 (s, 1H); Anal. Calcd for C33H26N4O▪2.3 TFA: C, 59.67; H, 3.77; N, 7.40. Found: C, 59.61; H, 4.04; N, 7.36.
    • EXAMPLE 376 6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinolin-5-ylamine
  • The desired product was prepared as the trifluoroacetate by substituting 5-amino-6-bromoisoquinoline for 6-bromophthalimide in Example 32. MS (APCI) m/z 410 (M+1)[0806] +; 1H NMR (300 MHz, CD3OD) δ 3.32 (m, 2H), 4.00 (m, 1H), 4.27 (dd, J=10.51, 5.76 Hz, 1H), 4.44 (dd, J=10.51, 3.39 Hz, 1H), 7.01 (t, J=7.46 Hz, 1H), 7.10 (t, J=7.46 Hz, 1H), 7.24 (s, 1H), 7.36 (d, J=7.80 Hz, 1H), 7.59 (d, J=7.80 Hz, 1H), 7.67 (d, J=8.14 Hz, 1H), 7.73 (s, 1H), 7.80 (d, J=8.48 Hz, 1H) 8.45 (s, 2H), 8.50 (d, J=6.78 Hz, 1H), 8.66 (d, J=6.78 Hz, 1H), 9.60 (s, 1H); Anal. Calcd for C25H23N5O▪3.3 TFA: C, 48.30; H, 3.37; N, 8.91. Found: C, 48.35; H, 3.44; N, 8.91.
    • EXAMPLE 377 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(8-methyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate by substituting 6-bromo-8-methyl-isoquinoline for 6-bromophthalimide in Example 32. MS (APCI) m/z 409 (M+1)[0807] +; 1H NMR (300 MHz, CD3OD) δ 2.91 (s, 3H), 3.32 (m, 2H), 4.02 (m, 1H), 4.32 (dd, J=10.51, 5.76 Hz, 1H), 4.47 (dd, J=10.51, 3.39 Hz, 1H), 7.02 (t, J=7.46 Hz, 1H), 7.11 (t, J=7.63 Hz, 1H), 7.25 (s, 1H), 7.37 (d, J=8.14 Hz, 1H), 7.60 (d, J=8.14 Hz, 1H), 7.91 (dd, J=8.31, 4.92 Hz, 1H), 7.96 (d, J=1.70 Hz, 1H), 8.15 (s, 1H), 8.31 (d, J=2.03 Hz, 1H), 8.46 (s, 1H), 8.74 (s, 1H), 8.87 (dd, J=8.48, 1.70 Hz, 1H), 9.08 (dd, J=4.92, 1.53 Hz, 1H); Anal. Calcd for C26H24N4O▪3.5 TFA: C, 49.08; H, 3.43; N, 6.94. Found: C, 49.23; H, 3.24; N, 6.87.
    • EXAMPLE 378 (1S)-2-[5-(4-Chloro-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine
  • The title compound was prepared by substituting 4-chlorothieno[2,3-c]pyridine for thieno[2,3-c]pyridine in Example 38. MS (APCI) m/z 435 (M+1)[0808] +; 1H NMR (300 MHz, CD3OD) δ 3.31 (m, 2H), 4.01 (m, 1H), 4.29 (dd, J=10.51, 5.76 Hz, 1H), 4.44 (dd, J=10.51, 3.05 Hz, 1H), 7.04 (t, J=8.14 Hz, 1H), 7.12 (t, J=6.95 Hz, 1H), 7.25 (s, 1H), 7.39 (d, J=8.14 Hz, 1H), 7.61 (d, J=7.80 Hz, 1H), 7.84 (t, J=2.71 Hz, 1H), 8.04 (s, 1H), 8.42 (d, J=2.03 Hz, 1H), 8.51 (s, 1H), 8.72 (s, 1H), 9.13 (s, 1H); Anal. Calcd for C23H19ClN4OS▪2.8 TFA: C, 45.55; H, 2.91; N, 7.43. Found: C, 45.42; H, 2.70; N, 7.28.
    • EXAMPLE 379 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethylamine
  • The title compound was prepared by substituting 4-phenylthieno[2,3-c]pyridine for thieno[2,3-c]pyridine in Example 38. MS (APCI) m/z 477 (M+1)[0809] +; 1H NMR (300 MHz, CD3OD) δ 3.31 (m, 2H), 4.00 (m, 1H), 4.26 (dd, J=10.51, 5.76 Hz, 1H), 4.41 (dd, J=10.51, 3.39 Hz, 1H), 6.99 (t, J=6.95 Hz, 1H), 7.10,(t, J=7.12 Hz, 1H), 7.22 (s, 1H), 7.36 (d, J=7.80 Hz, 1H), 7.57 (d, J=7.80 Hz, 1H), 7.65 (m, 3H), 7.73 (t, J=2.03 Hz, 1H), 7.76 (d, J=1.70 Hz, 1H), 7.84 (m, 1H), 8.11 (s, 1H), 8.46 (s, 1H), 8.62 (s, 1H), 8.74 (s, 1H), 9.52 (s, 1H);. Anal. Calcd for C29H24N4OS▪2.8 TFA: C, 52.22; H, 3.39; N, 7.04. Found: C, 52.11; H, 3.13; N, 6.91.
    • EXAMPLE 380 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenoxy-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethylamine
  • The title compound was prepared by substituting 4-phenoxythieno[2,3-c]pyridine for thieno[2,3-c]pyridine in Example 38. MS (APCI) m/z 493 (M+1)[0810] +; 1H NMR (300 MHz, CD3OD) δ 3.30 (m, 2H), 4.01 (m, 1H), 4.27 (dd, J=10.51, 5.76 Hz, 1H), 4.42 (dd, J=10.51, 3.05 Hz, 1H), 7.03 (t, J=7.46 Hz, 1H), 7.11 (t, J=7.46 Hz, 1H), 7.24 (s, 1H), 7.25 (d, J=8.82 Hz, 1H), 7.33 (t, J=7.46 Hz, 2H), 7.38 (d, J=7.80 Hz, 1H), 7.52 (t, J=7.97 Hz, 2H), 7.60 (d, J=7.80 Hz, 1H), 7.85 (s, 1H), 8.00 (s, 1H), 8.16 (s, 1H), 8.44 (d, J=2.03 Hz, 1H), 8.72 (s, 1H), 9.17 (s, 1H).
    • EXAMPLE 381 (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-vinyl-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethylamine Example 381A (1S)-[2-[5-(4-Chloro-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The title compound was prepared by substituting 4-chlorothieno[2,3-c]pyridine for thieno[2,3-c]pyridine in Example 38. MS (APCI) m/z 535 (M+1)[0811] +.
    • Example 381B (S)-{1-(1H-Indol-3-ylmethyl)-2-[5-(4-vinyl-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethyl}-carbamic Acid Tert-Butyl Ester
  • A 25 mL RBF was charged with Example 381A (102 mg, 0.19 mmol), Pd[0812] 2(dba)3 (18 mg, 0.019 mmol), and 2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl (15 mg, 0.038 mmol), and was purged with N2. Anhydrous DMF (5 mL), tributylvinyltin (111 μL, 0.38 mmol) and Et3N (80 μL) were added via syringe. The solution was purged with N2 again and was heated at 70° C. for 20 h. After cooled, ethyl acetate (50 mL) was added. The mixture was washed with brine (50 mL) and water (50 mL). The ethyl acetate solution was concentrated, and the residual oil was separated by flash chromatography (A: 2:1 EtOAc/hexane, 0-15% CH3OH in A) to give the desired product (72 mg, 72%). MS (APCI) m/z 527 (M+1)+.
    • Example 381C (1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-vinyl-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate by substituting Example 381B for Example 27B in Examples 27C. MS (APCI) m/z 427 (M+1)[0813] +; 1H NMR (300 MHz, CD3OD) δ 3.32 (m, 2H), 4.03 (m, 1H), 4.30 (dd, J=10.51, 5.76 Hz, 1H), 4.46 (dd, J=10.51, 3.39 Hz, 1H), 5.84 (d, J=11.19 Hz, 1H), 6.26 (d, J=17.29 Hz, 1H), 7.03 (t, J=7.46 Hz, 1H), 7.12 (t, J=7.63 Hz, 1H), 7.25 (s, 1H), 7.35 (d, J=10.85 Hz, 1H), 7.41 (d, J=10.85 Hz, 1H), 7.60 (d, J=7.80 Hz, 1H), 7.90 (m, 1H), 8.44 (s, 1H), 8.49 (d, J=2.37 Hz, 1H), 8.79 (s, 2H), 9.42 (s, 1H); Anal. Calcd for C25H22N4OS▪3.2 TFA: C, 47.65; H, 3.21; N, 7.08. Found: C, 47.74; H, 3.13; N, 6.96.
    • EXAMPLE 382 (1S)-2-[5-(4-Ethyl-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine
  • To a solution of Example 381A (50 mg, 0.063 mmol) in methanol (4 mL) was added triethylamine (56 μL) and 10% Pd/C (20 mg) under nitrogen. The suspension was purged with H[0814] 2 (balloon) and was stirred at rt for 6 h. The solid material was filtered off. The filtrate was concentrated and the residue was purified by HPLC (Zorbax, C-18, 250×2.54 column, Mobile phase A: 0.1% TFA in HO; B: 0.1% TFA in CH3CN; 0-100% gradient) to provide the title compound (37.2 mg, 74%). MS (APCI) m/z 429 (M+1)+; 1H NMR (300 MHz, CD3OD) δ 1.46 (t, J=7.46 Hz, 3H), 3.23 (q, J=7.46 Hz, 2H), 3.36 (m, 2H), 4.03 (m, 1H), 4.31 (dd, J=10.51, 5.76 Hz, 1H), 4.47 (dd, J=10.51, 3.39 Hz, 1H), 7.02 (t, J=7.46 Hz, 1H), 7.12 (t, J=7.46 Hz, 1H), 7.25 (s, 1H), 7.38 (d, J=8.14 Hz, 1H), 7.60 (d, J=7.80 Hz, 1H), 7.92 (t, J=2.03 Hz, 1H), 8.39 (s, 1H), 8.49 (s, 1H), 8.49 (d, J=3.05 Hz, 1H), 8.81 (d, J=1.70 Hz, 1H), 9.45 (s, 1H); Anal. Calcd for C25H24N4OS▪3.3 TFA: C, 47.16; H, 3.42; N, 6.96. Found: C, 47.03; H, 3.34; N, 6.96.
    • EXAMPLE 383 (1S)-(2-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-thieno[2,3-c]pyridin-4-yl)-phenyl-amine Example 383A (1S)-{1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenylamino-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethyl}-carbamic Acid Tert-Butyl Ester
  • A 25 mL RBF was charged with Example 381A (100 mg, 0.186 mmol), Pd[0815] 2(dba)3 (17 mg, 0.0186 mmol), and 1,3-bis(2,6-di-1-propylphenyl)imidazolium chloride (Nolan ligand) (16 mg, 0.0372 mmol), and was purged with N2. Anhydrous dioxane (3 mL), aniline (21 mg, 0.224 mmol) and potassium tert-butoxide (1.0 M solution in THF, 0.279 mL) were added via syringe. The solution was purged with N2 again, and was heated at 100° C. for 20 h. After cooled, ethyl acetate (50 mL) was added, and the mixture was washed with brine (50 mL) and water. The EtOAc solution was concentrated, and the residue was separated by flash chromatography (30-80% EtOAc in hexane) to provide the desire product (34 mg, 31%). MS (APCI) m/z 592 (M+1)+.
    • Example 383B (1S)-(2-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-thieno[2,3-c]pyridin-phenyl-amine
  • The desired product was prepared as the trifluoroacetate by substituting Example 383A for Example 27B in Examples 27C. MS (APCI) m/z 492 (M+1)[0816] +; 1H NMR (300 MHz, DMSO-d6) δ 3.19 (d, J=7.12 Hz, 2H), 3.88 (m, 1H), 4.20 (dd, J=10.51, 5.42 Hz, 1H), 4.38 (d, J=10.51 Hz, 1H), 7.01 (t, J=7.46 Hz, 1H), 7.11 (m, 3H), 7.38 (m, 6H), 7.62 (d, J=8.14 Hz, 1H), 7.78 (s, 1H), 8.22 (s, 2H), 8.29 (s, 1H), 8.47 (s, 1H), 8.74 (s, 1H), 8.98 (s, 1H), 9.06 (s, 1H), 11.04 (s, 1H); Anal. Calcd for C29H25N5OS▪3 TFA: C, 50.42;,H, 3.39; N, 8.40. Found: C, 50.40; H, 3.58; N, 8.23.
    • EXAMPLE 384 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3,3-difluoro-1,3-dihydro-indol-2-one
  • The desired product was prepared as the trifluoroacetate by substituting 5-Bromo-3,3-difluoro-1,3-dihydro-indol-2-one for 6-bromophthalimide in Example 32. MS (APCI) m/z 435 (M+1)[0817] +; 1H NMR (300 MHz, CD3OD) δ 3.36 (m, 2H), 4.01 (m, 1H), 4.26 (dd, J=10.51, 5.76 Hz, 1H), 4.43 (dd, J=10.51, 3.05 Hz, 1H), 7.03 (t, J=7.46 Hz, 1H), 7.13 (t, J=7.46 Hz, 2H), 7.24 (s, 1H), 7.39 (d, J=8.14 Hz, 1H), 7.60 (d, J=8.14 Hz, 1H), 7.79 (m, 2H), 7.90 (d, J=1.70 Hz, 1H), 8.36 (d, J=2.03 Hz, 1H), 8.56 (s, 1H); Anal. Calcd for C24H20F2N4O2▪2.5 TFA: C, 48.41; H, 3.15; N, 7.79. Found: C, 48.66; H, 3.20; N, 7.82.
    • EXAMPLE 385 6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3H-oxazolo[4,5-b]pyridin-2-one
  • The desired product was prepared as the trifluoroacetate by substituting 6-Bromo-3H-oxazolo[4,5-b]pyridin-2-one for 6-bromophthalimide in Example 32. MS (APCI) m/z 402 (M+1)[0818] +; 1H NMR (300 MHz, CD3OD) δ 3.34 (m, 2H), 4.00 (m, 1H), 4.28 (dd, J=110.51, 5.76 Hz, 1H), 4.42 (dd, J=10.51, 3.05 Hz, 1H), 7.02 (t, J=7.46 Hz, 1H), 7.12 (t, J=7.63 Hz, 1H), 7.23 (s, 1H), 7.38 (d, J=8.14 Hz, 1H), 7.59 (d, J=7.80 Hz, 1H), 7.74 (d, J=1.70 Hz, 1H), 7.83 (d, J=1.70 Hz, 1H), 8.33 (d, J=2.03 Hz, 1H), 8.38 (d, J=2.37 Hz, 1H), 8.55 (s, 1H); Anal. Calcd for C22H19N5O3▪2.6 TFA: C, 46.81; H, 3.12; N, 10.04. Found: C, 46.67; H, 2.98; N, 9.89.
    • EXAMPLE 386 N1-(5-Isoquinolin-6-yl-pyridin-3-yl)-ethane-1,2-diamine Example 386A [2-(5-Bromo-pyridin-3-ylamino)-ethyl]-carbamic Acid Tert-Butyl Ester
  • A 50 mL RBF was charged with 3,5-dibromopyridine (3.70 g, 15.6 mmol), t-butyl N-(2-aminoethyl)carbamate (2.50 g, 15.6 mmol), Pd[0819] 2(dba)3 (714 mg, 0.78 mmol), (R)-BINAP (1.46 g, 2.34 mol) and Cs2CO3 (7.62 g, 23.4 mmol), and was purged with N2. Anhydrous toluene (120 mL) was added via syringe. The solution was purged with N2 again, and was heated at 100° C. overnight. After cooled, ethyl acetate (500 mL) was added and the mixture was washed with water. The EtOAc solution was concentrated and the residue was separated by flash chromatography (20-80% EtOAc in hexane) to provide the desried product (2.1 g, 43%). MS (DCI) m/z 316, 318 (M+1)+.
    • Example 386B [2-(5-Isoquinolin-6-yl-pyridin-3-ylamino)-ethyl]-carbamic Acid Tert-Butyl Ester
  • The desired product was prepared by substituting Example 386A for Example 2A in Example 27B. MS (APCI) m/z 365 (M+1)[0820] +.
    • Example 386C N1-(5-Isoquinolin-6-yl-pyridin-3-yl)-ethane-1,2-diamine
  • The desired product was prepared as the trifluoroacetate by substituting Example 386B for Example 27B in Examples 27C. MS (APCI) m/z 265 (M+1)[0821] +; 1H NMR (300 MHz, CD3OD) δ 3.26 (t, J=5.76 Hz, 2H), 3.70 (t, J=5.76 Hz, 2H), 8.10 (s, 1H), 8.25 (s, 1H), 8.33 (d, J=8.82 Hz, 1H), 8.45 (d, J=6.44 Hz, 1H), 8.56 (s, 1H), 8.63 (m, 3H), 9.76 (s, 1H).
    • EXAMPLE 387 Naphthalene-2-sulfonic Acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide Example 387A {2-[(5-Isoquinolin-6-yl-pyridin-3-yl)-(naphthalene-2-sulfonyl)-amino]-ethyl}-carbamic Acid Tert-Butyl Ester
  • To a solution of Example 386B (70 mg, 0.192 mmol) in pyridine (3 mL) was added 2-naphthalenesulfonyl chloride (87 mg, 0.384 mmol) at rt. The formed yellow solution was stirred at rt for 15 h. Pyridine was removed under reduced pressure and the residual oil was purified by flash chromatography (0-15% CH[0822] 3OH in 2:1 EtOAc/hexane) to provide the desire product (69 mg, 65%). MS (APCI) m/z 555 (M+1)+.
    • Example 387B Naphthalene-2-sulfonic Acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide
  • The desired product was prepared as the trifluoroacetate by substituting Example 387B for Example 27B in Examples 27C. MS (APCI) m/z 455 (M+1)[0823] +; 1H NMR (300 MHz, CD3OD) δ 3.17 (t, J=5.76 Hz, 2H), 4.09 (t, J=5.43 Hz, 2H), 7.66 (t, J=6.78 Hz, 1H), 7.75 (t, J=7.46 Hz, 1H), 7.99 (m, 2H), 8.06 (m, 3H), 8.13 (d, J=8.82 Hz, 1H), 8.26 (m, 2H), 8.31 (s, 1H), 8.47 (d, J=8.48 Hz, 1H), 8.59 (m, 2H), 9.08 (d, J=2.03 Hz, 1H), 9.69 (s, 1H).
    • EXAMPLE 388 Naphthalene-1-sulfonic Acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide
  • The desired product was prepared as the trifluoroacetate by substituting 1-naphthalenesulfonyl chloride for 2-naphthalenesulfonyl chloride in Examples 387. MS (APCI) m/z 455 (M+1)[0824] +; 1H NMR (300 MHz, CD3OD) δ 3.14 (t, J=5.76 Hz, 2H), 4.04 (t, J=5.76 Hz, 2H), 7.33 (t, J=7.46 Hz, 1H), 7.51 (t, J=7.12 Hz, 1H), 7.70 (t, J=8.14 Hz, 1H), 7.85 (t, J=2.20 Hz, 1H), 7.92 (dd, J=8.48, 1.70 Hz, 1H), 8.04 (dd, J=8.31, 3.56 Hz, 2H), 8.15 (s, 1H), 8.29 (d, J=4.75 Hz, 1H), 8.31 (d, J=5.42 Hz, 2H), 8.47 (d, J=8.48 Hz, 1H), 8.60 (d, J=6.44 Hz, 1H), 8.63 (d, J=2.37 Hz, 1H), 9.03 (d, J=2.03 Hz, 1H), 9.67 (s, 1H).
    • EXAMPLE 389 5-Dimethylamino-naphthalene-1-sulfonic Acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide
  • The desired product was prepared as the trifluoroacetate by substituting dansyl chloride for 2-naphthalenesulfonyl chloride in Example 387. MS (APCI) m/z 498 (M+1)[0825] +; 1H NMR (300 MHz, CD3OD) δ 2.81 (s, 6H), 3.16 (d, J=5.76 Hz, 2H), 4.06 (d, J=5.76 Hz, 2H), 7.16 (d, J=7.12 Hz, 1H), 7.25 (t, J=7.80 Hz, 1H), 7.67 (dd, J=8.48, 7.80 Hz, 1H), 7.75 (d, J=8.48 Hz, 1H), 7.85 (t, J=2.20 Hz, 1H), 7.98 (dd, J=8.48, 1.70 Hz, 1H), 8.29 (d, J=7.12 Hz, 1H), 8.30 (s, 1H), 8.43 (d, J=6.44 Hz, 1H), 8.53 (d, J=8.82 Hz, 1H), 8.64 (m, 3H), 9.03 (d, J=2.03 Hz, 1H), 9.76 (s, 1H); Anal. Calcd for C21H27N5O2S▪4 TFA: C, 45.34; H, 3.28; N, 7.34. Found: C, 45.28; H, 3.11; N, 7.23.
    • EXAMPLE 390 Quinoline-5-sulfonic Acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide
  • The desired product was prepared as the trifluoroacetate by substituting 8-quinolinesulfonyl chloride for 2-naphthalenesulfonyl chloride in Example 387. MS (APCI) m/z 456 (M+1)[0826] +; 1H NMR (300 MHz, CD3OD) δ 3.29 (t, J=5.43 Hz, 2H), 4.57 (t, J=5.43 Hz, 2H), 7.65 (t, J=7.46 Hz, 1H), 7.76 (dd, J=8.48, 4.41 Hz, 1H), 8.12 (dd, J=8.48, 1.70 Hz, 1H), 8.18 (t, J=2.03 Hz, 1H), 8.29 (s, 1H), 8.31 (d, J=7.12 Hz, 1H), 8.33 (dd, J=7.46, 1.36 Hz, 1H), 8.41 (s, 1H), 8.42 (d, J=7.80 Hz, 1H), 8.55 (d, J=8.82 Hz, 1H), 8.56 (dd, J=8.31, 1.87 Hz, 1H), 8.62 (d, J=6.44 Hz, 1H), 8.95 (d, J=1.70 Hz, 1H), 9.08 (dd, J=4.41, 1.70 Hz, 1H), 9.74 (s, 1H); Anal. Calcd for C25H21N5O2S▪3.3 TFA: C, 45.63; H, 2.94; N, 8.42. Found: C, 45.70; H, 2.64; N, 8.18.
    • EXAMPLE 391 Biphenyl-4-sulfonic Acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide
  • The desired product was prepared as the trifluoroacetate by substituting biphenyl-4-sulfonyl chloride for 2-naphthalenesulfonyl chloride in Example 387. MS (APCI) m/z 481 (M+1)[0827] +; 1H NMR (300 MHz, CD3OD) δ 3.16 (t, J=5.76 Hz, 2H), 4.10 (t, J=5.76 Hz, 2H), 7.49 (m, 3H), 7.68 (d, J=8.14 Hz, 2H), 7.72 (d, J=8.82 Hz, 2H), 7.89 (d, J=8.48 Hz, 2H), 8.07 (t, J=2.03 Hz, 1H), 8.22 (dd, J=8.48, 1.70 Hz, 1H), 8.29 (d, J=6.44 Hz, 1H), 8.45 (s, 1H), 8.53 (d, J=8.82 Hz, 1H), 8.57 (d, J=6.44 Hz, 1H), 8.63 (d, J=2.03 Hz, 1H), 9.10 (d, J=1.70 Hz, 1H), 9.72 (s, 1H); Anal. Calcd for C21H24N4O2S▪3.1 TFA: C, 49.25; H, 3.27; N, 6.72. Found: C, 49.20; H, 3.24; N, 6.62.
    • EXAMPLE 392 1-Methyl-1H-imidazole-4-sulfonic Acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide
  • The desired product was prepared as the trifluoroacetate by substituting 1-methylimidazole-4-sulfonyl chloride for 2-naphthalenesulfonyl chloride in Example 387. MS (APCI) m/z 409 (M+1)[0828] +; 1H NMR (300 MHz, CD3OD) δ 3.19 (t, J=5.59 Hz, 2H), 3.77 (s, 3H), 4.18 (t, J=5.59 Hz, 2H), 7.71 (s, 1H), 7.89 (s, 1H), 8.31 (m, 2H), 8.50 (d, J=6.44 Hz, 1H), 8.57 (d, J=8.14,Hz, 1H), 8.59 (s, 1H), 8.62 (d, J=8.48 Hz, 1H), 8.64 (d, J=6.44 Hz, 1H), 9.07 (d, J=2.03 Hz, 1H), 9.78 (s, 1H); Anal. Calcd for C20H20N6O2S▪3.8 TFA: C, 39.38; H, 2.85; N, 9.98. Found: C, 39.35; H, 2.73; N, 9.79.
    • EXAMPLE 393 3-Amino-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propan-1-ol Example 393A [3-(tert-Butyl-dimethyl-silanyloxy)-2-hydroxy-propyl]-carbamic Acid Tert-Butyl Ester
  • To a solution of t-butyl N-(2,3-dihydroxypropyl)carbamate (9.0 g, 47 mmol) in CH[0829] 2Cl2 (75 mL) was added t-butyldimethylsilyl chloride (7.80 g, 51.7 mmol), triethylamine (7.86 mL, 56.4 mmol) and DMAP (230 mg). The solution was stirred at rt overnight. After diluting with CH2Cl2 (50 mL), the solution was washed with water (2×100 mL), dried over MgSO4 and concentrated. The residual oil was distilled by Kugelrohr under vacuum to give the desired product (13.6 g, 95%). MS (DCI) m/z 306 (M+1)+.
    • Example 393B [2-(5-Bromo-pyridin-3-yloxy)-3-(tert-butyl-dimethyl-silanyloxy)-propyl]-carbamic Acid Tert-Butyl Ester
  • A 100 mL RBF was charged with 3-bromo-5-hydroxypyridine (949 mg, 5.45 mmol), Example 393A (2.0 g, 6.45 mmol) and Ph[0830] 3P (1.72 g, 6.54 mmol), and was purged with nitrogen. THF (22 mL) was added at 0° C. After stirring at 0° C. for 10 min, DEAD (1.03 mL, 6.54 mmol) was added via syringe. The reaction mixture was stirred at 0° C. for 1 h and at rt overnight. The reaction mixture was concentrated and the residue was separated by flash chromatography (5-30% EtOAc in hexane) to provide the desired product (1.76 g, 70%). MS (DCI) m/z 461, 463 (M+1)+.
    • Example 393C 5-{5-[2-tert-Butoxycarbonylamino-1-(tert-butyl-dimethyl-silanyloxymethyl)-ethoxy]-pyridin-3-yl}-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • A 100 mL RBF was charged with Example 393B (1.60 g, 3.47 mmol), Example 203B (1.37 g, 3.47 mmol), Pd[0831] 2(dba)3 (318 mg, 0.347 mmol), and tri-o-tolylphosphine (318 mg), and was purged with N2. Anhydrous DMF (50 mL) and Et3N (1.45 mL) were added via syringe. The solution was purged with N2 again and was heated at 75° C. for 5 h. After cooled, ethyl acetate (200 mL) was added. The mixture was washed with brine (250 mL) and water (250 mL). The ethyl acetate solution was concentrated and the residual oil was separated by flash chromatography (20-60% EtOAc in hexane) to give the desired product (1.51 g, 71%). MS (DCI) m/z 613 (M+1)+.
    • Example 393D 5-[5-(2-tert-Butoxycarbonylamino-1-hydroxymethyl-ethoxy)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • To a solution of Example 393C (1.122 g, 1.83 mmol) in THF (20 mL) was added TBAF (1.92 mL) at rt. The solution was stirred at rt for 1 h and was concentrated. The residual oil was separated by flash chromatography (0-15% CH[0832] 3OH in 2:1 EtOAc/hexane) to give the title compound (0.82 g, 90%). MS (DCI) m/z 499 (M+1)+.
    • Example 393E 3-Amino-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propan-1-ol
  • The desired product was prepared as HCl salt by substituting Example 393D for Example 27B in Examples 27C. MS (APCI) m/z 299 (M+1)[0833] +; 1H NMR (300 MHz, DMSO-d6) δ 2.58 (s, 3H), 3.26 (m, 2H), 3.68 (dd, J=12.21, 5.09 Hz, 1H), 3.75 (dd, J=12.54, 4.75 Hz, 1H), 5.05 (m, J=4.07 Hz, 1H), 7.62 (d, J=8.81 Hz, 1H), 7.85 (dd, J=8.81, 1.70 Hz, 1H), 8.35 (s, 4H), 8.52 (s, 1H), 8.64 (d, J=2.37 Hz, 1H), 8.90 (s, 1H); Anal. Calcd for C16H18N4O2▪3.2 HCl: C, 46.31; H, 5.15; N, 13.50. Found: C, 46.46; H, 5.12; N, 13.42.
    • EXAMPLE 394 2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-phenoxy-propylamine Example 394A 5-[5-(2-tert-Butoxycarbonylamino-1-phenoxymethyl-ethoxy)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • A 25 mL RBF was charged with phenol (42 mg, 0.45 mmol), Example 393D (150 mg, 0.3 mmol) and Ph[0834] 3P (142 mg, 0.54 mmol), and was purged with nitrogen. THF (4 mL) was added at 0° C. After stirring at 0° C. for 10 min, DEAD (85 μL, 0.54 mmol) was added via syringe. The reaction mixture was stirred at 0° C. for 1 h and at rt overnight. The reaction mixture was concentrated and the residue was separated by flash chromatography (20-60% EtOAc in hexane) to provide the desire product (163 mg, 95%). MS (DCI) m/z 575 (M+1)+.
    • Example 394B 2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-phenoxy-propylamine
  • The desired product was prepared as the trifluoroacetate by substituting Example 394A for Example 27B in Examples 27C. MS (APCI) m/z 375 (M+1)[0835] +; 1H NMR (300 MHz, CD3OD) δ 2.62 (s, 3H), 3.58 (d, J=5.76 Hz, 2H), 4.34 (dd, J=11.19, 5.09 Hz, 1H), 4.42 (dd, J=11.19, 3.73 Hz, 1H), 5.33 (m, 1H), 6.94 (m, 3H), 7.26 (dd, J=8.81, 7.46 Hz, 2H), 7.62 (d, J=7.80 Hz, 1H), 7.72 (dd, J=8.81, 1.70 Hz, 1H), 8.09 (s, 1H), 8.27 (s, 1H), 8.52 (d, J=2.37 Hz, 1H), 8.75 (d, J=1.36 Hz, 1H); Anal. Calcd for C22H22N4O2▪2 TFA: C, 51.83; H, 4.02; N, 9.30. Found: C, 51.97; H, 3.97; N, 9.41.
    • EXAMPLE 395 2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(naphthalen-2-yloxy)-propylamine
  • The desired product was prepared as the trifluoroacetate by substituting 2-naphthol for phenol in Examples 394. MS (APCI) m/z 425 (M+1)[0836] +; 1H NMR (300 MHz, CD3OD) δ 2.56 (s, 3H), 3.62 (d, J=5.76 Hz, 2H), 4.47 (dd, J=11.19, 5.09 Hz, 1H), 4.56 (dd, J=11.19, 3.73 Hz, 1H), 5.36 (m, 1H), 7.08 (dd, J=8.98, 2.54 Hz, 1H), 7.28 (m, 1H), 7.33 (d, J=8.14 Hz, 1H), 7.40 (t, J=8.14 Hz, 1H), 7.54 (d, J=8.48 Hz, 1H), 7.62 (dd, J=10.17, 1.70 Hz, 1H), 7.71 (d, J=8.14 Hz, 1H), 7.72 (d, J=2.03 Hz, 1H), 7.74 (s, 1H), 8.00 (s, 1H), 8.11 (m, 1H), 8.50 (d, J=2.37 Hz, 1H), 8.68 (d, J=1.36 Hz, 1H); Anal. Calcd for C26H24N4O2▪2.8 TFA: C, 51.03; H, 3.63; N, 7.53. Found: C, 51.18; H, 3.47; N, 7.55.
    • EXAMPLE 396 3-(Biphenyl-4-yloxy)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propylamine
  • The desired product was prepared as the trifluoroacetate by substituting 4-phenylphenol for phenol in Examples 394. MS (APCI) m/z 452 (M+1)[0837] +; 1H NMR (300 MHz, CD3OD) δ 2.57 (s, 3H), 3.58 (d, J=6.10 Hz, 2H), 4.39 (dd, J=11.19, 5.09 Hz, 1H), 4.47 (dd, J=1.53, 3.73 Hz, 1H), 5.30 (m, 1H), 6.99 (d, J=8.81 Hz, 2H), 7.27 (d, J=7.12 Hz, 1H), 7.36 (t, J=7.46 Hz, 2H), 7.51 (m, 4H), 7.57 (d, J=8.48 Hz, 1H), 7.67 (dd, J=8.81, 1.70 Hz, 1H), 8.03 (s, 1H), 8.09 (dd, J=4.41, 2.37 Hz, 1H), 8.49 (d, J=2.37 Hz, 1H), 8.69 (s, 1H); Anal. Calcd for C28H26N4O2▪3.2 TFA: C, 50.67; H, 3.61; N, 6.87. Found: C, 50.77; H, 3.51; N, 6.64.
    • EXAMPLE 397 2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(quinolin-7-yloxy)-propylamine
  • The desired product was prepared as the trifluoroacetate by substituting 7-hydroxyquinoline for phenol in Examples 394. MS (APCI) m/z 426 (M+1)[0838] +; 1H NMR (300 MHz, CD3OD) δ 2.59 (s, 3H), 3.64 (d, J=5.76 Hz, 2H), 4.62 (dd, J=10.85, 5.09 Hz, 1H), 4.70 (d, J=11.19 Hz, 1H), 5.42 (m, 1H), 7.50 (dd, J=9.32, 2.20 Hz, 1H), 7.58 (dd, J=5.26, 3.22 Hz, 2H), 7.69 (d, J=8.48 Hz, 1H), 7.78 (dd, J=8.14, 5.43 Hz, 1H), 8.03 (s, 1H), 8.07 (s, 1H), 8.16 (d, J=9.16 Hz, 1H), 8.47 (s, 1H), 8.67 (s, 1H), 8.88 (d, J=8.14 Hz, 1H), 8.98 (d, J=4.41 Hz, 1H); Anal. Calcd for C25H23N5O2▪3.9 TFA: C, 45.27; H, 3.12; N, 8.05. Found: C, 45.26; H, 3.05; N, 7.92.
    • EXAMPLE 398 2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(pyridin-4-yloxy)-propylamine
  • The desired product was prepared as HCl salt by substituting 4-hydroxypyridine for phenol in Examples 394. MS (APCI) m/z 376 (M+1)[0839] +; 1H NMR (300 MHz, DMSO-d6) δ 2.58 (s, 3H), 3.40 (br s, 2H), 4.75 (d, J=11.87 Hz, 1H), 4.85 (d, J=11.49 Hz, 1H), 5.61 (m, 1H), 7.59 (m, 2H), 7.86 (d, J=8.82 Hz, 1H), 8.37 (s, 1H), 8.56 (s, 1H), 8.66 (s, 1H), 8.73 (s, 2H), 8.79 (s, 1H), 8.81 (s, 1H), 8.92 (s, 1H); Anal. Calcd for C21H21N5O2▪4.5 HCl: C, 46.75; H, 4.76; N, 12.98. Found: C, 46.77; H, 4.41; N, 12.83.
    • EXAMPLE 399 2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(naphthalen-1-yloxy)-propylamine
  • The desired product was prepared as the trifluoroacetate by substituting 1-naphthol for phenol in Examples 394. MS (APCI) m/z 426 (M+1)[0840] +; 1H NMR (300 MHz, CD3OD) δ 3.34 (s, 3H), 3.65 (d, J=5.76 Hz, 2H), 4.57 (m, 2H), 5.49 (m, 1H), 6.97 (d, J=7.46 Hz, 1H), 7.23 (t, J=7.63 Hz, 1H), 7.37 (d, J=7.46 Hz, 1H), 7.41 (d, J=8.82 Hz, 1H), 7.44 (d, J=8.48 Hz, 1H), 7.56 (s, 2H), 7.74 (d, J=8.48 Hz, 1H), 7.84 (d, J=7.80 Hz, 1H), 7.92 (s, 1H), 8.15 (s, 1H), 8.50 (d, J=2.03 Hz, 1H), 8.65 (s, 1H); Anal. Calcd for C26H24N4O2▪3.1 TFA: C, 49.71; H, 3.51; N, 7.20. Found: C, 49.70; H, 3.47; N, 7.07.
    • EXAMPLE 400 3-{(2S)-2-Amino-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propyl}-1H-indol-5-ol Example 400A (2S)-2-tert-Butoxycarbonylamino-3-(5-hydroxy-1H-indol-3-yl)-propionic Acid Methyl Ester
  • To a solution of BOC-5-hydroxy-tryptophan (5.9 g, 18.4 mmol) and iodomethane (3.43 mL) in DMF (80 mL) was added powered KHCO[0841] 3 (3.68 g). The reaction mixture was stirred at rt for 4 hours. EtOAc (500 mL) was added and the mixture was washed with brine (500 mL) and water (500 mL). The organic phase was concentrated and the residual oil was triturated with CH2Cl2 (20 mL). The formed white solid was collected by filtration, washed with CH2Cl2 (20 mL) and dried to give the desired product (4.48 g, 73%). MS (DCI) m/z 335 (M+1)+.
    • Example 400B (2S)-2-tert-Butoxycarbonylamino-3-[5-(tert-butyl-dimethyl-silanyloxy)-1H-indol-3-yl]-propionic Acid Methyl Ester
  • To a solution of Example 400A (1.20 g, 3.59 mmol) in DMF (20 mL) was added t-butyldimethylsilyl chloride (649 mg, 4.3 mmol), imidazole (293 mg, 4.3 mmol) and DMAP (50 mg) at rt. The reaction mixture was stirred at rt for 16 hours. EtOAc (100 mL) was added and the mixture was washed with brine (100 mL) and water (100 mL). The organic phase was concentrated and the residual oil was purified by flash chromatography (10-40% EtOAc in hexane) to give the desire product (1.6 g, 100%). MS (DCI) m/z 466 (M+18)[0842] +.
    • Example 400C (1S)-{2-[5-(tert-Butyl-dimethyl-silanyloxy)-1H-indol-3-yl]-1-hydroxymethyl-ethyl}-carbamic Acid Tert-Butyl Ester
  • To a solution of Example 400B (1.50 g, 3.3 mmol) in THF (15 mL) was slowly added LiAlH[0843] 4 powder (127 mg, 3.3 mmol) in several portion at rt. After the addition, the reaction mixture was becoming sticky and the stirring stopped. The temperature of the mixture arises to ˜50° C. Ether (30 mL) was added and the mixture was stirred for 20 min. Methanol (2 mL) and diluted HCl was added slowly and the mixture was extracted with ether. The organic phase was washed with water and concentrated. The residue was separated by flash chromatography (20-60% EtOAc in hexane) to give the desired product (982 mg, 70%). MS (DCI) m/z 421 (M+1)+.
    • Example 400D (1S)-{2-(5-Bromo-pyridin-3-yloxy)-1-[5-(tert-butyl-dimethyl-silanyloxy)-1H-indol-3-ylmethyl]-ethyl}-carbamic Acid Tert-Butyl Ester
  • A 100 mL RBF was charged with 3-bromo-5-hydroxypyridine (432 mg, 2.48 mmol), Example 400C (950 mg, 2.26 mmol) and Ph[0844] 3P (711 mg, 2.71 mmol), and was purged with nitrogen. THF (15 mL) was added at 0° C. After stirring at 0° C. for 10 min, DEAD (427 μL, 2.71 mmol) was added via syringe. The reaction mixture was stirred at 0° C. for 1 h and at rt overnight. The reaction mixture was concentrated and the residue was separated by flash chromatography (10-50% EtOAc in hexane) to provide the desired product (1.05 g, 80%). MS (APCI) m/z 576, 578 (M+1)+.
    • Example 400E 5-(5-{(2S)-2-tert-Butoxycarbonylamino-3-[5-(tert-butyl-dimethyl-silanyloxy)-1H-indol-3-yl]-propoxy}-pyridin-3-yl)-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • The desire product was prepared by substituting Example 400D for Example 202A in Example 203C. MS (DCI) m/z 728 (M+1)[0845] +.
    • Example 400F 5-{5-[(2S)-2-tert-Butoxycarbonylamino-3-(5-hydroxy-1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • To a solution of Example 400E (850 mg, 1.17 mmol) in THF (10 mL) was added TBAF (1.28 mL, 1.28 mmol) at rt. The solution was stirred at rt for 2 h and was concentrated. The residual oil was purified by flash chromatography (0-15% CH[0846] 3OH in 2:1 EtOAc/hexane) to give the desired product (530 mg, 74%). MS (DCI) m/z 614 (M+1)+.
    • Example 400G 3-{(2S)-2-Amino-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propyl}-1H-indol-5-ol
  • The desired product was prepared as the trifluoroacetate by substituting Example 400F for Example 27B in Examples 27C. MS (APCI) m/z 414 (M+1)[0847] +; 1H NMR (300 MHz, CD3OD) δ 2.63 (s, 3H), 3.25 (dd, J=7.12, 2.37 Hz, 2H), 3.98 (m, 1H), 4.35 (dd, J=10.51, 5.76 Hz, 1H), 4.48 (dd, J=10.51, 3.39 Hz, 1H), 6.70 (dd, J=8.48, 2.37 Hz, 1H), 6.93 (d, J=2.03 Hz, 1H), 7.18 (s, 1H), 7.20 (d, J=8.48 Hz, H), 7.63 (d, J=8.81 Hz, 1H), 7.71 (dd, J=8.81, 2.03 Hz, 1H), 8.11 (m, 2H), 8.41 (d, J=2.37 Hz, 1H), 8.74 (d, J=1.70 Hz, 1H); Anal. Calcd for C24H23N5O2▪3.7 TFA: C, 45.15; H, 3.22; N, 8.38. Found: C, 45.15; H, 3.45; N, 8.43.
    • EXAMPLE 401 (1S)-1-(5-Methoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine Example 401A 5-{5-[(2S)-2-tert-Butoxycarbonylamino-3-(5-methoxy-1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • A 25 mL RBF was charged with Example 400F (100 mg, 0.163 mmol) and Ph[0848] 3P (85 mg, 0.325 mmol), and was purged with nitrogen. THF (4 mL) and methanol (14 μL) were added at 0° C. After stirring at 0° C. for 10 min, DEAD (51 μL, 0.325 mmol) was added via syringe. The reaction mixture was stirred at 0° C. for 1 h and at rt over weekend. The reaction mixture was concentrated and the residue was separated by flash chromatography (50-80% EtOAc in hexane) to provide the desired product (33 mg, 32%). MS (APCI) m/z 628 (M+1)+.
    • Example 401B (1S)-1-(5-Methoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate by substituting Example 401A for Example 27B in Examples 27C. MS (APCI) m/z 428 (M+1)[0849] +; 1H NMR (300 MHz, CD3OD) δ 2.62 (s, 3H), 3.33 (m, 2H), 3.70 (s, 3H), 3.98 (m, 1H), 4.32 (dd, J=10.51, 5.42 Hz, 1H), 4.45 (dd, J=10.51, 3.05 Hz, 1H), 6.78 (dd, J=8.81, 2.37 Hz, 1H), 7.05 (d, J=2.03 Hz, 1H), 7.21 (s, 1H), 7.27 (d, J=8.81 Hz, 1H), 7.60 (d, J=7.80 Hz, 1H), 7.67 (dd, J=8.81, 1.70 Hz, 1H), 7.91 (m, 1H), 8.03 (s, 1H), 8.35 (d, J=2.03 Hz, 1H), 8.65 (s, 1H).
    • EXAMPLE 402 (1S)-1-(5-Ethoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate by substituting ethanol for methanol in Example 401. MS (APCI) m/z 442 (M+1); [0850] 1H NMR (300 MHz, CD3OD) δ 1.26 (t, J=6.95 Hz, 3H), 2.62 (s, 3H), 3.35 (m, 2H), 3.86 (q, J=7.12 Hz, 2H), 3.95 (m, 1H), 4.32 (dd, J=10.51, 5.42 Hz, 1H), 4.45 (dd, J=10.51, 3.39 Hz, 1H), 6.78 (dd, J=8.82, 2.37 Hz, 1H), 7.02 (d, J=2.37 Hz, 1H), 7.21 (s, 1H), 7.26 (d, J=8.81 Hz, 1H), 7.61 (d, J=9.49 Hz, 1H), 7.68 (d, J=8.81 Hz, 1H), 7.97 (s, 1H), 8.05 (s, 1H), 8.37 (d, J=2.37 Hz, 1H), 8.68 (d, J=1.36 Hz, 1H); Anal. Calcd for C26H27N5O2▪3.2 TFA: C, 48.26; H, 3.77; N, 8.68. Found: C, 48.14; H, 3.60; N, 8.45.
    • EXAMPLE 403 (1S)-1-(5-Butoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate by substituting n-butanol for methanol in Example 401. MS (APCI) m/z 470 (M+1)[0851] +; 1H NMR (300 MHz, CD3OD) δ 0.87 (t, J=7.36 Hz, 3H), 1.37 (m, 2H), 1.59 (m, 2H), 2.61 (s, 3H), 3.29 (m, 2H), 3.81 (m, 2H), 3.97 (s, 1H), 4.35 (dd, J=10.13, 4.91 Hz, 1H), 4.46 (d, J=7.98 Hz, 1H), 6.76 (d, J=8.59 Hz, 1H), 7.01 (s, 1H), 7.21 (s, 1H), 7.25 (d, J=8.59 Hz, 1H), 7.61 (d, J=8.59 Hz, 1H), 7.68 (d, J=8.59 Hz, 1H), 8.06 (s, 2H), 8.38 (s, 1H), 8.71 (s, 1H); Anal. Calcd for C21H31N5O2▪2.8 TFA: C, 51.16; H, 4.32; N, 8.88. Found: C, 51.36; H, 4.51; N, 8.99.
    • EXAMPLE 404 (1S)-1-(5-Isopropoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired product was prepared as the trifluoroacetate by substituting isopropanol for methanol in Example 401. MS (APCI) m/z 456 (M+1)[0852] +; 1H NMR (400 MHz, CD3OD) δ 1.18 (m, 6H), 2.61 (s, 3H), 3.30 (m, 2H), 3.97 (s, 1H), 4.38 (m, 2H), 4.48 (d, J=8.29 Hz, 1H), 6.77 (d, J=7.98 Hz, 1H), 7.07 (s, 1H), 7.23 (s, 1H), 7.26 (d, J=8.90 Hz, 1H), 7.61 (d, J=8.90 Hz, 1H), 7.69 (d, J=8.59 Hz, 1H), 8.08 (s, 1H), 8.12 (s, 1H), 8.42 (s, 1H), 8.74 (s, 1H); Anal. Calcd for C27H29N5O2.3.2 TFA: C, 48.90; H, 3.96; N, 8.54. Found: C, 48.93; H, 3.88; N, 8.55.
    • EXAMPLE 405 3-(1H-Indol-3-yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propan-1-ol Example 405A 2-(5-Bromo-pyridin-3-yloxy)-3-(1H-indol-3-yl)-propionic Acid Methyl Ester
  • A 100 mL RBF was charged with 3-bromo-5-hydroxypyridine (1.67 g, 9.58 mmol), 2-hydroxy-3-(1H-indol-3-yl)-propionic acid methyl ester (2.1 g, 9.58 mmol) which was synthesized according to literature method (M. E. Jung et al [0853] J. Org. Chem. 1999, 64, 2976) and Ph3P (3.01 g, 11.5 mmol), and was purged with nitrogen. THF (40 mL) was added at 0° C. After stirring at 0° C. for 10 min, DEAD (1.81 mL, 11.5 mmol) was added via syringe. The reaction mixture was stirred at 0° C. for 1 h and at rt overnight. The reaction mixture was concentrated and the residue was separated by flash chromatography (20-60% EtOAc in hexane) to provide the desired product (3.4 g, 94%). MS (DCI) m/z 375, 377 (M+1)+.
    • Example 405B 2-(5-Bromo-pyridin-3-yloxy)-3-(1H-indol-3-yl)-propan-1-ol
  • To a solution of Example 405A (3.2 g, 8.5 mmol) in THF (20 mL) and ether (30 mL) was slowly added LiAlH[0854] 4 powder (323 mg, 8.5 mmol) in several portion at rt. While LAH was added a lot of solid material precipitated from the solution and the temperature arises to about 40° C. Water (2 mL) and diluted HCl was added slowly and the mixture was neutralized with NaHCO3 and extracted with ethyl acetate. The organic phase was washed with water and concentrated. The residue was separated by flash chromatography (20-80% EtOAc in hexane) to give the desired product (1.24 g, 42%). MS (DCI) m/z 347, 349 (M+1)+.
    • Example 405C 5-{5-[1-Hydroxymethyl-2-(1H-indol-3-yl)-ethoxy]-pyridin-3-yl}-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • A 50 mL RBF was charged with Example 405B (580 mg, 1.67 mmol), Example 203B (660 mg, 1.67 mmol), Pd[0855] 2(dba)3 (153 mg, 0.167 mmol), and tri-o-tolylphosphine (153 mg), and was purged with N2. Anhydrous DMF (22 mL) and Et3N (0.698 mL) were added via syringe. The solution was purged with N2 again and was heated at 70° C. for 15 h. After cooled, ethyl acetate (100 mL) was added. The mixture was washed with brine (100 mL) and water (100 mL). The ethyl acetate solution was concentrated and the residual oil was separated by flash chromatography (0-15% CH3OH in 2:1 EtOAc/hexane) to give the desired product (656 mg, 79%). MS (APCI) m/z 499 (M+1)+.
    • Example 405D 3-(1H-Indol-3-yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propan-1-ol
  • The desired product was prepared as the trifluoroacetate by substituting Example 405C for Example 27B in Examples 27C. MS (APCI) m/z 399 (M+1)[0856] +; 1H NMR (400 MHz, CD3OD) δ 2.56 (s, 3H), 3.09 (dd, J=14.73, 8.90 Hz, 1H), 3.19 (dd, J=15.04, 3.99 Hz, 1H), 3.85 (dd, J=12.12, 6.60 Hz, 1H), 3.92 (m, 1H), 4.99 (m, 1H), 6.97 (dd, J=6.14, 3.07 Hz, 2H), 7.07 (s, 1H), 7.16 (m, 1H), 7.25 (dd, J=8.75, 1.38 Hz, 1H), 7.49 (d, J=8.90 Hz, 1H), 7.57 (dd, J=6.14, 2.76 Hz, 1H), 7.84 (d, J=10.43 Hz, 2H), 8.14 (s, 1H), 8.38 (s, 1H); Anal. Calcd for C24H22N4O2▪1.7 TFA: C, 55.56; H, 4.03; N, 9.46. Found: C, 55.69; H, 4.02; N, 9.58.
    • EXAMPLE 406 3-(1H-Indol-3-yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propylamine Example 406A 5-{5-[1-Azidomethyl-2-(1H-indol-3-yl)-ethoxy]-pyridin-3-yl}-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • A 50 mL RBF was charged with Example 405C (580 mg, 1.16 mmol) and Ph[0857] 3P (456 mg, 1.74 mmol), and was purged with nitrogen. THF (14 mL) was added at 0° C., followed by addition of DPPA (375 μL, 1.74 mmol). After stirring at 0° C. for 1 min, DEAD (274 μL, 1.74 mmol) was added via syringe. The reaction mixture was stirred at 0° C. for 0.5 h and at rt overnight. The reaction mixture was concentrated and the residue was separated by flash chromatography (20-80% EtOAc in hexane) to provide the desired product (534 mg, 87%). MS (APCI) m/z 524 (M+1)+.
    • Example 406B 5-{5-[1-Aminomethyl-2-(1H-indol-3-yl)-ethoxy]-pyridin-3-yl}-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • To a solution of Example 406A (480 mg) in ethanol was added 10% Pd/C (160 mg) under nitrogen. This suspension was purged with hydrogen (3 circles) and was stirred under hydrogen (balloon) for 4 h. The solid material was filtered off and the filtrate was concentrated to give the desired product (443 mg, 97%). MS (APCI) m/z 498 (M+1)[0858] +.
    • Example 406C 3-(1H-Indol-3-yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propylamine
  • The desired product was prepared as the trifluoroacetate by substituting Example 406B for Example 27B in Examples 27C. MS (APCI) m/z 398 (M+1)[0859] +; 1H NMR (300 MHz, CD3OD) δ 2.62 (s, 3H), 3.29 (m, 2H),3.40 (dd, J=13.56, 9.15 Hz, 1H), 3.53 (dd, J=13.90, 2.71 Hz, 1H), 5.32 (m, 1H), 7.03 (m, 2H), 7.14 (s, 1H), 7.20 (dd, J=6.27, 2.54 Hz, 1H), 7.28 (dd, J=8.81, 1.70 Hz, 1H), 7.55 (d, J=8.48 Hz, 1H), 7.59 (dd, J=6.10, 2.37 Hz, 1H), 7.80 (s, 1H), 7.85 (s, 1H), 8.22 (d, J=2.37 Hz, 1H), 8.47 (s, 1H); Anal. Calcd for C24H23N5O▪3.3 TFA: C, 47.50; H, 3.43; N, 9.05. Found: C, 47.41; H, 3.71; N, 9.11.
    • EXAMPLE 407 Naphthalene-2-sulfonic Acid (2-amino-ethyl)-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-amide Example 407A {2-[(5-Bromo-pyridin-3-yl)-(naphthalene-2-sulfonyl)-amino]-ethyl}-carbamic Acid Tert-Butyl Ester
  • To a solution of Example 386A (50 mg, 0.158 mmol) in pyridine (2 mL) was added 2-naphthalenesulfonyl chloride (72 mg, 0.316 mmol) at rt. The formed yellow solution was stirred at rt for 15 h. Pyridine was removed by blowing with nitrogen and the residual yellow solid was purified by flash chromatography (30-60% EtOAc in hexane) to the desired product (81 mg, 100%). MS (DCI) m/z 506, 508 (M+1)[0860] +.
    • Example 407B {2-[[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yl]-(naphthalene-2-sulfonyl)-amino]-ethyl}-carbamic Acid Tert-Butyl Ester
  • A 25 mL RBF was charged with Example 407A (78 mg, 0.154 mmol), Example 203B (45 mg, 0.154 mmol), Pd[0861] 2(dba)3 (14 mg, 0.0154 mmol), and tri-o-tolylphosphine (14 mg), and was purged with N2. Anhydrous DMF (4 mL) and Et3N (64 μL) were added via syringe. The solution was purged with N2 again and was heated at 70° C. for 15 h. After cooled, ethyl acetate (50 mL) was added. The mixture was washed with brine (50 mL) and water (50 mL). The ethyl acetate solution was concentrated and the residual oil was separated by flash chromatography (A: 2:1 EtOAc/hexane, 0-15% CH3OH/A) to give the desired product (54 mg, 63%). MS (APCI) m/z 558 (M+1)+.
    • Example 407C Naphthalene-2-sulfonic Acid (2-amino-ethyl)-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-amide
  • The desired product was prepared as the trifluoroacetate by substituting Example 407B for Example 27B in Examples 27C. MS (APCI) m/z 458 (M+1)[0862] +; 1H NMR (300 MHz, CD3OD) δ 2.50 (s, 3H), 3.14 (t, J=5.59 Hz, 2H), 4.06 (t, J=5.59 Hz, 2H), 7.48 (m, 2H), 7.66 (m, 2H), 7.74 (d, J=8.14 Hz, 1H), 7.77 (d, J=8.14 Hz, 1H), 7.80 (t, J=2.03 Hz, 1H), 8.02 (d, J=8.14 Hz, 1H), 8.06 (d, J=8.48 Hz, 1H), 8.14 (d, J=8.48 Hz, 1H), 8.28 (s, 1H), 8.47 (d, J=2.37 Hz, 1H), 8.92 (d, J=1.70 Hz, 1H); Anal. Calcd for C25H23N5O2S▪3.3 TFA: C, 45.52; H, 3.18; N, 8.40. Found: C, 45.42; H, 3.13; N, 8.43.
    • EXAMPLE 408 Biphenyl-4-sulfonic Acid (2-amino-ethyl)-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-amide
  • The desired product was prepared as the trifluoroacetate by substituting 4-biphenylsulfonyl chloride for 2-naphthalenesulfonyl chloride in Examples 407. MS (APCI) m/z 484 (M+1)[0863] +; 1H NMR (300 MHz, DMSO-d6) δ 2.42 (s, 3H), 2.96 (m, 2H), 3.95 (m, 2H), 7.54 (m, 4H), 7.69 (d, J=8.48 Hz, 2H), 7.77 (d, J=7.12 Hz, 2H), 7.95 (m, 5H), 8.45 (s, 1H), 8.98 (s, 1H); Anal. Calcd for C27H25N5O2S▪1.3 TFA: C, 56.27; H, 4.20; N, 11.08. Found: C, 56.00; H, 4.21; N, 10.87.
    • EXAMPLE 409 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-isopropylidene-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-isopropylidene-1,3-dihydro-indol-2-one (L. Sun, et al., [0864] J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimide in Example 32. 1H NMR (400 MHz, CD3OD) δ ppm 2.47 (s, 3H), 2.60 (s, 3H), 3.31 (m, 2H), 4.01 (m, 1H), 4.34 (dd, J=10.43, 5.83 Hz, 1H), 4.47 (dd, J=10.43, 3.38 Hz, 1H), 7.01 (t, J=7.06 Hz, 1H), 7.04 (d, J=7.98 Hz, 1H), 7.12 (t, J=7.06 Hz, 1H), 7.24 (s, 1H), 7.38 (d, J=8.29 Hz, 1H), 7.50 (dd, J=7.98, 1.84 Hz, 1H), 7.58 (d, J=7.98 Hz, 1H), 7.79 (d, J=1.53 Hz, 1H), 7.97 (d, J=1.84 Hz, 1H), 8.37 (s, 1H), 8.63 (s, 1H); Anal. Calcd for C27H26N4O2: C, 52.14; H, 3.88; N, 7.51. Found: C, 52.19; H, 3.67; N, 7.42.
    • EXAMPLE 410 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1H-imidazol-2-ylmethylene)-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(1H-imidazol-2-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun, et al., [0865] J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimide in Example 32. MS (DCI/NH3) m/z 477 (M+1)+; 1H NMR (500 MHz, CD3OD) δ ppm 3.31 (m, 2H), 4.04 (m, 1H), 4.37 (dd, J=10.45, 5.77 Hz, 1H), 4.50 (dd, J=10.29, 3.12 Hz, 1H), 7.02 (t, J=7.49 Hz, 1H), 7.11 (d, J=7.49 Hz, 1H), 7.13 (m, 1H), 7.25 (s, 1H), 7.38 (d, J=8.11 Hz, 1H), 7.60 (d, J=7.80 Hz, 1H), 7.72 (d, J=8.11 Hz, 1H), 7.77 (s, 2H), 7.85 (s, 1H), 8.02 (s, 1H), 8.13 (s, 1H), 8.42 (s, 1H), 8.67 (s, 1H).
    • EXAMPLE 411 5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyridin-2-ylmethylene-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-pyridin-2-ylmethylene-1,3-dihydro-indol-2-one (L. Sun, et al., [0866] J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimide in Example 32. MS (DCI/NH3) m/z 488 (M+1)+; 1H NMR (500 MHz, CD3OD) δ ppm 3.32 (m, 2H), 4.02 (m, 1H), 4.34 (dd, J=10.61, 5.62 Hz, 1H), 4.47 (dd, J=10.45, 3.28 Hz, 1H), 7.03 (t, J=7.02 Hz, 1H), 7.13 (m, 1H), 7.19 (d, J=8.11 Hz, 1H), 7.25 (s, 1H), 7.38 (d, J=8.42 Hz, 1H), 7.60 (d, J=7.80 Hz, 1H), 7.76 (dd, J=8.11, 1.87 Hz, 1H), 7.94 (dd, J=2.50, 1.87 Hz, 1H), 8.14 (m, 1H), 8.17 (s, 1H), 8.26 (d, J=1.56 Hz, 1H), 8.38 (d, J=7.80 Hz, 1H), 8.41 (s, 1H), 8.66 (s, 1H), 8.72 (m, 1H), 9.08 (dd, J=5.62, 1.56 Hz, 1H); Anal. Calcd for C30H25N5O2: C, 47.41; H, 3.02; N, 7.16. Found: C, 47.40; H, 2.93; N, 6.98.
    • EXAMPLE 412 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-furan-2-ylmethylene-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-furan-2-ylmethylene-1,3-dihydro-indol-2-one (L. Sun, et al., [0867] J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimide in Example 32. MS (DCI/NH3) m/z 477 (M+1)+; 1H NMR (500 MHz, CD3OD) δ ppm 3.34 (m, 4H), 4.06 (m, 2H), 4.37 (dd, J=10.45, 5.77 Hz, 2H), 4.51 (dd, J=10.45, 3.28 Hz, 2H), 6.68 (dd, J=3.28, 1.40 Hz, 1H), 6.72 (dd, J=3.59, 1.72 Hz, 1H), 7.02 (t, J=7.64 Hz, 2H), 7.05 (d, J=8.11 Hz, 2H), 7.12 (m, 3H), 7.26 (s, 1H), 7.27 (s, 1H), 7.38 (d, J=8.11 Hz, 2H), 7.43 (s, 1H), 7.55 (d, J=1.87 Hz, 1H), 7.58 (dd, J=8.11, 1.87 Hz, 1H), 7.61 (d, J=7.80 Hz, 2H), 7.73 (s, 1H), 7.77 (d, J=1.56 Hz, 1H), 7.85 (d, J=1.87 Hz, 1H), 7.97 (d, J=1.56 Hz, 1H), 8.06 (d, J=4.37 Hz, 1H), 8.15 (d, J=1.87 Hz, 1H), 8.30 (d, J=3.43 Hz, 1H), 8.44 (m, 2H), 8.69 (s, 1H), 8.73 (d, J=1.87 Hz, 2H); Anal. Calcd for C29H24N4O3: C, 50.33; H, 3.24; N, 6.61. Found: C, 50.30; H, 3.12; N, 6.65.
    • EXAMPLE 413 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(5-methyl-furan-2-ylmethylene)-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(5-methyl-furan-2-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun, et al., [0868] J. Med. Chem., 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (DCI/NH3) m/z 477 (M+1)+; 1H NMR (500 MHz, CD3OD) δ ppm 2.41 (s, 3H), 3.32 (m, 2H), (4.02 (m, 1H), 4.31 (dd, J=10.45, 5.77 Hz, 1H), 4.45 (dd, J=10.45, 3.28 Hz, 1H), 6.38 (dd, J=3.43, 0.94 Hz, 1H), 7.03 (m, 3H), 7.12 (t, J=7.18 Hz, 1H), 7.24 (s, 1H), 7.37 (s, 1H), 7.38 (d, J=8.11 Hz, 1H), 7.54 (dd, J=8.11, 1.87 Hz, 1H), 7.60 (d, J=8.11 Hz, 1H), 7.90 (dd, J=2.50, 1.87 Hz, 1H), 8.38 (s, 1H), 8.64 (s, 1H), 8.73 (s, 1H); Anal. Calcd for C30H26N4O3: C, 49.59; H, 3.31; N, 6.22. Found: C, 49.90; H, 3.18; N, 6.10.
    • EXAMPLE 414 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(4,5-dimethyl-furan-2-ylmethylene)-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(4,5-dimethyl-furan-2-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun, et al., [0869] J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimide in Example 32. MS (DCI/NH3) m/z 505 (M+1)+; 1H NMR (500 MHz, CD3OD) δ ppm 1.99 (s, 3H), 2.27 (s, 3H), 3.34 (m, 2H), 4.06 (m, 1H), 4.37 (dd, J=10.45, 5.77 Hz, 1H), 4.51 (dd, J=10.45, 3.28 Hz, 1H), 6.82 (s, 1H), 6.99 (d, J=8.42 Hz, 1H), 7.03 (t, J=7.02 Hz, 1H), 7.13 (t, J=7.02 Hz, 1H), 7.21 (s, 1H), 7.27 (s, 1H), 7.39 (d, J=8.11 Hz, 1H), 7.52 (dd, J=8.11, 1.87 Hz, 1H), 7.61 (d, J=8.11 Hz, 1H), 8.05 (s, 1H), 8.45 (s, 1H), 8.62 (d, J=1.56 Hz, 1H), 8.66 (s, 1H); Anal. Calcd for C31H28N4O3: C, 52.92; H, 3.73; N, 6.71. Found: C, 52.90; H, 3.45; N, 6.97.
    • EXAMPLE 415 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-thiophen-2-ylmethylene-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-thiophen-2-ylmethylene-1,3-dihydro-indol-2-one (L. Sun, et al., [0870] J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimide in Example 32. MS (APCI) m/z 493 (M+1)+; 1H NMR (500 MHz, CD3OD) δ ppm 3.32 (m, 4H), 4.03 (m, 2H), 4.30 (dd, J=10.45, 5.77 Hz, 1H), 4.35 (dd, J=10.61, 5.93 Hz, 1H), 4.44 (dd, J=10.29, 3.12 Hz, 1H), 4.48 (dd, J=10.61, 3.12 Hz, 1H), 7.02 (m, 2H), 7.04 (s, 1H), 7.06 (d, J=0.94 Hz, 1H), 7.08 (d, J=8.11 Hz, 1H), 7.14 (t, J=7.49 Hz, 2H), 7.20 (dd, J=4.99, 3.74 Hz, 1H), 7.23 (d, J=1.25 Hz, 1H), 7.24 (s, 1H), 7.26 (m, 1H), 7.37 (s, 1H), 7.39 (d, J=8.11 Hz, 1H), 7.53 (dd, J=8.11, 1.87 Hz, 1H), 7.56 (dd, J=8.11, 1.56 Hz, 1H), 7.59 (s, 1H), 7.61 (d, J=7.80 Hz, 1H), 7.71 (d, J=2.50 Hz, 1H), 7.74 (d, J=5.30 Hz, 1H), 7.79 (d, J=4.99 Hz, 1H), 7.92 (s, 1H), 7.93 (s, 1H), 7.96 (s, 1H), 7.98 (d, J=1.56 Hz, 1H), 8.09 (s, 1H), 8.37 (s, 2H), 8.48 (d, J=1.56 Hz, 1H), 8.56 (s, 1H), 8.65 (s, 1H); Anal. Calcd for C29H24N4O2S: C, 50.37; H, 3.26; N, 6.71. Found: C, 50.52; H, 3.45; N, 6.84.
    • (A-441246) EXAMPLE 416 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1-methyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(1-methyl-1 H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun, et al., [0871] J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimide in Example 32. MS (APCI) m/z 490 (M+1)+; 1H NMR (500 MHz, CD3OD) δ ppm 3.32 (m, 4H), 3.81 (s, 3H), 3.89 (s, 3H), 4.03 (m, 2H), 4.30 (dd, J=10.61, 5.93 Hz, 1H), 4.37 (dd, J=10.61, 5.93 Hz, 1H), 4.44 (dd, J=10.45, 3.28 Hz, 1H), 4.50 (dd, J=10.29, 3.12 Hz, 1H), 6.28 (m, 2H), 7.02 (m, 3H), 7.07 (m, 3H), 7.12 (m, 2H), 7.19 (d, J=3.74 Hz, 1H), 7.24 (s, 1H), 7.26 (s, 1H), 7.38 (d, J=8.11 Hz, 1H), 7.39 (d, J=8.11 Hz, 1H), 7.46 (dd, J=8.11, 1.87 Hz, 1H), 7.50 (dd, J=8.27, 1.72 Hz, 1H), 7.59 (d, J=7.80 Hz, 1H), 7.61 (d, J=8.11 Hz, 1H), 7.70 (s, 1H), 7.74 (s, 1H), 7.86 (s, 1H), 7.98 (d, J=1.87 Hz, 1H), 8.08 (s, 1H), 8.30 (dd, J=4.37, 1.56 Hz, 1H), 8.34 (d, J=1.56 Hz, 1H), 8.38 (s, 2H), 8.57 (s, 1H), 8.73 (s, 1H); Anal. Calcd for C30H27N5O2: C, 55.28; H, 3.93; N, 9.32. Found: C, 55.32; H, 3.57; N, 9.08
    • EXAMPLE 417 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1H-indol-3-ylmethylene)-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(1H-indol-3-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun, et al., [0872] J. Med. Chem., 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (APCI) m/z 526 (M+1)+; 1H NMR (500 MHz, CD3OD) δ ppm 3.32 (m, 4H), 4.05 (m, 2H), 4.15 (m, 1H), 4.25 (m, 1H), 4.38 (d, J=5.93 Hz, 1H), 4.49 (dd, J=10.29, 3.12 Hz, 1H), 7.02 (m, 2H), 7.06 (m, 1H), 7.09 (m, 2H), 7.14 (t, J=7.64 Hz, 2H), 7.23 (m, 4H), 7.28 (s, 1H), 7.39 (m, 2H), 7.43 (d, J=4.99 Hz, 1H), 7.47 (m, 4H), 7.56 (d, J=8.11 Hz, 1H), 7.59 (s, 1H), 7.63 (d, J=8.11 Hz, 2H), 8.01 (m, 2H), 8.06 (d, J=1.56 Hz, 1H), 8.12 (s, 2H), 8.24 (s, 1H), 8.28 (s, 1H), 8.35 (s, 2H), 8.72 (s, 1H), 9.40 (s, 1H); Anal. Calcd for C33H27N5O2: C, 53.99; H, 3.48; N, 8.07. Found: C, 54.27; H, 3.64; N, 7.84
    • EXAMPLE 418 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1-phenyl-1H-pyrrol-3-ylmethylene)-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun, et al., [0873] J. Med. Chem., 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (APCI) m/z 580 (M+1)+; 1H NMR (500 MHz, CD3OD) δ ppm 1.98 (s, 3H) 2.01 (s, 3H) 2.18 (s, 3H) 2.28 (s, 3H) 3.32 (m, 4H), 4.02 (m, 2H) 4.32 (dd, J=10.45, 5.46 Hz, 1H) 4.37 (dd, J=10.61, 5.93 Hz, 1H) 4.49 (m, 2H) 6.68 (m, 1H) 7.01 (m, 3H) 7.10 (m, 3H) 7.25 (m, 6H) 7.36 (t, J=8.73 Hz, 2H) 7.47 (m, 3H) 7.57 (m, 8H) 7.84 (d, J=2.18 Hz, 2H) 7.93 (s, 2H) 8.13 (s, 1H) 8.32 (s, 1H) 8.38 (s, 2H) 8.60 (s, 1H) 8.73 (s, 1H); Anal. Calcd for C37H33N5O2: C, 54.38; H, 3.79; N, 7.24. Found: C, 54.45; H, 3.92; N, 6.97.
    • EXAMPLE 419 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyridin-3-ylmethylene-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-pyridin-3-ylmethylene-1,3-dihydro-indol-2-one (L. Sun, et al., [0874] J. Med. Chem., 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (APCI) m/z 488 (M+1)+; 1H NMR (500 MHz, CD3OD) δ ppm 3.32 (m, 4H), 4.03 (m, 2H), 4.26 (dd, J=10.45, 5.46 Hz, 1H), 4.36 (dd, J=10.45, 5.77 Hz, 1H), 4.40 (dd, J=10.29, 3.12 Hz, 1H), 4.49 (dd, J=10.29, 3.12 Hz, 1H), 7.01 (m, 1H), 7.05 (m, 3H), 7.08 (d, J=8.11 Hz, 1H), 7.12 (t, J=7.64 Hz, 2H), 7.23 (s, 1H), 7.25 (s, 1H), 7.38 (d, J=8.11 Hz, 1H), 7.57 (m, 1H), 7.59 (m, 1H), 7.61 (s, 1H), 7.64 (dd, J=8.11, 1.87 Hz, 1H), 7.66 (m, 1H), 7.71 (m, 1H), 7.78 (s, 1H), 7.93 (s, 1H), 7.99 (m, J=8.27, 5.77 Hz, 3H), 8.09 (d, J=1.56 Hz, 1H), 8.34 (d, J=8.11 Hz, 2H), 8.41 (m, 2H), 8.56 (d, J=4.68 Hz, 1H), 8.67 (s, 1H), 8.77 (d, J=5.30 Hz, 1H), 9.01 (s, 1H), 9.11 (d, J=8.11 Hz, 1H), 9.69 (s, 1H); Anal. Calcd for C30H25N5O2: C, 49.22; H, 3.17; N, 7.65. Found: C, 49.23; H, 3.15; N, 7.38.
    • EXAMPLE 420 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1H-pyrrol-3-ylmethylene)-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(1H-pyrrol-3-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun, et al., [0875] J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimde in Example 32. MS (APCI) m/z 476 (M+1)+; 1H NMR (500 MHz, CD3OD) δ ppm 3.32 (m, 4H), 4.04 (m, 2H), 4.32 (dd, J=10.45, 5.77 Hz, 1H), 4.38 (dd, J=10.61, 5.93 Hz, 1H), 4.46 (dd, J=10.45, 3.28 Hz, 1H), 4.50 (dd, J=10.29, 3.12 Hz, 1H), 6.77 (dd, J=2.81, 1.56 Hz, 1H), 6.85 (dd, J=2.65, 2.03 Hz, 1H), 6.91 (m, 1H), 7.04 (m, 5H), 7.13 (m, 2H), 7.24 (s, 1H), 7.26 (s, 1H), 7.39 (t, J=7.49 Hz, 2H), 7.43 (s, 1H), 7.48 (m, 2H), 7.60 (m, J=8.73, 8.73 Hz, 2H), 7.80 (s, 1H), 7.84 (s, 1H), 7.90 (m, 2H), 8.09 (s, 1H), 8.16 (s, 1H), 8.28 (d, J=1.56 Hz, 1H), 8.39 (s, 2H), 8.59 (s, 1H), 8.70 (s, 1H); Anal. Calcd for C29H25N5O2: C, 51.42; H, 3.45; N, 8.57. Found: C, 51.73; H, 3.41; N, 8.58.
    • EXAMPLE 421 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(tetrahydro-pyran-4-ylidene)-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(tetrahydro-pyran-4-ylidene)-1,3-dihydro-indol-2-one (L. Sun, et al., [0876] J. Med. Chem., 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (APCI) m/z 481 (M+1)+; 1H NMR (400 MHz, DMSO-d6) δ ppm 3.02 (t, J=5.52 Hz, 2H), 3.19 (m, 2H) 3.44 (t, J=5.52 Hz, 2H), 3.80 (m, 5H), 4.18 (dd, J=10.74, 5.83 Hz, 1H), 4.34 (m, 1H), 7.00 (m, 1H), 7.10 (t, J=7.06 Hz, 1H), 7.29 (d, J=2.15 Hz, 1H), 7.38 (d, J=7.98 Hz, 1H), 7.49 (dd, J=8.13, 1.69 Hz, 1H), 7.62 (m, 2H), 7.85 (s, 1H), 8.23 (s, 2H), 8.24 (s, 1H), 8.32 (d, J=2.76 Hz, 1H), 8.55 (d, J=1.53 Hz, 1H), 10.67 (s, 1H), 11.03 (d, J=1.84 Hz, 1H); Anal. Calcd for C29H29N4O3: C, 55.38; H, 4.21; N, 7.78. Found: C, 55.29; H, 4.12; N, 7.70.
    • EXAMPLE 422 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(4-ethyl-3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-(4-ethyl-3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun, et al., [0877] J. Med. Chem., 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (APCI) m/z 530 (M-1)+; 1H NMR (500 MHz, CD3OD) δ ppm 1.10 (t, J=7.52 Hz, 3H), 2.31 (s, 3H), 2.34 (s, 3H), 2.49 (q, J=7.57 Hz, 2H), 3.32 (m, 2H), 4.03 (m, 1H), 4.36 (dd, J=10.59, 5.68 Hz, 1H), 4.49 (m, 1H), 7.05 (m, 2H), 7.13 (t, J=7.06 Hz, 1H), 7.25 (s, 1H), 7.41 (m, 2H), 7.61 (d, J=7.67 Hz, 1H), 7.66 (s, 1H), 7.93 (d, J=1.53 Hz, 1H), 8.07 (m, 1H), 8.37 (s, 1H), 8.72 (s, 1H); Anal. Calcd for C33H33N5O2: C, 54.94; H, 4.29; N, 8.34. Found: C, 55.03; H, 4.09; N, 8.20.
    Figure US20030187026A1-20031002-C00097
    • (A-485149) EXAMPLE 423 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-cyclopropylmethylene-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-cyclopropylmethylene-1,3-dihydro-indol-2-one (L. Sun, et al., [0878] J. Med. Chem., 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (APCI) m/z 451 (M+1)+; 1H NMR (400 MHz, DMSO-d6) δ ppm 0.79 (m, J=4.30, 2.45 Hz, 2H), 0.93 (m, 3H), 1.19 (m, 5H), 2.52 (m, 4H), 3.84 (s, 2H), 4.19 (m, 2H), 4.35 (m, 2H), 6.33 (d, J=11.66 Hz, 1H), 6.59 (d, J=11.05 Hz, 1H), 6.92 (d, J=7.98 Hz, 1H), 7.00 (m, 1H), 7.10 (t, J=7.06 Hz, 2H), 7.29 (d, J=2.15 Hz, 2H), 7.38 (d, J=8.29 Hz, 2H), 7.51 (m, 2H), 7.62 (d, J=7.67 Hz, 2H), 7.69 (m, J=5.06, 3.22 Hz, 2H), 7.86 (d, J=1.84 Hz, 1H), 8.03 (d, J=1.53 Hz, 1H), 8.23 (br s, 3H), 8.24 (br s, 3H), 8.32 (d, J=2.76 Hz, 1H), 8.33 (d, J=2.76 Hz, 1H), 8.57 (d, J=1.53 Hz, 1H), 8.60 (d, J=1.84 Hz, 1H), 10.54 (s, 1H), 10.58 (s, 1H), 11.03 (d, J=1.84 Hz, 2H); Anal. Calcd for C29H26N4O2: C, 55.48; H, 4.05; N, 7.99. Found: C, 55.63; H, 3.98; N, 7.90.
    • EXAMPLE 424 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyrrolidin-2-ylmethylene-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-3-pyrrolidin-2-ylmethylene-1,3-dihydro-indol-2-one (L. Sun, et al., [0879] J. Med. Chem., 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (APCI) m/z 480 (M+1)+; 1H NMR (400 MHz, CD3OD) δ ppm 1.53 (m, 1H), 1.60 (m, 1H), 1.70 (m, 1H), 2.01 (m, 1H), 2.20 (m, 2H), 2.49 (m, 1H), 3.44 (m, 2H), 4.01 (m, 1H), 4.32 (dd, J=10.43, 5.83 Hz, 1H), 4.46 (m, 1H), 7.05 (m, 3H), 7.13 (t, J=7.67 Hz, 1H), 7.24 (s, 1H), 7.38 (d, J=8.29 Hz, 1H), 7.61 (m, 2H), 7.92 (m, 2H), 8.36 (s, 1H), 8.59 (s, 1H); Anal. Calcd for C29H29N5O2: C, 52.24; H, 4.03; N, 8.83. Found: C, 52.32; H, 4.24; N, 8.63.
    • EXAMPLE 425 5-(5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-furan-2-carboxylic Acid
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-furan-2-carboxylic acid (L. Sun, et al., [0880] J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimide in Example 32. MS (APCI) m/z 521 (M+1)+; 1H NMR (400 MHz, DMSO-d6) δ ppm 3.16 (d, J=6.75 Hz, 2H), 3.86 (m, 1H), 4.21 (dd, J=10.74, 6.44 Hz, 1H), 4.41 (m, 1H), 6.97 (t, J=6.90 Hz, 1H), 7.03 (d, J=7.98 Hz, 1H), 7.08 (t, J=7.06 Hz, 1H), 7.29 (d, J=2.46 Hz, 1H), 7.37 (d, J=8.29 Hz, 1H), 7.40 (d, J=3.99 Hz, 1H), 7.44 (m, 1H), 7.47 (s, 1H), 7.62 (m, 2H), 7.71 (m, 1H), 8.17 (br s, 2H), 8.33 (d, J=2.45 Hz, 1H), 8.71 (d, J=1.84 Hz, 1H), 8.98 (d, J=1.84 Hz, 1H), 10.84 (s, 1H), 11.01 (d, J=2.15 Hz, 1H); Anal. Calcd for C30H24N4O5: C, 51.75; H, 3.28; N, 6.86. Found: C, 51.69; H, 3.16; N, 6.71.
    • EXAMPLE 426 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-benzylidene-1,3-dihydro-indol-2-one
  • The desired compound was prepared by as the trifluoroacetate salt substituting 3-Benzylidene-5-bromo-1,3-dihydro-indol-2-one (L. Sun, et al., [0881] J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimide in Example 32. MS (APCI) m/z 485 (M−1)+; 1H NMR (500 MHz, CD3OD) δ ppm 3.32 (m, 2H), 4.01 (m, 1H), 4.23 (dd, J=10.61, 5.62 Hz, 1H), 4.37 (m, 1H), 7.03 (m, 2H), 7.13 (t, J=7.64 Hz, 1H), 7.22 (s, 1H), 7.34 (t, J=7.49 Hz, 1H), 7.39 (d, J=8.42 Hz, 1H), 7.44 (m, 2H), 7.53 (dd, J=8.27, 1.72 Hz, 1H), 7.58 (d, J=8.11 Hz, 1H), 7.62 (s, 1H), 7.69 (d, J=7.80 Hz, 1H), 7.78 (d, J=1.87 Hz, 1H), 7.83 (s, 1H), 8.00 (d, J=1.56 Hz, 1H), 8.31 (m, J=6.40, 2.96 Hz, 1H), 8.37 (s, 1H); Anal. Calcd for C31H26N4O2: C, 55.53; H, 3.68; N, 7.16. Found: C, 55.74; H, 3.50; N, 7.05.
    • EXAMPLE 427 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indole-2,3-dione 3-oxime
  • The desired compound was prepared by as the trifluoroacetate salt substituting 5-Bromo-1H-indole-2,3-dione 3-oxime (L. Sun, et al., [0882] J. Med. Chem., 1998, 41, 2588.) 6-bromophthalimide in Example 32. MS (ESI) m/z 428 (M+1)+; 1H NMR (500 MHz, CD3OD) δ ppm 3.32 (m, 2H), 4.00 (m, 1H), 4.29 (dd, J=10.45, 5.77 Hz, 1H), 4.44 (dd, J=10.61, 3.12 Hz, 1H), 7.05 (m, 2H), 7.13 (t, J=7.17 Hz, 1H), 7.24 (s, 1H), 7.38 (d, J=8.11 Hz, 1H), 7.60 (d, J=8.11 Hz, 1H), 7.65 (dd, J=8.27, 2.03 Hz, 1H), 7.78 (m, 1H), 8.32 (d, J=1.87 Hz, 1H), 8.34 (s, 1H), 8.52 (s, 1H); Anal. Calcd for C24H21N5O3: C, 51.30; H, 3.54; N, 10.68. Found: C, 50.99; H, 3.33; N, 10.47.
  • The following compounds were prepared by substituting the appropriate tributylsannyl reagents for (1,1,1-tributylstannyl)benzene and Example 362A for 80E in Example 364. [0883]
    • EXAMPLE 428 (1S)-2-(5-Benzo[b]thiophen-2-yl-6-furan-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine
  • MS (APCI) m/z 465 (M−1)[0884] +; 1H NMR (500 MHz, CD3OD) δ ppm 3.32 (m, 2H), 3.99 (m, 1H), 4.27 (dd, J=10.61, 5.62 Hz, 1H), 4.41 (m, 1H), 6.47 (dd, J=3.43, 1.87 Hz, 1H), 6.66 (d, J=3.43 Hz, 1H), 7.01 (t, J=7.02 Hz, 1H), 7.10 (t, J=8.11 Hz, 1H), 7.23 (s, 1H), 7.35 (d, J=8.11 Hz, 1H), 7.39 (d, J=1.25 Hz, 1H), 7.56 (d, J=2.81 Hz, 1H), 7.58 (d, J=7.80 Hz, 1H), 7.72 (s, 1H), 8.31 (d, J=6.24 Hz, 1H), 8.50 (d, J=2.81 Hz, 1H), 8.61 (d, J=6.24 Hz, 1H), 9.51 (s, 1H); Anal. Calcd for C27H22N4O2S: C, 52.57; H, 3.40; N, 7.81. Found: C, 52.35; H, 3.20; N, 7.73.
    • EXAMPLE 429 (1S)-2-(5-Benzo[b]thiophen-2-yl-6-vinyl-pyridin-3-yloxy)-1(1H-indol-3-ylmethyl)-ethylamine
  • MS (APCI) m/z 427 (M+1)[0885] +; 1H NMR (400 MHz, DMSO-d6) δ ppm 3.15 (m, 2H), 3.85 (m, 1H), 4.17 (dd, J=10.76, 6.08 Hz, 1H), 4.33 (dd, J=10.76, 2.96 Hz, 1H), 5.44 (m, 1H), 6.30 (dd, J=16.85, 2.18 Hz, 1H), 6.93 (dd, J=16.69, 10.76 Hz, 1H), 7.00 (t, J=7.33 Hz, 1H), 7.08 (t, J=7.49 Hz, 1H), 7.29 (d, J=2.18 Hz, 1H), 7.36 (d, J=8.11 Hz, 1H), 7.51 (d, J=2.81 Hz, 1H), 7.60 (d, J=8.11 Hz, 1H), 7.77 (s, 1H), 8.18 (d, J=5.93 Hz, 1H), 8.25 (m, 2H), 8.51 (d, J=2.81 Hz, 1H), 8.67 (d, J=5.93 Hz, 1H), 9.56 (s, 1H), 11.02 (s, 1H); Anal. Calcd for C25H22N4OS: C, 48.44; H, 3.28; N, 7.29. Found: C, 48.38; H, 3.32; N, 7.02.
    • EXAMPLE 430 (1S)-2-(5-Benzo[b]thiophen-2-yl-6-thiophen-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine
  • MS (APCI) m/z 481 (M−1)[0886] +; 1H NMR (500 MHz, DMSO-d6) δ ppm 3.15 (m, 2H), 3.85 (m, 1H), 4.18 (dd, J=10.76, 6.08 Hz, 1H), 4.34 (dd, J=10.61, 3.12 Hz, 1H), 6.71 (dd, J=3.59, 1.09 Hz, 1H), 6.90 (dd, J=4.99, 3.74 Hz, 1H), 7.00 (t, J=7.02 Hz, 1H), 7.08 (t, J=7.18 Hz, 1H), 7.29 (d, J=2.18 Hz, 1H), 7.36 (d, J=7.80 Hz, 1H), 7.55 (dd, J=5.15, 1.09 Hz, 1H), 7.57 (d, J=2.81 Hz, 1H), 7.60 (d, J=7.80 Hz, 1H), 7.78 (s, 1H), 8.13 (d, J=5.93 Hz, 1H), 8.23 (br s, 2H), 8.50 (d, J=2.81 Hz, 1H), 8.64 (d, J=5.93 Hz, 1H), 9.50 (s, 1H), 11.02 (d, J=1.56 Hz, 1H); Anal. Calcd for C21H22N4OS2: C, 48.83; H, 3.12; N, 6.99. Found: C, 48.74; H, 3.07; N, 6.88.
    • EXAMPLE 431 (1S)-2-(5-Benzo[b]thiophen-2-yl-6-thiazol-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine
  • MS (APCI) m/z 484 (M+1)[0887] +; 1H NMR (500 MHz, DMSO-d6) δ ppm 3.15 (m, 2H), 3.84 (m, J=14.12 Hz, 1H), 4.22 (dd, J=10.89, 5.98 Hz, 1H), 4.38 (dd, J=10.74, 3.07 Hz, 1H), 6.98 (t, J=7.06 Hz, 1H), 7.07 (t, J=7.52 Hz, 1H), 7.29 (d, J=2.15 Hz, 1H), 7.35 (d, J=7.98 Hz, 1H), 7.60 (d, J=7.98 Hz, 1H), 7.63 (d, J=2.76 Hz, 2H), 7.73 (s, 1H), 7.77 (d, J=3.38 Hz, 1H), 8.16 (d, J=5.83 Hz, 1H), 8.29 (br s, 2H), 8.56 (d, J=2.76 Hz, 1H), 8.63 (d, J=5.83 Hz, 1H), 9.52 (s, 1H), 11.02 (d, J=1.84 Hz, 1H); Anal. Calcd for C26H21N5OS: C, 46.55; H, 2.93; N, 8.48. Found: C, 46.87; H, 2.97; N, 8.46.
    • EXAMPLE 432 (1S)-2-(5-Benzo[b]thiophen-2-yl-6-pyrazin-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine
  • MS (APCI) m/z 479 (M−1)[0888] +; 1H NMR (500 MHz, CD3OD) δ ppm 3.32 (m, 2H), 4.02 (m, 1H), 4.33 (dd, J=10.61, 5.62 Hz, 1H), 4.47 (dd, J=10.61, 3.12 Hz, 1H), 7.02 (t, J=7.02 Hz, 1H), 7.10 (t, J=7.18 Hz, 1H), 7.25 (s, 1H), 7.36 (d, J=8.11 Hz, 1H), 7.60 (d, J=7.80 Hz, 1H), 7.63 (s, 1H), 7.67 (d, J=2.50 Hz, 1H), 8.25 (d, J=5.93 Hz, 1H), 8.32 (s, 1H), 8.52 (d, J=1.87 Hz, 1H), 8.58 (d, J=6.24 Hz, 1H), 8.63 (d, J=2.18 Hz, 1H), 9.09 (s, 1H), 9.46 (s, 1H).
    • EXAMPLE 433 {5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-benzo[b]thiophen-2-yl-pyridin-2-yl}-phenyl-amine
  • The title compound was prepared by substituting Example 362A for Example 381A in Example 318. MS (APCI) m/z 492 (M+1)[0889] +; 1H NMR (500 MHz, DMSO-d6) δ ppm 3.16 (m, 2H), 3.83 (m, J=2.50 Hz, 1H), 4.13 (dd, J=10.61, 5.93 Hz, 1H), 4.29 (dd, J=10.45, 2.96 Hz, 1H), 6.86 (t, J=7.18 Hz, 1H), 7.01 (t, J=7.49 Hz, 1H), 7.09 (t, J=7.33 Hz, 1H), 7.20 (t, J=7.80 Hz, 2H), 7.25 (m, 2H), 7.30 (d, J=2.18 Hz, 1H), 7.38 (d, J=8.11 Hz, 1H), 7.62 (d, J=7.80 Hz, 1H), 7.72 (d, J=3.12 Hz, 1H), 8.11 (s, 1H), 8.16 (d, J=3.12 Hz, 1H), 8.20 (d, J=6.24 Hz, 1H), 8.25 (br s, 2H), 8.38 (s, 1H), 8.64 (d, J=6.24 Hz, 1H), 9.55 (s, 1H), 11.03 (d, J=1.56 Hz, 1H); Anal. Calcd for C29H25N5OS: C, 48.90; H, 3.26; N, 7.96. Found: C, 48.88; H, 3.13; N, 7.90.
    • EXAMPLE 434 {5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-benzo[b]thiophen-2-yl-pyridin-2-yl}-pyridin-3-yl-amine
  • The title compound was prepared by substituting 3-aminopyridine for aniline in Example 433. MS (APCI) m/z 491 (M−1)[0890] +; 1H NMR (500 MHz, CD3OD) δ ppm 3.32 (m, 2H), 3.97 (m, 1H), 4.24 (dd, J=10.29, 5.93 Hz, 1H), 4.37 (dd, J=10.45, 3.28 Hz, 1H), 7.03 (t, J=7.18 Hz, 1H), 7.11 (t, J=7.18 Hz, 1H), 7.24 (s, 1H), 7.37 (d, J=8.42 Hz, 1H), 7.59 (d, J=8.11 Hz, 1H), 7.68 (d, J=3.12 Hz, 1H), 7.87 (dd, J=8.74, 5.62 Hz, 1H), 8.05 (s, 1H), 8.24 (d, J=3.12 Hz, 1H), 8.30 (d, J=5.30 Hz, 1H), 8.32 (d, J=6.24 Hz, 1H), 8.42 (dd, J=8.73, 1.56 Hz, 1H), 8.63 (d, J=6.24 Hz, 1H), 9.15 (d, J=2.18 Hz, 1H), 9.53 (s, 1H); Anal. Calcd for C28H24N6OS: C, 48.93; H, 3.26; N, 10.07. Found: C, 48.82; H, 3.35; N, 9.92.
    • EXAMPLE 435 6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3H-benzooxazol-2-one
  • The desired compound was prepared by substituting 6-Bromo-3H-benzooxazol-2-one (C. Flouzat, et al, [0891] J. Med. Chem., 1993, 36, 497) for 6-bromophthalimide in Example 32. MS (APCI) m/z 401 (M+1)+; 1H NMR (500 MHz, DMSO-d6) δ ppm 3.16 (d, J=9.67 Hz, 2H), 3.85 (m, 1H), 4.18 (dd, J=10.61, 5.93 Hz, 1H), 4.34 (dd, J=10.76, 2.96 Hz, 1H), 7.01 (t, J=7.49 Hz, 1H), 7.10 (t, J=7.49 Hz, 1H), 7.20 (d, J=8.11 Hz, 1H), 7.29 (d, J=2.18 Hz, 1H), 7.38 (d, J=8.11 Hz, 1H), 7.50 (dd, J=8.11, 1.56 Hz, 1H), 7.62 (d, J=7.80 Hz, 1H), 7.65 (s, 1H), 7.70 (s, 1H), 8.18 (s, 2H), 8.33 (d, J=2.81 Hz, 1H), 8.55 (d, J=1.56 Hz, 1H), 11.02 (s, 1H), 11.81 (s, 1H); Anal. Calcd for C23H20N4O3: C, 50.53; H, 3.44; N, 8.60. Found: C, 50.71; H, 3.46; N, 8.42.
    • EXAMPLE 436 1-Benzoimidazol-1-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine Example 436A 3-Bromo-5-oxiranylmethoxy-pyridine
  • To a solution of 5-Bromo-pyridin-3-ol (0.50 g, 2.87 mmol), oxiranyl-methanol (0.38 mL, 5.74 mmol) and triphenylphosphine (1.50 g, 5.74 mmol) in anhydrous THF (20 mL) was added di-tert-butyl azodicarboxylate (DBAD) (1.32 g, 5.74 mmol) and the reaction mixture stirred at room temperature for 18 hrs and concentrated. The residue was purified by flash column chromatography on silica gel eluting with 10%-35% ethyl acetate/hexanes to provide the desire product (0.48 g, 73%). [0892]
    • Example 436B 1-Benzoimidazol-1-yl-3-(5-bromo-pyridin-3-yloxy)-propan-2-ol
  • A solution of Example 436A (500 mg, 2.17 mmol) and 1H-Benzoimidazole (28 mg, 2.39 mmol) in 2-propanol (10 mL) was refluxed under N[0893] 2 for 2 hrs. The reaction mixture was cooled, diluted with ethyl acetate(50 mL) and washed with brine (2×25 mL). The residue was concentrated and purified by flash column chromatography on silica gel eluting with 100% ethyl acetate to 5% methanol/ethyl acetate to provide the desire product (1.08 mmol, 50%).
    • Example 436C 5-[5-(3-Benzoimidazol-1-yl-2-hydroxy-propoxy)-pyridin-3-yl]-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
  • The product was prepared by substituting Example 436B for Example 202A in Example 203B. [0894]
    • Example 436D 1-Benzoimidazol-1-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired compound was prepared by as trifluoroacetic acid salt by substituting Example 436C for Example 27B in Example 27C. MS (APCI) m/z 400 (M+1)[0895] +; 1H NMR (400 MHz, CD3OD) δ ppm 2.53 (m, 3H), 4.31 (dd, J=13.81, 4.91 Hz, 2H), 4.42 (m, J=7.98, 3.38 Hz, 1H), 4.54 (m, 2H), 7.56 (m, 3H), 7.67 (dd, J=8.75, 1.07 Hz, 1H), 7.78 (dd, J=5.83, 3.38 Hz, 1H), 7.94 (dd, J=6.14, 3.07 Hz, 1H), 8.05 (s, 1H), 8.12 (s, 1H), 8.35 (s, 1H), 8.64 (s, 1H), 9.36 (s, 1H).
    • EXAMPLE 437 2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-morpholin-4-ylmethyl-ethylamine Example 437A 1-(5-Bromo-pyridin-3-yloxy)-3-morpholin-4-yl-propan-2-ol
  • The desired compound was prepared by substituting morpholine for 1H-Benzoimidazole in Example 437B [0896]
    • Example 437B [2-(5-Bromo-pyridin-3-yloxy)-1-morpholin-4-ylmethyl-ethyl]-carbamic Acid Tert-Butyl Ester
  • To a solution of the Example 437A (250 mg, 0.79 mmol), isoindole-1,3-dione (121 mg, 0.82 mmol) and triphenylphosphine (240 mg, 0.92 mmol) in anhydrous THF (10 mL) was added DIAD (0.16 mL, 0.83 mmol) and stirred at room temperature for 45 mins. The concentrated residue was then purified by flash column chromatography eluting with 60% ethyl acetate/hexanes to give the desired intermediate which was dissolved in absolute ethanol (10 mL). Hydrazine monohydrate (40 μL) was added and the reaction mixture refluxed for 3 hrs. The cloudy solution was cooled, concentrated and dissolved in DMF (10 mL). Di-tert-butyl-dicarbonate (271 mg, 1.25 mmol) and triethyl amine (0.18 mL, 1.25 mmol) were added and the clear solution stirred at room temperature for 15 hrs. The clear solution was diluted with ethyl acetate (25 mL) and washed with brine (25 mL) and water (25 mL). The concentrated residue was further purified by flash column chromatography eluting with 15% ethyl acetate/hexanes to give the desired product. [0897]
    • Example 437C 5-[5-(2-tert-Butoxycarbonylamino-3-morpholin-4-yl-propoxy)-pyridin-3-yl]-3-methylindazole-1-carboxylic Acid Tert-Butyl Ester
  • The product was prepared by substituting Example 437B for Example 202A in Example 203B. [0898]
    • Example 437D 2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-morpholin-4-ylmethyl-ethylamine
  • The desired compound was prepared as trifluoroacetic acid salt by substituting Example 437C for Example 27B in Example 27C. MS (APCI) m/z 369 (M+1)[0899] +; 1H NMR (400 MHz, CD3OD) δ ppm 2.62 (s, 3H), 2.73 (dd, J=11.51, 4.76 Hz, 2H), 2.86 (m, 2H), 2.98 (m, 2H), 3.79 (t, J=4.45 Hz, 4H), 4.04 (m, J=8.59, 3.38 Hz, 1H), 4.47 (dd, J=10.43, 5.52 Hz, 1H), 4.59 (m, 1H), 7.64 (d, J=8.59 Hz, 1H), 7.76 (dd, J=8.90, 1.23 Hz, 1H), 8.15 (s, 1H), 8.24 (s, 1H), 8.48 (s, 1H), 8.78 (s, 1H); Anal. Calcd for C20H21N5O2: C, 44.01; H, 3.98; N, 9.87. Found: C, 43.92; H, 3.92; N, 9.73.
    • EXAMPLE 438 5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1,3-dihydro-indol-2-one
  • The desired product was prepared by substituting Boc-phenylalaminol for Boc-tryptophanol in Example 36. MS (APCI) m/z 360 (M+1)[0900] +; 1H NMR (500 MHz, CD3OD) δ ppm 3.15 (d, J=7.49 Hz, 2H), 3.61 (s, 2H), 3.95 (m, 1H), 4.26 (dd, J=10.61, 5.62 Hz, 1H), 4.40 (dd, J=10.61, 3.12 Hz, 1H), 7.04 (d, J=8.11 Hz, 1H), 7.33 (m, 5H), 7.58 (d, J=8.11 Hz, 1H), 7.62 (s, 1H), 7.96 (s, 1H), 8.38 (d, J=2.50 Hz, 1H), 8.60 (s, 1H); Anal. Calcd for C22H21N3O2: C, 51.39; H, 3.78; N, 6.76. Found: C, 51.48; H, 3.63; N, 6.75.
    • EXAMPLE 439 5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one
  • The desired product was prepared by substituting Boc-phenylalaminol for Boc-tryptophanol in Example 39. MS (APCI) m/z 437 (M+1)[0901] +; 1H NMR (500 MHz, CD3OD) δ ppm 3.17 (d, J=7.80 Hz, 2H), 3.97 (m, 1H), 4.28 (dd, J=10.61, 5.62 Hz, 1H), 4.43 (dd, J=110.45, 2.96 Hz, 1H), 6.38 (m, 1H), 6.85 (d, J=3.74 Hz, 1H), 7.06 (d, J=8.11 Hz, 1H), 7.25 (s, 1H), 7.34 (m, 5H), 7.51 (dd, J=8.11, 1.87 Hz, 1H), 7.73 (s, 1H), 7.94 (s, 1H), 8.03 (s, 1H), 8.38 (d, J=1.87 Hz, 1H), 8.67 (s, 1H), 13.32 (s, 1H); Anal. Calcd for C27H24N4O2: C, 53.27; H, 3.70; N, 7.76. Found: C, 53.46; H, 3.69; N, 7.77.
    • EXAMPLE 440 5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-3-furan-2-ylmethylene-1,3-dihydro-indol-2-one
  • The desired product was prepared by substituting Boc-phenylalaminol for Boc-tryptophanol in Example 412. MS (APCI) m/z 438 (M+1)[0902] +; 1H NMR (500 MHz, CD3OD) δ ppm 3.85 (m, 4H), 4.75 (m, 2H), 4.93 (m, 2H), 5.10 (dd, J=10.61, 3.12 Hz, 2H), 7.64 (dd, J=3.43, 1.56 Hz, 1H), 7.77 (d, J=8.11 Hz, 1H), 7.82 (d, J=8.11 Hz, 1H), 8.08 (m, 2H), 8.14 (m, 8H), 8.22 (s, 1H), 8.39 (d, J=1.87 Hz, 1H), 8.42 (dd, J=8.11, 1.87 Hz, 1H), 8.45 (s, 1H), 8.53 (s, 1H), 8.68 (s, 1H), 8.80 (d, J=1.56 Hz, 1H), 8.90 (d, J=1.87 Hz, 1H), 9.00 (d, J=1.56 Hz, 1H), 9.07 (s, 2H), 9.11 (d, J=3.43 Hz, 1H), 9.16 (br s, 2H), 9.44 (d, J=1.56 Hz, 1H), 11.54 (s, 1H), 11.57 (s, 1H); Anal. Calcd for C27H23N3O3: C, 55.36; H, 3.74; N, 6.21. Found: C, 55.09; H, 3.74; N, 6.07.
    • EXAMPLE 441 (1S)-1-Benzoimidazol-1-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine Example 441A (2R)-1-Benzoimidazol-1-yl-3-benzyloxy-propan-2-ol
  • A solution of 2-(3-phenyl-propyl)-oxirane (3.0 g, 18.27 mmol) and benzimidazole (2.37 g, 20.1 mmol) in anhydrous 2-propanol (50 mL) was purged with nitrogen and refluxed for 2.5 hrs. The reaction mixture was cooled, concentrated and purified by flash column chromatography on silica gel [0(1 min)−15% (16 min) methanol in 2:1 ethyl acetate/hexanes to provide the desired product (4.72 g, 91%). [0903]
    • Example 441B (2S)-1-(2-Azido-3-benzyloxy-propyl)-1H-benzoimidazole
  • To a solution of Example 441A (1.0 g, 3.54 mmol) and triphenylphosphine (1.39 g, 5.31 mmol) in anhydrous THF (30 mL) was added diphenylphosphoryl azide (1.14 mL, 5.31 mmol) at 0° C. followed by the addition of DEAD (836 μL). The reaction mixture was stirred at 0° C. for 30 mins and at room temperature for 15 hrs. The concentrated residue was then purified by flash column chromatography on silica gel eluting with 60%-80% ethyl acetate/hexanes to provide the desired product. [0904]
    • EXAMPLE 441C (2-Benzoimidazol-1-yl-1-benzyloxymethyl-ethyl)-carbamic Acid Tert-Butyl Ester
  • To a solution of the Example 441B (˜1 g, ˜3.54 mmol) in ethanol (25 mL) was added 10% Pd/C (230 mg) under nitrogen. This suspension was purged with hydrogen and was stirred under hydrogen (balloon) for 1 h. The solid material was filtered off and the filtrate was concentrated. The residual foam was dissolved in anhydrous DMF (20 mL). Triethylamine (1.08 mL, 7.78 mmol) and di-tert-butyl dicarbonate (0.85 g, 3.89 mmol) were then added at room temperature and the solution stirred under nitrogen for 2 h. EtOAc (200 mL) was added and the mixture was washed with brine (200 mL), and water (100 mL). The organic phase was concentrated and the residue was purified by flash chromatography [60-80%(5 min) EtOAc in hexane] to give desired product. [0905]
    • EXAMPLE 441D (1S)-(2-Benzoimidazol-1-yl-1-hydroxymethyl-ethyl)-carbamic Acid Tert-Butyl Ester
  • To a solution of the Example (0.78 g) in methanol (20 mL) was added 10% Pd-C (450 mg) under nitrogen. This reaction mixture was purged with hydrogen and was stirred under hydrogen at 86° C. for 3.5 days (balloon). The filtrate was concentrated and the residual oil was separated by flash chromatography (0-15% CH[0906] 3OH in 2:1 EtOAc/hexane) to give the desired product (199.7 mg, 33%).
    Figure US20030187026A1-20031002-C00098
    • Example 441E (1S)-[1-Benzoimidazol-1-ylmethyl-2-(5-bromo-pyridin-3-yloxy)-ethyl]-carbamic Acid Tert-Butyl Ester
  • To a solution of 5-bromo-pyridin-3-ol (102 mg, 0.58 mmol), Example 441D (154 mg, 0.53 mmol) and triphenylphosphine (208 mg, 0.793 mmol) in anhydrous THF (20 mL) was added DEAD (125 μL, 0.79 mmol) and the reaction mixture stirred at room temperature for 2 hrs and concentrated. The residue was purified by flash column chromatography on silica gel (0-15% CH[0907] 3OH in 2:1 EtOAc/hexane) to give the desired product (100 mg, 43%).
    • Example 441F 5-[5-(3-Benzoimidazol-1-yl-2-tert-butoxycarbonylamino-propoxy)-pyridin-3-yl]-3-methylindazole-1-carboxylic Acid Tert-Butyl Ester
  • The product was prepared by substituting Example 447E for Example 202A in Example 203B. [0908]
    • Example 441G (1S)-1-Benzoimidazol-1-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
  • The desired compound was prepared by as trifluoroacetic acid salt by substituting Example 441F for Example 27B in Example 27C. [0909] 1H NMR (300 MHz, CD3OD) δ ppm 2.63 (m, 3H), 4.53 (m, 2H), 4.65 (m, 1H), 5.09 (d, J=6.78 Hz, 2H), 7.66 (m, 2H), 7.74 (d, J=1.70 Hz, 1H), 7.77 (d, J=1.70 Hz, 1H), 7.90 (m, 1H), 8.02 (m, 1H), 8.12 (m, 1H), 8.15 (d, J=2.37 Hz, 1H), 8.46 (d, J=2.71 Hz, 1H), 8.77 (d, J=1.70 Hz, 1H), 9.40 (s, 1H); Anal. Calcd for C23H22N6O: C, 42.16; H, 2.93; N, 9.22. Found: C, 42.08; H, 3.24; N, 9.13.
    • EXAMPLE 442 3-{3-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-5-isoquinolin-6-yl-pyridin-4-yl}-acrylonitrile Example 442A 3-Chloro-5-(4-methoxy-benzyloxy)-pyridine
  • To a solution of 3-chloro-5-hydroxypyridine (2.0 g, 17.0 mmol), 4-methoxybenzyl alcohol (2.85 g, 25.5 mmol) and triphenylphosphine (6.68 g, 25.5 mmol) in dry THF (100 ml) DEAD (4.44 g, 25.5 mmol) was added dropwise. The resulting solution was stirred 3 hours at room temperature. The reaction solution was partitioned between ethyl acetate and water. The organic layer was washed (brine), dried (Na[0910] 2SO4), filtered and concentrated under vacumm. Purification on silica gel with 20% ethyl acetate/hexane to provide the title compound (1.9 g, 53%). MS (DCI/NH3) m/e 250 (M+1)+.
    • Example 442B 3-Chloro-5-(4-methoxy-benzyloxy)-pyridine-4-carbaldehyde
  • A solution of DIPA (1.73 g, 17.16 mmol) in THF (100 ml) was treated dropwise with n-BuLi (6.86 ml, 17.16 mmol) at 0° C., stirred for 30 min. at 0° C. To the reaction Example 442A (3.56 g, 14.3 mmol) in THF (10 ml) was added dropwise at −78° C. The resulting solution was stirred 1 hours at −78° C. The mixture was quenched with methyl formate (2.0 ml). The reaction solution was partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na[0911] 2SO4), filtered and concentrated under vacumm. Purification on silica gel with 20% ethyl acetate/hexane to provide the title compound (2.2 g, 56%). MS (DCI/NH3) m/e 278 (M+1)+.
    • Example 442C 3-[3-Chloro-5-(4-methoxy-benzyloxy)-pyridin-4-yl]-acrylonitrile
  • A solution of diethylmethylcyanophosponate (212 mg, 1.2 mmol) in THF (4 ml) was treated dropwise with LiHMDS (1.2 ml, 1.2 mmol) at 0° C., stirred for 30 min. at 0° C. treated with Example 442B (277 mg, 1 mmol) in THF (1 ml). The resulting solution was stirred 1 hours. The mixture was quenched with water. The reaction solution was partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na[0912] 2SO4), filtered and concentrated under vacumm. Purification on silica gel with 20% ethyl acetate/hexane to provide the title compound (210 mg, 70%). MS (DCI/NH3) m/e 301 (M+1)+.
    • Example 442D 3-(3-Chloro-5-hydroxy-pyridin-4-yl)-acrylonitrile
  • To a solution of Example 442C (1.02 g, 3.4 mmol) in dichloromethane (10 ml) THA (1 ml) was added. The resulting solution was stirred for two hours. The reaction solution was partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na[0913] 2SO4), filtered and concentrated under vacumm. Purification on silica gel with 40% ethyl acetate/hexane to provide the title compound (600 mg, 98%). MS (DCI/NH3) m/e 181 (M+1)+.
    Figure US20030187026A1-20031002-C00099
    • Example 442E (1S)-[2-[5-Chloro-4-(2-cyano-vinyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • To a solution of Example 442D (430 mg, 2.39 mmol), N-alpha-(tert-butoxycarbonyl)-L-tryptophanol (762 mg, 2.6 mmol) and triphenylphosphine (1.38 g, 5.26 mmol) in dry THF (40 ml) DBAD (880 mg, 3.82 mmol) was added. The resulting solution was stirred 3 hours at room temperature. The reaction solution was partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na[0914] 2SO4), filtered and concentrated under vacumm. Purification on silica gel with 20% ethyl acetate/hexane to provide the title compound (340 g, 32%). MS (DCI/NH3) m/e 453 (M+1)+.
    Figure US20030187026A1-20031002-C00100
    • Example 442F (1S)-[2-[4-(2-Cyano-vinyl)-5-isoquinolin-6-yl-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
  • To a solution of Example 442E (330 mg, 0.73 mmol), 6-(1,1,1-trimethylstannyl)-isoquinoline(276 mg, 0.95 mmol), tris(dibenzylideneacetone)-dipalladium (66.8 mg, 0.073 mmol) and 2-dicyclohexylphosphino-2′-dimethylamino-1,1′-biphenyl (57.3 mg, 0.146 mmol) in dry DMF (10 ml) triethyl amine was added under N[0915] 2. The resulting solution was stirred 3 hours at 100° C. The reaction solution was partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na2SO4), filtered and concentrated under vacumm. Purification on silica gel with 60% ethyl acetate/hexane to provide the title compound (61 mg, 17%).MS (DCI/NH3) m/e 546 (M+1)+.
    • Example 442G 3-{3-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-5-isoquinolin-6-yl-pyridin-4-yl}-acrylonitrile
  • MS (DCI/NH[0916] 3) m/e 446 (M+1)+; 1H NMR (300 MHz, D6-DMSO) δ 11.06 (s; 1H), 9.68 (s; 1H), 8.68 (d; 1H; J=6.0 Hz), 8.58 (s; 1H), 8.44 (d; 1H; J=8.4 Hz), 8.40 (s; 1H), 8.23 (d; 1H; J=6.0 Hz), 8.20 (s; 3H), 7.80 (d; 1H; J=8.4 Hz), 7.60 (d; 1H; J=8.4 Hz), 7.44 (d; 1H; J=17.1 Hz), 7.40 (d; 1H; J=8.4 Hz), 7.30 (s; 1H), 7.11 (t; 1H; J=8.4 Hz), 7.01 (t; 1H; J=8.4 Hz), 6.24 (d; 1H; J=17.1 Hz), 4.48 (m; 1H), 4.31 (m; 1H), 3.97 (m; 1H), 3.17 (m; 2H)
    • EXAMPLE 443 (1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-4-methyl-pyridin-3-yloxy)-ethylamine
  • The desire product was prepared by substituting methyl iodide for ethyl acetate in Example 442, omitting the step of Example 442C. MS (DCI/NH[0917] 3) m/e 409 (M+1)+; 1H NMR (300 MHz, D6-DMSO) δ 11.06 (s; 1H), 9.72 (s; 1H), 8.68 (d; 1H; J=6.0 Hz), 8.47 (d; 1H; J=8.4 Hz), 8.37 (s; 1H), 8.32 (s; 1H), 8.22 (m; 4H), 7.91 (d; 1H; J=8.4 Hz), 7.61 (d; 1H; J=8.4 Hz), 7.40 (d; 1H; J=8.4 Hz), 7.30 (s; 1H), 7.12 (t; 1H; J=8.4 Hz), 7.02 (t; 1H; J=8.4 Hz), 4.37 (m; 1H), 4.22 (m; 1H), 3.89 (m; 1H), 3.20 (m; 2H), 2.29 (s; 3H).
    • EXAMPLE 444 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-methyl-1,3-dihydro-indol-2-one Example 444A 3-Methyl-1,3-dihydro-indol-2-one
  • A solution of oxindole (665 mg, 5.0 mmol) in THF (10 ml) was treated dropwise with n-BuLi (4.4 ml, 11.0 mmol) at −78° C., stirred for 30 min. at −78° C. To the reaction methyliodine (2 ml) was added dropwise at −78° C. The resulting solution was warmed up to room temperature. The mixture was quenched with water. The reaction solution was partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na[0918] 2SO4), filtered and concentrated under vacumm. Purification on silica gel with 30% ethyl acetate/hexane to provide the title compound (630 mg, 86%). MS (DCI/NH3) m/e 148 (M+1)+.
    • Example 444B 5-Bromo-3-methyl-1,3-dihydro-indol-2-one
  • To a solution of Example 444B (625 mg, 4.25 mmol) in acetonitrile (10 ml) NBS (757 mg, 4.25 mmol) was added at −10° C. The mixture was stirred at −10° C. for 1 hours and 0° C. for 2 hours. The reaction solution was partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na[0919] 2SO4), filtered and concentrated under vacumm. Purification on silica gel with 30% ethyl acetate/hexane to provide the title compound (640 mg, 66%). MS (DCI/NH3) m/e 227 (M+1)+.
    • Example 444C 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-methyl-1,3-dihydro-indol-2-one
  • The desired product was prepared by substituting Example 44B for 6-bromophthalimide in Example 32. [0920] 1H NMR (300 MHz, D6-DMSO) δ 11.04 (s; 1H), 10.49 (s; 1H), 8.53 (s; 1H), 8.30 (s; 1H), 8.16 (s; 2H), 7.64 (s; 1H), 7.62 (d; 1H; J=7.5 Hz), 7.53 (d; 1H; J=7.5 Hz), 7.38 (d; 1H; J=8.7 Hz), 7.30 (s; 1H), 7.10 (t; 1H; J=8.7 Hz), 7.01 (t; 1H; J=8.7 Hz), 6.93 (d; 1H; J=8.7 Hz), 4.33 (m; 1H), 4.14 (m; 1H), 3.84 (m; 1H), 3.49 (q; 1H; J=7.5), 3.14 (m; 2H), 1.39 (d; 3H; J=7.5 Hz); MS (DCI/NH3) m/e 413 (M+1)+.
    • EXAMPLE 445 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3,3-dimethyl-1,3-dihydro-indol-2-one Example 445A 3,3-Dimethyl-1,3-dihydro-indol-2-one
  • A solution of Example 444A (500 mg, 3.4 mmol) in THF (10 ml) was treated dropwise with n-BuLi (2.7 ml, 6.8 mmol) at −78° C., stirred for 30 min. at −78° C. To the reaction methyliodine (2 ml) was added dropwise at −78° C. The resulting solution was warmed up to room temperature. The mixture was quenched with water. The reaction solution was partitioned between ethylacetate and water. The organic layer was washed (brine), dried (Na[0921] 2SO4), filtered and concentrated under vacumm. Purification on silica gel with 30% ethyl acetate/hexane to provide the title compound (410 mg, 75%). MS (DCI/NH3) m/e 162 (M+)+.
    • Example 445B 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3,3-dimethyl-1,3-dihydro-indol-2-one
  • The title compound was prepared by substituting Example 445A for Example 444A in Example 444. [0922] 1H NMR (300 MHz, D6-DMSO) δ 11.03 (s; 1H), 10.49 (s; 1H), 8.56 (s; 1H), 8.31 (s; 1H), 8.18 (s; 2H), 7.70 (s; 1H), 7.64 (s; 1H), 7.61 (d; 1H; J=7.5 Hz), 7.57 (d; 1H; J=7.5 Hz), 7.38 (d; 1H; J=8.7 Hz), 7.27 (s; 1H), 7.10 (t; 1H; J=8.7 Hz), 7.01 (t; 1H; J=8.7 Hz), 6.96 (d; 1H; J=8.7 Hz), 4.33 (m; 1H), 4.17 (m; 1H), 3.84 (m; 1H), 3.17 (m; 2H), 1.31 (s; 6H); MS (DCI/NH3) m/e 427 (M+1)+.
    • EXAMPLE 446 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1,3,3-trimethyl-1,3-dihydro-indol-2-one Example 446A 1,3,3-Trimethyl-1,3-dihydro-indol-2-one
  • The title compound was prepared by substituting Example 445A for Example 102A in Example 112. MS (DCI/NH[0923] 3) m/e 176 (M+1)+.
    • Example 446B 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1,3,3-trimethyl-1,3-dihydro-indol-2-one
  • The title compound was prepared by substituting Example 446A for Example 444A in Example 444. [0924] 1H NMR (300 MHz, D6-DMSO) δ 11.03 (s; 1H), 8.60 (s; 1H), 8.32 (s; 1H), 8.20 (s; 2H), 7.78 (s; 1H), 7.67 (d; 1H; J=7.5 Hz), 7.62 (d; 1H; J=7.5 Hz), 7.39 (d; 1H; J=8.7 Hz), 7.29 (s; 1H), 7.14 (d; 1H; J=8.7 Hz), 7.10 (t; 1H; J=8.7 Hz), 7.01 (t; 1H; J=8.7 Hz), 4.35 (m; 1H), 4.28 (m; 1H), 3.83 (m; 1H), 3.19 (s; 3H), 3.17 (m; 2H), 1.33 (s; 6H); MS (DCI/NH3) m/e 441 (M+1)+.
    • EXAMPLE 447 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-ethyl-1,3-dihydro-indol-2-one
  • The title compound was prepared by substituting iodoethane for iodomethane in Example 444. [0925] 1H NMR (300 MHz, D6-DMSO) δ 11.04 (s; 1H), 10.51 (s; 1H), 8.53 (s; 1H), 8.30 (s; 1H), 8.16 (s; 2H), 7.64 (s; 1H), 7.62 (d; 1H; J=7.5 Hz), 7.53 (d; 1H; J=7.5 Hz), 7.38 (d; 1H; J=8.7 Hz), 7.28 (s; 1H), 7.10 (t; 1H; J=8.7 Hz), 7.01 (t; 1H; J=8.7 Hz), 6.93 (d; 1H; J=8.7 Hz), 4.33 (m; 1H), 4.16 (m; 1H), 3.84 (m; 1H), 3.49 (t; 1H; J=7.5), 3.14 (m; 2H), 1.85 (m; 2H), 1.09 (d; 3H; J=7.5 Hz); MS (DCI/NH3) m/e 427 (M+1)+.
    • EXAMPLE 448 5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-benzyl-1,3-dihydro-indol-2-one
  • The title compound was prepared by substituting benzyl chloride for iodomethane in Example 444. [0926] 1H NMR (300 MHz, D6-DMSO) δ 11.04 (s; 1H), 10.48 (s; 1H), 8.38 (s; 1H), 8.27 (s; 1H), 8.15 (s; 2H), 7.62 (d; 1H; J=7.5 Hz), 7.44 (d; 1H; J=7.5 Hz), 7.40 (s; 1H), 7.39 (d; 1H; J=8.7 Hz), 7.29 (s; 1H), 7.17 (m; 5H), 7.10 (t; 1H; J=8.7 Hz), 7.01 (t; 1H; J=8.7 Hz), 6.82 (d; 1H; J=8.7 Hz), 4.30 (m; 1H), 4.12 (m; 1H), 3.86 (m; 1H), 3.40 (m; 1H), 3.17 (m; 2H), 3.01 (m; 1H); MS (DCI/NH3) m/e 489 (M+1)+.
  • It will be evident to one skilled in the art that the present invention is not limited to the foregoing illustrative examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein. [0927]

Claims (22)

What is claimed is:
1. A compound of formula (I)
Figure US20030187026A1-20031002-C00101
or a therapeutically acceptable salt thereof, wherein
X is selected from the group consisting of C(R8) and N; wherein R8 is selected from the group consisting of hydrogen, alkyl, amino, carboxy, cyano, halo, hydroxy, and amido;
X′ is selected from the group consisting of C and N;
Y is selected from the group consisting of C and N;
Y′ is selected from the group consisting of C(R9) and N; wherein R9 is selected from the group consisting of hydrogen and -L2-L3(R3)(R6);
Z is selected from the group consisting of C and N;
provided that 0, 1, or 2 of X, X′, Y, Y′, and Z are N;
L1 is selected from the group consisting of a bond, —O—, —NR5—, alkenyl, alkynyl, —C(O)—, —S—, —S(O)—, —S(O)2—, —S(O)2N(R5)—, —N(R5)S(O)2—, —C(R12)2—, —C(R12)2N(R5)—, —N(R5)C(O)—, and —C(O)N(R5)—; wherein each group is drawn with its left end attached to R1 and its right end attached to the aromatic ring;
L2 is selected from the group consisting of a bond, —O—, —C(R12)2—, —S—, —N(R5)—, —N(R5)C(O)—, and —C(O)N(R5)—;
L3 is selected from the group consisting of a bond, alkylidene and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of alkoxy, amino, cyano, and hydroxy;
R1 is selected from the group consisting of aryl, heteroaryl, and heterocycle;
R2 and R4 are independently absent or selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, arylalkynyl, cyano, cyanoalkenyl, halo, heteroaryl, heterocycle, hydroxyalkyl, and nitro; or
R2 and L1, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle; or
R4 and L2, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle;
provided that when L3 is alkylidene, R4 and L2, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle;
R3 is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;
R6 is selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;
provided that when L1 and L2 are bonds, at least one of R3 and R6 is other than hydrogen;
R5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl;
R7 is absent or selected from the group consisting of hydrogen, alkyl, cyanoalkenyl, and -L2-L3(R3)(R6); or
R7 and L1, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of aryl, heteroaryl, and heterocycle; and
each R12 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo, heteroaryl, heterocycle, and nitro.
2. A compound of formula (II)
Figure US20030187026A1-20031002-C00102
or a therapeutically acceptable salt thereof, wherein
L1 is selected from the group consisting of a bond, —O—, —N(R5)—, alkenyl, alkynyl, —N(R5)C(O)—, and —C(O)N(R5)—;
L2 is selected from the group consisting of a bond, —O—, —N(R5)—, —N(R5)C(O)—, and —C(O)N(R5)—;
L3 is selected from the group consisting of a bond, alkylidene, and alkylene, wherein the alkylidene and the alkylene are optionally substituted with one or two substituents independently selected from the group consisting of amino, cyano, and hydroxy;
R1 is selected from the group consisting of aryl, heteroaryl, and heterocycle;
R2 and R4 are independently selected from the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl; wherein the heteroaryl is selected from the group consisting of furyl, pyrazinyl, thiazolyl, and thienyl; or
R2 and L1, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, pyrazolyl, and phenyl; or
R4 and L2, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, phenyl, pyridinyl, and pyrrolyl; wherein the ring can be optionally substituted with oxo;
provided that when L3 is alkylidene, R4 and L2, together with the carbon atoms to which they are attached, form a ring selected from the group consisting of dihydropyrrolyl, phenyl, pyridinyl, and pyrrolyl; wherein the ring can be optionally substituted with oxo;
R3 is absent or selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;
R6 are independently selected from the group consisting of hydrogen, aryl, arylalkoxy, arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl, and heteroarylalkoxy, heteroaryloxy, and heterocycle;
provided that when L1 and L2 are bonds, at least one of R3 and R6 is other than hydrogen;
R5 is selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; and
X is selected from the group consisting of C(R8) and N; wherein R8 is selected from the group consisting of hydrogen, amino, carboxy, cyano, and halo.
3. A compound of formula (III)
Figure US20030187026A1-20031002-C00103
or a therapeutically acceptable salt thereof, wherein
L1 is selected from the group consisting of a bond, —O—, —N(R5)—, alkenyl, alkynyl, and —N(R5)C(O)—;
L2 is selected from the group consisting of a bond, —O—, —N(R5)—, —N(R5)C(O)—, and —C(O)N(R5)—;
L3 is alkylene, wherein the alkylene is substituted with one or two substituents independently selected from the group consisting of amino and hydroxy;
R1 is selected from the group consisting of aryl, heteroaryl, and heterocycle;
R2 and R4 are independently selected from the group consisting of hydrogen and halo;
R3 and R6 are independently selected from the group consisting of hydrogen, aryl, arylalkoxy, and heteroaryl; provided that when L1 and L2 are bonds, at least one of R3 and R6 is other than hydrogen; and
R5 is selected from the group consisting of hydrogen and alkyl.
4. The compound according to claim 1 wherein L1 is alkenyl.
5. The compound according to claim 4 wherein Y′ is C(R9) wherein R9 is -L2-L3(R3)(R6) and wherein L2 is —O—.
6. The compound according to claim 5 selected from the group consisting of
N,N-dimethyl-N-[2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine;
(1S)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine;
(1R)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine;
1-(1H-indol-3-yl)-3-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)propan-2-ol;
(1S)-2-(1-benzothien-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine;
(1S)-2,2-diphenyl-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine;
(1S)-1-{4-[(2,6-dichlorobenzyl)oxy]benzyl}-2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethylamine;
(1S)-2-(benzyloxy)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine;
N,N-dimethyl-N-[(1S,2S)-1-methyl-2-phenyl-2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine;
(1S)-2-(2-naphthyl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-y]}oxy)methyl]ethylamine;
(1S)-2-({2-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-3-ylmethyl)ethylamine;
(1S)-2-({6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-3-ylmethyl)ethylamine;
(1S)-2-(1H-indol-3-yl)-1-[({5-[(Z)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine; and
N-[(2E)-3-(4-bromophenyl)prop-2-enyl]-N-[2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine.
7. The compound according to claim 4 wherein Y′ is C(R9) wherein R9 is -L2-L3(R3)(R6) and whereein L2 is selected from the group consisting of a bond, —N(R5)—, —N(R5)C(O)—, and —C(O)N(R5)—.
8. The compound according to claim 7 selected from the group consisting of
N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-{5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}amine;
(2S)-2-amino-4-phenyl-N-{5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}butanamide;
N-(aminomethyl)-5-[(E)-2-pyridin-4-ylvinyl]nicotinamide; and
(1R)-3-{6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}-1-(1H-indol-3-ylmethyl)propylamine.
9. The compound according to claim 1 wherein L1 is a bond.
10. The compound according to claim 9 wherein Y′ is C(R9) wherein R9 is -L2-L3(R3)(R6) and wherein L2 is —O—.
11. The compound according to claim 10 selected from the group consisting of
4-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)benzonitrile;
(1S)-2-(1H-indol-3-yl)-1-{[(5-isoquinolin-6-ylpyridin-3-yl)oxy]methyl}ethylamine;
(1R)-2-(1H-indol-3-yl)-1-{[(5-quinolin-6-ylpyridin-3-yl)oxy]methyl}ethylamine;
(1S)-2-[(6-chloro-5-isoquinolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamine;
(1S)-2-[(2-chloro-5-isoquinolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamine;
5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1H-isoindole-1,3(2H)-dione;
5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)isoindolin-1-one;
(1S)-2-[(5-cinnolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamine;
(1S)-2-{[5-(1H-indazol-5-yl)pyridin-3-yl]oxy}-1-(1H-indol-3-ylmethyl)ethylamine;
5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1,3-dihydro-2H-indol-2-one;
(1S)-2-{[5-(2,1,3-benzoxadiazol-5-yl)pyridin-3-yl]oxy}-1-(1H-indol-3-ylmethyl)ethylamine;
(1S)-2-(1H-indol-3-yl)-1-{[(5-thieno[2,3-c]pyridin-2-ylpyridin-3-yl)oxy]methyl}ethylamine;
(3Z)-5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydro-2H-indol-2-one; and
6-(5-{[(2R)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1,3-benzothiazol-2(3H)-one.
12. The compound according to claim 9 wherein Y′ is C(R9) wherein R9 is -L2-L3(R3)(R6) and wherein L2 is selected from the group consisting of a bond, —N(R5)C(O)—, and —N(R5)—.
13. The compound according to claim 12 selected from the group consisting of
(2S)-2-amino-3-(1H-indol-3-yl)-N-[5-(1,6-naphthyridin-2-yl)pyridin-3-yl]propanamide;
N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-[5-(1,6-naphthyridin-2-yl)pyridin-3-yl]amine;
(1R)-1-(1H-indol-3-ylmethyl)-3-(5-isoquinolin-6-ylpyridin-3-yl)propylamine;
2-(1H-indol-3-yl)-2-(5-isoquinolin-6-ylpyridin-3-yl)ethanamine; and
2-(1H-indol-3-yl)-3-(5-isoquinolin-6-ylpyridin-3-yl)propan-1-amine.
14. The compound according to claim 9 wherein Y′ is C(R9) wherein R9 is -L2-L3(R3)(R6) and wherein L2 and R4, together with the atoms to which they are attached, form a heterocycle ring.
15. The compound according to claim 14 which is
(3Z)-3-[(2S)-2-amino-3-(1H-indol-3-yl)propylidene]-5-isoquinolin-6-yl-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one.
16. The compound according to claim 1 wherein L1 is selected from the group consisting of alkynyl, —N(R5)C(O)—, —N(R5)—, and —O—.
17. The compound according to claim 16 selected from the group consisting of
(1S)-2-(1H-indol-3-yl)-1-({[5-(pyridin-4-ylethynyl)pyridin-3-yl]oxy}methyl)ethylamine;
5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-N-pyridin-4-ylnicotinamide;
N4-(3-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}phenyl)pyrimidine-2,4-diamine;
N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N′-isoquinolin-5-ylpyridine-3,5-diamine; and
N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-[5-(isoquinolin-5-yloxy)pyridin-3-yl]amine.
18. The compound according to claim 1 wherein L1 and R2, together with the atoms to which they are attached, form an aryl ring.
19. The compound according to claim 18 which is
(1S)-2-(1H-indol-3-yl)-1-{[(6-pyridin-4-ylquinolin-3-yl)oxy]methyl}ethylamine.
20. The compound according to claim 1 selected from the group consisting of
3-Butoxyl-5-[2-(4-pyridinyl)vinyl]pyridine;
3-Methoxyl-5-[2-(4-pyridinyl)vinyl]pyridine;
S-3-[2-Amino-3-phenyl-propyloxyl]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride;
3-[2-(1H-3-Indolyl)-ethoxyl]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride;
3-[2-(1H-3-Indolyl)-propyloxyl]-5-[2-(4-pyridinyl)vinyl]pyridine;
S-3-[2-Amino-3-(4-benzyloxylphenyl)-propyloxyl]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride;
3-(Piperidin-4-yl)-5-[2-(4-pyridinyl)vinyl]pyridine;
R-3-{2-Amino-3-benzyloxypropyloxyl}-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride;
3-(1-Methyl-imidazole-4-methoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine;
S-3-{2-Amino-3-[3-hydroxylphenyl]-propyloxyl}-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
S-3-{2-Amino-3-[3-cyanophenyl]-propyloxyl}-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt;
3-[-(4-Cyanobenzyl)-imidazole-4-methoxyl]-5-[2-(4-pyridinyl)vinyl]pyridine;
S-3-[2-Amino-3-(1-methyl-1H-3-indolyl)-propyloxyl]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt;
S-3-[2-Dimethylamino-3-(1H-3-indolyl)-propyloxyl]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt;
S-3-[2-Amino-3-(1-naphthyl)-propyloxyl]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt;
3-(2-Aminoethoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine hydrochcloride salt;
3-(3-Aminopropyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt;
S-3-(2-Amino3-methylbutyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt;
3-(i-Methyl-3-piperidinyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
3-(2-Chlorobenzyl)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
3-(N-Benzyl-N-methylaminoethoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
3-(6-(N,N-Dimathylamino)hexyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
3-(2-Thiophenoxyl-ethoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
3-(1-Methyl-3-pyrrolidinyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
3-[(1-Methyl-2-piperidinyl)methoxyl]-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
3-(1-Pyridinyl-ethoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
4-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-N-hydroxyl-benzamidine trifluoroacetic acid salt;
4-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-benzamidine trifluoroacetic acid salt;
3-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxyl]-6-(3-pyridinyl)-quinoline;
3-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxyl]-6-(3-quinolinyl)-quinoline;
3-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxyl]-5-[2-(2-amino-4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
5-[(2S)-2-(Amino-3-(1H-3-indolyl)-propyloxyl]-3-[2-(2-amino-4-pyridinyl)vinyl]-2-chloro-pyridine trifluoroacetic acid salt;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-naphthalen-2-yl-pyridin-3-yloxy)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-5-yl-pyridin-3-yloxy)-ethylamine;
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2H-isoquinolin-1-one;
(1S)-2-[5-(3-Chloro-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-2-([3,4′]Bipyridinyl-5-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine trifluoroacetic acid;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(2-pyridin-2-yl-vinyl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-pyridin-3-ylethynyl-pyridin-3-yloxy)-ethylamine trifluoroacetic acid salt;
(1S)-2-[5-(2-Fluoro-pyridin-4-ylethynyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine trifluoroacetic acid salt;
(1S)-4-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-ylethynyl}-pyridin-2-ol trifluoroacetic acid salt;
(1S)-2-[6-Chloro-5-(1-chloro-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine trifluoroacetic acid salt;
Bis-[3-(4-Bromo-phenyl)-allyl]-{2-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yloxy]-ethyl}-amine hydrochloride;
N4-[3-(2-Amino-ethoxy)-phenyl]-pyrimidine-2,4-diamine hydrochloride;
trans-[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propylamino]-pyridin-3-yl}-vinyl)-pyrimidin-2-yl]-carbamic acid ethyl ester trifluoroacetic acid salt;
1-Amino-6-{5-[(2S)-2-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinoline trifluoroacetic acid salt;
6-{5-[(2S)-2-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1-chloro-isoquinoline trifluoroacetic acid salt;
(2S)-2-Amino-3-(1H-indol-3-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide;
(2S)-2-Amino-3-(naphtha-1-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide hydrochloride;
(2S)-2-Amino-3-phenyl-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide hydrochloride;
S-2-Amino-3-(imidazol-4-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide hydrochloride;
(1R)-2-(1H-indol-3-yl)-1-{[(5-isoquinolin-6-ylpyridin-3-yl)oxy]methyl}ethylamine;
(1S)-5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-ylamine;
(1S)-6-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-ylamine;
2-Amino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-acetamide;
(2S)-2-Amino-N-[(S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-propionamide;
2-Dimethylamino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-acetamide;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(1H-pyrrol-2-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-ethyl amine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Cyclopropyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl amine;
(1S)-2-[5-(3-Ethyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(1-methyl-1H-imidazol-2-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-thiazol-2-yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-{5-[3-(1H-Imidazol-2-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-thiophen-2-yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-morpholin-4-yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethyl amine;
(1S)-2-[5-(1,3-Dimethyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(4-methyl-piperazin-1-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-ethylamine;
(1S)-(5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-yl)-dimethyl-amine;
(1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-benzyl)-phenylamine;
(1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-methanol;
(1S)-2-(5-(4-Fluoro-phenyl)-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-benzoic acid;
(1S)-2-(3-Bromo-5-isoquinolin-6-yl-phenoxyoxy)-1-(1H-indol-3-ylmethyl)-ethylamine;
N4-(3-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidine-2,4-diamine;
(1S)-3-(2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-phenylamine;
4-(5-Isoquinolin-6-yl-pyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester;
6-(5-Piperazin-1-yl-pyridin-3-yl)-isoquinoline;
((2S)-2-Amino-5-(5-(2-amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl-(3-chloro-phenyl-methanone;
(1S)-N-6-(3-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-9H-purine-2,6-diamine;
(3-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidin-2yl-amine;
(3-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-thiazol-2yl-amine;
N-(3-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-acetamide;
6-(5-(4-(1H-Indol-3-ylmethyl)-piperazin-1-yl)-pyridin-3-yl)-isoquinoline;
3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-benzoic acid;
4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenylamine;
N-(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-acetamide;
N6-(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-9H-purine-2,6-diamine;
N4-(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidine-2,4-diamine;
(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidin-2-yl-amine;
3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-benzonitrile;
5′-Benzyloxy-5-isoquinolin-6-yl-(3,3′)bipyridinyl;
(7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)pyrimidin-4-yl)-phenyl-amine;
(7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)pyrimidin-4-yl)-ethyl-amine;
(7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)pyrimidin-4-yl)-benzyl-amine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(6-isoquinolin-6-yl-pyrazin-2-yloxy)-ethylamine;
(1S)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-1-phenyl-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(6-(3-methyl-1H-indazol-5-yl)-pyrazin-2-yloxy)-ethylamine;
(1S)-1-Cyclohexylmethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine;
(1S)-1-Benzyl-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-phenyl-ethylamine;
(1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-phenyl-ethylamine;
4-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)propyl)-benzonitrile;
(1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-napthalen-2-ylmethyl-ethylamine;
4-((2S)-2-Amino-3-(5-isoquinolin-6-yl-pyridin-3-yloxy-propyl)-benzonitrile;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-nanpthalen-2-ylmethyl)-ethylamine;
(1S)-1-Benzyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine;
(1S)-1-(4-Fluoro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-1-(4-Fluoro-benzyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine;
2-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-propyl)-benzonitrile;
2-((2S)-2-Amino-3-(5-isoquinolin-6-yl)-pyridin-3-yloxy)-propyl)-benzonitrile;
(1 s)-2-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-pyridin-4-ylmethyl-ethylamine;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-pyridin-4-ylmethyl-ethylamine;
(1S)-1-(4-Methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(4-methyl-benzyl)-ethylamine;
(1S)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-quinolin-3-ylmethyl-ethylamine;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-quinolin-3-ylmethyl-ethylamine;
(1R)-1-Benzyl-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1R)-1-Benzyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine;
4-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-propyl)-phenol;
(1S)-1-(4-Benzyloxy-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-1-(3-Methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-1-(2-Methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-(4-nitro-benzyl)-ethylamine;
(1S)-1-(4-Methoxy-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-1-Biphenyl-4-ylmethyl-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-napthalen-1-ylmethyl-ethylamine;
(1S)-1-(3-Chloro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
3-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-propyl)-benzonitrile;
(1S)-1-(3,4-Difluoro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-1-(3,4-Dimethoxy-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-1-(3-Fluoro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-(3-trifluoromethyl-benzyl)-ethylamine;
(1S)-1-(4-Ethoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-tert-Butyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-1-(4-Methoxy-3-methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
2-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-propyl)-4-methyl-phenol;
(1S)-1-Methyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(±)-1-(1H-Benzoimidazol-2-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine;
(±)-1-(1H-Indazol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine;
(1S)-1-(2-Fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-thiophen-2-ylmethyl-ethylamine;
(1R)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
1-(4-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-pyrrol-1-yl-benzyl)-ethylamine;
(1S)-1-(4-Methyl-benzylsulfanylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethyl amine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-trifluoromethyl-benzyl)-ethylamine;
(1R)-1-Benzyl-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propylamine;
(1R)-1-Benzyl-4-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-butylamine;
(1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-3-phenyl-propylamine;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(1-methyl-I 1H-indol-3-ylmethyl)-ethylamine trifloroacetic acid salt;
(1S)-[1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-dimethyl-amine;
(1S)-1-Benzo[b]thiophen-3-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-thiophen-3-ylmethyl-ethylamine;
(1S)-1-Benzyloxymethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine;
(1S)-1-Benzyloxymethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(naphthalen-2-yloxymethyl)-ethylamine;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(pyridin-3-yloxymethyl)-ethylamine;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(quinolin-7-yloxymethyl)-ethylamine;
(2S)-4-[2-Amino-3-(5-isoquinolin-6-yl-pyridin-3-yloxy)-propoxy]-benzonitrile;
(2S)-N′-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl)-3-phenyl-propane-1,2-diamine;
(2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-methanesulfonamide;
(2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-benzenesulfonamide;
(2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-benzamide;
(2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-acetamide;
(2S)-3-[2-Amino-3-(1H-indol-3-yl)-propylidene]-5-isoquinolin-6-yl-1,3-dihydro-indol-2-one;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(1-methyl-1H-indol-3-ylmethyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(1H-pyrrolo[2,3-b]pyridin-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-{5-[2-(2-Fluoro-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-methoxy-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-phenoxy-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethylamine;
(1S)-2-{5-[2-(2-Benzylsulfanyl-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-1-(1H-indol-3-ylmethyl)-ethylamine;
[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-cyclopropyl-amine;
[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-benzyl-amine;
[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-ethyl-amine;
[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-methyl-amine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-indol-1-yl-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethylamine;
(±)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-methyl-1H-indol-3-ylmethyl)-ethylamine;
7-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-quinazolin-2-ylamine;
2-Phenyl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-ethylamine;
Naphthalen-2-yl-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-acetonitrile;
2-Naphthalen-2-yl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-ethylamine;
(3-Isoquinolin-6-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-phenyl-acetonitrile;
2-(3-Isoquinolin-6-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-2-phenyl-ethylamine;
(1S)-1-Benzyl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-5-yloxy)-ethylamine;
2-Benzyl-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphthyridin-5-yloxy)-ethylamine;
(1R)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphthyridin-5-yloxy)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-ylsulfanyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylsulfanyl]-ethylamine;
(1S)-1-(4-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(2-methyl-quinazolin-7-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(1H-indol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[4-(1H-tetrazol-5-yl)-phenyl]-pyridin-3-yloxy}-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyrimidin-4-yloxy)-ethylamine;
(1S)-1-Benzyl-2-[3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethylamine;
(1S)-1-Benzyl-2-[6-(3-methyl-1H-indazol-5-yl)-pyridin-2-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-thiophen-3-yl-benzyl)-ethylamine;
(1S)-1-(4-Iodo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
[4-((2S)-2-Amino-3-phenyl-propoxy)-2-(3-methyl-1H-indazol-5-yl)-phenyl]-methanol;
(1S)-2-[5-(1H-Benzotriazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-2-[5-(1H-Benzotriazol-5-yl)-pyridin-3-yloxy]-1-benzyl-ethylamine;
(1S)-1-Benzyl-2-[5-(3-morpholin-4-yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-Benzyl-2-{5-[3-(4-methyl-piperazin-1-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-ethylamine;
(1S)-{5-[5-(2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-dimethyl-amine;
(1S)-{5-[5-(2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-methoxy-ethyl)-amine;
{5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-morpholin-4-yl-ethyl)-amine;
5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-ylamine;
N-{5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-2,2,2-trifluoro-acetamide;
(2S)-2-Amino-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-3-phenyl-propionamide;
(1S)-2-[5-(3-Benzyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-1-Benzyl-2-[5-(3-benzyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Benzyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-methyl-ethylamine;
(6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl)-phenyl-amine;
(1S)-2-[5-(1H-Indazol-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2,3-dihydro-isoindol-1-one;
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-cinnolin-4-one;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-cinnolin-6-yl)-pyridin-3-yloxy]-ethylamine;
(6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl)-benzyl-amine;
(6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl)-methyl-amine;
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-ylamine;
[(3S)-3-(5-Isoquinolin-6-yl-pyridin-3-yloxymethyl)-1,2,3,4-tetrahydro-b-carbolin-9-yl]-methanol;
3-(5-Isoquinolin-6-yl-pyridin-3-yloxymethyl)-2,3,4,9-tetrahydro-1H-□-carboline;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazole-3-carboxylic acid;
5-[5-((2S)-2-tert-Butoxycarbonylamino-3-hydroxy-propoxy)-pyridin-3-yl]-3-methylindazole-1-carboxylic acid tert-butyl ester;
5-[5-((2S)-Aziridin-2-ylmethoxy)-pyridin-3-yl]-3-methyl-1H-indazole;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3-trifluoromethoxy-benzyl)-ethylamine;
(1S)-1-(3,5-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,3-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-Biphenyl-3-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3-Chloro-4-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Chloro-3-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-trifluoromethoxy-benzyl)-ethylamine;
(1S)-1-(2-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3-Fluoro-5-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2-Methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(3-{(2S)-2-Amino-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propyl}-phenyl)-dimethyl-amine;
(1S)-1-(4-Chloro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3-Iodo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-(1S)-1-(3-Fluoro-4-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3-Fluoro-4-methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3,4-dichloro-benzyl)-ethylamine;
(1S)-1-(2-Fluoro-6-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Fluoro-3-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-Furan-2-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-Benzofuran-2-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Chloro-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-Furan-3-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2-Fluoro-5-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3-Chloro-5-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3,4,5-trifluoro-benzyl)-ethylamine;
(1S)-1-(4-Fluoro-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,4-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Chloro-3-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-trifluoromethoxy-benzyl)-ethylamine;
(1S)-1-(2,5-Dimethoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-methylsulfanyl-benzyl)-ethylamine;
(1S)-1-(2-Cyclohexyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,5-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,5-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,3-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3,4-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,4-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3,5-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-Biphenyl-2-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3,4-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,3-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,5-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,6-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,4-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,6-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3,5-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,6-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-Benzo[1,3]dioxol-5-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Fluoro-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,4,6-trimethyl-benzyl)-ethylamine;
(1S)-1-(2,4-Dimethoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-trifluoromethyl-benzyl)-ethylamine;
(1S)-1-(5-Fluoro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3,5-Bis-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Fluoro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(5-Fluoro-2-methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-methyl-naphthalen-1-ylmethyl)-ethylamine;
(1S)-1-(2,2-Difluoro-benzo[1,3]dioxol-4-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Fluoro-naphthalen-1-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,2,3,3-tetrafluoro-2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-methyl-naphthalen-1-ylmethyl)-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,4,6-trifluoro-benzyl)-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,3,4-trifluoro-benzyl)-ethylamine;
(1S)-1-(4-Bromo-2-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Bromo-3-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2-Bromo-4,6-difluoro-benzyl)-2-[5-(3-methyl-I 1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Bromo-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-Bromo-benzyl)-2-[5-(3-methyl-I 1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3-Methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2-Methoxy-naphthalen-1-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1R)-1-(4-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1R)-1-Benzo[1,3]dioxol-5-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1R)-1-(3-Fluoro-4-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethyl amine;
(1S)-1-Benzyl-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Bromo-benzyl)-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Chloro-benzyl)-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-cyclohexylmethyl-ethylamine;
(1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,6-dimethyl-benzyl)-ethylamine;
(1S)-1-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-2-phenyl-propylamine;
(1S)-1-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-2,2-diphenyl-ethylamine;
(1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-2-phenyl-propylamine;
(1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-2,2-diphenyl-ethylamine;
(1S)-3-Methyl-1-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-butylamine;
(1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-2-(6-Chloro-5-thieno[2,3-c]pyridin-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;
5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-isoquinolin-6-yl-pyridine-2-carbonitrile;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Ethyl-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-pyridin-4-yl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Furan-2-yl-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenylethynyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-prop-1-ynyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-vinyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-6-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinoline-3-carbonitrile;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-6-vinyl-pyridin-3-yloxy)-ethylamine;
(1S)-2-(6-Ethynyl-5-isoquinolin-6-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-2-(6-Furan-2-yl-5-isoquinolin-6-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-6-phenylethynyl-pyridin-3-yloxy)-ethylamine;
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinolin-5-ylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(8-methyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(4-Chloro-thieno [2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenoxy-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-vinyl-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(4-Ethyl-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-(2-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-thieno[2,3-c]pyridin-4-yl)-phenyl-amine;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3,3-difluoro-1,3-dihydro-indol-2-one;
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3H-oxazolo[4,5-b]pyridin-2-one;
N1-(5-Isoquinolin-6-yl-pyridin-3-yl)-ethane-1,2-diamine;
Naphthalene-2-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide;
Naphthalene-1-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide;
5-Dimethylamino-naphthalene-1-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide;
Quinoline-5-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide;
Biphenyl-4-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide;
1-Methyl-1 H-imidazole-4-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide;
3-Amino-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propan-1-ol;
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-phenoxy-propylamine;
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(naphthalen-2-yloxy)-propylamine;
3-(Biphenyl-4-yloxy)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propylamine;
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(quinolin-7-yloxy)-propylamine;
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(pyridin-4-yloxy)-propylamine;
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(naphthalen-1-yloxy)-propylamine;
3-{(2S)-2-Amino-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propyl}-1H-indol-5-ol;
(1S)-1-(5-Methoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(5-Ethoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(5-Butoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethyl amine;
(1S)-1-(5-Isopropoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
3-(1H-Indol-3-yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propan-1-ol;
3-(1H-Indol-3-yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propylamine;
Naphthalene-2-sulfonic acid (2-amino-ethyl)-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-amide;
Biphenyl-4-sulfonic acid (2-amino-ethyl)-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-amide;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-isopropylidene-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1H-imidazol-2-ylmethylene)-1,3-dihydro-indol-2-one;
5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyridin-2-ylmethylene-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-furan-2-ylmethylene-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(5-methyl-furan-2-ylmethylene)-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(4,5-dimethyl-furan-2-ylmethylene)-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-thiophen-2-ylmethylene-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1-methyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1H-indol-3-ylmethylene)-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1-phenyl-1H-pyrrol-3-ylmethylene)-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyridin-3-ylmethylene-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1H-pyrrol-3-ylmethylene)-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(tetrahydro-pyran-4-ylidene)-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(4-ethyl-3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-cyclopropylmethylene-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyrrolidin-2-ylmethylene-1,3-dihydro-indol-2-one;
5-(5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2-oxo-1,2-dibydro-indol-3-ylidenemethyl)-furan-2-carboxylic acid;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-benzylidene-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indole-2,3-dione 3-oxime;
(1S)-2-(5-Benzo[b]thiophen-2-yl-6-furan-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-2-(5-Benzo[b]thiophen-2-yl-6-vinyl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-2-(5-Benzo[b]thiophen-2-yl-6-thiophen-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-2-(5-Benzo[b]thiophen-2-yl-6-thiazol-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-2-(5-Benzo[b]thiophen-2-yl-6-pyrazin-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;
{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-benzo[b]thiophen-2-yl-pyridin-2-yl}-phenyl-amine;
{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-benzo[b]thiophen-2-yl-pyridin-2-yl}-pyridin-3-yl-amine;
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3H-benzooxazol-2-one;
1-Benzoimidazol-1-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-morpholin-4-ylmethyl-ethylamine;
5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1,3-dihydro-indol-2-one;
5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one;
5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-3-furan-2-ylmethylene-1,3-dihydro-indol-2-one;
(1S)-1-Benzoimidazol-1-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
3-{3-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-5-isoquinolin-6-yl-pyridin-4-yl}-acrylonitrile;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-4-methyl-pyridin-3-yloxy)-ethylamine;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-methyl-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3,3-dimethyl-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1,3,3-trimethyl-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-ethyl-1,3-dihydro-indol-2-one; and
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-benzyl-1,3-dihydro-indol-2-one.
21. A pharmaceutical composition comprising a compound of claim 1, or a therapeutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
22. A method of inhibiting protein kinases in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of claim 1, or a therapeutically acceptable salt thereof.
US10/295,833 2001-12-13 2002-11-18 Kinase inhibitors Abandoned US20030187026A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US10/295,833 US20030187026A1 (en) 2001-12-13 2002-11-18 Kinase inhibitors
EP02790126A EP1463505A2 (en) 2001-12-13 2002-12-12 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
US10/317,914 US6831175B2 (en) 2001-12-13 2002-12-12 Kinase inhibitors
AU2002353147A AU2002353147A1 (en) 2001-12-13 2002-12-12 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
JP2003552299A JP2005516927A (en) 2001-12-13 2002-12-12 3- (Phenyl-alkoxy) -5- (phenyl) -pyridine derivatives and related compounds as kinase inhibitors for cancer treatment
PCT/US2002/039915 WO2003051366A2 (en) 2001-12-13 2002-12-12 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
CA002470214A CA2470214A1 (en) 2001-12-13 2002-12-12 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
TW91136090A TW200301122A (en) 2001-12-13 2002-12-13 Kinase inhibitors
ARP020104851 AR037832A1 (en) 2001-12-13 2002-12-13 COMPOUND DERIVED FROM PIRIDINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT
MXPA04005810 MXPA04005810A (en) 2001-12-13 2004-06-14 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer.

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34135601P 2001-12-13 2001-12-13
US2336301A 2001-12-13 2001-12-13
US34147401P 2001-12-17 2001-12-17
US10/295,833 US20030187026A1 (en) 2001-12-13 2002-11-18 Kinase inhibitors
US10/317,914 US6831175B2 (en) 2001-12-13 2002-12-12 Kinase inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US2336301A Continuation-In-Part 2001-12-13 2001-12-13

Publications (1)

Publication Number Publication Date
US20030187026A1 true US20030187026A1 (en) 2003-10-02

Family

ID=29554492

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/295,833 Abandoned US20030187026A1 (en) 2001-12-13 2002-11-18 Kinase inhibitors
US10/317,914 Expired - Lifetime US6831175B2 (en) 2001-12-13 2002-12-12 Kinase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/317,914 Expired - Lifetime US6831175B2 (en) 2001-12-13 2002-12-12 Kinase inhibitors

Country Status (2)

Country Link
US (2) US20030187026A1 (en)
WO (1) WO2003051366A2 (en)

Cited By (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092546A1 (en) * 2002-08-12 2004-05-13 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
US20050245519A1 (en) * 2004-04-30 2005-11-03 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
US20050250823A1 (en) * 2003-09-05 2005-11-10 Kraig Yager Gyrase inhibitors
US20060084644A1 (en) * 2004-09-23 2006-04-20 Manojit Pal Novel pyridine compounds, process for their preparation and compositions containing them
US20060247250A1 (en) * 2005-03-16 2006-11-02 Targegen, Inc. Pyrimidine inhibitors of kinases
US20070149508A1 (en) * 2005-11-02 2007-06-28 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
US20070155739A1 (en) * 2005-12-30 2007-07-05 Alantos Pharmaceuticals, Inc. Substituted bis-amide metalloprotease inhibitors
US20070155794A1 (en) * 2005-08-29 2007-07-05 Jean-Damien Charrier Pyridones useful as inhibitors of kinases
US20070185152A1 (en) * 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
US20070225315A1 (en) * 2006-03-15 2007-09-27 Theralogics, Inc. Methods of Treating Muscular Wasting Diseases Using NF-kB Activation Inhibitors
WO2007135398A1 (en) * 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
US20070287708A1 (en) * 2006-06-13 2007-12-13 Cole Derek C Substituted 3-cyanopyridines as protein kinase inhibitors
US20080081809A1 (en) * 2006-08-23 2008-04-03 Kudos Pharmaceuticals Limited Novel Compounds
US20080161309A1 (en) * 2004-04-30 2008-07-03 Paul Vincent Fish Novel Compounds
US20080194546A1 (en) * 2005-11-22 2008-08-14 Kudos Pharmaceuticals Limited Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors
WO2009038784A1 (en) * 2007-09-21 2009-03-26 Amgen Inc. Triazole fused heteroaryl compounds as p38 kinase inhibitors
US20090118284A1 (en) * 2005-12-13 2009-05-07 Cooper Alan B Novel compounds that are ERK inhibitors
US20090124602A1 (en) * 2007-01-31 2009-05-14 Francois Maltais Kinase inhibitors
US20090264429A1 (en) * 2008-02-19 2009-10-22 Richard Apodaca Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase
US20090318434A1 (en) * 2008-06-20 2009-12-24 Astrazeneca Ab Composition and process - 356
US20100016311A1 (en) * 2006-09-30 2010-01-21 University Of Strathclyde Novel minor groove binders
US7700601B2 (en) 2006-03-31 2010-04-20 Schering Corporation Substituted indazoles of formula 1.0 that are kinase inhibitors
US7776589B1 (en) 2006-08-31 2010-08-17 Schering Corporation Polynucleotides encoding polypeptide fragments of protein kinase B gamma (AKT3)
US7786130B2 (en) 2005-08-29 2010-08-31 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
US7786120B2 (en) 2005-08-29 2010-08-31 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
US20100256373A1 (en) * 2006-03-31 2010-10-07 Edwards James P Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
US20100330030A1 (en) * 2002-10-03 2010-12-30 Targegen, Inc. Vasculostatic Agents and Methods of Use Thereof
WO2011022348A1 (en) 2009-08-18 2011-02-24 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid amide hydrolase
US20110183966A1 (en) * 2008-08-06 2011-07-28 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
US20110189192A1 (en) * 2008-02-21 2011-08-04 Cooper Alan B Novel compounds that are erk inhibitors
US8148391B2 (en) 2006-10-23 2012-04-03 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
US8299055B2 (en) 2008-10-02 2012-10-30 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and the use thereof
US8372971B2 (en) 2004-08-25 2013-02-12 Targegen, Inc. Heterocyclic compounds and methods of use
US8455522B2 (en) 2009-05-15 2013-06-04 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
US8541445B2 (en) 2009-05-06 2013-09-24 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
US8563576B2 (en) 2008-07-23 2013-10-22 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2014034898A1 (en) 2012-08-30 2014-03-06 日本新薬株式会社 Pyridine derivative and medicine
US8778972B2 (en) 2009-05-15 2014-07-15 Novartis Ag 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1
US8809335B2 (en) 2010-01-27 2014-08-19 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
US8846909B2 (en) 2010-05-24 2014-09-30 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
US8859575B2 (en) 2013-03-06 2014-10-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
US8877772B2 (en) 2008-11-25 2014-11-04 University Of Rochester Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors
US8895740B2 (en) 2010-01-27 2014-11-25 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9018210B2 (en) 2011-12-28 2015-04-28 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
US9067932B2 (en) 2010-01-27 2015-06-30 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
US9137973B2 (en) 2008-07-23 2015-09-22 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9447071B2 (en) 2014-02-07 2016-09-20 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9688698B2 (en) 2014-04-25 2017-06-27 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US9957250B2 (en) 2013-03-15 2018-05-01 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9981939B2 (en) 2013-03-15 2018-05-29 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10004725B2 (en) 2015-03-30 2018-06-26 Global Blood Therapeutics, Inc. Methods of treatment
US10077249B2 (en) 2016-05-12 2018-09-18 Global Blood Therapeutics, Inc. Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US10266488B2 (en) 2013-10-10 2019-04-23 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US10450269B1 (en) 2013-11-18 2019-10-22 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
US10493035B2 (en) 2016-10-12 2019-12-03 Global Blood Therapeutics, Inc. Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US10894797B2 (en) 2018-09-18 2021-01-19 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US11053195B2 (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11236109B2 (en) 2013-03-15 2022-02-01 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2022058344A1 (en) 2020-09-18 2022-03-24 Bayer Aktiengesellschaft Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
CN115197195A (en) * 2021-04-09 2022-10-18 江苏豪森药业集团有限公司 Preparation method of flumatinib intermediate
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
CN115417816A (en) * 2022-09-05 2022-12-02 江苏南大光电材料股份有限公司 Preparation method of 3,6-dibromo-1-chloro-isoquinoline
WO2024056782A1 (en) 2022-09-16 2024-03-21 Bayer Aktiengesellschaft Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer
WO2024079252A1 (en) 2022-10-13 2024-04-18 Bayer Aktiengesellschaft Sos1 inhibitors
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034026B2 (en) 2001-04-10 2006-04-25 Merck & Co., Inc. Inhibitors of Akt activity
SE0102764D0 (en) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US7223738B2 (en) 2002-04-08 2007-05-29 Merck & Co., Inc. Inhibitors of Akt activity
EP1541559A4 (en) * 2002-07-22 2007-08-22 Asahi Kasei Pharma Corp 5-substituted isoquinoline derivative
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7129260B2 (en) 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
EP1633710A1 (en) * 2003-06-02 2006-03-15 Abbott Laboratories Isoindolin-1-one compounds as kinase inhibitors
US7531529B2 (en) * 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
WO2005003101A2 (en) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
AU2004274013A1 (en) * 2003-09-17 2005-03-31 Icos Corporation Use of Chk1 inhibitors to control cell proliferation
MXPA06003951A (en) * 2003-10-07 2006-06-27 Renovis Inc Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same.
CN1905873A (en) * 2003-11-19 2007-01-31 阵列生物制药公司 Heterocyclic inhibitors of MEK and methods of use thereof
NZ590160A (en) * 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
US20050137204A1 (en) * 2003-12-22 2005-06-23 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050245531A1 (en) * 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7655657B2 (en) * 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20070060588A1 (en) * 2003-12-22 2007-03-15 Jianguo Ji Fused bicycloheterocycle substituted quinuclidine derivatives
US7160876B2 (en) * 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
EP2543376A1 (en) * 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
WO2005110410A2 (en) * 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
NZ551253A (en) 2004-06-01 2010-07-30 Hoffmann La Roche Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
FR2871158A1 (en) * 2004-06-04 2005-12-09 Aventis Pharma Sa SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
EP1763526B1 (en) * 2004-06-28 2009-06-24 Bayer Schering Pharma AG 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
MX2007000265A (en) * 2004-07-02 2007-07-20 Icos Corp Compounds useful for inhibiting chk1.
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CA2573573A1 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
EP1784175A4 (en) * 2004-08-23 2009-07-22 Merck & Co Inc INHIBITORS OF AKT ACTIVITY
EP1828180A4 (en) * 2004-12-08 2010-09-15 Glaxosmithkline Llc 1h-pyrrolo[2,3-beta]pyridines
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EA200701835A1 (en) * 2005-02-28 2008-02-28 Реновис, Инк. AMIDIC DERIVATIVES AS THE LIGANDS OF IONIC CHANNELS, THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR APPLICATION
RU2007131400A (en) * 2005-03-01 2009-04-10 Вайет (Us) COMPOUNDS OF CINNOLINE AND THEIR APPLICATION AS MODULATORS OF LIVER X-RECEPTORS
HRP20100678T1 (en) 2005-03-29 2011-02-28 Icos Corporation HETEROARYLUREE DERIVATIVES USED AS CHK1 INHIBITORS
US20060264439A1 (en) * 2005-05-17 2006-11-23 Supergen, Inc. Inhibitors of polo-like kinase-1
ES2405785T3 (en) * 2005-05-18 2013-06-03 Array Biopharma Inc. MEK heterocyclic inhibitors and methods of use thereof
AU2006254825A1 (en) * 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
SI1898903T1 (en) * 2005-06-10 2013-07-31 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP1898903B8 (en) * 2005-06-10 2013-05-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
KR101346902B1 (en) 2005-07-09 2014-01-02 아스트라제네카 아베 Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP1915146A4 (en) 2005-07-27 2010-06-02 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
JP5191391B2 (en) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド Bi-aryl meta-pyrimidine inhibitors of kinases
NL2000284C2 (en) 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine derivatives.
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
US7910595B2 (en) * 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
MX2008008328A (en) 2005-12-22 2008-09-15 Alcon Res Ltd (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions.
JP2009528280A (en) * 2006-02-16 2009-08-06 シェーリング コーポレイション Pyrrolidine derivatives as ERK inhibitors
PL2018380T3 (en) 2006-05-19 2012-05-31 Abbvie Bahamas Ltd Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
ATE532789T1 (en) 2006-07-06 2011-11-15 Array Biopharma Inc DIHYDROTHIENOPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ATE523499T1 (en) * 2006-07-06 2011-09-15 Array Biopharma Inc CYCLOPENTA [D]-PYRIMIDINE AS AN AKT PROTEIN KINASE INHIBITOR
CA2656566C (en) 2006-07-06 2014-06-17 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
CA2661436A1 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Isoquinoline, quinazoline and phthalazine derivatives
US7674091B2 (en) * 2006-11-14 2010-03-09 The Boeing Company Rotor blade pitch control
JP2010510222A (en) * 2006-11-17 2010-04-02 シェーリング コーポレイション Combination therapy for proliferative disorders
AR064010A1 (en) * 2006-12-06 2009-03-04 Merck & Co Inc AKT ACTIVITY INHIBITORS
JP2010512312A (en) * 2006-12-06 2010-04-22 メルク エンド カムパニー インコーポレーテッド Inhibitor of AKT activity
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
WO2008082840A1 (en) * 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
EP2132196A1 (en) 2007-02-26 2009-12-16 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
CA2684105C (en) 2007-05-03 2011-09-06 Pfizer Limited Pyridine derivatives
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2009006567A2 (en) 2007-07-05 2009-01-08 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
CN101918373B (en) * 2007-07-05 2013-06-05 阵列生物制药公司 Pyrimidyl cyclopentanes as akt protein kinase inhibitors
TW200924762A (en) * 2007-11-02 2009-06-16 Vertex Pharma Kinase inhibitors
WO2009067586A1 (en) 2007-11-21 2009-05-28 Abbott Laboratories Biaryl substituted diazabicycloalkane derivatives
ES2422733T3 (en) * 2008-01-09 2013-09-13 Array Biopharma Inc Hydroxylated pyrimidylcyclopentanes as AKT protein kinase inhibitors
EP2240455B1 (en) * 2008-01-09 2012-12-26 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
SG165655A1 (en) 2008-04-16 2010-11-29 Portola Pharm Inc 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
ES2921576T3 (en) 2008-12-19 2022-08-29 Vertex Pharma Compounds useful as ATR kinase inhibitors
UY32582A (en) 2009-04-28 2010-11-30 Amgen Inc 3 KINASE PHOSPHINOSITI INHIBITORS AND / OR MAMMAL OBJECTIVE
NZ596302A (en) 2009-05-15 2014-01-31 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
CN102595899A (en) * 2009-08-10 2012-07-18 埃皮瑟瑞克斯有限公司 Indazoles as WNT/B-catenin signaling pathway inhibitors and therapeutic uses thereof
CN105037355B (en) 2009-08-10 2017-06-06 萨穆梅德有限公司 The indazole inhibitors and its therapeutical uses of Wnt signal transduction paths
EP2493863B1 (en) 2009-10-30 2015-02-25 Janssen Pharmaceutica NV Phenoxy-substituted pyrimidines as opioid receptor modulators
CN102741240B (en) 2009-10-30 2015-05-06 詹森药业有限公司 Pyrimidine compounds as delta opioid receptor modulators
JP5770197B2 (en) 2009-10-30 2015-08-26 ヤンセン ファーマシューティカ エヌ．ベー． Pyrazine as a delta opioid receptor modulator
LT3001903T (en) 2009-12-21 2018-01-10 Samumed, Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2011076744A1 (en) 2009-12-21 2011-06-30 Novartis Ag Disubstituted heteroaryl-fused pyridines
MX2012008642A (en) * 2010-01-27 2012-11-23 Vertex Pharma Pyrazolopyridine kinase inhibitors.
NZ603477A (en) 2010-05-12 2014-09-26 Vertex Pharma Compounds useful as inhibitors of atr kinase
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
RU2013148817A (en) 2011-04-01 2015-05-10 Дженентек, Инк. COMBINATIONS OF ACT AND MEK INHIBITOR COMPOUNDS AND WAYS OF THEIR APPLICATION
WO2012135781A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
IN2014CN02646A (en) 2011-09-14 2015-08-07 Samumed Llc
CN108685922A (en) 2011-09-30 2018-10-23 沃泰克斯药物股份有限公司 With ATR inhibitor for treating cancer of pancreas and non-small cell lung cancer
CN106496173A (en) 2011-09-30 2017-03-15 沃泰克斯药物股份有限公司 Method for preparing the compound that can be used as ATR kinase inhibitors
TW201329025A (en) 2011-11-01 2013-07-16 Astex Therapeutics Ltd Pharmaceutical compound
EP2776423B1 (en) * 2011-11-11 2020-05-06 Georgetown University Phenyl-substituted nicotinic ligands, and methods of use thereof
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
CN108478577A (en) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 It can be used as the compound of ATR kinase inhibitors and combinations thereof therapy
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
NZ629282A (en) 2012-05-04 2017-04-28 Samumed Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
EP2943198B1 (en) 2013-01-08 2019-07-17 Samumed, LLC 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
AR094812A1 (en) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd DERIVED FROM MONOCYCLIC PYRIDINE AS AN FGFR INHIBITOR
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
JP6744218B2 (en) 2013-11-15 2020-08-19 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー EBNA1 inhibitors and methods for their use
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
CN106103421B (en) 2014-02-14 2019-04-09 武田药品工业株式会社 Pyrazine modulators of GPR6
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
CN106535890A (en) 2014-03-20 2017-03-22 萨穆梅德有限公司 5-substituted indazole-3-carboxamides and preparation and use thereof
SI3126351T1 (en) * 2014-04-02 2018-11-30 Bristol-Myers Squibb Company Biaryl kinase inhibitors
AR101198A1 (en) 2014-07-16 2016-11-30 Gruenenthal Gmbh PYRIMIDINES 2,5-REPLACED AS PDE4B INHIBITORS
AR101196A1 (en) 2014-07-16 2016-11-30 Gruenenthal Gmbh SUBSTITUTED PYRIMIDINE COMPOUNDS
KR102344105B1 (en) 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 Salt of monocyclic pyridine derivative and crystal thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
CN104370813A (en) * 2014-10-22 2015-02-25 上海大学 Preparation method of isoquinoline-6-formaldehyde
CN104610229B (en) * 2015-01-21 2017-01-18 上海皓元生物医药科技有限公司 Synthesis method of ATP competitive small-molecule AKT inhibitor A443654
EP3275442B1 (en) 2015-03-25 2021-07-28 National Cancer Center Therapeutic agent for bile duct cancer
BR112017024481B1 (en) * 2015-05-14 2020-11-17 The Wistar Institute Of Anatomy And Biology ebna1 inhibitory compound, pharmaceutical composition comprising said compound and therapeutic uses thereof
CN106265660B (en) * 2015-05-21 2019-08-02 中国科学院合肥物质科学研究院 Application of A674563 in acute leukemia carrying FLT3 mutant gene
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017023986A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017024004A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
WO2017044623A1 (en) 2015-09-09 2017-03-16 Lau Warren C Methods, compositions, and uses of novel fyn kinase inhibitors
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
PE20181198A1 (en) 2015-10-26 2018-07-23 Bayer Cropscience Ag DERIVATIVES OF CONDENSED BICYCLE HETEROCYCLES AS PEST CONTROL AGENTS
MX380092B (en) 2015-11-06 2025-03-11 Samumed Llc TREATMENT OF OSTEOARTHRITIS.
CN108367000A (en) 2015-12-17 2018-08-03 卫材R&D管理有限公司 Therapeutic agent for breast cancer
AR108325A1 (en) 2016-04-27 2018-08-08 Samumed Llc ISOQUINOLIN-3-IL CARBOXAMIDS AND PREPARATION AND USE OF THE SAME
MX390577B (en) 2016-06-01 2025-03-20 Samumed Llc Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
JP2019535672A (en) 2016-10-21 2019-12-12 サミュメッド リミテッド ライアビリティ カンパニー Methods of using indazole-3-carboxamides and their use as inhibitors of WNT / Β-catenin signaling pathway
MA46696A (en) 2016-11-07 2019-09-11 Samumed Llc READY-TO-USE SINGLE-DOSE INJECTABLE FORMULATIONS
CN110177581B (en) * 2016-11-16 2023-01-03 通用医疗公司 Myeloperoxidase imaging agents
MA47450A (en) 2017-02-07 2019-12-18 Oblique Therapeutics Ab SULFINYLPYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER
JP2020507625A (en) 2017-02-07 2020-03-12 オブリーク セラピューティクス アーベー Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
CA3051539A1 (en) 2017-02-07 2018-08-16 Oblique Therapeutics Ab Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer
AU2018218521C1 (en) 2017-02-07 2022-06-09 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
US11219619B2 (en) 2018-03-28 2022-01-11 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
TW201946919A (en) 2018-05-17 2019-12-16 威斯塔研究所 EBNA1 inhibitor crystalline forms, and methods of preparing and using same
JP7824282B2 (en) * 2020-09-28 2026-03-04 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド Fused heteroaryl compounds and their use as camkii inhibitors - Patent Application 20070122997
EP4173674A1 (en) * 2021-10-26 2023-05-03 Perha Pharmaceuticals Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
CN115353508B (en) * 2022-08-24 2023-07-21 中国药科大学 5-pyridine-1H-indazole compound, pharmaceutical composition and application
JP2026503568A (en) * 2023-01-20 2026-01-29 ダームビオント インコーポレイテッド Compositions and formulations for the prevention, treatment, and amelioration of skin disorders, diseases, and disorders
WO2024159287A1 (en) * 2023-01-30 2024-08-08 Eurofarma Laboratórios S.A. Nav1.7- and/or nav1.8-inhibiting hydroxamates, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits
PY2404641A (en) * 2023-01-30 2024-10-03 Eurofarma Laboratorios S A Phenolic compounds that block Nav 1.7 and/or Nav 1.8, their production processes, their compositions, their uses, the methods of treating them, and their kits
PY2405420A (en) * 2023-01-30 2024-11-14 Eurofarma Laboratorios S A NAV 1.7 AND/OR NAV 1.8 BLOCKING AMIDES, THEIR OBTAINING PROCESSES, COMPOSITIONS, USES, TREATMENT METHODS AND KITS

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179563A (en) 1978-05-19 1979-12-18 Warner-Lambert Company 3-Aryloxy-substituted-aminopyridines and methods for their production
GB9124578D0 (en) 1991-11-20 1992-01-08 Smithkline Beecham Plc Chemical compounds
GB9326136D0 (en) 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9611797D0 (en) 1996-06-06 1996-08-07 Pharmacia Spa Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
AR007857A1 (en) 1996-07-13 1999-11-24 Glaxo Group Ltd HETERO-CYCLIC COMPOUNDS FUSED AS PROTEIN INHIBITORS, THYROSINE KINASE, THEIR PREPARATION METHODS, INTERMEDIARY USE IN MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2217428T3 (en) 1996-09-25 2004-11-01 Ss Pharmaceutical Co., Ltd. VINILPIRIDINE DERIVATIVES REPLACED AND MEDICINES CONTAINING THEM
AU743024B2 (en) 1997-03-05 2002-01-17 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE69814151T2 (en) 1997-12-12 2004-03-25 Abbott Laboratories, Abbott Park TRIAZINE ANGIOGENESIS INHIBITORS
US6030969A (en) 1998-04-09 2000-02-29 Abbott Laboratories 5,6,7-trisubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
EP1077971A1 (en) 1998-05-14 2001-02-28 G.D. SEARLE &amp; CO. 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
JP4554816B2 (en) 1998-05-22 2010-09-29 アボット・ラボラトリーズ Anti-angiogenic drugs for the treatment of cancer, arthritis and retinopathy
SK287132B6 (en) 1998-05-29 2009-12-07 Sugen, Inc. Pharmaceutical composition containing pyrrole substituted 2-indolinone, kit containing mentioned composition and use pyrrole substituted 2-indolinone
WO1999065875A1 (en) 1998-06-17 1999-12-23 Geron Corporation Telomerase inhibitors
AU5574799A (en) 1998-08-25 2000-03-14 Ortho-Mcneil Pharmaceutical, Inc. Pyridyl ethers and thioethers as ligands for nicotinic acetylcholine receptor and its therapeutic application
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
JP2002523455A (en) 1998-08-31 2002-07-30 スージェン・インコーポレーテッド Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
HRP20010216A2 (en) 1998-09-25 2002-04-30 Boehringer Ingelheim Pharma New substituted indolinones, their preparation and their use as medicaments
WO2000023444A1 (en) 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6462036B1 (en) * 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
MXPA01006742A (en) 1998-12-31 2004-04-21 Sugen Inc 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy.
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
EP1165513A1 (en) 1999-03-24 2002-01-02 Sugen, Inc. Indolinone compounds as kinase inhibitors
CO5170498A1 (en) 1999-05-28 2002-06-27 Abbott Lab BIARIL SULFONAMIDS ARE USEFUL AS CELL PROLIFERATION INHIBITORS
CA2381821A1 (en) 1999-08-27 2001-03-08 Boehringer Ingelheim Pharma Kg Substituted indolinones, their manufacture and their use as medicaments
MXPA02002115A (en) 1999-09-14 2002-10-31 Abbott Lab 3-pyrrolidinyloxy-3 -pyridyl ether compounds useful for controlling chemical synaptic transmission.
JP2003509428A (en) 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー Pyrazolopyrimidines as therapeutics
DE19949209A1 (en) 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma 5-substituted indolinones, their preparation and their use as pharmaceuticals
UA75054C2 (en) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Substituted in position 6 indolinones, producing and use thereof as medicament
MXPA02004010A (en) 1999-10-26 2002-10-23 Univ Texas Southwestern Med Ct Methods of treating hair loss comprising administering indoline compound.
JP2003535038A (en) 1999-12-30 2003-11-25 スージェン・インコーポレーテッド 3-Heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
WO2001055116A2 (en) 2000-01-28 2001-08-02 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
WO2001057018A1 (en) 2000-02-02 2001-08-09 Abbott Laboratories Azaazulene inhibitors of p38 map kinase and tnf-alpha
WO2001057040A1 (en) 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
JP3663382B2 (en) 2000-02-15 2005-06-22 スージェン・インコーポレーテッド Pyrrole-substituted 2-indolinone protein kinase inhibitor
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1259236A4 (en) 2000-02-25 2004-11-03 Merck & Co Inc TYROSINE KINASE INHIBITORS
EP1265992A2 (en) 2000-03-08 2002-12-18 Zealand Pharma A/S Materials and methods relating to the degradation of cdc25a in response to dna damage
WO2001070687A1 (en) 2000-03-23 2001-09-27 Bayer Aktiengesellschaft Indoles for treating diseases that can be treated using thyroid hormones
WO2001081316A2 (en) 2000-04-27 2001-11-01 Abbott Laboratories Substituted phenyl farnesyltransferase inhibitors
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
JP2003535847A (en) 2000-06-02 2003-12-02 スージェン・インコーポレーテッド Indolinone derivatives as protein kinase / phosphatase inhibitors
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors

Cited By (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092546A1 (en) * 2002-08-12 2004-05-13 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
US7186716B2 (en) 2002-08-12 2007-03-06 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
US20100330030A1 (en) * 2002-10-03 2010-12-30 Targegen, Inc. Vasculostatic Agents and Methods of Use Thereof
US20050250823A1 (en) * 2003-09-05 2005-11-10 Kraig Yager Gyrase inhibitors
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
US20070185152A1 (en) * 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
US7659394B2 (en) 2004-04-30 2010-02-09 Pfizer Inc Substituted morpholine compounds for the treatment of central nervous system disorders
US20050245519A1 (en) * 2004-04-30 2005-11-03 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
US20080161309A1 (en) * 2004-04-30 2008-07-03 Paul Vincent Fish Novel Compounds
US20100137316A1 (en) * 2004-04-30 2010-06-03 Paul Vincent Fish Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof
US8372971B2 (en) 2004-08-25 2013-02-12 Targegen, Inc. Heterocyclic compounds and methods of use
US7622486B2 (en) 2004-09-23 2009-11-24 Reddy Us Therapeutics, Inc. Pyridine compounds, process for their preparation and compositions containing them
US20060084644A1 (en) * 2004-09-23 2006-04-20 Manojit Pal Novel pyridine compounds, process for their preparation and compositions containing them
US20060247250A1 (en) * 2005-03-16 2006-11-02 Targegen, Inc. Pyrimidine inhibitors of kinases
US7786120B2 (en) 2005-08-29 2010-08-31 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
US7691885B2 (en) 2005-08-29 2010-04-06 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
US7786130B2 (en) 2005-08-29 2010-08-31 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
US20070155794A1 (en) * 2005-08-29 2007-07-05 Jean-Damien Charrier Pyridones useful as inhibitors of kinases
US20070161645A1 (en) * 2005-11-02 2007-07-12 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
US20070149508A1 (en) * 2005-11-02 2007-06-28 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
US20080194546A1 (en) * 2005-11-22 2008-08-14 Kudos Pharmaceuticals Limited Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors
US20090118284A1 (en) * 2005-12-13 2009-05-07 Cooper Alan B Novel compounds that are ERK inhibitors
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US20070155739A1 (en) * 2005-12-30 2007-07-05 Alantos Pharmaceuticals, Inc. Substituted bis-amide metalloprotease inhibitors
US9173920B2 (en) 2006-03-15 2015-11-03 Theralogics, Inc. Methods of treating muscular wasting diseases using NF-KB activation inhibitors
US8426355B2 (en) 2006-03-15 2013-04-23 Theralogics, Inc. Methods of treating muscular wasting diseases using NF-κB activation inhibitors
US20070225315A1 (en) * 2006-03-15 2007-09-27 Theralogics, Inc. Methods of Treating Muscular Wasting Diseases Using NF-kB Activation Inhibitors
US9365548B2 (en) 2006-03-31 2016-06-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
US7700601B2 (en) 2006-03-31 2010-04-20 Schering Corporation Substituted indazoles of formula 1.0 that are kinase inhibitors
US8343989B2 (en) 2006-03-31 2013-01-01 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
US8598189B2 (en) 2006-03-31 2013-12-03 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
US8962644B2 (en) 2006-03-31 2015-02-24 Janssen Pharmaceutica, Nv Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
US20100256373A1 (en) * 2006-03-31 2010-10-07 Edwards James P Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
WO2007135398A1 (en) * 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
US7781591B2 (en) * 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
US20070287708A1 (en) * 2006-06-13 2007-12-13 Cole Derek C Substituted 3-cyanopyridines as protein kinase inhibitors
US8435985B2 (en) 2006-08-23 2013-05-07 Keith Menear Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
US9102670B2 (en) 2006-08-23 2015-08-11 Kudos Pharmaceuticals Limited Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
US20110124638A1 (en) * 2006-08-23 2011-05-26 Kudos Pharmaceuticals Limited Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors
US9717736B2 (en) 2006-08-23 2017-08-01 Kudos Pharmaceuticals Limited Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
US10034884B2 (en) 2006-08-23 2018-07-31 Kudos Pharmaceuticals Limited Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
US20080081809A1 (en) * 2006-08-23 2008-04-03 Kudos Pharmaceuticals Limited Novel Compounds
US7902189B2 (en) 2006-08-23 2011-03-08 Astrazeneca Ab Compounds
US8101602B2 (en) 2006-08-23 2012-01-24 Kudos Pharmaceuticals, Ltd. Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
US20100267053A1 (en) * 2006-08-31 2010-10-21 Schering Corporation Akt3 polypeptides
US7776589B1 (en) 2006-08-31 2010-08-17 Schering Corporation Polynucleotides encoding polypeptide fragments of protein kinase B gamma (AKT3)
US8088611B2 (en) 2006-08-31 2012-01-03 Schering Corp. Kinase domain polypeptide of human protein kinase B gamma (AKT3)
US8012967B2 (en) 2006-09-30 2011-09-06 University Of Strathclyde Minor groove binders
US20100016311A1 (en) * 2006-09-30 2010-01-21 University Of Strathclyde Novel minor groove binders
US8148391B2 (en) 2006-10-23 2012-04-03 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
US8552186B2 (en) 2006-10-23 2013-10-08 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors
US20090124602A1 (en) * 2007-01-31 2009-05-14 Francois Maltais Kinase inhibitors
US8188071B2 (en) 2007-01-31 2012-05-29 Vertex Pharmaceuticals Incorporated Amino substituted pyridines as potent kinase inhibitors
US8741931B2 (en) 2007-01-31 2014-06-03 Juan-Miguel Jimenez Kinase inhibitors
WO2009038784A1 (en) * 2007-09-21 2009-03-26 Amgen Inc. Triazole fused heteroaryl compounds as p38 kinase inhibitors
US20100292234A1 (en) * 2007-09-21 2010-11-18 Amgen Inc. Triazole fused heteroaryl compounds and methods of use thereof
US8314131B2 (en) 2007-09-21 2012-11-20 Amgen Inc. Triazole fused heteroaryl compounds and methods of use thereof
US20090264429A1 (en) * 2008-02-19 2009-10-22 Richard Apodaca Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase
US8598202B2 (en) 2008-02-19 2013-12-03 Janssen Pharmaceutica Nv Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
US20110189192A1 (en) * 2008-02-21 2011-08-04 Cooper Alan B Novel compounds that are erk inhibitors
US8716483B2 (en) 2008-02-21 2014-05-06 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US20090318434A1 (en) * 2008-06-20 2009-12-24 Astrazeneca Ab Composition and process - 356
US8198441B2 (en) 2008-06-20 2012-06-12 Astrazeneca Ab Process for the preparation of novel pyridopyrazines as mTOR kinase inhibitors
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
US8563576B2 (en) 2008-07-23 2013-10-22 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
US9137973B2 (en) 2008-07-23 2015-09-22 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
US20110183966A1 (en) * 2008-08-06 2011-07-28 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
US8377926B2 (en) 2008-08-06 2013-02-19 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
US8815866B2 (en) 2008-08-06 2014-08-26 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
US8299055B2 (en) 2008-10-02 2012-10-30 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and the use thereof
US8877772B2 (en) 2008-11-25 2014-11-04 University Of Rochester Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors
US9814704B2 (en) 2008-11-25 2017-11-14 The University Of Rochester Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors
US9181247B2 (en) 2008-11-25 2015-11-10 The University Of Rochester Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors
US8541445B2 (en) 2009-05-06 2013-09-24 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
US8455522B2 (en) 2009-05-15 2013-06-04 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
US8778972B2 (en) 2009-05-15 2014-07-15 Novartis Ag 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
WO2011022348A1 (en) 2009-08-18 2011-02-24 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid amide hydrolase
US8895740B2 (en) 2010-01-27 2014-11-25 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
US8809335B2 (en) 2010-01-27 2014-08-19 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
US9067932B2 (en) 2010-01-27 2015-06-30 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
US8846909B2 (en) 2010-05-24 2014-09-30 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
US9018210B2 (en) 2011-12-28 2015-04-28 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
US10377741B2 (en) 2011-12-28 2019-08-13 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US10806733B2 (en) 2011-12-28 2020-10-20 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
US10822326B2 (en) 2011-12-28 2020-11-03 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US10034879B2 (en) 2011-12-28 2018-07-31 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
WO2014034898A1 (en) 2012-08-30 2014-03-06 日本新薬株式会社 Pyridine derivative and medicine
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
US9278952B2 (en) 2013-03-06 2016-03-08 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor
US9434715B2 (en) 2013-03-06 2016-09-06 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor
US9663497B2 (en) 2013-03-06 2017-05-30 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor
US8859575B2 (en) 2013-03-06 2014-10-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9776960B2 (en) 2013-03-15 2017-10-03 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10858317B2 (en) 2013-03-15 2020-12-08 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9957250B2 (en) 2013-03-15 2018-05-01 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9981939B2 (en) 2013-03-15 2018-05-29 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10829470B2 (en) 2013-03-15 2020-11-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10017491B2 (en) 2013-03-15 2018-07-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US11053195B2 (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US11236109B2 (en) 2013-03-15 2022-02-01 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100040B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US11530191B2 (en) 2013-03-15 2022-12-20 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10315991B2 (en) 2013-03-15 2019-06-11 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10435393B2 (en) 2013-03-15 2019-10-08 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266488B2 (en) 2013-10-10 2019-04-23 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase
US11274077B2 (en) 2013-10-10 2022-03-15 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase
US10752581B2 (en) 2013-10-10 2020-08-25 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase
US10450269B1 (en) 2013-11-18 2019-10-22 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10137118B2 (en) 2014-02-07 2018-11-27 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US11452720B2 (en) 2014-02-07 2022-09-27 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US9447071B2 (en) 2014-02-07 2016-09-20 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US10722502B2 (en) 2014-02-07 2020-07-28 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US9688698B2 (en) 2014-04-25 2017-06-27 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US10695330B2 (en) 2015-03-30 2020-06-30 Global Blood Therapeutics, Inc. Methods of treatment
US10004725B2 (en) 2015-03-30 2018-06-26 Global Blood Therapeutics, Inc. Methods of treatment
US11858939B2 (en) 2015-07-06 2024-01-02 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US11944612B2 (en) 2015-12-04 2024-04-02 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US10077249B2 (en) 2016-05-12 2018-09-18 Global Blood Therapeutics, Inc. Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
US10577345B2 (en) 2016-05-12 2020-03-03 Global Blood Therapeutics, Inc. Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
US12006302B2 (en) 2016-07-18 2024-06-11 Janssen Pharmaceutica Nv Tau PET imaging ligands
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
US10493035B2 (en) 2016-10-12 2019-12-03 Global Blood Therapeutics, Inc. Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US11225479B2 (en) 2017-01-11 2022-01-18 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11987580B2 (en) 2017-01-11 2024-05-21 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US10696673B2 (en) 2017-01-11 2020-06-30 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10793567B2 (en) 2017-01-11 2020-10-06 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11286256B2 (en) 2017-01-11 2022-03-29 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US10519149B2 (en) 2017-01-11 2019-12-31 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11912702B2 (en) 2017-08-07 2024-02-27 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11034705B2 (en) 2018-09-18 2021-06-15 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US12264167B2 (en) 2018-09-18 2025-04-01 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors
US11518772B2 (en) 2018-09-18 2022-12-06 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US10894797B2 (en) 2018-09-18 2021-01-19 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US11459340B2 (en) 2018-09-18 2022-10-04 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
WO2022058344A1 (en) 2020-09-18 2022-03-24 Bayer Aktiengesellschaft Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
CN115197195A (en) * 2021-04-09 2022-10-18 江苏豪森药业集团有限公司 Preparation method of flumatinib intermediate
WO2022219035A1 (en) 2021-04-14 2022-10-20 Bayer Aktiengesellschaft Phosphorus derivatives as novel sos1 inhibitors
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
CN115417816A (en) * 2022-09-05 2022-12-02 江苏南大光电材料股份有限公司 Preparation method of 3,6-dibromo-1-chloro-isoquinoline
WO2024056782A1 (en) 2022-09-16 2024-03-21 Bayer Aktiengesellschaft Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer
WO2024079252A1 (en) 2022-10-13 2024-04-18 Bayer Aktiengesellschaft Sos1 inhibitors

Also Published As

Publication number Publication date
WO2003051366A2 (en) 2003-06-26
US20030199511A1 (en) 2003-10-23
WO2003051366A3 (en) 2004-03-25
US6831175B2 (en) 2004-12-14

Similar Documents

Publication Publication Date Title
US6831175B2 (en) Kinase inhibitors
CN106458934B (en) Quinoxaline compounds and uses thereof
AU2002341921B2 (en) Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
US7572914B2 (en) Kinase inhibitors
KR101477553B1 (en) Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
AU732863B2 (en) Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity
WO2001068585A1 (en) Novel amide compounds
CN115427404B (en) Collagen 1 translation inhibitors and methods of use thereof
NO313520B1 (en) Indole derivatives such as 5-HT receptor agonists, process for their preparation and pharmaceutical preparations containing them
KR20070027584A (en) Gonadotropin releasing hormone receptor antagonists
EP2474540A1 (en) Gpr119 agonist
EP1379239A2 (en) N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
JP2013523715A (en) Isoquinolin-3-ylurea derivatives
JP2020511452A (en) Somatostatin modulator and its use
CN112601747A (en) Pyrazole derivatives as MALT1 inhibitors
JP2024542145A (en) 2-Aminoimidazole Derivatives as PRMT5 Inhibitors
EP1463505A2 (en) 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
JP2018509377A (en) Heterocyclic compounds as biogenic amine transport modulators
WO2017008708A1 (en) Method for preparing indazole compound and use thereof
TW202321232A (en) Small molecule sting antagonists
JP5323059B2 (en) ((Phenyl) imidazolyl) methyl heteroaryl compounds
EP1019050B1 (en) Use of somatostatin agonists and antagonists for treating diseases related to the eye
CN120500481A (en) Inhibitors of cyclic ADP-ribose hydrolase and methods of use thereof
AU2020260426A1 (en) Phenylimidazole compound
KR20250106307A (en) Pyridine derivatives as protein kinase inhibitors

Legal Events

Date Code Title Description
AS Assignment

Owner name: ABBOTT LABORATORIES, ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, QUN;WOODS, KEITH W.;ZHU, GUI-DONG;AND OTHERS;REEL/FRAME:013531/0057;SIGNING DATES FROM 20030131 TO 20030225

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION